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Certolizumab pegol and secukinumab for treating active
psoriatic arthritis following inadequate response to
disease-modifying antirheumatic drugs: a systematic
review and economic evaluation
Mark Corbett,1 Fadi Chehadah,2 Mousumi Biswas,1
Thirimon Moe-Byrne,1 Stephen Palmer,2 Marta Soares,2
Matthew Walton,1 Melissa Harden,1 Pauline Ho,3 Nerys Woolacott1*
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1Centre for Reviews and Dissemination, University of York, York, UK
2Centre for Health Economics, University of York, York, UK
3The Kellgren Centre for Rheumatology, Central Manchester and Manchester Children’s University
Hospitals Trust, Manchester, UK
*Corresponding author nerys.woolacott@york.ac.uk
Background: Several biologic therapies are approved by the National Institute for Health and Care
Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or
more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend
switching from one biologic to another, and only ustekinumab (UST; STELARA®, Janssen Pharmaceuticals,
Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Secukinumab (SEC;
COSENTYX®, Novartis International AG, Basel, Switzerland) and certolizumab pegol (CZP; CIMZIA®, UCB
Pharma, Brussels, Belgium) have not previously been appraised by NICE.
Objective: To determine the clinical effectiveness and cost-effectiveness of CZP and SEC for treating active
PsA in adults in whom DMARDs have been inadequately effective.
Design: Systematic review and economic model.
Data sources: Fourteen databases (including MEDLINE and EMBASE) were searched for relevant studies
from inception to April 2016 for CZP and SEC studies; update searches were run to identify new
comparator studies.
Review methods: Clinical effectiveness data from randomised controlled trials (RCTs) were synthesised
using Bayesian network meta-analysis (NMA) methods to investigate the relative efficacy of SEC and CZP
compared with comparator therapies. A de novo model was developed to assess the cost-effectiveness
of SEC and CZP compared with the other relevant comparators. The model was specified for three
subpopulations, in accordance with the NICE scope (patients who have taken one prior DMARD, patients
who have taken two or more prior DMARDs and biologic-experienced patients). The models were further
classified according to the level of concomitant psoriasis.
Results: Nineteen eligible RCTs were included in the systematic review of short-term efficacy. Most studies
were well conducted and were rated as being at low risk of bias. Trials of SEC and CZP demonstrated
clinically important efficacy in all key clinical outcomes. At 3 months, patients taking 150 mg of SEC
[relative risk (RR) 6.27, 95% confidence interval (CI) 2.55 to 15.43] or CZP (RR 3.29, 95% CI 1.94 to 5.56)
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were more likely to be responders than patients taking placebo. The NMA results for the biologic-naive
subpopulations indicated that the effectiveness of SEC and CZP relative to other biologics and each other
was uncertain. Limited data were available for the biologic-experienced subpopulation. Longer-term
evidence suggested that these newer biologics reduced disease progression, with the benefits being similar
to those seen for older biologics. The de novo model generated incremental cost-effectiveness ratios (ICERs) for
three subpopulations and three psoriasis subgroups. In subpopulation 1 (biologic-naive patients who had taken
one prior DMARD), CZP was the optimal treatment in the moderatesevere psoriasis subgroup and 150mg
of SEC was optimal in the subgroups of patients with mildmoderate psoriasis or no concomitant psoriasis.
In subpopulation 2 (biologic-naive patients who had taken two or more prior DMARDs), etanercept (ETN;
ENBREL®, Pfizer Inc., New York City, NY, USA) is likely to be the optimal treatment in all subgroups. The ICERs
for SEC and CZP versus best supportive care are in the region of £20,00030,000 per quality-adjusted life-year
(QALY). In subpopulation 3 (biologic-experienced patients or patients in whom biologics are contraindicated),
UST is likely to be the optimal treatment (ICERs are in the region of £21,00027,000 per QALY). The optimal
treatment in subpopulation 2 was sensitive to the choice of evidence synthesis model. In subpopulations 2 and
3, results were sensitive to the algorithm for Health Assessment Questionnaire-Disability Index costs. The
optimal treatment is not sensitive to the use of biosimilar prices for ETN and infliximab (REMICADE®, Merck
Sharp & Dohme, Kenilworth, NJ, USA).
Conclusions: SEC and CZP may be an effective use of NHS resources, depending on the subpopulation
and subgroup of psoriasis severity. There are a number of limitations to this assessment, driven mainly by
data availability.
Future work: Trials are needed to inform effectiveness of biologics in biologic-experienced populations.
Study registration: This study is registered as PROSPERO CRD42016033357.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Adverse effect An abnormal or harmful effect, such as death, a physical symptom or visible illness,
caused by, and attributable to, exposure to a chemical (e.g. a drug). An effect may be classed as adverse if
it causes functional or anatomical damage or irreversible change in the homeostasis of the organism, or if
it increases the susceptibility of the organism to another chemical or biological stress.
American College of Rheumatology improvement criteria Measures of the improvement in disease
severity based on threshold percentage improvements of 20%, 50% or 70%. To meet the criteria, a
reduction in the tender joint count and swollen joint count and an improvement in at least three out of
the five additional measures (patient and physician global health assessment, pain, disability and levels of
an acute-phase reactant) are required.
Anti-tumour necrosis factor/biologic experienced Previously treated with a biologic therapy.
Anti-tumour necrosis factor/biologic naive Not previously treated with a biologic therapy.
Apremilast An orally administered small-molecule drug that inhibits an enzyme involved in tumour
necrosis factor production. Apremilast (Otezla®, Celgene Corporation, Summit, NJ, USA) is not a
biologic therapy.
Arthritis A disorder involving inflammation of the joint(s), but which is often taken to include all joint
disorders. Joints can be permanently damaged through the disease process of arthritis.
Articular Of or relating to joints.
Between-study variance A measure of statistical heterogeneity that depends on the scale of the
outcome measured. It represents the variation in reported study effects over and above the variation
expected given the within-study variation.
Biological therapy (biologic) Any pharmaceutical product derived from biological sources. Biologics used
in the treatment of psoriatic arthritis treatment are generally monoclonal antibodies that bind to, and
inactivate, immune cell-signalling molecules (e.g. tumour necrosis factor and interleukins), thereby dampening
the inflammatory response.
Biosimilar An imitation biological medical product (such as an anti-tumour necrosis factor) usually
marketed by a manufacturer other than the manufacturer of the original biological product once a patent
has expired. It should be similar to the original licensed product in terms of safety and efficacy.
C-reactive protein A protein found in the blood, the concentration of which is a raised by inflammation,
for example in rheumatoid arthritis, and the level of which is used as a measure of disease activity.
Ciclosporin A medication originally developed to prevent the immune system from rejecting transplanted
organs but which has also proved helpful in treating psoriasis.
Confidence interval The typical (classical or frequentist) definition is the range within which the true
value (e.g. size of effect of an intervention) would be expected to lie if sampling could be repeated a large
number of times (e.g. 95% or 99%).
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Cost–benefit analysis An economic analysis that converts the effects or consequences of interventions
into the same monetary terms as the costs and compares them using a measure of net benefit or a
costbenefit ratio.
Cost-effectiveness analysis An economic analysis that expresses the effects or consequences of
interventions on a single dimension. This would normally be expressed in natural units (e.g. cases cured,
life-years gained). The difference between interventions in terms of costs and effects is typically expressed
as an incremental cost-effectiveness ratio (e.g. the incremental cost per life-year gained).
Cost–utility analysis The same as a cost-effectiveness analysis, but the effects or consequences of
interventions are expressed in generic units of health gain, usually quality-adjusted life-years.
Credible interval In Bayesian statistics, a posterior probability interval estimation that incorporates
problem-specific contextual information from the prior distribution. It is used for a purpose similar to that
of a confidence interval in frequentist statistics.
Crohn’s disease An inflammatory condition of the digestive tract; rheumatic diseases are often associated
with it and ulcerative colitis is related to it.
Dactylitis Inflammation of an entire digit caused by simultaneous joint and tendon inflammation.
Deviance information criterion A model fit statistic and used for Bayesian model comparison. The
model with the smallest deviance information criterion is estimated to be the model that would best
predict a replicate data set that has the same structure as that currently observed.
Disease-modifying antirheumatic drugs Drugs capable of modifying the progression of rheumatic
disease. The term is, however, applied to what are now considered to be traditional (or conventional)
disease-modifying drugs, in particular sulfasalazine, methotrexate and ciclosporin, as well as azathioprine,
cyclophosphamide, antimalarials, penicillamine and gold. The newer agent leflunomide is also a disease-
modifying antirheumatic drug. Biologics are not generally referred to as disease-modifying antirheumatic
drugs, although occasionally biological disease-modifying antirheumatic drugs may be used.
Dominated A term, used in this report in the cost-effectiveness sections, that describes a treatment
associated with higher costs and a lower number of quality-adjusted life-years than another treatment.
Enthesitis Inflammation of the region where tendons and ligaments attach to the bone (enthesis).
Erythrocyte sedimentation rate One of the tests designed to measure the degree of inflammation.
EuroQol-5 Dimensions questionnaire A standardised instrument for measuring generic health-related
quality of life, used in the computation of the number of quality-adjusted life-years gained.
Extendedly dominated A term, used in this report in the cost-effectiveness sections, to describe a
strategy in which the incremental cost-effectiveness ratio is higher than that of the next most effective
strategy. Therefore, an extendedly dominated strategy produces additional gains in effectiveness at
incremental costs higher than those of the next most effective strategy.
Fixed-effect model A statistical model that stipulates that the units under analysis (e.g. people in a trial
or study in a meta-analysis) are the ones of interest, and thus constitute the entire population of units.
Only within-study variation is taken to influence the uncertainty of results (as reflected in the confidence
interval) of a meta-analysis using a fixed-effect model.
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Health Assessment Questionnaire-Disability Index A self-administered questionnaire measuring an
individuals physical disability and pain. It scores ability to perform various activities between 0 (without any
difficulty) and 3 (unable to do). It is reported as an average of all activity scores.
Heterogeneity In systematic reviews, the variability or differences between studies in the estimates of
effects. A distinction is sometimes made between statistical heterogeneity (differences in the reported
effects), methodological heterogeneity (differences in study design) and clinical heterogeneity
(differences between studies in key characteristics of the participants, interventions or outcome measures).
Intention-to-treat analysis An analysis in which all the participants in a trial are analysed according to
the intervention to which they were allocated, whether they received it or not.
Leeds Dactylitis Index A measure of swelling between digital joints. A dactylometer is used to measure
the circumference of an affected digit, and the contralateral unaffected digit, and the ratio of the
circumferences is calculated. If both hands are affected, a standard reference is used to calculate the ratio.
A difference in circumference of ≥ 10% defines a finger with dactylitis. The tenderness of each digit is also
taken into account to generate a score for each. If multiple digits are affected, the scores for each are
added together.
Leeds Enthesitis Index A measure of tenderness over six tendon attachment sites (enthuses). It also
includes an assessment for soft tissue swelling. It is scored from 0 to 6.
Methotrexate One of the oldest chemotherapy drugs used in the treatment of cancer and autoimmune
diseases, such as rheumatoid and psoriatic arthritis.
Modified total Sharp score One of several radiological assessments used to measure joint damage in
psoriatic arthritis. This method grades all joints of the hand separately for erosions and joint space
narrowing for 64 and 52 joints (out of a maximum score of 149), respectively, with higher scores
representing greater damage. The total Sharp score is modified to include other joints in the assessment.
Monoclonal antibody An antibody produced using a single clone of cells with affinity for one
particular antigen.
Network meta-analysis (Synonyms: mixed treatment comparison, indirect treatment comparison.)
Used when there is insufficient direct evidence linking two interventions, this is a type of meta-analysis
comparing three or more different treatments using both direct comparison within randomised controlled
trials and indirect comparison between trials based on a common comparator (such as placebo).
Non-steroidal anti-inflammatory drug Any of a large range of drugs in the aspirin family, prescribed
for different kinds of arthritis, that reduces inflammation and controls pain, swelling and stiffness.
Placebo An inactive substance or procedure administered to a patient, usually to compare its effects with
those of a real drug or other intervention, but sometimes for the psychological benefit to the patient
through a belief that she/he is receiving treatment.
Plaque psoriasis The most common form of psoriasis, also known as psoriasis vulgaris, characterised by
red, raised lesions covered by silvery scales. About 80% of patients with psoriasis have this type.
Psoriasis A chronic skin disease characterised by inflammation and scaling. Scaling occurs when cells in
the outer layer of skin are produced faster than normal and build up on the skins surface. It is thought to
be caused by a disorder of the immune system.
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Psoriasis Area and Severity Index A measure of the extent of skin affected and of the redness,
scaliness and thickness of psoriatic plaques. Response is presented as PASI 50, PASI 75 or PASI 90,
the number being the percentage reduction in Psoriasis Area and Severity Index score from baseline.
Psoriatic arthritis A disease characterised by stiffness, pain and swelling in the joints, especially of the
hands and feet. It affects about 30% of people with psoriasis. Early diagnosis and treatment can help
inhibit the progression of joint deterioration.
Psoriatic Arthritis Response Criteria response An improvement of at least 30% in the tender or
swollen joint count as well as a 1-point improvement on a 5-point scale of the patients and/or physicians
assessment. The National Institute for Health and Care Excellence defines a response as an improvement in
two or more of the four assessment criteria (with no worsening of any of these four measures).
Quality-adjusted life-year An index of health gain according to which survival duration is weighted or
adjusted by the patients quality of life during the survival period. It has the advantage of incorporating
changes in both quantity (mortality) and quality (morbidity) of life.
Quality of life A concept incorporating all the factors that might have an impact on an individuals life,
including factors such as the absence of disease or infirmity as well as other factors that might affect that
individuals physical, mental and social well-being.
Random-effects model A statistical model sometimes used in meta-analysis in which both within-study
sampling error (variance) and between-studies variation are included in the assessment of the uncertainty
(confidence interval) of the results of a meta-analysis.
Randomised controlled trial (Synonym: randomised clinical trial.) An experiment in which investigators
randomly allocate eligible people to intervention groups to receive or not receive one or more interventions
that are being compared.
Relative risk (Synonym: risk ratio.) The ratio of risk in the intervention group to the risk in the control
group. The risk (proportion, probability or rate) is the ratio of people with an event in a group to the total
number in the group. A relative risk of 1 indicates no difference between comparison groups. In the case
of undesirable outcomes, a relative risk of < 1 indicates that the intervention was effective in reducing the
risk of that outcome.
Remission A lessening or abatement of the symptoms of a disease.
Residual deviance An analysis used for model comparison and goodness of fit. It is equal to the deviance
for a given model minus the deviance for a saturated model. A saturated model is one in which all of the
predictions from the model are equal to the observed data values. Total residual deviance should
approximate the number of data points for a good fit.
Rheumatoid arthritis A chronic autoimmune disease characterised by pain, stiffness, inflammation,
swelling, and, sometimes, destruction of joints.
Sensitivity analysis An analysis used to determine how sensitive the results of a study or systematic
review are to changes in how it was done. It is used to assess how robust the results are to uncertain
decisions or assumptions about the data and the methods that were used.
Short Form questionnaire-36 items A patient-reported survey of general health status.
Statistical significance An estimate of the probability of an association (effect) as large as or larger than
what is observed in a study occurring by chance, usually expressed as a p-value.
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Subpopulation 1 Patients who are biologic naive but have tried one previous conventional disease-
modifying antirheumatic drug.
Subpopulation 2 Patients who are biologic naive but have tried two or more previous conventional
disease-modifying antirheumatic drugs.
Subpopulation 3 Patients who are biologic experienced.
Tender joint count and swollen joint count Assessment of the condition of 28 joints important to
functional status. Used in the calculation of several composite disease activity scores such as Disease
Activity Score 28.
Tumour necrosis factor alpha A cell signalling molecule (cytokine) involved in the inflammatory
response pathway, known to be fundamental to the pathological processes causing psoriasis and psoriatic
arthritis. Plays a key role in onset and persistence of joint and skin inflammation.
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List of abbreviations
ACR American College of Rheumatology
ACR 20 20% improvement in the American
College of Rheumatology criteria
ACR 50 50% improvement in the American
College of Rheumatology criteria
ACR 70 70% improvement in the American
College of Rheumatology criteria
ADA adalimumab
ADEPT ADalimumab Effectiveness in
Psoriatic arthritis Trial
AE adverse event
AG Assessment Group
APR apremilast
BNF British National Formulary
BSA body surface area
BSC best supportive care
BSR British Society for Rheumatology
BSRBR British Society for Rheumatology
Biologics Register
CASPAR Classification Criteria for Psoriatic
Arthritis
cDMARD conventional disease-modifying
antirheumatic drug
CDSR Cochrane Database of Systematic
Reviews
CENTRAL Cochrane Central Register of
Controlled Trials
CI confidence interval
CLEAR Efficacy of Secukinumab Compared
to Ustekinumab in Patients with
Plaque-type Psoriasis
CPCI-S Conference Proceedings Citation
Index  Science
CrI credible interval
CRP C-reactive protein
CS company submission
CZP certolizumab pegol
DA deterministic analysis
DANBIO Danish Database for Biological
Therapies
DARE Database of Abstracts of Reviews
of Effects
DIC deviance information criterion
DMARD disease-modifying antirheumatic
drug
EQ-5D EuroQol-5 Dimensions
ERASURE Efficacy of Response and Safety of
Two Fixed Secukinumab Regimens
in Psoriasis
ERG Evidence Review Group
ESR erythrocyte sedimentation rate
ETN etanercept
EULAR European League Against
Rheumatism
FIXTURE Full Year Investigative Examination
of Secukinumab vs. Etanercept
Using Two Dosing Regimens to
Determine Efficacy in Psoriasis
FUTURE Efficacy at 24 Weeks and Long
Term Safety, Tolerability and
Efficacy up to 2 Years of
Secukinumab (AIN457) in Patients
With Active Psoriatic Arthritis
GO-REVEAL Golimumab  A Randomized
Evaluation of Safety and Efficacy in
Subjects with Psoriatic Arthritis Using
a Human Anti-TNF Monoclonal
Antibody
GOL golimumab
GP general practitioner
HAQ-DI Health Assessment Questionnaire-
Disability Index
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HR hazard ratio
HRQoL health-related quality of life
HTA Health Technology Assessment
i.v. intravenous
ICER incremental cost-effectiveness ratio
IL interleukin
IMPACT Infliximab Multinational Psoriatic
Arthritis Controlled Trial
INF infliximab
ITT intention to treat
LDI Leeds Dactylitis Index
LEI Leeds Enthesitis Index
LOCF last observation carried forward
MeSH medical subject heading
MIMS online and print prescribing
database for health professionals
MTA multiple technology appraisal
mTSS modified total Sharp score
MTX methotrexate
NHS EED NHS Economic Evaluation Database
NICE National Institute for Health and
Care Excellence
NMA network meta-analysis
NOAR Norfolk Arthritis Register
NOR-DMARD Norwegian Antirheumatic Drug
Register
NSAID non-steroidal anti-inflammatory
drug
OR odds ratio
PALACE Psoriatic Arthritis Long-term
Assessment of Clinical Efficacy
PASI Psoriasis Area and Severity Index
PASI 50 50% reduction in the Psoriasis
Area and Severity Index
PASI 75 75% reduction in the Psoriasis
Area and Severity Index
PASI 90 90% reduction in the Psoriasis
Area and Severity Index
PNR placebo non-responder
PR placebo responder
PRESTA Psoriasis Randomized Etanercept
study in Subjects with psoriaTic
Arthritis
PsA psoriatic arthritis
PSA probabilistic sensitivity analysis
PsARC Psoriatic Arthritis Response Criteria
PSSRU Personal Social Services Research Unit
PSUMMIT Study of the Safety and
Effectiveness of Ustekinumab in
Patients With Psoriatic Arthritis
QALY quality-adjusted life-year
RA rheumatoid arthritis
RAPID-PsA Certolizumab Pegol in Subjects
With Adult Onset Active and
Progressive Psoriatic Arthritis
RCT randomised controlled trial
RR relative risk
SAE serious adverse event
SCI Science Citation Index
SD standard deviation
SE standard error
SEC secukinumab
SF-36 Short Form questionnaire-36 items
SJC swollen joint count
SoC standard of care
SPIRIT-P1 Study of Ixekizumab in Participants
With Active Psoriatic Arthritis
STA single technology appraisal
TA technology appraisal
TB tuberculosis
THIN The Health Improvement Network
TJC tender joint count
LIST OF ABBREVIATIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxxiv
TNF tumour necrosis factor
TNF-α tumour necrosis factor alpha
TNR treatment non-responder
TR treatment responder
UST ustekinumab
VAS visual analogue scale
YODA Yale University Open Data Access
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed confidential. The full report
was used by the Appraisal Committee at NICE in their deliberations. The full report with each
piece of confidential data removed and replaced by the statement confidential information
(or data) removed is available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Plain English summary
Psoriatic arthritis (PsA) is an inflammatory disease that involves both skin (psoriasis) and joints. It cangreatly reduce a persons quality of life. For patients who have severe active PsA who have not
responded sufficiently to conventional treatments, the National Institute for Health and Care Excellence
(NICE) currently recommends a number of effective biologic therapies. The purpose of this project was to
assess the benefits, harms and cost-effectiveness of two new biologic therapies  certolizumab pegol (CZP;
CIMZIA®, UCB Pharma, Brussels, Belgium) and secukinumab (SEC; COSENTYX®, Novartis International AG,
Basel, Switzerland)  and to compare them with existing therapies.
We identified and analysed all of the data from relevant clinical trials. The results showed that both CZP
and SEC are effective therapies for improving the symptoms of PsA. Although side effects might result
from these treatments, they are uncommon. It is not clear which, if any, of the many biologic therapies is
best, although SEC seems particularly good at improving psoriasis symptoms.
Economic modelling found that these new biologics can be considered a cost-effective use of NHS
resources when compared with the other therapies currently recommended by NICE for treating PsA.
Which treatment is most cost-effective depends on which previous treatments a patient has tried and not
responded to, the severity of the psoriasis symptoms, and the price of the treatment. Some of the studys
results were somewhat limited because not enough relevant clinical trial data were available.
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Scientific summary
Background
Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory arthritis, closely associated with
psoriasis of the skin and nails, that typically affects joints in the hands, feet and spine. It can cause joint
damage so early diagnosis and treatment is important. Current practice typically involves early use of
non-steroidal anti-inflammatory drugs followed by disease-modifying antirheumatic drugs (DMARDs),
if necessary. When conventional disease-modifying antirheumatic drugs (cDMARDs) are ineffective, biologic
therapies may be used; for example, anti-tumour necrosis factor (TNF) biologics such as etanercept
[(ETN); ENBREL®; Pfizer Inc., New York City, NY, USA)], infliximab [(INF) REMICADE®; Merck Sharp & Dohme,
Kenilworth, NJ, USA], adalimumab [(ADA) HUMIRA®; AbbVie Inc., North Chicago, IL, USA] and golimumab
[(GOL) SIMPONI®; Merck Sharp & Dohme, Kenilworth, NJ, USA] are approved by the National Institute
for Health and Care Excellence (NICE) for patients who have had an inadequate response to two or more
DMARDs. Ustekinumab [(UST) STELARA®; Janssen Pharmaceuticals, Inc., Horsham, PA, USA], which is an
anti-interleukin (IL)-12/23  a different kind of biologic therapy to anti-TNFs - is also recommended as a
possible treatment, specifically when DMARDs have not worked well enough, provided that treatment with
anti-TNFs is not suitable, or the patient has had an anti-TNF before. NICE does not specifically recommend
switching anti-TNF treatments other than the guidance for UST and switching decisions can vary depending
on local guidelines. The newer biologics, secukinumab [(SEC) COSENTYX®; Novartis International AG, Basel,
Switzerland; an anti-IL-17] and certolizumab pegol [(CZP) CIMZIA®; UCB Pharma, Brussels, Belgium; an
anti-TNF], have not previously been appraised by NICE for treating PsA.
Objective
To determine the clinical effectiveness and cost-effectiveness of CZP and SEC within their marketing
authorisations for treating active PsA in adults in whom DMARDs have been inadequately effective.
Methods
For the systematic review of clinical efficacy, randomised controlled trials (RCTs) were eligible, including
open-label extensions. Adverse events (AEs) data were sought from existing safety reviews of biologics.
Patient registry studies (of patients taking biologics) and studies of natural history of disease (in patients
not taking biologics) were also sought. Eligible studies were of adults with PsA. The treatments of interest
were SEC and CZP with the relevant comparators being ETN, INF, ADA, GOL, UST, apremilast (APR;
Otezla®, Celgene Corporation, Summit, NJ, USA) and placebo.
Fourteen databases (including MEDLINE and EMBASE) were searched for relevant studies from inception to
April 2016 for CZP and SEC studies; update searches were run to identify new comparator studies. Clinical
effectiveness data from RCTs were synthesised using Bayesian network meta-analysis (NMA) methods to
formally investigate the relative efficacy of SEC and CZP compared with the other active comparators.
Analyses were conducted on four outcomes: Psoriatic Arthritis Response Criteria (PsARC); Health
Assessment Questionnaire-Disability Index (HAQ-DI), conditional on PsARC response; Psoriasis Area and
Severity Index (PASI); and American College of Rheumatology improvement criteria. Results from other
studies were summarised narratively.
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Methods of cost-effectiveness review
A systematic review was undertaken to identify published evidence on the cost-effectiveness of CZP and
SEC in PsA. This also includes the company submissions (CSs) from Novartis (SEC) and UCB Pharma (CZP).
The systematic review also includes a broader assessment of published decision-analytic models for relevant
comparators INF, ETN, ADA, GOL and UST. The differences in the model structures and assumptions used
across the studies were examined to identify any important differences in approaches and areas of
remaining uncertainty.
Methods of economic modelling
A de novo decision-analytic model was developed to estimate the cost-effectiveness of SEC and CZP
compared with other relevant comparators including ETN, INF, ADA, GOL, UST and best supportive care
(BSC) for the treatment of adult PsA. A different set of comparators are defined according to each
subpopulation of interest. Here BSC includes the use of cDMARDs. The cost-effectiveness model takes the
form of a lifetime (40 years) Markov cohort model, developed using the R programming language (The
R Foundation for Statistical Computing, Vienna, Austria). Outcomes are expressed using quality-adjusted
life-years (QALYs). The parameters of the model were obtained from published literature, manufacturers
reported data and the results of the evidence synthesis. Probabilistic sensitivity analysis (PSA) was used to
explore decision uncertainty.
Although the model shares a number of important characteristics with the previous York model [Rodgers M,
Epstein D, Bojke L, Yang H, Craig D, Fonseca T, et al. Etanercept, infliximab and adalimumab for the treatment
of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10)],
several significant changes have also been implemented. These include:
l incorporation of subsequent biologic treatments following primary lack of response or secondary failure
l three subpopulations specified in the NICE scope for this appraisal
l three subgroups according to the level of concomitant psoriasis.
Results of the clinical effectiveness review
Nineteen eligible RCTs were included in the systematic review of short-term efficacy. Most studies were
well conducted and were rated as being at low risk of bias.
Short-term efficacy in pivotal randomised controlled trials
Four eligible trials were of SEC and one was of CZP. Results from the pivotal RCTs of SEC and CZP
demonstrated their short-term efficacy. Both therapies were associated with statistically significant
improvements in all key clinical outcomes. At 3 months, patients taking SEC (150 or 300 mg) were
around six times more likely to show 50% improvement in the American College of Rheumatology criteria
(ACR 50)  an important clinical outcome to patients  than patients taking placebo. Patients taking CZP
were around three times more likely to be ACR 50 responders than placebo patients. Clinically important
improvements in activities of daily living (as assessed using HAQ-DI) were also evident for both therapies,
particularly in patients who were PsARC responders. Both SEC and CZP also significantly improved
measures of health-related quality of life and the resolution of enthesitis and dactylitis.
However, when the populations from these two trials were split into subgroups based on previous biologic
experience, the results for the biologic-experienced subgroups became difficult to interpret. This was
because of the low numbers of placebo-treated patients (and placebo events) and the differences in
placebo response rates across subgroups. A further complication is that the evidence for CZP does not
include patients who failed to respond to a first anti-TNF. Although SEC and, probably, CZP are efficacious
in both subgroups, it is not possible to make robust conclusions about any difference in efficacy of these
drugs across these subgroups.
Subgroup results from PsA patients recruited to trials of patients with quite severe psoriasis suggested that
SEC may be particularly efficacious in treating the psoriasis symptoms of PsA.
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Short-term efficacy compared with other therapies from network meta-analyses
The trials identified to inform a comparison of SEC and CZP with other therapies were performed across a
15-year period and variation in the placebo response was evident for some important outcomes: larger
placebo response rates were seen in the more recent trials. There was also important variation across trials
with regard to patients previous use of a biologic therapy: subgroups of biologic-experienced patients
were recruited only in more recent trials. The NMAs were therefore performed on the biologic-naive and
biologic-experienced subpopulations separately, and included models that adjusted for, and explored, the
different rates of placebo response across trials.
Across all outcomes, the NMA results for the biologic-naive subpopulation indicated that, although SEC
and CZP were effective, their relative effectiveness compared with ETN, ADA, GOL and INF and with each
other was uncertain (the rankings of treatment varied with outcome and analysis). However, both agents
did seem consistently more effective than APR. The results indicate that SEC and INF are the most effective
in terms of PASI response.
Only SEC and UST could be included in the analyses of the biologic-experienced subpopulation. The results
showed that, across all outcomes analysed, both SEC and UST were significantly more effective than
placebo. Most of the results suggested SEC may be better than UST. However, the patient numbers in this
subpopulation were quite low; the results were therefore uncertain (with wide overlapping credible intervals).
Long-term efficacy
Results from open-label trial extension studies that radiographically assessed joint damage indicated that,
after 2 years of treatment, CZP effectively reduced disease progression with the benefits appearing similar
to those observed in the open-label studies of the other biologics. Fewer result details were available for
SEC at 2 years, although the results also indicated effective reduction in radiographic disease progression.
Meaningful treatment comparisons of longer-term data for other outcomes were difficult to undertake as
a result of the variation in both time points assessed and in methodological approaches used for data
analyses. (Confidential information has been removed.)
Results from other studies
Patient registry studies suggested that, although patients benefit from a second or further anti-TNFs, the
expected benefit from anti-TNFs diminishes after switching, with a reduced chance of response and reduced
drug survival. The paucity of observational data on the natural history of PsA meant that it was difficult to
produce accurate estimates of yearly disease progression rates in patients not receiving anti-TNF therapy.
The results from three systematic reviews of AEs suggested that CZP was associated with statistically
significantly more serious AEs and serious infections than placebo. Although the safety data for SEC
appear promising, there is still some uncertainty regarding the safety of this drug.
Results of the cost-effectiveness evaluation
Cost-effectiveness reported in existing published studies and manufacturer submissions
No previously published cost-effectiveness studies of SEC or CZP for PsA were identified. The companies
submitted de novo analyses for SEC (Novartis) and CZP (UCB Pharma).
For the broader set of comparators, the systematic search of published literature identified nine studies
that met the inclusion criteria for the cost-effectiveness review, including seven UK studies, only one of
which was not directly related to a previous NICE technology appraisal (TA). All of these models employed
similar model structures to that originally proposed by Rodgers et al. [Rodgers M, Epstein D, Bojke L,
Yang H, Craig D, Fonseca T, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic
arthritis: a systematic review and economic evaluation. Health Technol Assess 2011;15(10)] for TA199
(the previous York model). The main differences between these models are in relation to the comparators
and associated evidence base, which has altered since TA199, rather than in terms of major structural
differences. The choice of optimal treatment, ETN, is consistent across the published models.
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The manufacturers models are the only studies that directly assess the decision problem in relation to the
new interventions [i.e. the positioning of SEC and CZP across the pathway for PsA (biologic-naive and
biologic-experienced populations)]. Both have a similar structure to the previous York model. However,
there are a number of key differences, including the comparators included in each of the subpopulations;
clinical evidence used and the methods employed in the evidence synthesis; the source of cost data for
HAQ-DI and PASI data; and the rate of withdrawal for patients who have initially responded to biologic
therapy and baseline characteristics in terms of HAQ-DI and particularly PASI scores. Neither submission
reports a list price analysis, instead reporting results using confidential Patient Access Scheme prices.
Cost-effectiveness results from de novo modelling
The de novo model, which addressed many of the issues of earlier published models, generated
incremental cost-effectiveness ratios (ICERs) for three subpopulations according to the position in the
pathway of treatment and three subgroups according to severity of psoriasis:
l For subpopulation 1 (one prior DMARD): in the moderatesevere subgroup, the pairwise ICERs for CZP
and 300 mg of SEC compared with BSC are £20,870 and £26,064 per QALY, respectively. In the fully
incremental analysis, the ICER for 300 mg of SEC compared with CZP is £134,783; therefore, CZP is
likely to be the optimal treatment. In the mildmoderate psoriasis group, the pairwise ICERs for CZP
and 150 mg of SEC compared with BSC are £23,052 and £21,772 per QALY, respectively. In the fully
incremental analysis, CZP is dominated by 150 mg of SEC and, therefore, 150 mg of SEC is likely to be
the optimal treatment. In the no concomitant psoriasis subgroup, pairwise ICERs for 150 mg of SEC
and CZP compared with BSC are £23,928 and £24,774 per QALY, respectively. In the fully incremental
analysis, the ICER for CZP compared with 150 mg of SEC is £346,785 and, therefore, 150 mg of SEC is
likely to be the optimal treatment.
l For subpopulation 2 (two or more prior DMARDs): in the moderatesevere subgroup, the pairwise
ICERs for CZP and 300 mg of SEC compared with BSC are £21,564 and £29,569 per QALY,
respectively. In the fully incremental analysis, 300 mg of SEC is dominated and CZP is extendedly
dominated. Of the remaining non-dominated alternatives, ETN is likely to be the optimal treatment,
with an ICER of £21,215 compared with GOL. For the mildmoderate psoriasis subgroup, the pairwise
ICERs for CZP and 150 mg of SEC compared with BSC are £24,103 and £22,032 per QALY,
respectively. In the fully incremental analysis, CZP and GOL are dominated and ADA is extendedly
dominated. Of the remaining non-dominated alternatives, ETN is likely to be the optimal treatment,
with an ICER of £23,256 per QALY compared with 150 mg of SEC. For the no concomitant psoriasis
subgroup, the individual pairwise ICERs for CZP and 150 mg of SEC compared with BSC are £24,103
and £22,032 per QALY, respectively. ETN is likely to be the optimal treatment in this subgroup with an
ICER of £23,883 compared with BSC (fully incremental analysis).
l For subpopulation 3 (biologic experienced): in the moderatesevere subgroup, the individual pairwise
ICER for 300 mg of SEC compared with BSC is £36,013. In the fully incremental analysis, the ICER
for UST versus BSC is £21,684 per QALY and the ICER for 300 mg of SEC is £85,013 per QALY. In the
mildmoderate subgroup the pairwise ICER for 300 mg of SEC compared with BSC is £40,639. In the
fully incremental analysis, the ICER for UST versus BSC is £24,510 per QALY and the ICER for 300 mg
of SEC versus UST is £97,713 per QALY. In the no concomitant subgroup the pairwise ICER for 300 mg
of SEC compared with BSC is £44,774. In the fully incremental analysis, the ICER for UST versus BSC is
£26,797 per QALY and the ICER for 300 mg of SEC versus UST is £111,927 per QALY.
The model also explores a number of uncertainties through the use of scenario analysis, and found that:
l The optimal treatment in subpopulation 2 was sensitive to the choice of evidence synthesis model.
l In the contraindicated subgroup (subpopulation 4), UST appears to be the most cost-effective treatment in
patients with moderatesevere psoriasis (ICER of £19,969 compared with BSC); however, in those with
mildmoderate psoriasis or no concomitant psoriasis, 150mg of SEC appears to be the most cost-effective
treatment (ICERs of £19,349 and £22,334 compared with BSC for these two subgroups, respectively).
SCIENTIFIC SUMMARY
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l In the biologic-experienced subgroup including only secondary failures, CZP seems to be cost-effective
compared with BSC, with ICERs of £16,573, £19,113 and £20,973 for the moderatesevere,
mildmoderate and no concomitant psoriasis group, respectively.
l The optimal treatment is not sensitive to the use of biosimilar prices for ETN and INF.
l In subpopulation 1, the optimal treatment is consistent across the two scenarios for baseline HAQ-DI
score, base-case assumption (1.22) and using a subpopulation-specific baseline HAQ-DI score.
l In subpopulations 2 and 3, aside from the use of the Poole et al. (Poole CD, Lebmeier M, Ara R, Rafia R,
Currie CJ. Estimation of health care costs as a function of disease severity in people with psoriatic arthritis
in the UK. Rheumatology 2010;49:194956) HAQ-DI costs, the optimal treatment is consistent across all
scenarios (subpopulation-specific baselines and alternative withdrawal rates).
The PSA demonstrated that, despite the ICERs being broadly consistent between the deterministic analysis
and the means of the PSA, there is considerable decision uncertainty regarding the optimal treatment, at
both £20,000 and £30,000 per QALY thresholds.
Discussion
The key strengths of the systematic review are the rigorous methods used and the breadth of the types of
study included. The updated York model confers several advantages over current published cost-effectiveness
studies, namely the inclusion of the three subpopulations according to the position in the pathway of
treatment, the explicit consideration of the severity of concomitant psoriasis and the modelling of subsequent
treatments following primary non-response or secondary failure. The York model also facilitates a more
consistent basis for evaluating CZP and SEC by ensuring comparability of methods and inputs.
Conclusions
The NMA results for the biologic-naive subpopulation indicated that, although SEC and CZP were effective
across all outcomes after 3 months therapy, their relative effectiveness compared with other biologics and
with each other was uncertain. The results of the economic model indicated that CZP and SEC may be an
effective use of NHS resources, depending on the subpopulation (based on prior treatments) and subgroup
(according to psoriasis severity). There were a number of limitations to the assessment, mostly driven by
data availability issues.
Suggested research priorities
Adequately powered trials are needed to better inform the efficacy of biologics in biologic-experienced
populations. Further research is required to better elucidate the impact of biologics on radiographic disease
progression and HAQ-DI in the long term.
Study registration
This study is registered as PROSPERO CRD42016033357.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of health problem
Psoriatic arthritis (PsA) is a chronic autoimmune disease closely associated with psoriasis of the skin and
nails, but distinct from rheumatoid arthritis (RA). PsA is one of a family of inflammatory arthritis disorders
called spondyloarthritis (or spondyloarthropathy), which also includes ankylosing spondylitis.1 PsA is closely
linked with inflammatory bowel disease, especially the form called Crohns disease.2 Although any joint
may be affected, PsA typically affects joints in the hands, feet and spine. Its course may be erratic, with
flare-ups and remissions, but it can cause joint damage if it is not treated. Early diagnosis is important to
avoid damage to joints.3 Symptoms of arthritis include inflamed (swollen), stiff and painful joints; and
psoriasis symptoms include patchy, raised red areas of inflamed skin with scaling.4
The symptoms of psoriatic arthritis are similar to those of other forms of arthritis. The difference between
PsA and RA is that the pattern of joint involvement is commonly asymmetrical, and involves the distal
interphalangeal joints (in the hands and feet) and nail lesions. The following terms are used to present the
patterns of PsA: oligoarthritis (four or fewer affected joints; 2237% of patients); polyarthritis (five or more
affected joints; 3641% of patients); arthritis of distal interphalangeal joints (< 20% of patients); spondylitis
(723% of patients); and arthritis mutilans (approximately 4% of patients).5,6 Most patients with PsA will
have developed psoriasis first (i.e. joint complications occur around 10 years after initial diagnosis of
psoriasis), although joint involvement appears first in 19% of patients and concurrently with psoriasis in
16% of cases.7
As PsA can affect both skin and joints, it can result in significant quality-of-life impairment, joint deformity
and psychosocial disability.7,8 A recent survey of patients with RA, PsA and axial spondyloarthritis found
that disease burden in terms of patient-reported outcome measures was similar in PsA and axial
spondyloarthritis patients, but significantly lower for the RA patients.9 The physical and psychosocial
problems experienced by patients affect their ability to perform paid work and everyday tasks; PsA has a
substantial economic impact on the UK health-care system as a result of direct health-care costs as well as
indirect costs, such as reduced work capacity.10
Patients with PsA have a 60% higher risk of premature mortality than the general population, with
cardiovascular disease being the leading cause of death.1113 The estimated reduction in life expectancy for
patients with PsA is approximately 3 years,14 with a standardised mortality ratio of 1.62. A Canadian
outpatient clinic study reported that mortality due to cardiovascular disease was 30% higher in patients
with PsA than that in the general population.12
Diagnosis
It is difficult to define PsA because there are no precise diagnostic criteria or diagnostic markers.15
In general, diagnoses are primarily based on patient symptoms and physical examination. In most cases,
Moll and Wrights 1973 criteria16 have been used for diagnosis. Several classification criteria have have been
introduced since Moll and Wrights criteria, but none has been widely accepted or validated. In 2006, the
multicentre Classification Criteria for Psoriatic Arthritis (CASPAR) study developed new classification criteria
that are simple and have both a high sensitivity and a high specificity; they are currently a preferred method
to define cases of PsA (Table 1).17
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Epidemiology
The exact prevalence of PsA is unknown, but estimates vary from 0.3% to 1% of the population. It has
been estimated that in England, in 2013, there were around 53,900161,600 people with PsA. PsA affects
men and women equally, in contrast to RA, which is more common in women.18
Psoriatic arthritis can develop at any time, including childhood,19 but normally it appears between the ages
of 30 and 55 years.18 Its development is a complex process involving both environmental and genetic
factors.2022 Studies show a stronger genetic or family link to PsA than to other autoimmune rheumatic
diseases. Around 40% of people who are diagnosed with PsA and psoriasis also have family members
affected by the disease.2
Measurement of disease
In 2016, the Group for Research and Assessment of Psoriasis and the Psoriatic Arthritis Outcome Measures
in Rheumatology Organisation PsA working group updated the core set of domains to be assessed in
clinical trials to reflect both patient and physician priorities. The domain set includes musculoskeletal
disease activity (which now includes enthesitis, dactylitis and spine symptoms, in addition to peripheral
arthritis), skin disease activity, patient global assessment, pain, physical function, health-related quality of
life (HRQoL), fatigue and systemic inflammation. Four new items were added to the research agenda:
stiffness, independence, treatment burden and sleep.23
Many trials of PsA have used 20% improvement in the American College of Rheumatology criteria (ACR 20)
as the primary outcome;24 the American College of Rheumatology (ACR) criteria were, however, developed
to assess RA. The other outcome assessment tools that have commonly been used in clinical trials are:
l the Psoriatic Arthritis Response Criteria (PsARC), a multidomain measure which has similarities with
ACR criteria but which was developed specifically for PsA
l the Psoriasis Area and Severity Index (PASI), to assess psoriasis
TABLE 1 The Classification Criteria for Psoriatic Arthritis
To meet the CASPAR, a patient must have inflammatory articular disease (joint, spine or entheseal) with three
points or more from the following five categories17
1. Evidence of psoriasis Current psoriasis,a defined as psoriatic skin or scalp disease present today as
judged by a rheumatologist or dermatologist
A personal history of psoriasis, defined as a history of psoriasis that may be
obtained from a patient, family physician, dermatologist, rheumatologist or
other qualified health-care provider
A family history of psoriasis, defined as a history of psoriasis in a first- or
second-degree relative according to patient report
2. Psoriatic nail dystrophy Typical psoriatic nail dystrophy, including onycholysis, pitting and
hyperkeratosis, observed on current physical examination
3. Negative test result for rheumatoid
factor
A negative test result for the presence of rheumatoid factor by any method
except latex but preferably by an enzyme-linked immunosorbent assay or
nephelometry, according to the local laboratory reference range
4. Dactylitis Either current dactylitis, defined as swelling of an entire digit, or a history of
dactylitis recorded by a rheumatologist
5. Radiographic evidence of juxta-articular
new bone formation
Defined as ill-defined ossification near joint margins (but excluding
osteophyte formation) on plain radiographs of the hand or foot
a Current psoriasis is assigned a score of 2; all other features are assigned a score of 1.
BACKGROUND
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l the Health Assessment Questionnaire-Disability Index (HAQ-DI), to assess function (activities of daily living)
l various measures of enthesitis, dactylitis and radiographic progression of disease.
However, there are issues with some assessment tools:
l HAQ-DI concentrates on physical disability, which may not adequately capture disability in patients with
predominantly skin disease. Consequently, there is less change in the context of treatment that has a
predominant effect on the skin and not the joints.25
l PASI has poor sensitivity to change and responsiveness when skin psoriasis is < 10% of body surface
area (BSA) involvement. Furthermore, it has been stated that the correlation with quality-of-life
measures is poor.26 In addition, it is time-consuming and not practically very feasible in daily
clinical practice.
l PsARC identifies only relative changes from baseline and overestimates the number of responders.27
In general, PsARC placebo response rates are higher than other composite measures.28
Current service provision
If PsA is not treated early, the inflammation can affect the whole body, which may lead to lasting joint and
tissue damage.2 The clinical management of PsA therefore aims to suppress joint, tendon and ligament
inflammation, and to manage the skin symptoms of the disease. Current practice involves early diagnosis
and early use of non-steroidal anti-inflammatory drugs (NSAIDs) and/or intra-articular corticosteroid
injections. In patients who do not respond to these treatments, disease-modifying antirheumatic drugs
(DMARDs) are then used [most commonly beginning with methotrexate (MTX)]. When conventional
disease-modifying antirheumatic drugs (cDMARDs) are ineffective, or not tolerated, biologic therapies may
be used; for example, anti-tumour necrosis factor (TNF) therapies, such as etanercept [(ETN) ENBREL®;
Pfizer Inc., New York City, NY, USA], infliximab [(INF) REMICADE®; Merck Sharp & Dohme, Kenilworth, NJ, USA],
adalimumab [(ADA) HUMIRA®; AbbVie Inc., North Chicago, IL, USA] and golimumab [(GOL) SIMPONI®; Merck
Sharp & Dohme, Kenilworth, NJ, USA]. These anti-TNFs are approved by the National Institute for Health and
Care Excellence (NICE). Anti-TNFs have been shown to slow the progression of joint damage when assessed
radiographically.29,30 Ustekinumab [(UST) STELARA®; Janssen Pharmaceuticals, Inc., Horsham, PA, USA]  a
different type of biologic therapy to anti-TNFs [being an interleukin (IL)-12/23 inhibitor]  is also recommended
as a possible treatment, specifically when DMARDs have not worked well enough, provided that treatment with
anti-TNFs is not suitable, or the patient has had an anti-TNF before. Apremilast [(APR) Otezla®; Celgene
Corporation, Summit, NJ, USA], a phosphodiesterase 4 inhibitor, is not currently approved by NICE.
Current NICE guidance relates to the treatment of patients who have had an inadequate response
to two or more cDMARDs (administered either individually or in combination). The British Society for
Rheumatology (BSR)s guidelines make a provision for using a biologic after one DMARD in the presence
of adverse prognostic factors; these are defined as five or more swollen joints in association with an
elevated C-reactive protein (CRP) concentration for more than 3 months and structural joint damage due
to disease.31 Not all patients respond to an initial anti-TNF treatment, and in some patients the response
diminishes over time. One observational study showed that one-third of PsA patients had switched to a
second anti-TNF because of a lack of efficacy and side effects.32 NICE does not specifically recommend
switching anti-TNFs other than the guidance for UST, and switching decisions may depend on local Clinical
Commissioning Group guidelines: in some parts of the country patients are allowed to switch from one
anti-TNF to another.
Quite often PsA goes undetected and is sometimes not recognised and diagnosed by dermatologists or
general practitioners (GPs). In the UK, rheumatologists manage the majority of patients with PsA, but
patients with less severe joint disease may be managed by a dermatologist. However, patients with severe
problems with joints and skin will tend to be managed by both rheumatologists and dermatologists.
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
© Queens Printer and Controller of HMSO 2017. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3
Description of the technology under assessment
Certolizumab pegol (CZP; CIMZIA®, UCB Pharma, Brussels, Belgium) is a biologic therapy (a monoclonal
antibody that targets TNF) that is administered subcutaneously. Anti-TNFs target the activation of tumour
necrosis factor alpha (TNF-α) and subsequently activation of downstream inflammatory processes, and as
such have the potential to offer symptom control as well as altering disease progression. CZP in combination
with MTX has a marketing authorisation in the UK for treating active PsA in adults when the response to
previous DMARD therapy has been inadequate. CZP can be given as monotherapy if MTX cannot be
tolerated or when continued treatment with MTX is inappropriate.
Secukinumab (SEC; COSENTYX®, Novartis International AG, Basel, Switzerland), which is also administered
subcutaneously, is a different type of biologic therapy to CZP, being a monoclonal antibody that targets
the IL-17A cytokine molecule (rather than targeting TNF). SEC, alone or in combination with MTX, is
indicated for the treatment of active PsA in adult patients when the response to previous DMARD therapy
has been inadequate. SEC also has marketing authorisation from the European Medicines Agency for the
treatment of ankylosing spondylitis and moderatesevere plaque psoriasis.
BACKGROUND
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Chapter 2 Definition of the decision problem
The decision problem relates to the optimal use of CZP and SEC within their marketing authorisations fortreating active PsA in adults for whom DMARDs have been inadequately effective. Evaluations are
made at the following points in the treatment pathway:
l patients who have only received one prior non-biological DMARD
l patients whose disease has inadequately responded to at least two DMARDs
l patients whose disease has inadequately responded to both DMARDs and biological therapies.
Previous National Institute for Health and Care Excellence appraisals
There have been no previous NICE technology appraisals (TAs) of CZP or SEC for PsA, although there have
been several appraisals of other biologics for PsA: TA19933 (ETN, INF and ADA), TA22034 (GOL) and
TA34035 (UST). APR, which is not a biologic, is not currently recommended by NICE.
A number of key areas of uncertainty and potential limitations of the evidence base were identified from
the previous appraisals. These include:
l a lack of direct head-to-head trial evidence evaluating the relative efficacy and safety of the biologics
l some limitations in the external validity of the trial populations (i.e. the trial populations had some
differences from populations seen in routine clinical practice)
l a lack of patient registry data for PsA
l the long-term effectiveness of biologics in controlling disease activity
l the prescription cost of biologics and the cost of treating psoriasis at different levels of severity
l the progression of (HAQ-DI) score (a measure of patient function) in patients on and off treatment, and
the length of time biologics are assumed to be effective
l long-term progression of PsA with and without biologics
l a lack of an optimal outcome measure for PsA
l the rate of treatment withdrawal and the adverse effects associated with the long-term use of biologics
l a lack of evidence on the efficacy and safety of the sequential use of biologics.
This assessment has considered and attempted to address these limitations and areas of uncertainty using
relevant evidence where available.
Overall objective of assessment
To determine the clinical effectiveness and cost-effectiveness within the NHS of CZP and SEC within their
marketing authorisations for treating active PsA in adults for whom DMARDs have been inadequately effective.
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Chapter 3 Assessment of clinical effectiveness
This report contains reference to confidential information provided as part of the NICE appraisal process.This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
Methods for reviewing clinical effectiveness
Search strategies
The literature search aimed to identify all relevant randomised controlled trials (RCTs) of CZP and SEC,
and the comparators ETN, ADA, INF, GOL, APR and UST for the treatment of PsA.
The searches for CZP and SEC for PsA were not restricted by date. However, as ETN, ADA, INF, GOL, APR
and UST for PsA had been subject to previous TAs, updated searches were performed based on the search
dates of these previous TAs.
The search strategy was developed in MEDLINE (via Ovid) and then adapted for use in the other resources
searched. The strategy included terms for PsA combined, using the Boolean operator AND, with terms for
the eight treatments. No language or geographical limits were applied. A study design search filter to limit
retrieval to RCTs was used where available.
Search strategies were developed by an information specialist with input from the project team. The
MEDLINE search strategy was checked by a second information specialist. The searches were carried out
during December 2015 and then updated on 28 April 2016 to capture more recent studies.
The following databases were searched: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations,
Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews
(CDSR), Database of Abstracts of Reviews of Effects (DARE), EMBASE, Health Technology Assessment
(HTA) database, PubMed, and the Science Citation Index (SCI).
In addition, the following resources were searched for ongoing, unpublished or grey literature:
ClinicalTrials.gov, Conference Proceedings Citation Index  Science (CPCI-S), EU Clinical Trials Register,
PROSPERO and the World Health Organizations International Clinical Trials Registry Platform portal.
As DARE ceased at the end of March 2015, additional searches for systematic reviews were carried out in
MEDLINE and EMBASE to ensure that any relevant systematic reviews were identified.
Full search strategies can be found in Appendix 1.
Inclusion criteria
Two reviewers independently screened all titles and abstracts. Full manuscripts of any titles/abstracts that
were relevant were obtained, where possible, and the relevance of each study was assessed by two
reviewers according to the inclusion criteria, described below. Any discrepancies were resolved by involving
a third reviewer. Studies available only as abstracts were also included.
Study design
Randomised or quasi-RCTs were eligible for the review of clinical efficacy and safety. For the eligible
interventions (see Interventions), all open-label extension studies of RCTs were included. For the
comparators (see Comparators), open-label extensions were identified and listed with the main focus being
on those studies that reported data relating to the longest duration of follow-up available for each
individual comparator.
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To evaluate the adverse effect profiles of the different biologics, the eligible study designs were systematic
reviews that covered a range of diseases and large observational studies in patients with PsA.
Prospective registry studies that included PsA patients receiving biologics were eligible to provide data on
treatment adherence, treatment withdrawal, and the rates and efficacy of switching to new biologics
(i.e. sequential use). Potentially relevant registry studies were sought and identified, with a focus on those
deemed to be most clinically relevant and appropriate to the UK setting. This decision was based on an
examination of study characteristics and discussion with our clinical adviser.
Studies were also sought on the longer-term natural history of PsA in populations that have not taken a
biologic therapy.
Interventions
Certolizumab pegol and SEC were eligible at their licensed doses (see Table 2). Studies comparing these
two treatments with each other were also eligible.
Comparators
The relevant comparators were:
l placebo
l DMARDs: MTX, sulfasalazine, leflunomide, hydroxychloroquine, azathioprine and ciclosporin
l biologic therapies: ADA, ETN, GOL, INF and UST, including any licensed biosimilars
l APR
l best supportive care (BSC).
Biologics and APR may have been used with or without concomitant DMARDs. Only studies that included
treatments used at their licensed dose were eligible. Head-to-head trials of the five biologic comparators
(and biosimilars) and APR were eligible, but were anticipated to be rare. Therefore, to allow comparisons
of active treatments via network meta-analysis (NMA), the biologic comparators and APR could also have
been compared with either placebo or a DMARD.
Participants
For the evaluation of the effectiveness of CZP and SEC, the included studies were of adults with active PsA
for whom DMARDs had been inadequately effective.
Outcomes
For CZP and SEC, studies reporting any of the following outcomes were eligible:
l disease activity, using the following multidomain measures: PsARC, ACR 20, 50% improvement in the
American College of Rheumatology criteria (ACR 50) and 70% improvement in the American College
of Rheumatology criteria (ACR 70)
l functional capacity (assessed using HAQ-DI)
l radiographic assessment of disease progression
l response of psoriatic skin lesions (assessed using PASI)
l measures of dactylitis, enthesitis and tendonitis
l mortality
l HRQoL, assessed using EuroQol-5 Dimensions (EQ-5D) or Short Form questionnaire-36 items (SF-36)
l adverse effects of treatment, focusing on the key adverse events (AEs) identified from previous studies
of biologics: malignancies, serious infections, reactivation of latent tuberculosis (TB), injection site
reactions and withdrawals due to AEs.
Randomised controlled trials of comparators needed to report at least one of the following: PsARC, ACR
20/50/70, PASI 50 (50% reduction in PASI), PASI 75 (75% reduction in PASI), PASI 90 (90% reduction in
PASI) or HAQ-DI score.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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For patient registry studies, treatment adherence, treatment withdrawal, and the rates and efficacy of
switching to new biologics (i.e. sequential use) were the key outcomes of interest, and particularly those
which were identified as being useful to inform parameters in the economic model.
Data extraction
For SEC and CZP, data were extracted from published papers and abstracts supplemented by data from
the manufacturer submissions (when they were not available from other sources). Data were extracted
from previous single technology appraisal (STA) or multiple technology appraisal (MTA) reports for studies
of ETN, INF, ADA, GOL, UST and APR. When missing or further information on the trials of these
treatments was needed, data were extracted either from the relevant published trial reports or from
reviews.3639 Some data may have been missing in the original TAs because of commercial- or academic-in-
confidence restrictions; and some of these data may have subsequently been published. Data for UST at
the 12-week time point were extracted from the full clinical study reports of PSUMMIT (Study of the Safety
and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis) 1 and 2 trials, which were accessed
via the Yale University Open Data Access (YODA) project. For APR, although only the Psoriatic Arthritis
Long-term Assessment of Clinical Efficacy (PALACE) 1 trial has been published, data from the PALACE 2
and 3 trials were extracted from STA documents on NICEs website. All data for these treatments were
extracted by one reviewer and then checked for any transcription errors by a second reviewer.
For the dichotomous responder outcomes (PsARC, ACR 20/50/70 and PASI 50/75/90), intention-to-treat
(ITT) baseline denominators (i.e. the number of patients randomised for each trial arm) were used, with
patients assumed to be non-responders where data were missing. This explains why there is a small
difference in the ADalimumab Effectiveness in Psoriatic arthritis Trial (ADEPT) denominators used between
this current MTA, the previous MTA and the manufacturers submissions (the last two used the modified
ITT data whereby patients had to have received at least one dose of study treatment).
Data on study design, participant characteristics, efficacy outcomes and quality were extracted by one
reviewer using a standardised data extraction form and independently checked by a second reviewer for
the SEC and CZP trials. Disagreements were resolved through consensus. For the comparator treatments,
most of the data were copied (from previous reports) by one reviewer and then checked for any
transcription errors by a second reviewer.
Attempts were made, where possible, to contact authors for missing data. Data from studies with multiple
publications were extracted and reported as a single study. For the open-label extension studies of
comparator treatments, only the data relating to the latest time point were extracted. Data were also
extracted from the manufacturers submissions when they were not available from other sources.
Quality assessment
The quality of the RCTs was assessed using a modified version of the Cochrane risk-of-bias tool, which
incorporated an assessment of baseline imbalance.40 The assessments of baseline imbalance were made
based on evidence from a systematic review of predictors of treatment response to anti-TNFs.41 The review
identified several possible such predictors in patients with PsA, although none was identified as being
conclusive owing to the limited number of studies and the heterogeneity of response measures. We
looked at baseline CRP concentration, age and sex. The characteristics of young age, male sex and high
CRP concentration may be predictive of a better response. Risk-of-bias assessments were performed by
one reviewer and checked independently by a second reviewer. Any disagreements were resolved through
consensus or by involvement of a third reviewer if necessary. Open-label extension studies were less
formally evaluated. This was based on assessing imputation methods, the patient withdrawal criteria used
and the clinical relevance of any treatment stopping/changing rules.
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Methods of data synthesis
The study characteristics and quality assessment results were tabulated and summarised narratively. Where
possible, the clinical effectiveness data for the PsARC, ACR, PASI and HAQ-DI outcomes were synthesised
using Bayesian NMA methods (see Chapter 4). For other outcomes, or for studies not included in the
NMAs, studies were either summarised narratively or pooled using pairwise meta-analysis methods.
Quantity and quality of the identified evidence
A total of 1761 records were retrieved from the original December 2015 electronic database searches.
The searches were updated on 28 April 2016, with a further 200 records available for screening.
After screening titles and abstracts, full copies of 182 papers were assessed for inclusion in the review.
Two RCTs were excluded at the abstract stage for using unlicensed dosages (50 mg of ETN twice weekly,42
and 20 and 40 mg of APR43). Two RCTs were excluded at the full-paper stage: one did not report
subgroup results for PsA44 and the other included only patients who were naive to MTX.45 The FUTURE
[Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab
(AIN457) in Patients With Active PsA] 1 trial of SEC was excluded from the RCT short-term efficacy review
as it used an unlicensed, very high, loading dose. It was, however, included as an open-label extension
study as the impact of the initial high loading dose would probably be negligible at later time points.46
Fifty open-label studies of comparator treatments were excluded as they did not relate to the latest (longest)
duration of follow-up.
Details of the numbers of other eligible full publications or conference abstracts that relate to open-label
studies of the included RCTs and patient registry or safety studies are presented in Figure 1.
Records identified from
searches and citations
(n = 1961)
Full papers screened
(n = 182)
Excluded on title/abstract
(n = 1782)
RCTs included from 
previous MTAs and STAs
(n = 12)
Excluded
(n = 52)
• OL papers of comparators that did
   not relate to the latest time point,
   n = 50
• RCTs, n = 2
Eligible new papers identified
(n = 130)
• RCTs, n = 19 (including new trials, n = 7)
• OL SEC, n = 42
• OL CZP, n = 23
• OL comparators, n = 31
• Registries, n = 20
• Safety, n = 7
FIGURE 1 Flow chart showing the number of studies identified and eligible for inclusion. OL, open label.
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Characteristics of the randomised controlled trials included in the
systematic review of short-term efficacy
Of the 19 included RCTs, 17 were placebo controlled: one of CZP,47 three of SEC (two of which were
reported in one publication),48,49 one of GOL,50 two of INF,51,52 two of ETN,53,54 three of ADA,5557 two of
UST58,59 and three of APR.60,61 The FUTURE 1 trial of SEC was excluded from the RCT short-term efficacy
review as it used an unlicensed, and very high, loading dose.46
Two trials compared active treatments: one compared SEC with UST62,63 and one compared INF, ETN
and ADA.64
Most studies were conducted mainly in Europe and North America. All but two53,64 were multicentre trials.
Details of the trial durations, different phases and the dosing regimens of the main interventions studied
are presented in Table 2. Details of all interventions studied are presented in Table 3. For some trials we
excluded individual treatment arms from the systematic review (see Table 3). This was as a result of the
doses not being licensed or recommended in the populations studied. Some included trials were excluded
from the NMAs because of the populations being different from the other trial populations (see Table 3).
The design of many trials typically included a fully blinded, placebo-controlled phase followed by an early
escape crossover phase (from placebo to an active treatment) for non-responders, then finally crossover to
active treatment for the remaining placebo participants. Non-response in this context related to failure to
achieve prespecified minimum improvements (ranging between 5% and 20%) in tender joint count (TJC)
and swollen joint count (SJC). All the trials using an early escape design ran for 16 weeks before patients
were eligible for early escape. Trials then entered open-label extension phases (see Long-term effectiveness).
Table 4 describes the population characteristics of the included trials. Where available, this includes
subgroup characteristics for patients who had never previously taken a biologic (i.e. biologic-naive
populations) and patients who had previously taken a biologic (i.e. biologic-experienced populations).
Biologic-experienced patients were available only for the more recent trials (those of SEC, CZP, UST and
APR); in the earlier trials such patients were not eligible to participate. Trial sample sizes varied, with earlier
trials tending to be smaller than more recent trials. Variation in sample size was also evident within
treatments: the two trials of ETN had populations of 60 and 205,53,54 and the three trials of ADA had
populations of 100, 207 and 315.5557,67 The duration of PsA ranged from 3 to 12 years across trials;
the shortest durations (reported as medians) came from the UST PSUMMIT trials58,59,66 and the longest
(reported as means) came from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).51,52
The duration of psoriasis ranged from 11 to 23 years, although this information was not available for the
FUTURE 248 SEC and RAPID-PsA47 (Certolizumab Pegol in Subjects With Adult Onset Active and Progressive
Psoriatic Arthritis) CZP trials. Although not reported in all trials, baseline CRP concentration levels were
difficult to interpret as they appeared to have slightly skewed distributions, with means (range 1031 mg/l)
being generally higher than medians (range 715 mg/l).
Notwithstanding this limited heterogeneity, many key patient characteristics were broadly similar across
trials, including mean ages (which ranged from 45 to 51 years), the proportion of male participants (around
50% for most trials), and TJCs and SJCs (TJC, range 1829; SJC, range 918); an exception was the three-
arm head-to-head trial, which had notably lower TJC and SJC.64 The population in this trial, along with the
PsA populations from the large SEC psoriasis trials,49 also had markedly higher baseline PASI scores than the
other trials (typically around two to three times higher). The FUTURE 2 SEC trial had slightly higher baseline
PASI scores than the other trials, most notably in the 150 mg treatment arm. The PsA populations from two
of the SEC psoriasis trials49 also had lower baseline HAQ-DI scores (range 0.50.8 units) than the other trials
(range 0.91.6 units). In light of these differences, the characteristics of the PsA patients in the SEC psoriasis
trials were deemed to be too dissimilar to the other trials to be included in the NMAs. There were three of
these psoriasis trials: Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
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provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
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TABLE 2 Trial durations (including open-label extensions) and dosing regimens of key interventions studied
Main study
reference and
treatments
studied
Eligible licensed dosing
regimens (with timings)
Duration of truly
randomised and
blinded phase
(before any
treatment crossover) Crossover details
Latest time
point with
available
result data
Anticipated time to response:
information from SPC
FUTURE 2;48 SEC 150-mg subcutaneous injection at
weeks 0, 1, 2 and 3 followed by
monthly maintenance dosing
from week 4. For patients with
concomitant moderatesevere
plaque psoriasis or who are
anti-TNF inadequate responders,
the recommended dose is 300mg
(given as two 150-mg injections)
16 weeks Week 16: PNRs (not achieving ≥ 20%
improvement from baseline in TJC
and SJC) re-randomised to 150 or
300 mg every 4 weeks. Week 24: PRs
re-randomised to 150 or 300 mg every
4 weeks
52 weeks Clinical response is usually achieved
within 16 weeks of treatment.
Consideration should be given to
discontinuing treatment in patients who
have shown no response by 16 weeks
of treatment. Some patients with an
initial partial response may
subsequently improve with continued
treatment beyond 16 weeks
FIXTURE;49 SEC
and ETN
For patients with concomitant
moderatesevere plaque psoriasis
or who are anti-TNF inadequate
responders, the recommended SEC
dose is 300 mg
12 weeks At 12 weeks PNRs were re-randomised
to 150 or 300 mg of SEC
52 weeks
ERASURE;49 SEC
CLEAR;62,63 SEC
and UST
SEC: for patients with concomitant
moderatesevere plaque psoriasis
or who are anti-TNF inadequate
responders, the recommended dose
is 300 mg
UST: 45 mg at week 0, week 4 and
every 12 weeks
52 weeks, but data
currently available only
for up to 16 weeks
No crossovers 52 weeks
RAPID-PsA;47 CZP 200-mg subcutaneous injection
Loading dose: 2 × 200mg at
weeks 0, 2 and 4
Maintenance dose: 200 mg every
2 weeks
Alternative maintenance dose once
clinical response is confirmed can
be considered: 400 mg every
4 weeks
16 weeks Placebo patients failing to achieve
≥ 10% improvement in both TJC and
SJC at both weeks 14 and 16 were
re-randomised to 200 or 400 mg at
week 16. At week 24 the remaining
placebo patients were re-randomised
to 200 or 400 mg
216 weeks Clinical response is usually achieved
within 12 weeks of treatment.
Continued therapy should be carefully
reconsidered in patients who show no
evidence of therapeutic benefit within
the first 12 weeks of treatment
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Main study
reference and
treatments
studied
Eligible licensed dosing
regimens (with timings)
Duration of truly
randomised and
blinded phase
(before any
treatment crossover) Crossover details
Latest time
point with
available
result data
Anticipated time to response:
information from SPC
PALACE 1,
PALACE 2 and
PALACE 3;60,61,65
APR
30mg twice daily, oral tablets 16 weeks At week 16, patients without ≥ 20%
reduction in SJC and TJC were required
to be re-randomised equally to either
APR dose if initially randomised to
placebo or remained on their initial
APR dose. At week 24, all remaining
placebo-treated patients were switched
to APR
104 weeks
(PALACE 1)
During pivotal trials the greatest
improvement was observed within the
first 24 weeks of treatment. If a patient
shows no evidence of therapeutic
benefit after 24 weeks, treatment
should be reconsidered. The patients
response to treatment should be
evaluated on a regular basis
PSUMMIT 1;58 UST 45-mg subcutaneous injection
followed by a 45-mg dose 4 weeks
later, and then every 12 weeks
16 weeks At week 16, patients with < 5%
improvement in TJC/SJC entered
blinded early escape (placebo to 45mg,
45 to 90mg, 90 to 90 mg). At week 24,
all remaining patients in the placebo
group received 45mg of UST, which
they continued at week 28 and every
12 weeks thereafter
108 weeks
for safety and
100 weeks
for efficacy
evaluation
Consideration should be given to
discontinuing treatment in patients
who have shown no response up to
28 weeks of treatment
PSUMMIT 2;59,66
UST
45mg at week 0, week 4, and
every 12 weeks
16 weeks At week 16, patients with < 5%
improvement in TJC/SJC entered
blinded early escape (placebo to 45mg,
45 to 90mg, 90 to 90mg). At week 24,
all remaining patients in the placebo
group received 45mg of UST
100 weeks
GO-REVEAL;50 GOL 50mg once monthly, subcutaneous
injection
16 weeks At week 16, patients with < 10%
improvement in both TJC and SJC
entered blinded early escape (placebo
to 50mg, 50 to 100 mg, 100 to
100 mg). Open label from week 24 (in
which all patients were eligible for GOL)
256 weeks Clinical response is usually achieved
within 1214 weeks of treatment (after
three or four doses). Continued therapy
should be reconsidered in patients who
show no evidence of therapeutic
benefit within this time period
ADEPT;55 ADA 40mg every other week,
subcutaneous injection
24 weeks Open label from 24 weeks (in which all
patients were eligible for ADA)
144 weeks Clinical response is usually achieved
within 12 weeks of treatment.
Continued therapy should be carefully
reconsidered in a patient not
responding within this time period
SPIRIT-P1;57,67 ADA 40mg every other week,
subcutaneous injection
NR NR NR
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TABLE 2 Trial durations (including open-label extensions) and dosing regimens of key interventions studied (continued )
Main study
reference and
treatments
studied
Eligible licensed dosing
regimens (with timings)
Duration of truly
randomised and
blinded phase
(before any
treatment crossover) Crossover details
Latest time
point with
available
result data
Anticipated time to response:
information from SPC
Genovese et al.,
2007;56 ADA
40mg every other week,
subcutaneous injection
12 weeks Open label from 12 weeks (in which all
patients were eligible for ADA)
24 weeks
IMPACT;51 INF 5 mg/kg, i.v. infusion followed by
additional 5 mg/kg infusion doses
at 2 and 6 weeks after the first
infusion, then every 8 weeks
16 weeks At week 16 patients initially assigned to
receive placebo crossed over to receive
5 mg/kg INF
98 weeks NR
IMPACT 2;52 INF 5 mg/kg, i.v. infusion followed by
additional 5 mg/kg infusion doses
at 2 and 6 weeks after the first
infusion, then every 8 weeks
16 weeks At week 16 placebo patients with
< 10% improvement in both TJC and
SJC received 5mg/kg of INF. Open label
from 24 weeks (in which all patients
were eligible for INF)
54 weeks
Mease et al.,
2004;54 ETN
25mg twice weekly,
subcutaneous injection
24 weeks Open label from 24 weeks (in which all
patients were eligible for ETN)
104 weeks Clinical response is usually achieved
within 12 weeks of treatment.
Continued therapy should be carefully
reconsidered in a patient not
responding within this time period
Mease et al.,
2000;53 ETN
25mg twice weekly,
subcutaneous injection
12 weeks Open label from 12 weeks (in which all
patients were eligible for ETN)
36 weeks
Atteno et al.,
2010;64 INF, ETN
and ADA
5mg/kg every 68 weeks of INF;
25 mg of ETN twice weekly; 40 mg
of ADA every other week
52 weeks (blinding
not feasible)
No crossovers 52 weeks See details for trials of INF, ETN and
ADA
CLEAR, Efficacy of Secukinumab Compared to Ustekinumab in Patients with Plaque-type Psoriasis; ERASURE, Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in
Psoriasis; FIXTURE, Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis; GO-REVEAL, Golimumab  A
Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody; i.v., intravenous; NR, not reported; PNR, placebo
non-responder; PR, placebo responder; RAPID-PsA, Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis; SJC, swollen joint count; SPC, Summary of
Product Characteristics; SPIRIT-P1, Study of Ixekizumab in Participants With Active Psoriatic Arthritis; TJC, tender joint count.
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TABLE 3 Treatment doses studied in the review of short-term efficacy
Trial Trialled treatments and doses Doses included in the review Dose included in the NMA Comments
FUTURE 248 75mg of SEC; 150 mg of SEC;
300 mg of SEC; placebo
150mg of SEC; 300 mg of
SEC; placebo
150mg of SEC; 300 mg of SEC;
placebo
75mg is not a licensed dose for PsA
ERASURE49 150mg of SEC; 300mg of SEC;
placebo
300mg of SEC; placebo  The severity of psoriasis seen in the population studied in this
trial (> 30% BSA involvement) suggests that the 150-mg arm
results have very limited relevance to clinical practice (as these
patients are likely to receive 300 mg). Excluded from NMA as
baseline PASI and HAQ-DI scores very different from other trials
FIXTURE49 50mg of ETN twice weekly;
150 mg of SEC; 300mg of SEC;
placebo
300mg of SEC; placebo  The severity of psoriasis seen in the population studied in this
trial (> 30% BSA involvement) suggests that the 150-mg arm
results have very limited relevance to clinical practice (as these
patients are likely to receive 300 mg). Excluded from NMA as
baseline PASI and HAQ-DI scores very different from other
trials. 50 mg of ETN twice weekly excluded as not a licensed
dose in PsA
CLEAR62 300mg of SEC; 45 or 90 mga of
UST
300mg of SEC; 45 or 90 mg of
UST
 Baseline characteristics within the subgroup with PsA were not
reported, therefore it is not clear how severe the psoriasis is
within this subgroup. Excluded from the NMA based on high
mean PASI scores in whole-trial population
SPIRIT-P157,67 80mg of IXE every 2 weeks;
80 mg of IXE every 4 weeks;
40 mg of ADA; placebo
40mg of ADA; placebo 40mg of ADA; placebo IXE is not an eligible treatment for this review
RAPID-PsA47 200mg of CZP every 2 weeks;
400 mg of CZP every 4 weeks;
placebo
200mg of CZP every 2 weeks;
400 mg of CZP every 4 weeks;
placebo
200mg of CZP every 2 weeks;
400 mg of CZP every 4 weeks;
placebo
PALACE 160 20mg of APR; 30 mg of APR;
placebo
30mg of APR; placebo 30mg of APR; placebo 20mg is not a licensed dose
PALACE 265 20mg of APR; 30 mg of APR;
placebo
30mg of APR; placebo 30mg of APR; placebo 20mg is not a licensed dose
PALACE 365 20mg of APR; 30 mg of APR;
placebo
30mg of APR; placebo 30mg of APR; placebo 20mg is not a licensed dose
PSUMMIT 259 45mg of UST; 90 mg of UST;
placebo
45mg of UST; placebo 45mg of UST; placebo The 90-mg arm was excluded as it was not administered as per
the licence for all patients
continued
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TABLE 3 Treatment doses studied in the review of short-term efficacy (continued )
Trial Trialled treatments and doses Doses included in the review Dose included in the NMA Comments
PSUMMIT 166 45mg of UST; 90 mg of UST;
placebo
45mg of UST; placebo 45mg of UST; placebo The 90-mg arm was excluded as it was not administered as per
the licence
Atteno et al.
201064
25mg of ETN; 5 mg/kg INF;
40 mg of ADA
25mg of ETN; 5 mg/kg INF;
40 mg of ADA
 Excluded from the NMA  only 1 year of data are available
GO-REVEAL50 50mg of GOL; 100 mg of GOL;
placebo
50mg of GOL; placebo 50mg of GOL; placebo The 100-mg arm was excluded as it was not administered as
per the licence
Genovese
et al., 200756
40mg of ADA; placebo 40mg of ADA; placebo 40mg of ADA; placebo 
ADEPT55 40mg of ADA; placebo 40mg of ADA; placebo 40mg of ADA; placebo 
IMPACT51 5mg/kg INF; placebo 5 mg/kg INF; placebo 5 mg/kg INF; placebo 
IMPACT 252 5mg/kg INF; placebo 5 mg/kg of INF; placebo 5 mg/kg INF; placebo 
Mease et al.,
200454
25mg of ETN; placebo 25mg of ETN; placebo 25mg of ETN; placebo 
Mease et al.,
200053
25mg of ETN; placebo 25mg of ETN; placebo 25mg of ETN; placebo 
Trials excluded from the main review of short-term efficacy
FUTURE 141 150mg of SEC; placebo   Excluded: used unlicensed loading dose. Safety data from the
manufacturer submission are eligible though
PRESTA42 50mg of ETN twice weekly;
50 mg of ETN once weekly
  Excluded on comparator: not a placebo-controlled trial and
50mg of ETN twice weekly is not a licensed dose
Schett et al.,
201243
20mg of APR; 40 mg of APR;
placebo
  Excluded: did not include licensed dose (30 mg of APR)
CLEAR, Efficacy of Secukinumab Compared to Ustekinumab in Patients with Plaque-type Psoriasis; ERASURE, Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in
Psoriasis; FIXTURE, Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis; GO-REVEAL, Golimumab  A
Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody; IXE, ixekizumab; PRESTA, Psoriasis Randomized Etanercept
study in Subjects with psoriaTic Arthritis; RAPID-PsA, Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis; SPIRIT-P1, Study of Ixekizumab in Participants
With Active Psoriatic Arthritis.
a Dose given as per the licence  according to patient weight.
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TABLE 4 Baseline population characteristics of the included randomised trials
Trial
Characteristic
Trial arm
Number
randomised
Age (years),
mean (SD) % male
Duration of
PsA (years),
mean (SD)
Duration of
psoriasis
(years),
mean (SD)
CRP
concentration
(mg/l) (SD)
TJC,
mean (SD)
SJC,
mean (SD)
HAQ-DI,
mean (SD)
PASI-
evaluable
patients
≥ 3%
BSA (%)
PASI (0–72),
mean (SD)
MTX use at
randomisation
(%)
FUTURE 2;48
all patients
150mg of
SEC
100 46.5 (11.7) 55    Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
58 (58) 16.2 (14.3) 44
300mg of
SEC
100 46.9 (12.6) 51    Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
41 (41) 11.9 (8.4) 44
Placebo 98 49.9 (12.5) 40    Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
43 (44) 11.6 (8.3) 51
FUTURE 2;48
biologic
experienced
SEC; for
pooled
doses
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
FUTURE 2;48
biologic naive
SEC; for
pooled
doses
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
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TABLE 4 Baseline population characteristics of the included randomised trials (continued )
Trial
Characteristic
Trial arm
Number
randomised
Age (years),
mean (SD) % male
Duration of
PsA (years),
mean (SD)
Duration of
psoriasis
(years),
mean (SD)
CRP
concentration
(mg/l) (SD)
TJC,
mean (SD)
SJC,
mean (SD)
HAQ-DI,
mean (SD)
PASI-
evaluable
patients
≥ 3%
BSA (%)
PASI (0–72),
mean (SD)
MTX use at
randomisation
(%)
aERASURE49,68 300mg of
SEC
57 46.1 (12.0) 58  19.7 (12.7)    0.8 (0.8) 57 (100:
subgroup)
21.4 (8.7) 
Placebo 68 48.4 (12.4) 63  22.6 (13.7)    0.8 (0.6) 68 (100:
subgroup)
21.3 (10.1) 
aFIXTURE49 300mg of
SEC
50 47.8 (15.3) 52  21.7 (15.3)    0.7 (0.6) 50 (100:
subgroup)
25.8 (10.9) 
100mg of
ETN per
week
44 46.4 (12.0) 57  22.6 (13.0)    0.7 (0.6) 44 (100:
subgroup)
21.9 (7.5) 
Placebo 49 45.7 (11.6) 55  20.5 (13.1)    0.5 (0.6) 49 (100:
subgroup)
23.7 (8.4) 
aCLEAR62,63 300mg of
SEC
69 Baseline data not available for subgroup (the 123 patients with PsA)
UST 54
SPIRIT-P157,67 ADAb 101 Baseline data not available (trial reported only in conference abstracts)
Placebo 106
RAPID-PsA;47
all patients
200mg of
CZP
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
400mg of
CZP
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
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Trial
Characteristic
Trial arm
Number
randomised
Age (years),
mean (SD) % male
Duration of
PsA (years),
mean (SD)
Duration of
psoriasis
(years),
mean (SD)
CRP
concentration
(mg/l) (SD)
TJC,
mean (SD)
SJC,
mean (SD)
HAQ-DI,
mean (SD)
PASI-
evaluable
patients
≥ 3%
BSA (%)
PASI (0–72),
mean (SD)
MTX use at
randomisation
(%)
RAPID-PsA;47
biologic
experienced
Pooled CZP Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
RAPID-PsA;47
biologic naive
Pooled CZP Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
RAPID-PsA;47
biologic
experienced
(≥ 3% BSA and a
PASI score of
> 10 units at
baseline)
Pooled CZP Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
RAPID-PsA;47
biologic naive
(≥ 3% BSA and a
PASI score of
> 10 units at
baseline)
Pooled CZP Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
PALACE 160,69 30mg of
APR
168 51.4 (11.7) 45 8.1 (8.1) 16.50 (12.3) 8.4 (10.2) 23.1 (14.5) 12.8 (7.8) 1.2 (0.6) 82 (49) 9.2 (9.7) 52
Placebo 168 51.1 (12.1) 52 7.3 (7.1) 15.7 (13.0) 11 (14.4) 23.3 (15.2) 12.8 (8.8) 1.2 (0.6) 68 (41) 9.1 (9.5) 54
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TABLE 4 Baseline population characteristics of the included randomised trials (continued )
Trial
Characteristic
Trial arm
Number
randomised
Age (years),
mean (SD) % male
Duration of
PsA (years),
mean (SD)
Duration of
psoriasis
(years),
mean (SD)
CRP
concentration
(mg/l) (SD)
TJC,
mean (SD)
SJC,
mean (SD)
HAQ-DI,
mean (SD)
PASI-
evaluable
patients
≥ 3%
BSA (%)
PASI (0–72),
mean (SD)
MTX use at
randomisation
(%)
PALACE 261,65,69 30mg of
APR
162 50.5 (11.2) 41 6.8 (7.6) 18.7 (14.5)  21.8 (16.8) 10.3 (8.1) 1.2 (0.6)  7.8 (7.3) 70
Placebo 159 51.2 (11.0) 47 7.8 (8.3) 17.8 (13.9)  18.0 (13.5) 9.2 (6.6) 1.2 (0.6)  8.6 (10.0) 59
PALACE 361,65,69 30mg of
APR
167 49.9 (11.4) 47 7.5 (7.6) 17.1 (12.1)  20.9 (14.4) 11.6 (8.7) 1.2 (0.6)  7.9 (6.3) 50
Placebo 169 49.5 (11.6) 46 6.8 (6.5) 17.8 (13.3)  18.3 (14.9) 11.1 (7.9) 1.2 (0.6)  7.6 (7.2) 54
PSUMMIT 2;59,66
all patients
45mg of
UST
103 49.0 (40, 56)c 47 5.3 (2.3, 12.2)c 13.3
(5.0, 24.4)c
13.0 (4.5, 36.3)c 22 (15, 33)c 12 (8, 19)c 1.4 (0.8, 1.9)c 80 (78) 8.6 (4.5, 18.3)c 52
90mg of
UST
105 48.0 (41, 57)c 47 4.5 (1.7, 10.3)c 11.3
(4.5, 21.4)c
10.1 (4.8, 19.8)c 22 (14, 36)c 11 (7, 17)c 1.3 (0.8, 1.9)c 81 (77) 8.8 (4.5, 18.0)c 50
Placebo 104 48.0
(38.556.0)c
49 5.5 (2.312.2)c 11.4
(6.022.0)c
8.5 (4.6, 22.0)c 21 (1130)c 11 (718)c 1.3 (0.81.8)c 80 (77) 7.9 (4.516.0)c 47
PSUMMIT 2;59,66
biologic
experienced
45mg of
UST
60 49.0 (39, 55)c 38 7.3 (4.1, 13.7)c 15.5
(7.1, 24.7)c
15.0 (4.9, 37.0)c 24.0
(16.5, 40.5)c
14.5
(7.5, 20.5)c
1.4 (0.8, 2.0)c   
90mg of
UST
58 48 (40, 56)c 38 5.7 (2.5, 10.5)c 12.6
(7.3, 23.4)c
10.9 (6.9, 26.8)c 25.5
(17.0, 43.0)c
12.5
(7.0, 19.0)c
1.6 (0.9, 1.9)c   
Placebo 62 48.5 (37, 55)c 50 7.1 (4.1, 12.5)c 12.3
(8.3, 22.4)c
8.7 (4.2, 22.3)c 24.0
(12.0, 31.0)c
11.0
(7.0, 17.0)c
1.3 (0.8, 1.8)c   
PSUMMIT 158,66 45mg of
UST
205 48.0 (39, 55)c 52 3.4 (1.29.2)c 12.0
(4.122.2)c
10.0 (5.9, 21.1)c 18 (1228)c 10 (715)c 1.3 (0.81.8)c 145 (71) 7.1 (3.315.3)c 48
90mg of
UST
204 47.0
(38.554.0)c
57 4.9 (1.78.3)c 14.1
(5.422.4)c
12.3 (6.5, 21.7)c 20 (1232)c 10 (716)c 1.3 (0.81.6)c 149 (73) 8.4 (4.814.7)c 50
Placebo 206 48.0 (39, 57)c 52 3.6 (1.09.7)c 13.1
(5.323.5)c
9.6 (6.0, 18.6)c 22 (1333)c 12 (819)c 1.3 (0.81.8)c 146 (71) 8.8 (4.414.3)c 47
Atteno et al.,
201064
ETN 36 49.3 (13.4)     13 4 1.2 (0.4)b  26 (18.5)b 51
ADA 34 47.5 (11.5)     13 5 1.2 (0.3)b  18 (16.5)b 
INF 30 48.5 (12.9)     12 3 1.5 (0.5)b  15 (14.8)b 
GO-REVEAL50 50mg of
GOL
146 45.7 (10.7) 61 7.2 (6.8) 17.7 (11.9) 13 (16) 24.0 (17.1) 14.1 (11.4) 0.98 (0.65) 109 (75) 9.8 (8.6) 49
Placebo 113 47.0 (10.6) 61 7.6 (7.9) 19.0 (12.9) 13 (16) 21.9 (14.7) 13.4 (9.8) 1.03 (0.55) 79 (70) 8.4 (7.4) 48
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Trial
Characteristic
Trial arm
Number
randomised
Age (years),
mean (SD) % male
Duration of
PsA (years),
mean (SD)
Duration of
psoriasis
(years),
mean (SD)
CRP
concentration
(mg/l) (SD)
TJC,
mean (SD)
SJC,
mean (SD)
HAQ-DI,
mean (SD)
PASI-
evaluable
patients
≥ 3%
BSA (%)
PASI (0–72),
mean (SD)
MTX use at
randomisation
(%)
Genovese
et al., 200756
ADA 51 50.4 (11.0) 57 7.5 (7.0) 18.0 (13.2) 10 (10) 25.3 (18.3) 18.2 (10.9) 0.9 (0.5)   47
Placebo 49 47.7 (11.3) 51 7.2 (7.0) 13.8 (10.7) 16 (17) 29.3 (18.1) 18.4 (12.1) 1.0 (0.7)   47
ADEPT55 ADA 153 48.6 (12.5) 56 9.8 (8.3) 17.2 (12.0) 14 (21) 23.9 (17.3) 14.3 (12.2) 1.0 (0.6) 70 (46) 7.4 (6.0) 51
Placebo 162 49.2 (11.1) 55 9.2 (8.7) 17.1 (12.6) 14 (17) 25.8 (18.0) 14.3 (11.1) 1.0 (0.7) 70 (43) 8.3 (7.2) 50
IMPACT 252 INF 100 47.1 (12.8) 71 8.4 (7.2) 16.2 (11.0) 19 (21) 24.6 (14.1) 13.9 (7.9) 1.1 (0.6) 83 (83) 11.4 (12.7) 47
Placebo 100 46.5 (11.3) 51 7.5 (7.8) 16.8 (12.0) 23 (34) 25.1 (13.3) 14.4 (8.9) 1.1 (0.6) 87 (87) 10.2 (9.0) 45
IMPACT51 INF 52 45.7 (11.1) 58 11.7 (6.6) 16.9 (10.9) 22 (27) 23.7 (13.7) 14.6 (7.5) 1.2 (0.7) 22 (42)d 5.1 (5.9) 46
Placebo 52 45.2 (9.7) 58 11 (6.6) 19.4 (11.6) 31 (38) 20.4 (12.1) 14.7 (8.2) 1.2 (0.7) 17 (33)d 4.2 (5.8) 65
Mease et al.,
200454
ETN 101 47.6 57 9.0 18.3  20.4 ()b 15.9 ()b 1.1 ()b   45
Placebo 104 47.3 45 9.2 19.7  22.1 ()b 15.3 ()b 1.1 ()b   49
Mease et al.,
200053
ETN 30 46.0 (3070)e 53 9.0 (131)e 19.0 (453)e 14 (728)e 22.5 (11, 32)b 14.0 (8, 23)b 1.3 (0.9, 1.6)b 19 (63) 10.1
(2.330.0)d
47
Placebo 30 43.5 (2463)e 60 9.5 (130)e 17.5 (243)e 12 (822)c 19.0 (10, 39)c 14.7 (7, 24)c 1.2 (0.8, 1.6)c 19 (63) 6.0
(1.517.7)e
47
CLEAR, Efficacy of Secukinumab Compared to Ustekinumab in Patients with Plaque-type Psoriasis; ERASURE, Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in
Psoriasis; FIXTURE, Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis; GO-REVEAL, Golimumab  A
Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody; SD, standard deviation; SPIRIT-P1, Study of Ixekizumab in
Participants With Active Psoriatic Arthritis.
a Subgroup data for patients with moderatesevere psoriasis and PsA.
b Main intervention studied was ixekizumab (treatment not eligible for this review).
c Median (25th, 75th percentile; or interquartile range).
d Patients with a baseline PASI score of ≥ 2.5 units.
e Median (range).
Note
Data in italics relate to redactions.
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1
(ERASURE), Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens
to Determine Efficacy in Psoriasis (FIXTURE) and Efficacy of Secukinumab Compared to Ustekinumab in
Patients with Plaque-type Psoriasis (CLEAR; baseline data were not available for the PsA patients in CLEAR).
To be eligible for the ERASURE, FIXTURE and CLEAR trials, patients had to have moderatesevere psoriasis
based on a PASI score of > 12 units and BSA involvement of ≥ 10%.49 In the trials only of patients with PsA,
the proportion of patients with at least moderate psoriasis (i.e. PASI-evaluable patients, defined as a BSA
involvement of ≥ 3%) ranged between 41% and 87%.
In the FUTURE 2 (SEC)48 and RAPID-PsA (CZP)47 trials, the biologic-experienced and biologic-naive
subgroups were broadly similar except that the biologic-experienced subgroups tended to have slightly
higher TJCs and SJCs, and slightly longer durations of PsA.
All the trials of ETN, INF, ADA and GOL and one UST trial58 (nine in total) excluded patients who had
previously received an anti-TNF, so their populations comprised entirely biologic-naive patients (Table 5).
In the remaining trials, where reported, the proportion of biologic-experienced patients ranged from 15%
to 58%. Of the trials that allowed recruitment of biologic-experienced patients, the RAPID-PsA trial47 was
more selective than the FUTURE 2,48 PSUMMIT 259,66 and PALACE trials.60,61,65 RAPID-PsA47 was the only
trial that excluded patients with primary failure of a previous anti-TNF (primary failure was defined as no
response within the first 12 weeks of treatment with the anti-TNF). (See Appendix 2, which details the
eligibility criteria for all trials.) The results for the RAPID-PsA biologic-experienced subgroup may therefore
be somewhat inflated when compared with the other trials reporting results for this subgroup.
Risk-of-bias assessments
The proportion of patients who took concomitant MTX ranged from 44% to 70%; most trials allowed
concomitant MTX although the FIXTURE and ERASURE psoriasis trials49 did not. The reporting of data on
the number of previous DMARDs used was limited, although it appeared that most patients had tried one
or two DMARDs.
The results of the risk-of-bias assessments are presented in Table 6. All except one57,67 of the trials included
in the NMAs were judged as being at low overall risk of bias. Only one trial64 was rated as being at high
overall risk of bias for all outcomes, which was primarily due to lack of blinding. However, blinding would
have been both difficult and impractical as the trial compared INF, ETN and ADA.64 All the other trials were
appropriately blinded. Across the trials the randomisation methods were well reported; only the head-to-
head trial had unclear judgements for both sequence generation and allocation concealment.64 The only
chance imbalance of note occurred in the PSUMMIT 2 trial, in which median CRP concentration levels were
higher in the 45-mg group (13 mg/l) than in the placebo group (8.5 mg/l).59 Two of the three SEC trials in
patients with psoriasis and PsA had overall judgements as being at unclear risk of bias.49 This was because
PsA subgroup data were being assessed and no details were available on missing outcome data. IMPACT 252
was rated as being at high risk of bias for the PASI 75 outcome, as last observation carried forward (LOCF)
was used for missing data (instead of the more conservative non-responder imputation).
Short-term efficacy of secukinumab
The clinical effectiveness evidence identified for SEC consisted of four Phase III RCTs: FUTURE 2, ERASURE,
FIXTURE and CLEAR.48,49,62,63 The FUTURE 2 trial48 was of patients with PsA and the ERASURE,49 FIXTURE49
and CLEAR trials62,63 were trials of patients with psoriasis and reported subgroup data for patients who also
had PsA. The FUTURE 2 trial48 provides the main evidence for SEC. FUTURE 146 studied a non-licensed, very
high, loading dose (10 mg/kg) followed by a 150-mg maintenance dose. Although this trial was therefore
not eligible to contribute data to the review of efficacy of SEC, nor to be included in the evidence
synthesis, it has been used to provide supportive evidence on SEC as, unlike FUTURE 2, it reports data on
radiographic progression of joint damage (see Long-term effectiveness). FUTURE 248 and ERASURE49
compared 150 or 300 mg of SEC with placebo; FIXTURE49 compared 150 or 300 mg of SEC with ETN
(100 mg/week) and placebo; and CLEAR62,63 compared 300 mg of SEC with 45 or 90 mg of UST (dosing
was as per licence, 45 mg in patients weighing ≤ 100 kg and 90 mg for patients weighing > 100 kg).
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 5 Previous and concomitant treatment details for the included studies
Study
Interventions
and dose
Number of prior
DMARDs, mean
Percentage of patients with numbers
of previous DMARDs Previous biologic therapy
Concomitant treatments during
trial (%)
Corticosteroids NSAIDs MTX
FUTURE 248 150mg of SEC   0 = 63%, 1= 26%, 23= 11% 23  44
300mg of SEC   0 = 67%, 1= 16%, 23= 17% 18  44
Placebo   0 = 64%, 1= 16%, 23= 19% 21  51
aERASURE49 300mg of SEC   42% had a prior biologic   
Placebo   44% had a prior biologic   
aFIXTURE49 300mg of SEC   22% had a prior biologic   
100mg of ETN
per week
  18% had a prior biologic   
Placebo   18% had a prior biologic   
aCLEAR62,63 SEC      
UST      
SPIRIT-P157,67 ADA No data available, other than that biologic-experienced patients were excluded from the trial. This trial was reported only as conference
abstracts
Placebo
RAPID-PsA47 200mg of CZP  1 = 44%, ≥ 2= 53% 23% had a prior biologic   64
400mg of CZP  1 = 53%, ≥ 2= 45% 17% had a prior biologic   65
Placebo  1 = 54%, ≥ 2= 44% 19% had a prior anti-TNF   62
PALACE 160 30mg of APR 2% had never received a DMARD 24% had a prior biologic   52
Placebo 4% had never received a DMARD 24% had a prior anti-TNF   54
PALACE 261,65 30mg of APR 3% had never received a DMARD 14% had a prior biologic   70
Placebo 1% had never received a DMARD 15% had a prior biologic   59
continued
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TABLE 5 Previous and concomitant treatment details for the included studies (continued )
Study
Interventions
and dose
Number of prior
DMARDs, mean
Percentage of patients with numbers
of previous DMARDs Previous biologic therapy
Concomitant treatments during
trial (%)
Corticosteroids NSAIDs MTX
PALACE 361,65 30mg of APR All patients had previously received a
DMARD
26% had a prior biologic   50
Placebo All patients had previously received a
DMARD
28% had a prior biologic   54
PSUMMIT 259,66 45mg of UST  14% had never received a DMARD 180 (58%) had a prior anti-TNF 20 70 52
90mg of UST  15 67 50
Placebo  13 74 47
PSUMMIT 158,66 45mg of UST  20% had never received a DMARD Biologic-experienced patients
excluded
18 76 48
90mg of UST  14 74 50
Placebo  16 73 47
Atteno et al., 201064 ETN   Biologic-experienced patients
excluded
  51
ADA    
INF    
GO-REVEAL50 50mg of GOL  0 = 25%, 12 = 69%, > 2= 6% Biologic-experienced patients
excluded
13 75 49
Placebo  0 = 25%, 12 = 66%, > 2= 9% 17 78 48
Genovese et al.,
200756
ADA 1.7 All patients had a history of DMARD
therapy
Biologic-experienced patients
excluded
 73 47
Placebo 2.1  86 47
ADEPT55 ADA 1.5  Biologic-experienced patients
excluded
  51
Placebo 1.5    50
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Study
Interventions
and dose
Number of prior
DMARDs, mean
Percentage of patients with numbers
of previous DMARDs Previous biologic therapy
Concomitant treatments during
trial (%)
Corticosteroids NSAIDs MTX
IMPACT 252 INF  0 = 17%, 12 = 71%, > 2= 12% Biologic-experienced patients
excluded
15 71 47
Placebo  0 = 24%, 12 = 67%, > 2= 9% 10 73 45
IMPACT51 INF  0 = 0%, 1= 52%, 23= 37%, > 3 = 12% Biologic-experienced patients
excluded
17 89 46
Placebo  0 = 2%, 1= 38%, 23= 48%, > 3 = 12% 29 79 65
Mease et al., 200454 ETN 1.6 0 = 27%, 1= 40%, 2= 20% Biologic-experienced patients
excluded
19 88 45
Placebo 1.7 0 = 21%, 1= 50%, 2= 19% 15 83 49
Mease et al., 200053 ETN 1.5  Biologic-experienced patients
excluded
20 67 47
Placebo 2.0  40 77 47
GO-REVEAL, Golimumab  A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody; SPIRIT-P1, Study of Ixekizumab
in Participants With Active Psoriatic Arthritis.
a Subgroup data for patients with moderatesevere psoriasis and PsA.
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TABLE 6 Risk-of-bias judgements for randomised trials (for time points before early escape crossover)
Drug and
trial
Risk-of-bias domain
Overall
judgement
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of outcome
assessment
Incomplete outcome
data
Selective
reporting
SEC; FUTURE 248
Judgement Low Low Low Low Low Low Low Low
Support IVRS used IVRS used 15% difference in the
proportion of males
although this will be a
chance imbalance
(based on
randomisation
methods)
Doses were provided
in identical prefilled
syringes
Doses were provided in
identical prefilled
syringes
More withdrawals in the
placebo group but NRI
and LOCF were used for
missing data
Results reported
for all key
outcomes
SEC; FIXTURE (subgroup)49
Judgement Low Low Unclear Low Low Unclear Low Unclear
Support IVRS used IVRS used No data on CRP levels Adequate blinding
(placebo controlled).
Double-dummy
design used as there
was an active
comparator arm
Adequate blinding
(placebo controlled).
Double-dummy design
used as there was an
active comparator arm
Unclear for the PsA
subpopulation
Results reported
for all key
outcomes
SEC; ERASURE (subgroup)49
Judgement Low Low Unclear Low Low Unclear Low Unclear
Support IVRS used IVRS used No data on CRP levels Adequate blinding
(placebo controlled)
Adequate blinding
(placebo controlled)
Unclear for the PsA
subpopulation
Results reported
for all key
outcomes
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Drug and
trial
Risk-of-bias domain
Overall
judgement
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of outcome
assessment
Incomplete outcome
data
Selective
reporting
SEC; CLEAR62,63
Judgement Low Low Low Low Low Low Low Low
Support IVRS used IVRS used In the psoriasis trial as
a whole, demographic
and disease
characteristics were
similar between
treatment armsa
Treatments looked
identical
Treatments looked
identical
Dropouts for the
subgroup with PsA were
not reported. In the
psoriasis trial as a whole,
there were no
imbalances in dropouts
between groups
Results reported
for key
outcomes
ADA; SPIRIT-P157,67
Judgement Unclear Unclear Unclear Low Low Low Low Unclear
Support Randomisation
sequence not
reported
NR NR Double blind
(subject, caregiver,
investigator,
outcomes assessor)
Double blind (subject,
caregiver, investigator,
outcomes assessor)
NRI was used for
missing data; continuous
data of inadequate
responders were
excluded after 16 weeks
All main
outcomes
reported
CZP; RAPID-PsA47
Judgement Low Low Low Low Low Low Low Low
Support IVRS used IVRS used Balanced Blinded prefilled
syringes were used
Blinded prefilled
syringes were used
NRI and LOCF were used
for missing data
Results reported
for all key
outcomes
APR; PALACE 160,69
Judgement Low Low Low Low Low Low Low Low
Support IVRS used IVRS used Balanced EMA report states
that identical tablets
and blister cards were
used in the APR
psoriasis trialsb
See blinding of
participants and
researchers cell
NRI and LOCF (for the
sensitivity analysis only)
were used
All main
outcomes
reported
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TABLE 6 Risk-of-bias judgements for randomised trials (for time points before early escape crossover) (continued )
Drug and
trial
Risk-of-bias domain
Overall
judgement
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of outcome
assessment
Incomplete outcome
data
Selective
reporting
APR; PALACE 265,69
Judgement Low Low Unclear Low Low Low Low Low
Support IVRS used IVRS used Data not available for
individual trials
As for PALACE 1 As for PALACE 1 NRI and LOCF used.
Similar withdrawal rates
in pooled analysis
All main
outcomes
reported
APR; PALACE 365,69
Judgement Low Low Unclear Low Low Low Low Low
Support IVRS used IVRS used Data not available for
individual trials
As for PALACE 1 As for PALACE 1 NRI and LOCF used.
Similar withdrawal rates
in pooled analysis
All main
outcomes
reported
UST; PSUMMIT 259
Judgement Low Low Unclear Low Low Low Low Low
Support IVRS used IVRS used Chance imbalance in
median CRP levels
(placebo, 8.5 mg/l, vs.
45 mg of UST,
13.0 mg/l)
Based on details in
table 9 of Craig et al.s
2013 UST STA66
Based on details in
table 9 of Craig et al.s
2013 UST STA66
Low dropout rate. NRI
for ACR and PASI and
LOCF for change in
HAQ-DI score.
Otherwise, missing data
were not imputed for
the rest of the outcomes
All main
outcomes
reported
But
important
imbalance,
likely due to
chance
UST; PSUMMIT 166
Judgement Low Low Low Low Low Low Low Low
Support IVRS used IVRS used Balanced Based on details in
table 9 of Craig et al.s
2013 UST STA66
Based on details in
table 9 of Craig et al.s
2013 UST STA66
Low dropout rate. NRI
and LOCF used
All main
outcomes
reported
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Drug and
trial
Risk-of-bias domain
Overall
judgement
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of outcome
assessment
Incomplete outcome
data
Selective
reporting
INF vs. ETN vs. ADA; Atteno et al., 201064
Judgement Unclear Unclear Unclear High High Unclear Unclear High
Support Study drugs
were randomly
given
Study drugs
were
randomly
given
No data on CRP levels Head-to-head trial of
treatments with
different regimens
Head-to-head trial of
treatments with
different regimens
No information on
withdrawals nor on
imputation methods
No prior
registration
GOL; GO-REVEAL50
Judgement Low Low Low Low Low Low Low Low
Support IVRS used IVRS used Balanced Based on text in Yang
et al.s full STA
report70
Based on text in Yang
et al.s full STA report70
Although there was
insufficient detail on
imputation methods,
there were few dropouts
(and balanced across
groups)
All main
outcomes
reported
ADA; Genovese et al., 200756
Judgement Low Low Low Low Low Low Low Low
Support Based on
details in table
10 of Rodgers
et al.33
Based on
details in
table 10 of
Rodgers
et al.33
Balanced Based on details in
table 10 of Rodgers
et al.33
Based on details in
table 10 of Rodgers
et al.33
NRI and LOCF were used
for missing data
Results reported
for all key
outcomes
ADA; ADEPT55
Judgement Low Unclear Low Low Low Low Low Low
Support Based on
details in table
10 of Rodgers
et al.33
NR Balanced Based on details in
table 10 of Rodgers
et al.33
Based on details in
table 10 of Rodgers
et al.33
NRI was used for
missing data. In
addition, similar levels of
dropout across groups
and similar reasons
Results reported
for all key
outcomes
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TABLE 6 Risk-of-bias judgements for randomised trials (for time points before early escape crossover) (continued )
Drug and
trial
Risk-of-bias domain
Overall
judgement
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of outcome
assessment
Incomplete outcome
data
Selective
reporting
INF; IMPACT 252
Judgement Low Low Unclear Low Low High Low High, PASI
75; low,
other
outcomes
Support Based on
details in table
6 of Rodgers
et al.33
Based on
details in
table 6 of
Rodgers
et al.33
20% difference in
proportion of males
although this will be a
chance imbalance
(based on
randomisation
methods)
Based on details in
table 6 of Rodgers
et al.33
Based on details in
table 6 of Rodgers
et al.33
NRI was used for
missing PsARC and ACR
20 data. LOCF used for
PASI 75. Unclear for
HAQ-DI (appears to be
LOCF)
Results for all
key outcomes
reported
INF; IMPACT51
Judgement Low Low Low Low Low Low Low Low
Support Based on
details in table
6 of Rodgers
et al.33
Based on
details in
table 6 of
Rodgers
et al.33
Mean CRP levels were
31 mg/l for placebo
and 22mg/l for INFc
Based on details in
table 6 of Rodgers
et al.33
Based on details in
table 6 of Rodgers
et al.33
Very few dropouts Results for all
key outcomes
reported
Low
ETN; Mease et al., 200454
Judgement Low Low Unclear Low Low Low Low Low
Support Based on
details in table
2 of Rodgers
et al.33
Based on
details in
table 2 of
Rodgers
et al.33
12% difference in
proportion of males
although this will be a
chance imbalance
(based on
randomisation
methods)
Based on details in
table 2 of Rodgers
et al.33
Based on details in
table 2 of Rodgers
et al.33
More withdrawals in the
placebo group; NRI and
LOCF were used for
missing data
Results reported
for all key
outcomes
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Drug and
trial
Risk-of-bias domain
Overall
judgement
Sequence
generation
Allocation
concealment
Important baseline
imbalance
Blinding of
participants and
researchers
Blinding of outcome
assessment
Incomplete outcome
data
Selective
reporting
ETN; Mease et al., 200053
Judgement Low Low Low Low Low Low Low Low
Support Based on details
in table 2 of
Rodgers et al.33
Based on
details in
table 2 of
Rodgers
et al.33
Balanced Based on details in
table 2 of Rodgers
et al.33
Based on details in
table 2 of Rodgers
et al.33
Although LOCF was
used for missing data
(no NRI), there were
only four dropouts, all in
the placebo group
Results reported
for all key
outcomes
EMA, European Medicines Agency; GO-REVEAL, Golimumab  A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal
Antibody; IVRS, interactive voice-/web-response system; NR, not reported; NRI, non-responder imputation; SPIRIT-P1, Study of Ixekizumab in Participants With Active Psoriatic Arthritis.
a Baseline characteristics for the PsA subgroup were not reported.
b Assumed to be the same for the placebo-controlled trials in PsA.
c Medians of 14.0 and 9.9 mg/l, respectively (p= 0.15).
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1
There are three relevant ongoing trials for which results are not yet available (Table 7).
As previously discussed, the baseline characteristics of the ERASURE, FIXTURE and CLEAR49,62,63 subgroup
populations were different to the baseline characteristics of the other trials. The patients in these trials had
much higher baseline PASI scores and notably lower baseline HAQ-DI scores than the other trials,
suggesting that these patients had more severe psoriasis and less severe arthritis symptoms (see Table 4).
The FUTURE 248 and CLEAR62,63 trials were judged as being at a low overall risk of bias with an unclear risk
of overall judgements for ERASURE49 and FIXTURE49 (see Table 6).
FUTURE 2 trial
Tables 8 and 9 show FUTURE 2 trial48 results for the key review outcomes for the full-trial population
across the 12-, 16- and 24-week time points. Results for the biologic-naive and biologic-experienced
subgroups are presented in Tables 10 and 11. The corresponding relative risks (RRs) for the dichotomous
outcomes were calculated by the Evidence Review Group (ERG) and are presented in Table 12.
Efficacy at 12–24 weeks in the full-trial population
For the whole-trial population, SEC was associated with statistically significant improvements in all
outcomes at all time points. Patients taking SEC were around six times more likely to be ACR 50
responders  an outcome of particular clinical importance to patients  than patients taking placebo.
An increase in RRs is apparent when looking across the PsARC, ACR 20, ACR 50 and ACR 70 columns in
Table 12. These increases in RR are likely to be a consequence of the different placebo rates, with higher
rates for the lower threshold outcomes (see the placebo rates in Table 8). The lower threshold outcomes
(such as PsARC and ACR 20) appear to underestimate efficacy because the RRs tend to be diluted by the
high placebo response rates. This association of higher placebo responses with lower relative efficacy was
also noted across trials by outcome in the evidence synthesis and is discussed in Chapter 4.
FUTURE 248 trial patients taking 150 or 300 mg of SEC were also around six to seven times more likely to
be PASI 50 responders than patients taking placebo. Efficacy was also demonstrated for the higher PASI
thresholds (PASI 75 and PASI 90), with the 300-mg group having only slightly higher RRs than the
150-mg group.
TABLE 7 Ongoing trials of SEC in patients with active PsA
Trial name and
ClinicalTrials.gov reference Purpose of trial
FUTURE 3;71 NCT01989468 To provide 24- to 52-week efficacy, safety and tolerability data, as well as up to 3-year
efficacy, safety and tolerability data, in subjects with active PsA despite current or
previous NSAID, DMARD therapy and/or previous anti-TNF therapy using an
autoinjector. Initial data were due to be published in 2016. Estimated primary
completion date: January 2018
FUTURE 4;72 NCT02294227 To provide 16-week efficacy, safety and tolerability data vs. placebo to support the use
of 150 mg of SEC by subcutaneous self-administration with or without a loading
regimen and maintenance dosing using prefilled syringe and to assess efficacy, safety
and tolerability up to 2 years in subjects with active PsA despite current or previous
NSAID, non-biologic DMARD or biologic anti-TNF-α therapy. Recruitment closed
(nine patients in the UK), but the study is still active. Estimated primary completion
date: December 2017
FUTURE 5;73 NCT02404350 To demonstrate efficacy including effect on inhibition of progression of structural
damage, safety and tolerability up to 2 years with primary focus at week 24, to
support the use of SEC prefilled syringe by subcutaneous self-administration with or
without loading regimen in subjects with active PsA despite current or previous NSAID,
DMARD therapy and/or previous anti-TNF therapy. Patient recruitment began in 2015.
Estimated primary completion date: May 2019
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TABLE 8 Psoriatic Arthritis Response Criteria, ACR and HAQ-DI responses in the FUTURE 2 trial48
Population Drug
Time
point
(weeks)
Number of
patients
randomised
Responders, n (%) HAQ-DI
change from
baseline (SE)PsARC ACR 20 ACR 50 ACR 70
All 300 mg
of SEC
12 100 Confidential
information
has been
removed
57 (57) 30 (30)  
150mg
of SEC
100 Confidential
information
has been
removed
56 (56) 32 (32)  
Placebo 98 Confidential
information
has been
removed
25 (26) 5 (5)  
All 300 mg
of SEC
16 100 69 (69) 57 (57) 30 (30)  
150mg
of SEC
100 72 (72) 60 (60) 32 (32)  
Placebo 98 41 (42) 18 (18) 5 (5)  
All 300 mg
of SEC
24 100 Confidential
information
has been
removed
54 (54) 35 (35) 20 (20) 0.56 (0.05)
150 mg
of SEC
100 Confidential
information
has been
removed
51 (51) 35 (35) 21 (21) 0.48 (0.05)
Placebo 98 Confidential
information
has been
removed
15 (15) 7 (7) 1 (1) 0.31 (0.06)
SE, standard error.
TABLE 9 Psoriasis Area and Severity Index response rates in the FUTURE 2 trial48
Population Drug
Time point
(weeks)
Number of patients
with psoriasis
affecting ≥ 3% of BSA PASI 50 PASI 75 PASI 90
All 300 mg of SEC 12 41 34 (83%) 24 (59%) 16 (39%)
150mg of SEC 58 48 (83%) 31 (53%) 19 (33%)
Placebo 43 5 (12%) 2 (5%) 2 (5%)
All 300 mg of SEC 16 41 36 (88%)  
150mg of SEC 58 48 (83%)  
Placebo 43 6 (14%)  
All 300 mg of SEC 24 41  26 (63%) 20 (49%)
150mg of SEC 58  28 (48%) 19 (33%)
Placebo 43  7 (16%) 4 (9%)
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TABLE 10 Psoriatic Arthritis Response Criteria and ACR response rates for biologic-naive and biologic-experienced
subgroups in the FUTURE 2 trial48
Population Drug
Time
point
(weeks)
Number of
patients
randomised PsARC ACR 20 ACR 50 ACR 70
Biologic naive 300 mg of SEC 12 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
150mg of SEC Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Biologic
experienced
300mg of SEC 12 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
150mg of SEC Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Biologic naive 300 mg of SEC 16 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
150mg of SEC Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Biologic
experienced
300mg of SEC 16 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
150mg of SEC Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Biologic naive 300 mg of SEC 24 67  39 (58%) 26 (39%) 15 (22%)
150mg of SEC 63  40 (63%) 28 (44%) 17 (27%)
Placebo 63  10 (16%) 4 (6%) 1 (2%)
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TABLE 10 Psoriatic Arthritis Response Criteria and ACR response rates for biologic-naive and biologic-experienced
subgroups in the FUTURE 2 trial48 (continued )
Population Drug
Time
point
(weeks)
Number of
patients
randomised PsARC ACR 20 ACR 50 ACR 70
Biologic
experienced
300mg of SEC 24 33  15 (45%) 9 (27%) 5 (15%)
150mg of SEC 37  11 (30%) 7 (19%) 4 (11%)
Placebo 35  5 (14%) 3 (9%) 0 (0%)
TABLE 11 Psoriasis Area and Severity Index response rates for biologic-naive and biologic-experienced subgroups in
the FUTURE 2 trial48
Population Drug
Time
point
(weeks)
Number of
patients with
psoriasis
affecting
≥ 3% of BSA PASI 50 PASI 75 PASI 90
Biologic naive 300 mg of SEC 12 30 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
150mg of SEC 36 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Placebo 31 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Biologic
experienced
300mg of SEC 12 11 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
150mg of SEC 22 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Placebo 12 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Biologic naive 300 mg of SEC 16 30  21 (70%) 15 (50%)
150mg of SEC 36  23 (64%) 16 (44%)
Placebo 31  3 (10%) 3 (10%)
Biologic
experienced
300mg of SEC 16 11  6 (55%) 3 (27%)
150mg of SEC 22  10 (45%) 6 (27%)
Placebo 12  0 (0%) 0 (0%)
Biologic naive 300 mg of SEC 24 30  19 (63%) 16 (53%)
150mg of SEC 36  20 (56%) 14 (39%)
Placebo 31  6 (19%) 3 (10%)
Biologic
experienced
300mg of SEC 24 11  7 (64%) 4 (36%)
150mg of SEC 22  8 (36%) 5 (23%)
Placebo 12  1 (8%) 1 (8%)
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TABLE 12 Relative risks for key dichotomous outcomes in the FUTURE 2 trial:48 150 or 300mg of SEC vs. placebo
Treatment
Time point
(weeks) Population
RR (95% CI)
PsARC ACR 20 ACR 50 ACR 70 PASI 50 PASI 75 PASI 90
150mg of SEC 12 All 1.73
(1.31 to 2.29)
2.20
(1.50 to 3.21)
6.27
(2.55 to 15.43)
NR 7.12
(3.10 to 16.36)
11.49
(2.91 to 45.42)
7.04
(1.73 to 28.64)
16 1.72
(1.32 to 2.24)
3.27
(2.09 to 5.11)
6.27
(2.55 to 15.43)
NR 5.93
(2.80 to 12.57)
NR NR
24 Confidential
information has
been removed
3.33
(2.01 to 5.51)
4.90
(2.29 to 10.50)
20.58
(2.82 to 150.06)
NR 2.97
(1.43 to 6.14)
3.52
(1.29 to 9.61)
300 mg of SEC 12 All 1.81
(1.38 to 2.38)
2.23
(1.53 to 3.26)
5.88
(2.38 to 14.53)
NR 7.13
(3.09 to 16.45)
12.59
(3.17 to 49.91)
8.39
(2.06 to 34.24)
16 1.65
(1.26 to 2.16)
3.10
(1.98 to 4.87)
5.88
(2.38 to 14.53)
NR 6.29
(2.97 to 13.33)
NR NR
24 Confidential
information has
been removed
3.53
(2.14 to 5.81)
4.90
(2.29 to 10.50)
19.60
(2.68 to 143.24)
NR 3.90
(1.90 to 7.98)
5.24
(1.96 to 14.04)
150 mg of SEC 12 Biologic naive Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
16 NR Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NR Confidential
information has
been removed
Confidential
information has
been removed
24 Confidential
information has
been removed
4.00
(2.20 to 7.28)
7.00
(2.61 to 18.80)
17.00
(2.33 to 123.91)
NR 2.87
(1.32 to 6.23)
4.02
(1.27 to 12.70)
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Treatment
Time point
(weeks) Population
RR (95% CI)
PsARC ACR 20 ACR 50 ACR 70 PASI 50 PASI 75 PASI 90
300mg of SEC 12 Biologic naive Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
16 NR Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NR Confidential
information has
been removed
Confidential
information has
been removed
24 Confidential
information has
been removed
3.67
(2.01 to 6.71)
6.11
(2.26 to 16.53)
14.10
(1.92 to 103.68)
NR 3.27
(1.52 to 7.06)
5.51
(1.79 to 17.00)
300 mg of SEC 12 Biologic
experienced
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
16 NR Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NR Confidential
information has
been removed
Confidential
information has
been removed
24 Confidential
information has
been removed
3.18
(1.30 to 7.77)
3.18
(0.62 to 10.75)
11.65
(0.67 to 202.75)
NR 7.64
(1.11 to 52.56)
4.36
(0.57 to 33.32)
CI, confidence interval; NR, not reported.
Note
Results for the 150-mg biologic-experienced subgroup are not presented as licence states that biologic-experienced patients should take 300 mg.
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All three study arms showed improvements in physical function as assessed using HAQ-DI change from
baseline scores; HAQ-DI assesses a patients ability to perform eight categories of activities of daily living.
Patients taking SEC had greater reductions in HAQ-DI scores than patients taking the placebo (see Table 8).
At 24 weeks, the difference when compared with placebo (0.25 units) was statistically significant for
300 mg (p = 0.004), but the difference of 0.17 units for 150 mg did not quite reach statistical significance
(p = 0.055).48 The manufacturer also submitted HAQ-DI results based on PsARC responder status (Table 13).
These results show (confidential information has been removed).
Efficacy in the biologic-naive and biologic-experienced subgroups
Table 12 also presents RRs for the subgroups based on patients previous use of biologics. These subgroup
results are difficult to interpret for several reasons. Some of the subgroup sample sizes were particularly
small: there were no placebo responders (PRs) for some outcomes in the biologic-experienced subgroup
and the RR confidence intervals (CIs) were therefore extremely wide. The PASI results are effectively based
on subgroups (previous biologic status) of a subgroup (patients with psoriasis covering ≥ 3% of BSA).
Placebo response rates also differed across subgroups (see Evaluating the secukinumab and certolizumab
pegol trial results in comparison with other treatments). Similar subgroup issues were also seen for CZP
(see Efficacy in the RAPID-PsA biologic-naive and biologic-experienced subgroups).
The manufacturer also submitted HAQ-DI results based on PsARC responder status for the biologic-naive
and biologic-experienced population (Table 14). Again, comparisons between the two subgroups is difficult
as (confidential information has been removed).
Other efficacy results
Efficacy of secukinumab with or without concomitant methotrexate
Just under half of the patients in FUTURE 248 took concomitant MTX. In exploratory post hoc analyses,
SEC was found to be similarly efficacious whether or not patients were taking concomitant MTX.48 For
ACR 50, response rates were statistically significantly higher in the 300- and 150-mg groups than in the
placebo group for both the concomitant MTX subgroup (p = 0.001 and p = 0.006, respectively) and the no
concomitant MTX subgroup (p = 0.007 and p < 0.0001, respectively). Similar statistically significant
differences were also reported for the ACR 20 and 70 thresholds.48
Efficacy of secukinumab in the one prior DMARD subgroup
Data were presented in the manufacturers submission at week 24 for efficacy in the one prior DMARD
subgroup. (Confidential information has been removed.)
TABLE 13 Health Assessment Questionnaire-Disability Index changes based on PsARC responder status in the
FUTURE 2 trial48
Population
Time point
(weeks)
Group, HAQ-DI change (SE)
Placebo 150 mg 300 mg
Responders
Non-
responders Responders
Non-
responders Responders
Non-
responders
All 12 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
16 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
SE, standard error.
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Efficacy in treating dactylitis and enthesitis
At week 24, relative to placebo treatment with both 150 and 300 mg of SEC statistically significantly
improved the resolution of both dactylitis (as measured via the Leeds Dactylitis Index; LDI) and enthesitis
(as measured via the Leeds Enthesitis Index; LEI) (Table 15).
Health-related quality of life
Up to week 24, improvement in the EQ-5D overall health state (as measured by a visual analogue scale;
VAS) was higher in both SEC groups (150 and 300 mg) than in the placebo group. (Confidential
information has been removed.)
At week 24, self-reported quality of life and physical functioning, as measured by SF-36 Physical
Component Summary score, was found to have improved more in the SEC groups than in the placebo
group (SEC 150 mg, 6.39 points; SEC 300 mg, 7.25 points; placebo, 1.95 points).
Mortality
No deaths were reported during the trial.
ERASURE and FIXTURE trials
As the focus of the ERASURE and FIXTURE trials49 was on patient populations with psoriasis (subgroups of
which also had PsA), fewer outcomes that were relevant to this assessment were evaluated. Patients recruited
TABLE 14 Health Assessment Questionnaire-Disability Index changes based on PsARC responder status for
biologic-naive and biologic-experienced subgroups in the FUTURE 2 trial48
Population
Time point
(weeks)
Group, HAQ-DI change (SE)
Placebo 150 mg 300 mg
Responders
Non-
responders Responders
Non-
responders Responders
Non-
responders
Biologic
naive
12 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
16 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
24 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Biologic
experienced
12 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
16 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
24 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
SE, standard error.
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into in the ERASURE and FIXTURE trials had more severe psoriasis but lower baseline HAQ-DI scores than the
patients recruited into the FUTURE 2 trial and into the other trials included in the systematic review (see Table 4).
The FIXTURE trial was one of the very few identified in the systematic review that compared different biologics
(SEC with ETN).
Table 16 and Figure 2 (in which data from the ERASURE and FIXTURE trials have been pooled) illustrate
SECs superiority over placebo for the PASI outcomes. In the FIXTURE trial at 12 weeks, 300 mg of SEC was
statistically significantly more effective than 50 mg of ETN twice weekly in terms of patients achieving a
PASI 75 response (RR 1.86, 95% CI 1.24 to 2.81) and a PASI 90 response (RR 2.42, 95% CI 1.20 to 4.88).
Changes from baseline in the HAQ-DI scores were greater in SEC- and ETN-treated patients in ERASURE
and FIXTURE trials than with placebo.
CLEAR trial
The CLEAR trial,62,63 which compared SEC with UST, was similar to the ERASURE and FIXTURE trials49 with
respect to the population studied (patients with more severe psoriasis than those recruited into the FUTURE 2
trial) and the limited data assessed and reported (in the CLEAR trial only PASI 90 and HAQ-DI scores were
reported for the subgroup of patients with PsA).
TABLE 15 Efficacy in treating dactylitis and enthesitis in the FUTURE 2 trial48
Outcome
Trial arm
300mg of SEC 150mg of SEC Placebo
Resolution of dactylitis
at week 24
Confidential information has
been removed; p= 0.0021
Confidential information has
been removed; p = 0.0056
Confidential information
has been removed
Resolution of enthesitis
at week 24
Confidential information has
been removed; p= 0.0025
Confidential information has
been removed; p = 0.0108
Confidential information
has been removed
Dactylitis count at
week 16, mean change
from baseline± SD
2.3 ± 4.0 3.1 ± 4.5 0.6 ± 2.4
Enthesitis count at
week 16, mean change
from baseline± SD
1.7 ± 1.8 1.5 ± 2.0 0.9 ± 2.1
SD, standard deviation.
TABLE 16 Efficacy outcomes in the ERASURE and FIXTURE trials at 12 weeks49
Trial Treatment
Number of
PsA patients PASI 50 PASI 75 PASI 90
HAQ-DI change
from baselinea
ERASURE49 300mg of SEC 57  38 (67%) 30 (53%) 0.35
150mg of SEC 46  32 (70%) 20 (43%) 0.18
Placebo 68  3 (4%) 0 (0%) 0.08
FIXTURE49 300mg of SEC 50  36 (72%) 22 (44%) 0.41
150mg of SEC 49  29 (59%) 19 (39%) 0.19
50mg of ETN 44  17 (39%) 8 (18%) 0.29
Placebo 49  1 (2%) 1 (2%) 0.02
a Standard errors not reported.
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At 16 weeks, patients treated with 300 mg of SEC had a better PASI 90 response rate than patients
receiving 45 or 90 mg of UST, although the difference was not statistically significant (RR 1.23, 95% CI
0.98 to 1.55; p = 0.08). Patients treated with 300 mg of SEC had a greater improvement in HAQ-DI score
than patients receiving 45 or 90 mg of UST (Table 17).
Summary
The results of the FUTURE 2 trial48 demonstrated the short-term efficacy of SEC in treating PsA. When
considering the whole-trial population, SEC was associated with statistically and clinically significant
improvements in all key outcomes. Patients taking SEC were around six times more likely to be ACR 50
responders  a key clinical outcome to patients  than patients taking placebo. Clinically important
improvements in activities of daily living (assessed using the HAQ-DI) were also evident in patients taking
SEC, particularly in patients who were PsARC responders. However, when the trial population was split
into subgroups based on previous biologic experience, the resulting RRs for the biologic-experienced
subgroup became difficult to interpret. This was attributable to both the low numbers of placebo patients
and the differences in placebo response rates across subgroups (see Evaluating the secukinumab and
certolizumab pegol trial results in comparison with other treatments). Although SEC is efficacious in both
subgroups, it is not possible to make robust conclusions about any difference in the efficacy of SEC across
these subgroups. Similar efficacy across the ACR outcomes was evident in subgroups of patients based on
presence or absence of concomitant MTX, although limited data and analyses were available specifically
for the one prior DMARD group. Treatment with SEC resulted in statistically significant improvements in
HRQoL measures and in the resolution of both dactylitis and enthesitis.
Results from the trials of patients with more severe psoriasis demonstrated SECs superiority over placebo
in terms of psoriasis (as measured by the PASI) and function (as measured by the HAQ-DI) outcomes. SEC
was also found to be significantly more effective than ETN in improving psoriasis (assessed using PASI 75
and PASI 90). However, the populations studied in these trials had quite severe psoriasis and less
functional impairment (lower baseline HAQ-DI scores) than other trial populations. Their results should not
therefore be generalised to more typical PsA populations.
Trial
SEC 
300 mg Placebo Risk ratio
M–H, fixed, 95% CI
Risk ratio
M–H, fixed, 95% CIWeight
ERASURE49
FIXTURE49
15.11 (4.92 to 46.38)
33.84 (4.83 to 237.06)
0.1
72.6%
27.4%
Total (95% CI)
Total events
Heterogeneity: χ2 = 0.53, df = 1 (p = 0.47): I2 = 0%
Test for overall effect: z = 5.98 (p < 0.00001)
TotalEvents
57
50
38
38
107
74
TotalEvents
68
47
3
1
115
4
20.24 (7.56 to 54.19)100%
0.01 101
Favours placebo Favours SEC
100
FIGURE 2 Forest plot of the efficacy of 300mg of SEC vs. placebo for PASI 75 at 12 weeks in PsA patients with
moderate–severe psoriasis.49 df, degrees of freedom; M–H, Mantel–Haenszel.
TABLE 17 Efficacy outcomes in the CLEAR trial62,63 at 16 weeks for the subgroup of PsA patients
Treatment
Number of patients
randomised PASI 50 PASI 75 PASI 90 HAQ-DI change from baselinea
300mg of SEC 69   55 (80%) 0.29
45 or 90 mg of UST 54   35 (65%) 0.13
a Standard errors not reported.
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Short-term efficacy of certolizumab pegol
One eligible RCT of CZP was identified. RAPID-PsA47 compared 200 or 400 mg of CZP against placebo up
to 24 weeks. The trial was dose blinded to 48 weeks and then open label to 216 weeks. Placebo patients
who failed to achieve a 10% improvement from baseline in both swollen and tender joints at week 14
and 16 were re-randomised to active treatment at week 16. At week 24, all the remaining placebo
patients were re-randomised to receive 200 or 400 mg of CZP. The RAPID-PsA47 trial was judged as being
at low overall risk of bias (see Table 6).
Compared with the other PsA trials, the RAPID-PsA trial was more selective in recruiting biologic-
experienced patients; patients with primary failure of a previous anti-TNF were excluded (primary failure
was defined as no response within the first 12 weeks of treatment with the anti-TNF).
There are no UCB Pharma-sponsored ongoing studies of CZP in patients with PsA.
Tables 18 and 19 show the RAPID-PsA trial results47 for the key review outcomes for the full-trial
population across the 12-, 16- and 24-week time points. ACR 20 results, split into subgroups according to
the number of previous DMARDs taken by patients, are presented in Table 20. Results for the biologic-
naive and biologic-experienced subgroups are presented in Tables 21–24. The corresponding RRs for the
dichotomous outcomes were calculated by the ERG and are presented in Table 25.
TABLE 18 Psoriatic Arthritis Response Criteria, ACR and HAQ-DI responses in the RAPID-PsA trial47
Population Treatment
Time
point
(weeks)
Number of
patients
randomised
Responders, n (%) HAQ-DI
change
from baseline
(SE)PsARC ACR 20 ACR 50 ACR 70
All 200 mg of
CZP every
fortnight
12 138 101 (73) 80 (58) 50 (36) 34 (25) 0.45 (0.56)
400 mg of
CZP once a
month
135 89 (66) 70 (52) 44 (33) 17 (13) 0.39 (0.47)
Placebo 136 52 (38) 33 (24) 15 (11) 4 (3) 0.16 (0.36)
All 200 mg of
CZP every
fortnight
16 138  78 (57)   
400mg of
CZP once a
month
135  73 (54)   
Placebo 136  34 (25)   
All 200 mg of
CZP every
fortnight
24 138 108 (78) 88 (64) 61 (44) 39 (28) 0.52 (0.66)
400 mg of
CZP once a
month
135 104 (77) 76 (56) 54 (40) 32 (24) 0.43 (0.54)
Placebo 136 45 (33) 32 (24) 17 (13) 6 (4) 0.17 (0.43)
SE, standard error.
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TABLE 19 Psoriasis Area and Severity Index response rates in the RAPID-PsA trial47
Population Treatment
Time point
(weeks)
Number of
patients with
psoriasis affecting
≥ 3% BSA PASI 50 PASI 75 PASI 90
All 200 mg of CZP every fortnight 12 90 62 (69%) 42 (47%) 20 (22%)
400mg of CZP once a month 76 48 (63%) 36 (47%) 15 (20%)
Placebo 86 23 (27%) 12 (14%) 4 (5%)
All 200 mg of CZP every fortnight 24 90 67 (74%) 56 (62%) 42 (47%)
400mg of CZP once a month 76 55 (72%) 46 (61%) 27 (36%)
Placebo 86 24 (28%) 13 (15%) 5 (6%)
TABLE 20 The RAPID-PsA trial47 ACR 20 response rates at 12 weeks for subgroups of previous DMARD use
Population Treatment Number of patients randomised ACR 20
Previous use of one DMARD 200mg of CZP every fortnight 61 42 (69%)
400mg of CZP once a month 72 42 (58%)
Placebo 74 22 (30%)
Previous use of two or more DMARDs 200mg of CZP every fortnight 73 38 (52%)
400mg of CZP once a month 60 28 (47%)
Placebo 60 11 (18%)
TABLE 21 Biologic-naive and biologic-experienced subgroup PsARC, ACR and HAQ-DI results in the RAPID-PsA
trial47 at 12 weeks
Population Drug
Number of
patients
randomised PsARC ACR 20 ACR 50 ACR 70
HAQ-DI
change from
baseline (SE)
Biologic
naive
CZP
combined
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Biologic
experienced
CZP
combined
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
SE, standard error.
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TABLE 22 Biologic-naive and biologic-experienced subgroup PASI response rates in the RAPID-PsA trial47 at
12 weeks
Population Drug
Number of patients
with psoriasis affecting
≥ 3% BSA PASI 50 PASI 75 PASI 90
Biologic naive CZP combined 130 80 (62%) 56 (43%) 25 (19%)
Placebo 66 18 (27%) 11 (17%) 3 (5%)
Biologic experienced CZP combined 36 30 (83%) 22 (61%) 10 (28%)
Placebo 20 5 (25%) 1 (5%) 1 (5%)
TABLE 23 Biologic-naive and biologic-experienced PsARC, ACR and HAQ-DI subgroup results from the RAPID-PsA
trial47 at 24 weeks
Population Drug
Time
point
(weeks)
Number of
patients
randomised PsARC ACR 20 ACR 50 ACR 70
HAQ-DI
change
from
baseline
(SE)
Biologic
naive
CZP
combined
24 219 170 (78%) 132 (60%) 91 (42%) 57 (26%) 0.45 (0.6)
Placebo 110 59 (54%) 29 (26%) 16 (15%) 5 (5%) 0.2 (0.45)
Biologic
experienced
CZP
combined
24 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Placebo Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
SE, standard error.
TABLE 24 Biologic-naive and biologic-experienced PASI subgroup results from the RAPID-PsA trial47 at 24 weeks
Population Drug
Time point
(weeks)
Number of patients
with psoriasis affecting
≥ 3% BSA PASI 50 PASI 75 PASI 90
Biologic naive CZP combined 24 130 89 (68%) 73 (56%) 48 (37%)
Placebo 66 20 (30%) 13 (20%) 5 (8%)
Biologic experienced CZP combined 24 36 33 (92%) 29 (81%) 21 (58%)
Placebo 20 4 (20%) 0 (0%) 0 (0%)
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TABLE 25 Relative risks for key outcomes in the RAPID-PsA trial:47 200 or 400mg of CZP vs. placebo
Dose
Time point
(weeks) Population
RR (95% CI)
PsARC ACR 20 ACR 50 ACR 70 PASI 50 PASI 75 PASI 90
200mg every
fortnight
12 All 1.91
(1.51 to 2.42)
2.39
(1.72 to 3.32)
3.29
(1.94 to 5.56)
8.38
(3.06 to 12.39)
2.58
(1.77 to 3.75)
3.34
(1.89 to 5.91)
4.78
(1.70 to 13.41)
16 NR 2.26
(1.63 to 3.13)
NR NR NR NR NR
24 2.37
(1.83 to 3.05)
2.71
(1.95 to 3.76)
3.54
(2.18 to 5.73)
6.41
(2.80 to 14.64)
2.67
(1.86 to 3.83)
4.12
(2.43 to 6.97)
8.03
(3.33 to 19.33)
400mg every
4 weeks
12 All 1.72
(1.35 to 2.20)
2.14
(1.52 to 3.00)
2.96
(1.73 to 5.05)
4.28
(1.48 to 12.39)
2.36
(1.60 to 3.49)
3.39
(1.91 to 6.04)
4.24
(1.47 to 12.23)
16 NR 2.16
(1.55 to 3.01)
NR NR NR NR NR
24 2.33
(1.80 to 3.01)
2.39
(1.71 to 3.35)
3.20
(1.96 to 5.23)
5.37
(2.32 to 12.43)
2.59
(1.80 to 3.74)
4.00
(2.35 to 6.82)
6.11
(2.48 to 15.07)
Combined
arms
12 Biologic naive Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
24 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Combined
arms
12 Biologic
experienced
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
24 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NR, not reported.
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Efficacy at 12–24 weeks in the RAPID PsA full-trial population
For the full-trial population, the RRs in Table 25 are for comparisons of the different CZP regimens (200 mg
every 2 weeks or 400 mg every 4 weeks) with placebo, across the 12-, 16- and 24-week time points and
across the PsARC, ACR and PASI outcomes. For the subgroup analyses (based on previous biologic status),
combined data from the two CZP arms were used to calculate RRs.
For the full-trial population, when compared with placebo, CZP was associated with statistically significant
improvements in all outcomes at all time points (for which data were available). Patients taking CZP were
around three times more likely to be ACR 50 responders than patients taking placebo. Similar to the
pattern seen with the SEC FUTURE 2 trial48 results, an increase in RRs is apparent as the outcome
thresholds (for achieving a response) increase across the PsARC, ACR and PASI outcomes (see Table 25).
Again, these increases are likely to be a consequence of the different placebo rates, with higher rates of
placebo response in the lower threshold outcomes.
The RAPID-PsA trial47 patients taking CZP were around two-and-a-half times more likely to be PASI 50
responders than patients taking placebo. Efficacy was also demonstrated in the results for the higher PASI
thresholds. Improvements in physical function, as assessed using HAQ-DI change from baseline scores,
were also seen, with the difference being reported as being statistically significant (p < 0.001) at 24
weeks.47 The manufacturer also submitted HAQ-DI results based on PsARC responder status (Table 26).
(Confidential information has been removed.)
Efficacy in the RAPID-PsA biologic-naive and biologic-experienced subgroups
Table 25 presents RRs for subgroups based on patients previous use of biologics. When comparing results
for all outcomes across subgroups the efficacy of CZP appears somewhat better in the biologic-experienced
subgroup than in the biologic-naive subgroup; this trial evidence is contrary to evidence from large patient
registries suggesting that effectiveness may decrease with each new anti-TNF taken (see Drug survival and
anti-tumour necrosis factor switching). The differences between subgroups observed in the RAPID-PsA
trial47 are likely to have been influenced by two factors. First, there is a problem with sample size, with low
numbers of placebo patients and PRs in the biologic-experienced subgroup. There is therefore considerable
uncertainty about these estimates, which is reflected in the very wide CIs. Second, there is a notable
difference in placebo response rates between the two subgroups (see Table 21 and Evaluating the
secukinumab and certolizumab pegol trial results in comparison with other treatments). Furthermore, as
detailed previously in Characteristics of the randomised controlled trials included in the systematic review of
short-term efficacy, the RAPID-PsA trial excluded patients with primary failure of a previous biologic, so the
subgroups were not as different as they could have been (other trials did not exclude primary failures).
TABLE 26 The RAPID-PsA trial47 HAQ-DI changes from baseline based on PsARC responder status
Population
Time
point
(weeks)
Group, HAQ-DI change (SD)
Placebo 200 mg 400 mg
Responders
Non-
responders Responders
Non-
responders Responders
Non-
responders
All 12 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
24 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
SD, standard deviation.
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The manufacturer also submitted HAQ-DI results based on PsARC responder status for the biologic-naive
and biologic-experienced populations (Table 27). (Confidential information has been removed.)
Other efficacy results
Efficacy of certolizumab pegol with or without concomitant methotrexate
Results were not reported for subgroups based specifically on MTX use, although results were reported
based on concomitant use of a DMARD (which was mostly MTX). Concomitant DMARD use did not seem
to affect ACR 20 (57% with vs. 50% without) or PsARC (68% with vs. 73% without) response rates to
CZP (combined dose) at week 12.47
Efficacy of certolizumab pegol in the one prior DMARD subgroup
When compared with placebo, at weeks 12 and 24, CZP was associated with statistically significantly better
ACR 20 response rates (p < 0.001); 207 patients who had received one prior DMARD were included in the
analysis.47 Data in the manufacturers submission showed that (confidential information has been removed).
Efficacy in treating dactylitis and enthesitis
At week 24, patients treated with CZP achieved statistically significant improvements in dactylitis (assessed
using the LDI) when compared with placebo-treated patients; statistically significant improvements in
enthesitis, as assessed using the LEI, were also seen in the CZP group (Table 28).
Health-related quality of life
At week 12, EQ-5D VAS scores were higher in CZP-treated groups (confidential information has been removed).
In addition, at week 24, there was a significant improvement with pooled CZP in all domains of the SF-36,
including both the physical (confidential information has been removed) and mental components
(confidential information has been removed), regardless of the dose regimen and prior TNF inhibitor status.
(Confidential information has been removed.)
TABLE 27 The HAQ-DI changes based on PsARC responder status for biologic-naive and biologic-experienced
subgroups in the RAPID-PsA trial47
Population
Time
point
(weeks)
Group, HAQ-DI change (SD)
Placebo 200 mg 400 mg
Responders
Non-
responders Responders
Non-
responders Responders
Non-
responders
Biologic naive 12 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
24 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Biologic
experienced
12 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
24 Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
SD, standard deviation.
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47
Mortality
Two deaths were reported during the 24 weeks: one was in the 200-mg group and one was in the
400-mg group. The trial investigators considered both deaths to be unrelated to study medication.
Summary
The results of the RAPID-PsA trial47 demonstrated the short-term efficacy of CZP in treating PsA. When
considering the full-trial population, CZP was associated with statistically significant improvements in all
key outcomes. When the trial population was split into subgroups based on previous biologic experience,
the results became difficult to compare (as was seen in the FUTURE 2 trial). The small number of placebo
patients in the biologic-experienced subgroup coupled with higher placebo response rates in the
biologic-naive subgroup meant that it was not possible to make reliable conclusions about the difference
in the efficacy of CZP across these subgroups. Furthermore, patients with primary failure of a previous
biologic were excluded from the RAPID-PsA trial, so estimates of efficacy may have been slightly inflated
when comparisons were made with other trials that recruited biologic-experienced patients (e.g. FUTURE 248
and PSUMMIT 259,66). Similar efficacy across the ACR and PsARC outcomes was seen in subgroups of
patients based on presence or absence of a concomitant DMARD and (confidential information has been
removed). Treatment with CZP resulted in statistically significant improvements in HRQoL measures and
in the resolution of both dactylitis and enthesitis.
Evaluating the secukinumab and certolizumab pegol trial results in
comparison with other treatments
In order to more fully evaluate the clinical efficacy of SEC and CZP, the trial results of these two newer
biologics need to be compared with each other and with the results of the older biologics (and APR).
However, this is not straightforward for two reasons. First, there is variation across trials with respect to
previous biologic use.
l The populations recruited to clinical trials have changed over time, with earlier trials excluding
biologic-experienced patients and later trials including such patients.
l The RAPID-PsA trial was more selective than the FUTURE 2,48 PSUMMIT 259,66 and PALACE trials60,61,65 in
recruiting its biologic-experienced patients: only in RAPID-PsA were patients with primary failure of a
previous biologic excluded (see Characteristics of the randomised controlled trials included in the
systematic review of short-term efficacy).
Second, placebo response rates have increased markedly over time across the trials included in this review.
This issue is key when interpreting RRs because, although RRs are easy to interpret clinically, their ceilings
(maximum values) are limited by baseline response rates. For example, in the FUTURE 2 trial48 the placebo
response rate for PsARC was (confidential information has been removed) in the biologic-naive subgroup.
This high rate meant that the maximum possible RR would be (confidential information has been removed);
this maximum result is lower than some of the actual RRs for other biologics presented in Table 29, which
TABLE 28 Efficacy in treating dactylitis and enthesitis in the RAPID-PsA trial47
Treatment
Outcome, mean change from baseline at week 24
Dactylitis count± SD Enthesitis count± SD
200mg of CZP 40.7± 34.6; p≤ 0.003 2.0± 1.8; p < 0.001
400mg of CZP 53.5± 69.1; p< 0.001 1.8± 1.9; p ≤ 0.003
Placebo 22.0± 46.9 1.1± 1.8
SD, standard deviation.
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TABLE 29 Unadjusted RRs (compared with placebo) across the trials included in the evidence synthesis
Trial name Treatment
Time
point
(weeks) Population
RR (95% CI)
PsARC ACR 20 ACR 50 ACR 70 PASI 50 PASI 75 PASI 90
FUTURE 248 300mg of
SEC
12 All Confidential
information has
been removed
2.23
(1.53 to 3.26)
Confidential
information has
been removed
NR 7.13
(3.09 to 16.45)
12.59
(3.17 to 49.91)
8.39
(2.06 to 34.24)
150 mg of
SEC
12 All Confidential
information has
been removed
2.20
(1.50 to 3.21)
Confidential
information has
been removed
NR 7.12
(3.10 to 16.36)
11.49
(2.91 to 45.42)
7.04
(1.73 to 28.64)
300 mg of
SEC
12 Biologic
naive
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
6.20
(1.15 to 25.40)
150 mg of
SEC
12 Biologic
naive
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
5.60
(1.37 to 22.91)
300 mg of
SEC
12 Biologic
experienced
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
9.78
(0.59 to 162.47)
150 mg of
SEC
12 Biologic
experienced
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
7.22
(0.44 to 117.84)
SPIRIT-P157,67 ADA 12 All NR 1.65
(1.18 to 2.32)
6.30
(2.54 to 15.59)
38.82
(2.37 to 635.80)
NR 5.21
(2.50 to 10.85)
14.78
(2.01 to 108.77)
RAPID-PsA47 CZP
200mg
12 All Confidential
information has
been removed
2.39
(1.72 to 3.32)
3.29
(1.94 to 5.56)
8.38
(3.06 to 22.97)
2.58
(1.77 to 3.75)
3.34
(1.89 to 5.91)
4.78
(1.70 to 13.41)
CZP
400mg
12 All Confidential
information has
been removed
2.14
(1.52 to 3.00)
2.96
(1.73 to 5.05)
4.28
(1.48 to 12.39)
2.36
(1.60 to 3.49)
3.39
(1.91 to 6.04)
4.24
(1.47 to 12.23)
continued
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TABLE 29 Unadjusted RRs (compared with placebo) across the trials included in the evidence synthesis (continued )
Trial name Treatment
Time
point
(weeks) Population
RR (95% CI)
PsARC ACR 20 ACR 50 ACR 70 PASI 50 PASI 75 PASI 90
CZP
combined
12 Biologic
naive
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
5.56
(0.77 to 40.30)
CZP
combined
12 Biologic
experienced
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
4.70
(2.01 to 11.01)
PALACE 160,61 APR 16 All 1.56
(1.17 to 2.07)
2.00
(1.39 to 2.89)
2.70
(1.35 to 5.40)
3.50
(0.74 to 16.60)
2.71
(1.50 to 4.91)
4.98
(1.53 to 16.18)
NR
PALACE 261,65 APR 16 All 1.44
(1.10 to 1.90)
1.70
(1.15 to 5.52)
2.09
(0.93 to 4.69)
1.96
(0.18 to 21.43)
3.17
(1.69 to 5.96)
8.17
(1.95 to 34.14)
NR
PALACE 361,65 APR 16 All 1.94
(1.46 to 2.58)
2.22
(1.54 to 3.20)
1.81
(0.97 to 3.35)
1.52
(0.44 to 5.28)
1.71
(1.10 to 2.64)
2.83
(1.26 to 6.35)
NR
PSUMMIT 259,66 45mg of
UST
12 Biologic
naive
NR 2.08
(1.01 to 4.28)
1.63
(0.42 to 6.39)
2.93
(0.32 to 27.06)
NR 14.17
(2.00 to 100.35)
NR
PSUMMIT 259,66 45mg of
UST
24 Biologic
naive
1.47
(0.92 to 2.34)
1.87
(1.08 to 3.26)
2.93
(0.85 to 10.08)
1.95
(0.38 to 10.10)
NR 5.83
(1.93 to 17.67)
NR
45mg of
UST
12 Biologic
experienced
NR 2.64
(1.33 to 5.23)
9.30
(1.21 to 71.19)
9.30
(0.51 to 169.03)
NR 15.91
(2.18 to 116.14)
NR
45mg of
UST
24 Biologic
experienced
2.13
(1.32 to 3.44)
2.53
(1.27 to 5.03)
2.33
(0.76 to 7.15)
3.10
(0.33 to 28.98)
NR 22.73
(3.18 to 162.50)
NR
45mg of
UST
12 All 1.65
(1.18 to 2.31)
2.38
(1.44 to 3.91)
3.53
(1.20 to 10.38)
7.07
(0.89 to 56.44)
7.29
(3.52 to 15.07)
15.50
(3.84 to 62.60)
16.00
(2.17 to 117.80)
45 mg of
UST
24 All 1.80
(1.28 to 2.52)
2.16
(1.39 to 3.36)
2.60
(1.13 to 5.95)
2.36
(0.63 to 8.86)
NR 10.25
(3.85 to 27.28)
NR
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Trial name Treatment
Time
point
(weeks) Population
RR (95% CI)
PsARC ACR 20 ACR 50 ACR 70 PASI 50 PASI 75 PASI 90
PSUMMIT 158 45mg of
UST
12 Biologic
naive
1.62
(1.31 to 2.01)
1.94
(1.43 to 2.64)
3.47
(1.83 to 6.60)
2.68
(0.72 to 9.96)
NR 4.34
(2.48 to 7.58)
NR
45mg of
UST
24 Biologic
naive
1.50
(1.21 to 1.86)
1.86
(1.38 to 2.50)
2.85
(1.72 to 4.70)
5.02
(1.96 to 12.87)
2.89
(2.06 to 4.05)
5.22
(3.22 to 8.47)
NR
GO-REVEAL50 50mg of
GOL
14 All (biologic
naive)
3.45
(2.39 to 4.99)
5.73
(3.10 to 10.57)
17.03
(4.22 to 68.75)
13.93
(1.89 to 102.80)
6.52
(3.16 to 13.47)
15.94
(3.98 to 63.84)
32.67
(2.01 to 530.63)
Genovese et al.,
200756
ADA 12 All (biologic
naive)
1.86
(1.10 to 3.13)
2.50
(1.21 to 5.15)
13.00
(1.77 to 95.73)
15.00
(0.88 to 255.86)
NR NR NR
ADEPT55 ADA 12 All (biologic
naive)
2.37
(1.77 to 3.16)
4.05
(2.71 to 6.06)
9.53
(4.22 to 21.51)
31.76
(4.39 to 230.09)
5.00
(2.77 to 9.03)
11.33
(3.65 to 35.17)
43.00
(2.66 to 695.98)
IMPACT 252 INF 14 All (biologic
naive)
2.85
(2.03 to 4.01)
5.27
(2.95 to 9.44)
12.00
(3.82 to 37.70)
15.00
(2.02 to 111.42)
8.91
(4.57 to 17.38)
27.78
(6.99 to 110.35)
72.31
(4.50 to 1160.52)
IMPACT51 INF 16 All (biologic
naive)
3.55
(2.05 to 6.13)
6.80
(2.89 to 16.01)
49.00
(3.06 to 784.91)
31.00
(1.90 to 504.77)
33.00
(2.15 to 505.75)
22.73
(1.46 to 353.35)
12.47
(0.77 to 201.07)
Mease et al.,
200454
ETN 12 All (biologic
naive)
2.35
(1.72 to 3.21)
3.86
(2.39 to 6.23)
9.78
(3.62 to 26.41)
23.68
(1.41 to 396.59)
NR NR NR
Mease et al.,
200053
ETN 12 All (biologic
naive)
3.71
(1.91 to 7.21)
5.50
(2.15 to 14.04)
15.00
(2.11 to 106.49)
9.00
(0.51 to 160.07)
2.00
(0.72 to 5.54)
11.00
(0.65 to 185.70)
NR
GO-REVEAL, Golimumab  A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody; NR, not reported;
SPIRIT-P1, Study of Ixekizumab in Participants With Active Psoriatic Arthritis.
D
O
I:
1
0
.3
3
1
0
/h
ta
2
1
5
6
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
7
V
O
L
.
2
1
N
O
.
5
6
©
Q
u
een
s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
7
.
Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
C
o
rb
ett
e
t
a
l.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
llrep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
aljo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,
Evalu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,
So
u
th
am
p
to
n
SO
1
6
7
N
S,
U
K
.
5
1
compares unadjusted RRs across the trials in the NMAs. Comparisons between treatments using odds ratios
(ORs) and that adjust for the varying placebo rates were therefore necessary (see Chapter 4).
Examination of the trial baseline characteristics across trials offers no clear reason as to why placebo
response rates in biologic trials have increased over time. The PsARC placebo response rates increased
most markedly from 2013 onwards, starting with the PSUMMIT trials.60,61,65 One theory is that patient and
clinician expectations have increased over time (i.e. more caution and lower expectations when the first
biologics were trialled, and more confidence about the likely benefits in more recent trials). Subjective
patient- and clinician-reported outcomes such as PsARC and ACR may be prone to such expectation
effects. This theory might also explain why, within trials, higher placebo response rates are observed in the
biologic-naive subgroups than in biologic-experienced subgroups, where treatment expectations might be
lower. Coupled with this is the trend  beginning with the PSUMMIT trials  for increases in the number of
active treatment arms offered in trials: typically there was one active arm in the early trials and two or
more active arms in more recent trials (e.g. the FUTURE 2 SEC trial had three active treatment arms: 75,
150 and 300 mg). Patients in the more recent trials might therefore also be more confident and optimistic
about the likelihood that they are receiving an active treatment.
Ideally the different treatments would be compared in head-to-head trials. However, only one trial identified
in the systematic review compared two or more biologics directly in a PsA population. The Atteno et al. trial64
compared INF, ETN and ADA. It reported that patients on INF and ADA showed the greatest improvement
in terms of PASI (statistically significantly better than ETN), whereas patients on ETN showed the greatest
improvement in TJC (statistically significantly better than INF and ADA) and HAQ-DI (statistically significantly
better than ADA). However, the reliability of this studys results are limited somewhat by its small size
(100 patients were randomised in total). This trial also did not report its methods clearly (see Table 6), and
was rated as being at high risk of bias (although blinding would be difficult to achieve in such a trial). Finally,
by reporting results only at the 52-week time point, the results of this trial could not be included in our NMAs.
Long-term effectiveness
Open-label extension studies
Long-term efficacy of secukinumab
The Novartis submission to NICE for the appraisal in 2016 reported long-term data for both FUTURE 146
(to 104 weeks) and FUTURE 248 (to 52 weeks) trials. Although the FUTURE 1 trial46 was not eligible for the
systematic review of efficacy because it initiated the randomised phase of the study with a non-licensed
high loading dose (10 mg/kg), it did use a 150-mg maintenance dose and so can be considered to provide
useful long-term data. Importantly, this trial reported radiographic efficacy outcomes (at 2 years); the
FUTURE 2 trial48 did not report radiographic efficacy outcomes.
FUTURE 2
Of the FUTURE 2 trial 48 patients originally randomised to 150 or 300 mg of SEC, by week 52, 22 (11%) had
withdrawn for any reason, 10 of whom withdrew as a result of an AE or loss of efficacy. In the FUTURE 2
trial,48 most of the dichotomous data reported in the submission used non-responder imputations for
missing data; a mixed-effects repeated measures model was used for continuous outcomes. There were no
stopping rules up to week 52, so non-responding patients could keep taking SEC thus allowing the
possibility of achievement of much later responses than would be viable in the NHS. For time points after
week 52, the protocol stated that subjects who are deemed not to be benefiting from the study treatment
based on lack of improvement or worsening of their symptoms should discontinue the study. However,
results for post-week 52 time points are not yet available. Results for key review outcomes at week 52 are
presented in Table 30. The outcomes suggest that SEC continues to be an effective treatment for PsA at this
later time point.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Longer-term efficacy in FUTURE 2 trial patients who were responders at 16 weeks
In the NHS, patients will typically be allowed 16 weeks to achieve a response, after which SEC may be
stopped in non-responding patients. The Assessment Group (AG) requested results specifically for patients
who are responders at 16 weeks to inform what happens to this group of patients in the longer term. The
results (Figures 3 and 4) indicate that for the lower threshold outcomes  such as ACR 20 and PASI 50 
response rates remain high from week 16 to week 52. As the outcome thresholds increase, response rates
become more variable over time and there is generally a greater decrease in response rates than the lower
threshold outcomes. Around 70% of patients on 150 mg still achieve an ACR 50 response at week 52,
and around 55% still achieve an ACR 70 (see Figure 3); the corresponding results for PASI 75 and PASI 90
are around 85% and around 70%, respectively (see Figure 4).
FUTURE 1
Of the FUTURE 1 trial46 patients originally randomised to receive 75 or 150 mg of SEC or placebo, 15%
had withdrawn at week 52 for any reason, of which 6% of withdrawals were the result of an AE or loss of
efficacy.46 At week 104, 79% of patients remained in the study. Here, we report only on the long-term
efficacy of 150 mg of SEC. Results at 52 weeks are similar to those seen in the FUTURE 2 trial;48 observed
data were also available at 2 years (Table 31).
TABLE 30 Efficacy results for the FUTURE 2 trial48 at 52 weeks
Outcome
Trial arm
300mg of SEC 150mg of SEC
ACR response, n 100 100
% ACR 20 64 64
% ACR 50 44 39
% ACR 70 24 20
PASI response (≥ 3% BSA), n 41 58
% PASI 75 73 57
% PASI 90 56 43
PsARC response, n 100 100
% PsARC response Confidential information has been removed Confidential information has been removed
HAQ-DI, n 100 100
Mean (SD) 0.56 (0.05) 0.47 (0.05)
SF-36, n 100 100
Mean (SD) Confidential information has been removed Confidential information has been removed
SD, standard deviation.
FIGURE 3 Long-term response rates in the FUTURE 248 trial SEC patients who were (a) ACR 20, (b) ACR 50 or
(c) ACR 70 responders at 16 weeks. (Confidential information has been removed.)
FIGURE 4 Long-term response rates in the FUTURE 248 trial SEC patients who were (a) PASI 50, (b) PASI 75 or
(c) PASI 90 responders at 16 weeks. (Confidential information has been removed.)
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53
Radiographic progression of joint damage
In the FUTURE 1 trial,46 at week 52 the observed population comprised 189 of the 202 patients randomised
to 150 mg; this group had a mean Sharp/van der Heijde change from baseline score of 0.37 points.
At 104 weeks, 85% of patients treated with 150 mg of SEC had no radiographic progression  defined
as a change in Sharp/van der Heijde score of ≤ 0.5 units  between baseline and week 104. This result was
based on the observed population (n = 166).
Long-term efficacy of certolizumab pegol
The UCB Pharma submission reported long-term efficacy data for the RAPID-PsA trial47 at time points up to
around 4 years (216 weeks). By week 96, 20% of the 273 patients originally randomised to CZP had
withdrawn from the study; 13.5% of the total cohort had withdrawn as a result of an AE or loss of efficacy.
Non-responder imputations were used for dichotomous outcomes and LOCF was used for most of the
continuous outcomes (except for radiographic progression).
At week 96 the ACR 20, 50 and 70 response rates were 64%, 50% and 35%, respectively,74 and were
(confidential information has been removed). PASI 75 and 90 response rates were 53% and 44% at
week 96;74 and (confidential information has been removed).
(Confidential information has been removed.) The improvement in HAQ-DI score from baseline was
maintained (confidential information has been removed). Efficacy results for the overall population
together with the biologic-naive and biologic-experienced subgroups are presented in Table 32.
TABLE 31 Efficacy results for the FUTURE 1 trial46 at 52 weeks and 104 weeks
Outcome
Time point, 150mg of SEC
52 weeks 104 weeksa
ACR response, n 202 153
% ACR 20 60 74
% ACR 50 43 46
% ACR 70 24 28
PASI response (≥ 3% BSA), n 108 82
% PASI 75 77 83
% PASI 90 59 70
Dactylitis (LDI), n 104 
% resolution of dactylitis 69 
Enthesitis (LEI), n 126 
% resolution of enthesitis 66 
HAQ-DI, n 202 153
Mean (SE) 0.41 (0.04) 0.42 ()
SF-36, n 202 152
Mean (SE) 5.89 (0.54) 5.94 ()
, not available; SE, standard error.
a Observed data.
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(Confidential information has been removed.)
Longer-term efficacy in patients who were responders at 12 weeks
In the NHS, patients will typically be allowed 12 weeks to achieve a response, after which CZP may be
stopped in non-responding patients. The AG requested results specifically for patients who are responders
at 12 weeks to inform what happens to this group of patients in the longer term. The response rates at
1 year are similar to those seen with SEC. Later results show that, across outcomes, around two-thirds
(of responders at 12 weeks) remain responders at 4 years (Figures 5 and 6).
TABLE 32 Long-term efficacy results for Rapid-PsA trial47 at 216 weeks
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Radiographic progression of joint damage
At week 96, the modified total Sharp score (mTSS) non-progressor rate (non-progression defined as mTSS
change from baseline of ≤ 0.5 points) was 87%. This was based on observed data for the combined CZP
groups: 218 of the 273 randomised. For patients randomised to CZP (combined group), the mean level of
progression was 0.14 points [standard error (SE) 0.09 points], which is below the 0.5-point non-progression
cut-off point. Subgroup analyses indicated that patients (randomised to CZP) with a baseline mTSS of
> 3.5 points had a slightly greater radiographic progression at week 96 than patients with a baseline mTSS
of ≤ 3.5 points [mean 0.24 points (SE 0.19 points) for a mTSS of > 3.5 vs. mean 0.07 points (SE 0.04 points)
for a mTSS of ≤ 3.5 points].
Efficacy of other therapies
Methods and result details relating to the latest time point for which long-term data were available for
GOL, ETN, ADA, INF, UST and APR are presented in Table 33.
The Golimumab  A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis
Using a Human Anti-TNF Monoclonal Antibody (GO-REVEAL) study75 reported results at 5 years using
the originally randomised ITT groups. Across the groups the proportion of responders ranged from 63%
to 70% for ACR 20, from 43% to 51% for ACR 50 and from 61% to 72% for PASI 75. Mean changes
from baseline in the modified Sharp/van der Heijde score ranged from 0.1 to 0.3 units. Clinically important
improvements in HAQ-DI scores (a decrease of ≥ 0.3 units) were seen for 5258% of randomised patients.
The use of concomitant MTX at baseline did not affect ACR 20 or PASI 75, but did appear to reduce
radiographic progression when a comparison was made with patients who did not use concomitant MTX
at baseline. Although some method details were not fully clear, it appeared that the data imputations used
were not conservative enough. For example, it seems that LOCF was used for patients who stopped
treatment as a result of an AE (so a patient responding well to treatment but who discontinued treatment
early in the study as a result of an AE was counted as a responder at 5 years). In addition, it was unclear
whether or not there were any stopping rules  such as how long non-responders were allowed to remain
on treatment  which raises further uncertainties about the studys applicability to clinical practice.
The follow-up for the Mease et al. ETN trial54 extended to 2 years and consisted of three phases:
the 24-week initial randomised phase, an optional 24-week maintenance therapy phase (according to
randomised assignment) and a 48-week open-label phase. Most results were given as percentages and it
was not fully clear what the denominator was for some results. Several results were presented only as
graphs. Very few data were provided on reasons for withdrawal from the study and HAQ-DI results were
not reported. The ACR response results were similar to those seen in the GO-REVEAL trial (at 5 years),
although the proportions of PASI 75 responders were markedly lower.
The ADEPT ADA trial78 was extended to 2.75 years for radiographic progression outcomes and to 2 years
for other outcomes. The ACR 50 results were similar to those seen for the ETN and GOL open-label studies.
PASI 75 results were only presented in a graph; the response was around 60% (n = 128), which is similar
to the GO-REVEAL trials PASI 75 result at 5 years. Non-responders could increase their dose from 40 mg
every other week (the recommended dose) to 40 mg weekly; this occurred in 54 (19%) patients. The use of
LOCF imputation for missing data for the ACR, PASI and PsARC outcomes is different (potentially much less
conservative) from the imputations used in the placebo-controlled phase, where non-responder imputations
were used. This is likely to have inflated the response rates in the open-label phase. The results for HAQ-DI
FIGURE 5 Long-term response rates in the RAPID-PsA trial47 CZP patients who were (a) ACR 20, (b) ACR 50 or
(c) ACR 70 responders at 12 weeks. (Confidential information has been removed.)
FIGURE 6 Long-term response rates in the RAPID-PsA trial47 CZP patients who were (a) PASI 50, (b) PASI 75 or
(c) PASI 90 responders at 12 weeks. (Confidential information has been removed.)
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TABLE 33 Open-label extension studies of other therapies for PsA
Original trial name
with relevant OL
reference(s);
treatment and
dose; and latest
time pointa Number of patients
Analysis and imputation
methods used by the
study authors Main results (ITT data extracted where possible)
Key withdrawal
data
GO-REVEAL;75,76 50
or 100mg of GOL
(at investigators
discretion); 5 years
Of 405 randomised
(placebo, n= 113;
50mg of GOL,
n= 146; 100mg of
GOL, n= 146), 279
(69%) were still on
treatment at 5 years
It appeared that LOCF was
used except for lack of
efficacy discontinuations,
where NRI was used and
radiographic scores where
observed data were used
(n= 267)
At 5 years:
Trial arm
Modified
SHS scoreb
(SD)
HAQ-DI
(SD) ACR 20 ACR 50 PASI 75c
Placebo/50mg
of GOL
0.3 (3.8) 0.7 (0.6) 71/113 (63%) 49/113 (43%) 48/79 (61%)
50mg of GOL 0.3 (4.2) 0.6 (0.6) 96/146 (66%) 70/146 (48%) 67/109 (61%)
100mg of GOL 0.1 (2.7) 0.6 (0.6) 102/146 (70%) 74/146 (51%) 78/108 (72%)
126/405 (31%)
stopped treatment:
50 as a result of an
AE and 23 because
of lack of efficacy
Mease et al., 2004;77
25mg of ETN twice
weekly; up to 2 years
Of 205 randomised
(placebo, n= 104; ETN,
n= 101), 169 took
part in the extended
study
Analyses were based on
observed populations. All
analyses were performed
on the subset of patients
who had radiographic
data for the 2-year
assessment (n= 141:
placebo/ETN, n= 70;
ETN, n= 71)
At up to 2 years:
Trial arm mTSSb PsARC ACR 20 ACR 50 PASI 75c
Placebo/ETN 0.5 ≈80% 63% 49% ≈38% of
102 patients
ETN 0.38 ≈80% 64% 44%
44/205 (21%)
stopped treatment:
14 in RCT phase,
nine in maintenance
phase and 21 in
OL phase. Three
patients withdrew
from OL phase
because of an AE
continued
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TABLE 33 Open-label extension studies of other therapies for PsA (continued )
Original trial name
with relevant OL
reference(s);
treatment and
dose; and latest
time pointa Number of patients
Analysis and imputation
methods used by the
study authors Main results (ITT data extracted where possible)
Key withdrawal
data
ADEPT;78 40mg of
ADA every other
week, patients
without ≥ 20%
improvement in
TJC and SJC after
12 weeks of OL
phase could increase
to 40mg per week;
2 years, 2.75 years
for radiographic data
Of 313 randomised
(placebo, n= 162;
ADA, n= 151), 289
completed 24-week
RCT, of which 285
chose to enrol in the
extended study
Most analyses were based
on a modified ITT
population (any patients
who had received a dose
in either study phase,
n= 298) with LOCF
imputation
At 2 years (2.75 years for mTSS):
Trial arm mTSSb (SD)
HAQ-DI b
(SD) PsARC ACR 20 ACR 50
Placebo/ADA 0.9 (6.4),
n= 128
0.3 (0.5) 188/298 (63%) 161/298 (54%) 127/298 (43%)
ADA 0.5 (4.2),
n= 115
44/285 stopped
treatment in the
OL phase: 10 as a
result of AEs; and
12 because of lack
of efficacy
IMPACT;79 5mg/kg of
INF; up to 2 years
104 patients took part
in the RCT. 78 out of
the 87 patients who
completed the first
year continued to enrol
in the extended 2-year
study
Analyses were based on
the 78 patients who
entered year 2 (analysed
as one group)
At 98 weeks:
Trial arm
Modified
SHS scoreb
(SD) PsARC ACR 20 ACR 50 PASI 75d
Placebo/INF 1.2 (8.7),
n= 43
52/104
(50%)
48/104 (46%) 35/104 (34%)
64%
(n= unclear)INF
26 patients
withdrew over the
2 years: 12 as a
result of AEs; and
three because of
lack of efficacy
PSUMMIT 1;80,81 45 or
90mg of UST every
12 weeks; 100 weeks
615 randomised
(placebo, n= 206;
45mg of UST, n= 205;
90mg of UST, n= 204)
and 598 received at
least one dose of UST
Analyses were based on
ITT populations using
LOCF and NRI for most
analyses. Missing
radiographic data between
week 52 and week 100
were imputed using linear
extrapolation (if data were
available for two time
points), otherwise the
median change in the
total scores from all
patients within the MTX
stratification was used
At 100 weeks:
Trial arm
Total SHS
scoreb (SD)
HAQ-DI
(SD)b ACR 20 ACR 50 PASI 75c
Placebo/45mg
of UST
2.3 (12.6),
n= 189
0.36
(0.51)
111/206 (54%) 66/206 (32%) 78/136 (57%)
45mg of UST 1.0 (3.8) 0.36
(0.56)
101/205 (49%) 69/205 (34%) 87/145 (60%)
90mg of UST 1.2 (5.1) 0.45
(0.6)
112/204 (55%) 81/204 (40%) 92/149 (62%)
By week 88 (last
dose), 125 patients
(20.3%) had
discontinued
treatment: 31 as a
result of an AE;
and 40 because of
lack of efficacy
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Original trial name
with relevant OL
reference(s);
treatment and
dose; and latest
time pointa Number of patients
Analysis and imputation
methods used by the
study authors Main results (ITT data extracted where possible)
Key withdrawal
data
PALACE 1;61,82 30mg
of APR twice daily,
oral tablets; 2 years
504 patients were
randomised (placebo,
n= 168; 20mg of APR,
n= 168; 30mg of APR,
n= 168). 101 patients
received 30mg of APR
continuously for
2 years (observed
population)
Analyses were based on
the observed population
for the extension period
At 104 weeks:
Trial arm HAQ-DIb ACR 20 PASI 75c
30mg of APR 0.43, n= 101 67/168 (40%) 21/71 (29.6%)
8.2% discontinued
treatment as a
result of AEs
between weeks 0
and 52 and 1.5%
between weeks 53
and 104
GO-REVEAL, Golimumab  A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody; NRI, non-responder imputation;
SHS, Sharp/van der Heijde; OL, open label.
a With published results.
b Change from RCT baseline.
c In patients with a ≥ 3% BSA involvement.
d Patients with a baseline PASI score of ≥ 2.5 units.
D
O
I:
1
0
.3
3
1
0
/h
ta
2
1
5
6
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
7
V
O
L
.
2
1
N
O
.
5
6
©
Q
u
een
s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
7
.
Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
C
o
rb
ett
e
t
a
l.
u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,
th
e
fu
llrep
o
rt)
m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
aljo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,
Evalu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,
So
u
th
am
p
to
n
SO
1
6
7
N
S,
U
K
.
5
9
remained very stable throughout the 2 years. These open-label HAQ-DI results are similar to the placebo-
controlled, fully blinded 24-week phase in which HAQ-DI scores remained the same between week 12 and
week 24 in both the ADA and the placebo groups.
The UST PSUMMIT 1 trial80,81 was extended to 108 weeks, with efficacy data evaluated at 100 weeks.
The change from baseline Sharp/van der Heijde radiographic progression scores varied across the three
treatment groups. The change from baseline HAQ-DI results ranged between 0.36 and 0.45 units,
similar to the ADA study results.
For INF, IMPACT79 was extended to 98 weeks. The data for all patients were summarised as one group
(as for the ADA open-label study). At 98 weeks, 46% and 34% were ACR 20 and ACR 50 responders,
respectively. The mean change in the modified Sharp/van der Heijde score was 1.2 units, which is
similar to the results in the UST PSUMMIT 1.80,81 However, the result was based on 41% of the initial
104 patients. The authors also acknowledged that the 2-year radiographic progression result may have
reflected non-linear progression of damage, with more damage occurring in earlier disease stages.
Mean changes from baseline were not available for the HAQ-DI.
For APR, the PALACE 1 trial61,82 was extended to 2 years. There were no separate results for the patients at
104 weeks who were in the placebo group at the beginning of the trial. In the 30-mg group, at 2 years
40% of patients were ACR 20 responders and 30% were PASI 75 responders. The HAQ-DI result may be
an overestimate, as it was based on data from patients remaining in the study at 2 years (i.e. observed
data). No data were reported on any radiographic progression outcomes.
Summary
The uncontrolled nature of open-label extension studies means that it is often very difficult to determine
the magnitude of effects that can be ascribed only to active treatment; results should generally be viewed
with much more caution than the results of the earlier randomised controlled study phases. Furthermore,
it is not straightforward to compare long-term results across different treatments because of the variation
in outcomes and time points reported. There is also variation in the methodological approaches used for
analyses and for imputing missing data. Additionally, most studies did not report whether or not there
were any treatment stopping rules, and it is likely that the decisions made regarding continuation of
treatment were not reflective of those used in the NHS, limiting the applicability of many of these results.
For example, in the open-label ADEPT78 non-responders after 12 weeks had their dose doubled  the
opposite of what would be expected in practice (when treatment with ADA would have been stopped).
With these caveats in mind, the results relating specifically to those patients who were responders at 12 or
16 weeks appear to be the most clinically relevant and useful (for the dichotomous outcomes), although
such data were available only for CZP and SEC (confidential information has been removed).
The available data on disease progression based on radiographic assessments of joint damage indicate
that, after 2 years of treatment, CZP effectively reduces disease progression, with results being similar to
those observed in the open-label studies of the other anti-TNFs. For SEC, fewer result details were available
at 2 years, although the results also indicated effective reduction in radiographic disease progression.
For long-term HAQ-DI results, missing data were often imputed using LOCF, which is not the most
conservative of approaches for this outcome. Notwithstanding this, the results suggest that HAQ-DI gains
remain stable in PsA patients treated with biologics. The 2-year open-label HAQ-DI results from ADEPT were
similar to the placebo-controlled, fully blinded 24-week phase in which HAQ-DI scores remained the same
between week 12 and week 24 in both the ADA and the placebo groups. This stability of HAQ-DI scores
over time was also seen in the open-label studies of CZP (data up to 4 years) and SEC (data to 1 year).
Withdrawal rates as a result of AEs or loss of efficacy were low in both the FUTURE 248 (5% at 52 weeks)
and RAPID-PsA47 trials (around 10% at 52 weeks).
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Review of anti-tumour necrosis factor patient registry studies
Drug survival and anti-tumour necrosis factor switching
The database of references, which resulted from the searches for RCTs, was also screened to identify
registries containing PsA patients and the corresponding publication output. The results of this search were
supplemented by separate searches for the output of the identified patient registries reporting information
on their PsA cohorts. A library of 165 potentially relevant studies was assembled and screened fully, from
which there were 12 studies8393 reporting data on drug survival and switching of anti-TNF treatments. The
populations of all 12 studies were defined as having clinically diagnosed PsA. These studies are presented
in Table 34.
These studies were all retrospective analyses of prospective patient registers from primarily European
countries (10 studies8386,88,9094), along with one Australian study89 and another from the USA.87 The
majority of patients in each of the registries had been treated with ETN, ADA or INF; two of the studies
named other anti-TNF-α treatments, GOL and CZP, but neither had sufficient data to provide individual
drug survival information for these.
Drug survival was reported in a number of ways: as the number of patients remaining on treatment at a
given time point; as the proportion of patients remaining on treatment at each time point; or as the
median duration patients remained on treatment.
Treatment withdrawal rates in patients who had switched anti-TNFs were reported in three studies.83,94,95
The Danish Database for Biological Therapies (DANBIO) registry94 reported up to three sequential anti-TNFs,
with 548 patients who had switched treatment once, and 189 patients who had switched treatment twice.
The UKs British Society for Rheumatology Biologics Register (BSRBR)83 also reported drug survival rates for
its population of 178 one-time switchers over 2 years, whereas the 95 switchers in the Norwegian
Antirheumatic Drug Register (NOR-DMARD)95 were followed for 3 years.
For the first course of anti-TNF treatment, the proportion of patients remaining on treatment ranged from
60% to 88% at 1 year, from 57% to 81% at 2 years and from 55% to 73% at 3 years. Three studies
reported first anti-TNF drug survival rates for ≥ 5 years: (1) the BSRBR study,84 in which 47% of patients
were still on the initial anti-TNF treatment at 5 years; (2) the Southern Sweden Antirheumatic Therapy
Group study,85 which reported 5-year survival of around 40%; and (3) the study conducted by another
Swedish registry, Antirheumatic Therapies In Sweden,86 which reported 6-year first anti-TNF drug survival
of 37% and 8-year survival of 32%.
The median first anti-TNF survival time across all anti-TNFs was reported as 2.52.9 years.87,88 One study
reported this separately by anti-TNF: ETN, 2.62 years; ADA, 4.21 years; and INF, 1.92 years.89
Drug survival was consistently lower in patients who switched anti-TNF than in those who did not. The
DANBIO94 register had the largest population of switchers; the median drug survival for a first anti-TNF was
2.2 (95% CI 1.9 to 2.5) years, whereas median drug survival for a second anti-TNF was 1.3 years (95% CI 1.0
to 1.6 years) (n = 548), and was 1.1 years (95% CI 0.7 to 1.5 years) (n = 189) for those on a third anti-TNF.
There is some evidence suggesting that drug survival varies between types of anti-TNF; both the Australian
Rheumatology Association Database register and the BSRBR study report rates for individual therapies,
and both indicate that ADA and ETN are associated with considerably higher survival rates than INF. Two
studies reported the impact of concomitant MTX or other DMARDs.85,87 One reported a small increase in
drug survival at 1 year (from 65% to 80%), but this effect was diminished at 3 years (from 55% to 60%)
and 5 years (from 37.5% to 40%).85 The other study reported that median drug survival time for anti-TNF-α
monotherapy was 30.8 months, compared with 32.4 months for combination therapy (anti-TNF +MTX
or DMARD).87
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TABLE 34 Registry studies reporting data on anti-TNF drug survival and switching
Publication (first
author and year
of publication)
Registry
name
Number of
patients (length
of follow-up) Population
Anti-TNFs
included Drug survival data Reason for discontinuation
Carmona et al.,
200691
BIOBADASER 570 (5 years;
963.6 patient-
years)
PsA ETN, ADA
and INF
As a proportion, anti-TNF-α survival was 0.88 (95% CI 0.84 to 0.90)
at 1 year; 0.81 (95% CI 0.77 to 0.84) at 2 years; and 0.73 (95% CI
0.67 to 0.78) at 3 years
Not split by diagnosis
Chen et al.,
201489
ARAD 286 (10 years) PsA ETN, ADA
and INF
Median survival time: ETN (n= 110), 2.62 years (95% CI 1.10 to
4.45 years); ADA (n= 144), 4.21 years; INF (n= 23), 1.92 years
(95% CI 0.96 to 2.88 years)
Trial
arm
Any
(%)
LoE
(%)
AE
(%)
ETN 41 20.5 8
ADA 35 17.7 11.5
INF 70 29.6 11.1
Fagerli et al.,
201490
NOR-DMARD 439 (3 years; 547
patient-years)
PsA ETN, ADA,
INF, GOL
and CZP
The proportion of non-switchers (n= 344) remaining on their first
anti-TNF-α after 1 year was 0.83; at 3 years it was 0.71. The 1-year
survival for all patients on their first anti-TNF-α was 0.74. The
proportion of those patients who switched to a different anti-TNF-α
(n= 95) remaining on second treatment for 1 year was 0.56; the
3-year survival was 0.36
NR
Response rate at 3 months:
Response
Non-
switchers
(%) Switchers (%) p-value
switchers
first vs. secondFirst First Second
ACR 20 64.4 45.8 22.5 NS
ACR 50 40.0 30.5 12.5 NS
ACR 70 32.2 23.7 0.04
Fagerli et al.,
201484
BSRBR 666 (5 years) PsA ETN, ADA
and INF
After 5 years, 46.8% of patients were still on an initial anti-TNF-α
treatment LoE AE
Other/
missing
35.3% 28.8% 35.9%
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Publication (first
author and year
of publication)
Registry
name
Number of
patients (length
of follow-up) Population
Anti-TNFs
included Drug survival data Reason for discontinuation
Glintborg et al.,
201188
DANBIO 764 (9 years;
2135 patient-
years)
PsA ETN, ADA
and INF
The proportion of the cohort remaining on the same anti-TNF-α after
1 year was 0.70, and 0.57 at 2 years. The median drug survival was
2.9 years
LoE AE
23% 12%
Glintborg et al.,
201394
DANBIO 1422; 548
switchers
(10 years)
PsA ETN, ADA,
INF, GOL,
CZP and
other non-
anti-TNF
biologics
The median survival time for patients on their first course of
treatment was 2.2 years (95% CI 1.9 to 2.5 years). Second course
(n= 548), drug survival was 1.3 years (95% CI 1.0 to 1.6 years).
Third course (n= 189), median survival was 1.1 years (95% CI 0.7
to 1.5 years). The median drug survival of first anti-TNF-α among
switchers was 0.7 years (95% CI 0.6 to 0.8 years)
Course of
treatment
Any
(%)
LoE
(%)
AE
(%)
First 6 26 16
Second 55 28 15
Third 55 33 14
Glintborg et al.,
201492
DANBIO and
ICEBIO
462 (< 10 years;
1185 patient-
years)
PsA
(patients on
INF)
INF (variable
dose)
The 1-year drug survival for INF patients was 59.5% across both
registers. Dose did not affect drug survival or treatment response
LoE AE
25% 29%
Iannone et al.,
201593
GISEA 328 (2 years) PsA ETN, ADA
and INF
The 2-year overall drug survival was 0.67 NR
Kristensen et al.,
200885
SSATG 261 (7 years) PsA ETN, ADA
and INF
KaplanMeier graph estimates of drug survival were:
Time point
Treatment (proportion of patients
remaining on treatment)
Anti-TNF-α only Anti-TNF-α+MTX
1 year 0.65 0.8
3 years 0.55 0.6
5 years 0.375 0.4
Risk of AE lower with
concomitant MTX
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TABLE 34 Registry studies reporting data on anti-TNF drug survival and switching (continued )
Publication (first
author and year
of publication)
Registry
name
Number of
patients (length
of follow-up) Population
Anti-TNFs
included Drug survival data Reason for discontinuation
Mease et al.,
201587
CORRONA 497 (7 years) PsA ETN, ADA
and INF
The median survival time of patients being treated with anti-TNF-α
monotherapy was 30.8 months, and for those being treated with
combination therapy (anti-TNF+MTX or DMARD) was 32.4 months
NR
Saad et al., 200983 BSRBR 566 (3 years) PsA ETN, ADA
and INF
Treatment
Time point (proportion of
patients remaining on treatment)
1 year 2 years 3 years
Total first anti-TNF-α 0.82 0.70 0.59
ETN (n= 316) 0.86 0.79 0.65
ADA (n= 88) 0.91 0.70 0.66
INF (n= 162) 0.71 0.52 0.43
Switchers (n = 178) 0.74 0.66 
LoE AE
9.5% 10%
Simard et al.,
201186
ARTIS 1417 (9 years) PsA NR The KaplanMeier graph estimates of survival following treatment
with a first anti-TNF-α were 0.75 at 1 year, 0.63 at 2 years, 0.5 at
4 years, 0.37 at 6 years and 0.32 at 8 years
LoE AE
9.4% 8.2%
ARAD, Australian Rheumatology Association Database; ARTIS, Antirheumatic Therapies In Sweden; BIOBADASER, Spanish Society of Rheumatology Registry for AEs of Biological Therapies
in Rheumatic Diseases; BSRBR, British Society for Rheumatology Biologics Register; CORRONA, Consortium of Rheumatology Researchers of North America; GISEA, Italian Group for the
Study of Early Arthritis; ICEBIO, Icelandic Database for Biological Therapies; LoE, lack of efficacy; NOR-DMARD, Norwegian Antirheumatic Drug Register; NR, not reported; NS, not
significant; SSATG, Southern Sweden Antirheumatic Therapy Group.
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Reasons for discontinuation of treatment varied widely between studies, due in part to the inconsistency of
observation period duration. Across all registries, between 20% and 35% of patients withdrew from
treatment because of a lack of efficacy and, generally, a smaller proportion withdrew as a result of AEs.
The frequency of occurrence of AEs was linked to the types of anti-TNF used and whether or not patients
received concomitant MTX, which was generally found to reduce AE frequency when MTX subgroups
were analysed.
Only one study reported an analysis of response rates; this was based on the 3-month response rates
from the NOR-DMARD (n = 439).90 A retrospective comparison of response rates in switchers and non-
switchers found that switchers had a lower response rate to the first anti-TNF: for ACR 50, 30.5%
compared with 40%. In addition, the response to the second anti-TNF was lower than to the first: 22.5%
(compared with 30.5%, although this difference was not statistically significant). The same pattern was
seen for ACR 20 and 70 and, for the latter, the difference reached statistical significance.
In summary, across all relevant studies, those patients who switched treatment had a shorter median drug
survival time, also showing a continuously smaller proportion of patients remaining on each subsequent
treatment option. This may reflect a lack of improvement in treatment response after switching biologic;
however, there are limited direct data on the effect of sequential treatments on relevant outcome
measures. The proportion of patients withdrawing from treatment because of a lack of effect also seems
to increase with the number of times a patient switches anti-TNF therapy. The registry data suggest that,
although patients can benefit from a second (or further) anti-TNF, the expected benefit from anti-TNFs
diminishes after switching, with a reduced chance of response and reduced drug survival.
Effect of anti-tumour necrosis factors on radiographic progression and Health Assessment
Questionnaire-Disability Index score
Four patient registry studies that provided longitudinal data on the effect of anti-TNFs on HAQ-DI scores
were identified, one of which also reported on radiographic progression. The results of these are presented
in Table 35.
TABLE 35 Registries reporting the effects of anti-TNF treatment on HAQ-DI and radiographic progression
Publication (first
author and year
of publication) Study description Findings
Eder et al., 201496 Up to 4 years of radiographic
progression in 65 patients treated
with anti-TNF-α compared with 70
patients treated with MTX alone in
the University of Toronto cohort.
Only patients with bone erosions at
baseline were included
At the first assessment after baseline (12 years): MTX
group, 68% developed a new erosion in at least one joint,
80% of patients exhibited radiographic progression;
anti-TNF-α group, 56.4% had a new eroded joint and
58.9% had radiographic progression
At the 2- to 4-year assessment: MTX group, 84% developed
a new erosion, 88% had radiographic progression; anti-TNF-α
group, 75% had a new eroded joint and 61% with
radiographic progression
Time point
Treatment, HAQ-DI score (units)
Anti-TNF-α MTX
Baseline 0.9 ± 0.7 0.7 ± 0.7
12 years 0.6 ± 0.6 0.6 ± 0.6
34 years 0.6 ± 0.6 0.7 ± 0.7
continued
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One study96 reported on radiographic progression; a comparison of anti-TNF and MTX found an inhibitory
effect of anti-TNF on radiographic progression over 4 years of observation. Radiographic progression was
measured in terms of newly forming erosions and change in a modified Steinbrocker score; radiographic
progression according to both measures was significantly more prevalent in the MTX group at each
follow-up assessment.
TABLE 35 Registries reporting the effects of anti-TNF treatment on HAQ-DI and radiographic progression (continued )
Publication (first
author and year
of publication) Study description Findings
Fagerli et al.,
201490
Analysis of the effect of MTX co-
medication in 440 PsA patients in
the NOR-DMARD
The study found no difference in treatment response
between those on anti-TNF-α monotherapy and those with
concomitant MTX. Mean cohort HAQ-DI was recorded as
0.7 units at baseline, 0.39 units at 3 months and 0.38 units
at 6 months. Mean change from baseline at 3 months =
0.31 units
Glintborg et al.,
201188
Analysis of long-term anti-TNF
treatment response data from the
DANBIO register (n = 658). Measured
by HAQ-DI over 5 years
Time point
HAQ-DI score
(units)
Number of
patients
Baseline 1.0 658
2 weeks 0.75 275
6 weeks 0.6 366
6 months 0.6 406
1 year 0.4 318
2 years 0.4 229
3 years 0.3 127
4 years 0.3 104
5 years 0.5 45
Glintborg et al.,
201394
DANBIO (n= 1422; 548 switchers)
(10 years). PsA (ETN, ADA, INF, GOL,
CZP and other non-anti-TNF
biologics)
Anti-TNF
course of
treatment
Time point, median HAQ-DI score
(units) (IQR)
0 months 3 months 6 months
First
(n = 1422)
1 (0.51.5) 0.6 (0.11.1) 0.6 (0.11.0)
Second
(n = 548)
1.1 (0.61.6) 0.9 (0.41.5) 0.9 (0.41.4)
Third
(n = 189)
1.4 (0.92.9) 1.0 (0.61.5) 1.3 (0.51.6)
Saad et al., 201097 Evaluation of the effect of anti-TNF
therapies on quality of life and
functional status in the BSRBR cohort
of 596 PsA patients
Time point
Median HAQ-DI
score (units) (IQR)
Number of
patients
Baseline 1.88 (1.382.25) 562
6 months 1.25 (0.631.88) 424
12 months 1.38 (0.632.00) 382
18 months 1.38 (0.632.00) 344
IQR, interquartile range.
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Four studies88,90,96,97 reported on disease progression in terms of HAQ-DI score for between 6 months and
5 years at varying frequency. Eder et al.96 compared HAQ-DI score change in 70 patients treated with MTX
and 65 patients on an anti-TNF, finding no significant difference in HAQ-DI score between the groups at the
two assessments at up to 4 years from baseline. The HAQ-DI score was measured in 658 patients receiving
anti-TNFs for 5 years in the largest cohort88 (the DANBIO register). The baseline mean HAQ-DI score was
1.0 unit, decreasing to 0.3 units by 3 years, and increasing to 0.5 units at 5 years. This suggests sustained
long-term improvement of functional status during anti-TNF treatment, although the number of patients at
each time point after the 6-month assessment decreased significantly. Therefore, the trend of improving
HAQ-DI scores observed in this study is potentially due to a higher attrition of patients, with greater
functional impairment skewing the data. The third study on HAQ-DI change is from the NOR-DMARD,90
and showed an improvement in HAQ-DI score from 0.7 units at baseline to 0.39 units at 3 months, and
0.38 units at 6 months. This study also found no significant difference in HAQ-DI response in patients
receiving MTX compared with those on biologics alone. The BSRBR97 study followed an initial cohort of
562 patients on biologics for 18 months. This group of patients appears to have had more advanced disease
(12 years since onset) and poorer functional status than those in the other included studies, with a median
baseline HAQ-DI score of 1.88 units (95% CI 1.38 to 2.25 units). There is a 0.63-unit decrease in HAQ-DI
score between baseline and 6 months of treatment, representing what the authors describe as a clinically
important improvement. The median HAQ-DI score then increases to and remains at 1.38 units (95% CI
0.63 to 2.00 units) at both the 12- and 18-month assessments. Disease duration at the time of treatment
initiation in the BSRBR study was more than twice that in two of the aforementioned studies on the
HAQ-DI, showing that significant improvements in functional status are achievable using anti-TNF therapy in
advanced cases of PsA.
Treatment with anti-TNFs appears to yield significant improvement in radiographic progression and
long-term HAQ-DI score change in patient registry studies, although it is not clear to what extent the
treatment is responsible for the reduction in mean cohort HAQ-DI score over time. Estimation of HAQ-DI
score change using measures more robust to attrition bias or profiling those lost to follow-up based on
disease severity would have given a truer representation of HAQ-DI score change in these cohorts. The
paucity of radiographic data in these registry studies is perhaps surprising given the significance of
radiographic damage as a measure of disease progression and treatment effects. This lack of published
data may be because few of these registries were set up to record PsA-specific outcomes, and there has
historically been little consensus on a method for objectively taking and scoring joint radiographs in this
disease. It may be that HAQ-DI was usually preferred as an acceptable and standardised proxy for
assessing bone erosion and, as a patient-reported outcome measure, can be cheaply and routinely
recorded without the need for specialist assessment.
Review of the natural history of psoriatic arthritis: registry and cohort
study data
A total of four publications33,98100 analysing patterns of natural disease progression in registries or
long-term cohort data were found and are shown in Table 36. These were reviewed in order to gain an
understanding of the manner in which disease progresses in patients who do not receive anti-TNF therapy,
despite being eligible for treatment. Owing to the now ubiquitous nature of anti-TNFs and only recent
recognition of PsA as a separate and distinct form of arthritis, information on the long-term uncontrolled
progression of the disease is scarce. Two of the studies33,100 found in the literature search were different
analyses of the same data set derived from the Norfolk Arthritis Register (NOAR): one was a 2-year
prospective cohort study99 and the other a retrospective analysis of a Canadian single-site patient registry.98
The studies explore changes in functional disability in terms of HAQ-DI score and bone erosion as
measures of disease activity and progression over time. There is a great deal of variability between the
three cohorts under observation in terms of both baseline characteristics and patterns of disease. It should
be noted that disease classification of the NOAR cohort99,100 was performed retrospectively and both
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TABLE 36 Registries reporting on natural history of PsA
Publication
(first author
and year of
publication) Study description
Population
characteristics Findings
Husted et al.,
200598
Analysed long-term
change in physical
function of PsA patients
enrolled in the
University of Toronto
PsA cohort. Patients
were assigned to one of
three disability states
depending on physical
function and transition
between states was
recorded over time. 341
patients were observed
for up to 10 years
Anti-TNF-naive PsA
patients: male, n= 201;
female, n= 140; age
(mean), 45.9 years;
duration of PsA (mean),
10.6 years; PASI (mean),
7.1± 9.7 units; baseline
HAQ-DI score,
0.69± 0.67 units
Patients adhered to one of three longitudinal
patterns: 46% remained stable [28% of
patients remained in the no disability state
(HAQ-DI < 0.5 units)], 12% moderate
(0.51.5 units), and 6% in severe disability
(1.513 units) throughout the study.
26.7% made a single change to a lower or
higher disability group, reflecting steady
improvement or deterioration, and 27.3%
experienced two or more transitions between
states of disability. Mean time between
assessments was 1.29 years. Mean change in
HAQ-DI between consecutive assessments
in deteriorating patients was +0.55 units,
and was 0.57 units in improving patients.
Greater age was related to slower
improvement of HAQ-DI score in the
moderate and severe disability groups.
Decline in disability was slower in males than
in females, and time since diagnosis was
related to more frequent transition between
disability states. No association was found
between PASI score and transition between
disability states
Kane et al.,
200399
Analysis of 2-year
prospective study of
129 PsA patients at
St Vincents University
Hospital Early Arthritis
Clinic, Dublin, Ireland
Anti-TNF-naive PsA
patients: median PsA
symptom duration was
9.9 months and mean age
at presentation was
41.2 years. Baseline HAQ-DI
score was 0.71 units. 12%
of patients were on
DMARDS and 11% on
corticosteroids
The proportion of patients on DMARDs
increased to 59% at the 1-year assessment,
and was 56% at 2 years. Mean HAQ-DI
score decreased from 0.71 to 0.4 units at
both 1- and 2-year assessments and
measures of joint swelling also decreased.
DMARD-free remission at 1 and 2 years was
12% and 11%, respectively. Measures of
radiographic progression all increased from
baseline to 2 years and mean Sharp erosion
score increased from 1.2 units (SD 2.9 units)
at baseline to 3 units (SD 5.2 units) at 2 years
Morgan et al.,
2007100
Analysis of HAQ-DI
score change over
5 years in 79 patients
with inflammatory
arthritis plus psoriasis
in the NOAR data set
Patients with inflammatory
polyarthritis plus psoriasis:
Male, n= 36; female,
n= 43; age (median),
51.2 years; baseline
HAQ-DI score, 0.625 units
(IQR 0.251.375 units);
DMARD use, 16.5%
After 5 years, the median cohort HAQ-DI
score had increased from 0.625 to 0.75 units.
54% of the patients had used DMARDs over
the observational period
Rodgers et al.,
201133
Analysis of HAQ-DI
score change over
5 years in the NOAR
data set using inclusion
criteria specific to
eligibility for treatment
with biologics
(uncontrolled and have
tried two or more
DMARDs)
Included in the analysis
were patients with
inflammatory polyarthritis
plus psoriasis, three or
more tender joints and
three or more swollen
joints, and previous use of
two or more DMARDs
Patients meeting the eligibility criteria at
baseline (n= 27) had a HAQ-DI score of
1.55 units and for the first 2 years this
changed by 0.060 units per year. Between
years 3 and 5, the HAQ-DI score changed by
+0.077 units per year in those meeting the
eligibility criteria (n= 52)
IQR, interquartile range; SD, standard deviation.
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studies analysing the 79 patients emphasise that they are unlikely to be representative of PsA patients,
preferring instead to refer to them as having polyarthritis plus psoriasis. The Morgan et al.100 study
analysed the change in median cohort HAQ-DI score over 5 years in 79 patients, finding an increase of
0.125 units over the observation period, indicating a small increase of 0.025 units in HAQ-DI score every
year. The patients in this analysis may or may not have been treated with DMARDs over this period.
The analysis in Rodgers et al.33 includes only those patients who had previously received two or more
DMARDs at each time point, finding an annual HAQ-DI score change of 0.060 units per year over the first
2 years (n = 24), and an annual increase of 0.077 units over years 3 to 5 (n = 52). This represents a faster
progression of disease than that found in the Morgan et al.100 study, but is inconsistent and derived from a
small cohort of varying size.
A prospective cohort study of progression in early arthritis carried out by Kane et al.99 found that HAQ-DI
score changed from 0.71 units at baseline to 0.4 units at 1 year and remained as such until the end of the
2-year observation period, representing a decrease of 0.31 units. This decrease is likely to be explained by
the increase in uptake of DMARDs, as 12% of patients were receiving DMARD treatment at baseline,
compared with 59% at 1 year and 56% at 2 years. This was the only study that recorded radiographic
progression, finding consistent increases across all measures between baseline and 2 years, despite the
simultaneous drop in HAQ-DI score. The Sharp erosion score increased from 1.2 units at baseline to 3 units
at 2 years, demonstrating how HAQ-DI score change may not reflect progressive radiographic damage,
particularly during early disease.
The study by Husted et al.98 was the longest and largest study of natural history of PsA, with 341 patients
included and observed for up to 10 years. This study found that the patient population exhibited several
patterns of disease progression, rather than just universal consistent deterioration over time. Patients were
assigned to one of three disability states based on their HAQ-DI score. These were as follows: no disability
(a HAQ-DI score of < 0.5 units), moderate disability (a HAQ-DI score of 0.51.5 units) and severe disability
(a HAQ-DI score of 1.513.0 units). The transition of patients between groups was recorded over the course
of the observation period to ascertain the direction of change in their symptoms. Forty-six per cent
remained in the same disability group over the course of the study, with 28% of these in the no disability
state, 12% in the moderate state and 6% in the severely disabled state. A total of 26.7% of patients made
a single transition between disability groups, reflecting steady improvement or deterioration, and 27.3%
experienced two or more transitions between disability states. Although this methodology may reveal broad
patterns of disease progression, it appears to be insensitive to change within groups and weights HAQ-DI
score change near thresholds more highly (e.g. a patient with a baseline HAQ-DI score at the lower end of a
Markov group can experience a significant worsening of their disability without progressing into the next
group). Mean HAQ-DI score change between consecutive assessments was 0.55 units (± 0.32 units) for
those moving from a lower to a higher state and 0.57 units (± 0.36 units) for those moving to a lower
state, with assessments being on average 1.29 years apart. In those patients who did not move between
groups, the mean HAQ-DI score change was 0.002 units (± 0.215 units). A more complete picture
of patterns of disease progression would have been possible had there been more Markov states. The mean
HAQ-DI change for the majority of patients at any one time was effectively zero, but this may conceal
significant within-group changes in either direction. Greater age was associated with a slower improvement
in HAQ-DI score in those in the moderate and severe disability groups, and disability worsened more slowly
in males than in females. Time since PsA diagnosis was related to more frequent transition between
disability states, and there was no association between PASI score and transition between disability states.
In summary, this study indicates that functional disability (as measured via the HAQ-DI) in PsA is generally
stable over time in the majority of patients, but there are groups who exhibit patterns of more rapidly
worsening or improving symptoms at certain periods, with some experiencing fluctuating deterioration and
improvement over time.
Owing to the paucity of observational data on natural history of PsA, it is difficult to produce accurate
estimates of yearly disease progression rates without anti-TNF therapy. None of the included studies can
claim to provide accurate long-term estimates on uncontrolled disease progression. It is clear from the
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largest cohort that functional disability deteriorates over time, but the course of HAQ-DI progression is not
constant or predictable. Therefore, it is unclear if an average rate of HAQ-DI change is a useful statistic,
as this change is neither constant nor generalisable to the patient population. The Kane et al. study99
does show that, despite reductions in functional disability in early-stage disease under DMARD therapy,
radiographic progression continues to occur, which theoretically will ultimately result in worsening disability
in the long term; however, because of the lack of large and long-term observational studies, HAQ-DI
change over time in uncontrolled PsA is yet to be properly measured.
Review of adverse effects of certolizumab pegol, secukinumab
and comparators
Randomised trials of certolizumab pegol or secukinumab for psoriatic arthritis
Secukinumab: FUTURE 2
During the 16-week placebo-controlled period, AEs were reported in 54% and 58% of patients in the
pooled SEC and placebo groups, respectively. The most frequently reported AEs up to 16 weeks in any
SEC group (vs. placebo) were upper respiratory tract infection [(confidential information has been removed)
vs. 7%], nasopharyngitis [(confidential information has been removed) vs. 8%], headache [(confidential
information has been removed) vs. 4%], nausea [(confidential information has been removed) vs. 4%],
diarrhoea [(confidential information has been removed) vs. 3%] and urinary tract infection [(confidential
information has been removed) vs. 4%]. Rates of infections and infestations were similar across treatment
groups (27% on any SEC dose vs. 31% placebo), and no cases of active TB were reported.
The majority of AEs that occurred up to week 16 were mild [(confidential information has been removed)
of AEs on any SEC dose and (confidential information has been removed) on placebo] or moderate
[(confidential information has been removed) AEs on any SEC dose and (confidential information has been
removed) on placebo] in severity. Severe AEs were reported in five patients (1.7% of pooled SEC population),
compared with none in patients on placebo. Around 3% of patients in the SEC groups reported non-fatal
serious adverse events (SAEs), compared with 2% on placebo. More patients in the placebo group than in
the pooled SEC group discontinued study treatment as a result of an AE (confidential information has
been removed).
Certolizumab pegol: RAPID-PsA
During the 24-week period, the incidence of drug-related AEs was 26% in the pooled CZP group and
27% in the placebo group and they were mostly of mild intensity (51% pooled CZP vs. 54% placebo) or
moderate intensity (30% pooled CZP vs. 36% placebo). The incidence of serious AEs was 6.6% in the
pooled CZP group and 4.4% in the placebo group. The incidence of SAEs was 5.8% in the CZP 200 mg
group and 9.6% in the CZP 400 mg group.
(Confidential information has been removed.) The most common serious AEs were infections (confidential
information has been removed).
Open-label extensions of randomised controlled trials of certolizumab pegol
and secukinumab
Secukinumab: FUTURE 2
By the 52-week time point, the most common AEs experienced in patients receiving 300 mg were
infection and infestations (79 cases per 100 patient-years), upper respiratory tract infection (18 per 100
patient-years) and nasopharyngitis (14 per 100 patient-years). The rate of discontinuation as a result of AEs
in patients who received at least one dose of 150 mg of SEC was 2%. No deaths were reported.
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Secukinumab: FUTURE 1
At week 104, 79% of patients remained in the open-label extension study. Infections and infestations
were the most common AEs reported, occurring at a rate of 68 per 100 patient-years. Malignant or
unspecified tumours occurred at a rate of 0.3 per 100 patient-years, and major adverse cardiac event rates
occurred at a rate of 0.7 per 100 patient-years. No cases of active TB or suicide were reported. At week 52
the rate of discontinuation as a result of AEs was 3.9%.
Pooled safety analysis of plaque psoriasis and psoriatic arthritis trials
A conference abstract reported a pooled safety analysis for seven Phase III SEC trials: five plaque psoriasis
trials {ERASURE, FIXTURE, SCULPTURE [Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for
Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens], FEATURE
(First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response
at 12 Weeks) and JUNCTURE (Judging the Efficacy of Secukinumab in Patients With Psoriasis Using
AutoiNjector: a Clinical Trial Evaluating Treatment Results)} and two PsA trials (FUTURE 1 and FUTURE 2).101
All trials except FUTURE 2 contributed data up to (at least) 52 weeks; FUTURE had data up to 24 weeks.
A total of 3928 patients received at least one dose of SEC (3225 patient-years of exposure; mean exposure
299.8 days for SEC and 105.7 days for placebo). Exposure-adjusted incidence rates per 100 patient-years
for SEC and placebo were, respectively, 241 and 329 for AEs, 8 and 10 days for SAEs, and 93 and 94 for
infections/infestations. Around 3% of patients treated with SEC discontinued treatment as a result of an
AE. Nasopharyngitis and upper respiratory tract infections were the most commonly reported events.
Four deaths occurred in patients treated with SEC (one intracranial haemorrhage, one cardiorespiratory
arrest, one alcohol intoxication and one of unknown cause); all the deaths were deemed unrelated to the
SEC according to the investigators. There were two (0.05%) cases of suicidality with SEC: one attempted
suicide and one case of suicidal ideation.
Certolizumab pegol: RAPID-PsA
In the open-label extension study, 393 patients had been exposed to CZP by week 96 (total exposure
606 patient-years). At week 96, the incidence of overall treatment-emergent AEs was 87.8% (345/393
patients; 330 per 100 patient-years). The rate of SAEs was 17% (67 patients; 14.5 per 100 patient-years).
Around 4% of patients reported a serious infection (16 cases; 3.3 per 100 patient-years) and 14.2% of
patients reported an upper respiratory tract infection (56 patients; 13.7 per 100 patient-years), with no
cases of active TB. Malignancies were reported in 1% of patients (four patients; 0.7 per 100 patient-years).
By 96 weeks, 9.2% of patients had experienced an AE leading to withdrawal and six patients (1.5%)
had experienced an AE leading to death (two cardiac disorders, one sudden death, one case of breast
cancer, one case of sepsis and one lymphoma). According to the investigator, neither cardiac events was
considered to be related to the study medication.
Reviews of safety outcomes for other biologics
Six relevant reviews of AEs were identified from the searches. The key results for three of these reviews33,102,103
have been summarised in a recently published HTA journal publication of a MTA of anti-TNFs for ankylosing
spondylitis and non-radiographic axial spondyloarthritis.104
The Cochrane systematic review and NMA of AEs of nine biologics in adults with any disease (except
human immunodeficiency virus infection/acquired immunodeficiency syndrome) used data from 160 RCTs
(n = 48,676) and 46 open-label extension studies (n = 11,954).102 The most frequently studied disease in
the included trials was RA. When compared with control treatments, only INF and CZP were statistically
significantly associated with AEs. INF was associated with higher rates of total AEs [number needed to harm
13, 95% credible interval (CrI) 8 to 505] and withdrawals because of AEs (number needed to harm 10,
95% CrI 5 to 30). CZP was associated with higher rates of serious infections (number needed to harm 12,
95% CrI 4 to 79) and SAEs (number needed to harm 18, 95% CrI 9 to 162). An individual patient data
meta-analysis (n = 22,904 from 74 RCTs) examining short-term cancer risk associated with ETN, INF and
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ADA found no increase in risk of cancers excluding non-melanoma skin cancer (RR 0.99, 95% CI 0.61 to
1.68) when considering all three anti-TNFs together.103 However, a doubling in the risk of non-melanoma
skin cancer was found, with 332 events per 100,000 person-years in the control group and 655 events per
100,000 person-years in the anti-TNF group [hazard ratio (HR) 2.02, 95% CI 1.11 to 3.95]. NICE TA19933
included a review of studies (including both randomised and non-randomised studies) of the adverse
effects of ETN, INF and ADA. The rates of SAEs covered a broadly similar range across the three anti-TNFs.
However, all estimates were derived from a highly heterogeneous group of studies in terms of patients,
study design and treatment regimens so reliable estimates of the relative rate of SAEs for each anti-TNF
could not be made.33
Of the three more recent reviews identified,105107 two were reported only as conference abstracts.105,106 A
Danish guideline panel performed a NMA of SAEs from 87 RCTs (n = 27,333) of biologics for inflammatory
arthritis (RA, PsA and spondyloarthritis).105 The conference abstract reported the odds of a SAE to be
statistically significantly higher for CZP than for placebo (OR 1.6, 95% CI 1.19 to 2.16). Treatment with
CZP was also statistically significantly more likely to result in SAEs than treatment with GOL (OR 2.02,
95% CI 1.26 to 3.25), ETN (OR 1.70, 95% CI 1.15 to 2.51) or ADA (OR 1.44, 95% CI 1.02 to 2.02). The other
conference abstract reported a 2014 systematic review and meta-analysis on the safety profile of CZP in
patients with an immune-mediated inflammatory disease.106 The review identified 18 RCTs with 6992
participants; the results, presented in Table 37, also highlight the increased risk of SAEs associated with
CZP (compared with control), particularly the risk of infectious SAEs.
A review published in 2012 examined the safety of anti-TNFs for treating psoriasis and PsA and focused
mainly on data from European patient registries of biologics used across a range of diseases (mostly RA).107
It was (at least) partly funded by Pfizer, the manufacturer of ETN, and it did not appear to be systematic
in its methods of selection, critical appraisal and synthesis of the included studies. It concluded that the
safety profile of monoclonal antibodies (INF and ADA) seems generally less favourable than that of ETN,
particularly in terms of infections, cancer and hepatotoxicity. The conclusion for infections appeared largely
to be based on a BSRBR analysis, specifically on lower respiratory tract infections, even though a previous
BSRBR study reported no difference in the risk of infection between ADA, ETN and INF.108 The conclusion
for cancer appeared to be based on an analysis of a small number (38) of lymphomas in a casecontrol
study derived from the French Registry of Infections and Lymphoma in Patients Treated With TNF-α
TABLE 37 Results of a meta-analysis of safety outcomes for CZP47
Type of event Risk ratio vs. control (95% CI)
Overall AEs 1.07 (1.03 to 1.10)
Overall SAEs 1.58 (1.31 to 1.92)
Overall ADRs 1.20 (1.05 to 1.38)
Infectious SAEs 2.14 (1.34 to 3.43)
Injection site reactions 2.01 (0.95 to 4.29)
Neoplasms 1.18 (0.59 to 2.39)
TB 2.90 (0.73 to 11.43)
Withdrawals as a result of AEs 1.19 (0.96 to 1.47)
Fatal AEs 2.08 (0.83 to 5.17)
Infectious AEs 1.21 (1.09 to 1.34)
Upper respiratory tract infections 1.33 (1.15 to 1.53)
ADR, adverse drug reaction.
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Antagonists (the data were collected between 2004 and 2006).109 The conclusion for hepatotoxicity was
based on a very small number of case reports.
Recent large observational studies
One recent observational study on the safety of biologics in patients with PsA was identified. It was an
Israeli retrospective cohort study based on a health services database, which reported on 3128 patients
between 2002 and 2013. The study examined the association between traditional DMARDs or anti-TNFs
and infection by the herpes zoster virus (shingles). There were 182 cases of herpes zoster infection in
20,096 person-years. The risk of herpes zoster infection significantly increased in patients treated with a
combination of an anti-TNF and a traditional DMARD, but did not increase significantly with each of these
types of therapy alone.110
Summary
Safety assessments of new treatments can sometimes be limited in systematic reviews of RCTs because of
the small number of trials and relatively short follow-up durations for which data are available. Where
available, safety data from trials relating to the same treatment for other indications are therefore sometimes
evaluated. For this review, more data from trials of other patient populations were available for CZP than for
SEC. The results from three systematic reviews105107 (which looked specifically at AEs) suggested that CZP
was associated with statistically significantly more SAEs and serious infections than placebo. SEC was not
included in these systematic reviews of AEs, probably as a result of the limited availability of data at the time.
Although the safety data for SEC appear promising, the fairly small number of trials for which data are
currently available means there is still some uncertainty regarding its safety.
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Chapter 4 Evidence synthesis: relative efficacy
of treatments
The effectiveness of SEC and CZP has been summarised in Chapter 3. Results for the main outcomemeasures, ACR, PsARC, PASI, HAQ-DI and HAQ-DI conditional on PsARC, for all the comparator agents
(ETN, ADA, INF, GOL, UST and APR), have also been presented. These data indicate that all these agents
demonstrate statistically significant clinical efficacy in PsA. In order to determine the relative efficacy of these
agents it would be ideal to have the results from good-quality adequately powered RCTs comparing active
treatments with one another. However, as the evidence base is made up almost entirely of comparisons with
placebo, statistical methods for making indirect comparisons, such as a NMA, should be considered. NMA
enables the comparison of multiple treatments using both direct comparisons of interventions within RCTs
and indirect comparisons across trials based on a common comparator.111 As suggested by the term, NMA
needs a network of evidence to be established between all of the interventions of interest. The drugs being
evaluated here all have a common comparator: placebo. It is this common comparator that allows the
network between SEC, CZP and all the active comparators to be established and to provide information on
the benefits of these agents relative to placebo and each other. The relevant comparators included in the
evidence base are presented in Table 38 and the basic network diagram is presented in Figure 7.
Four separate outcomes were considered. Three outcomes were included in the NMA to inform the
economic model: PsARC response; change of HAQ-DI score conditional on PsARC response; and PASI 50,
PASI 75 and PASI 90 responses. In addition, ACR 20, ACR 50 and ACR 70 responses were analysed, as
ACR response is the primary outcome in most of the included trials. Trials with data suitable for the NMA
are identified in Table 39. Data from the 12-week time point were used, when available, otherwise data
relating to the closest time point after 12 weeks were used (normally 14 or 16 weeks). Not all trials
provided data for all of the outcomes analysed.
Framework of analyses
The evidence synthesis was undertaken using WinBUGS (version 1.4.3; MRC Biostatistics Unit, Cambridge, UK).
WinBUGS is a Bayesian analysis software tool that, through the use of Markov chain Monte Carlo methods,
evaluates posterior distributions for the parameters of interest given likelihood functions derived from data
and prior probabilities (uninformative priors were used throughout). There were few individual studies on
each treatment; therefore, fixed-effect models were used across studies in all analyses. Parameter estimates
TABLE 38 List of comparators included in evidence synthesis
Treatments, description Treatments, abbreviation Class of therapy
150mg of SEC SEC150 Anti-IL
300 mg of SEC SEC300 Anti-IL
400 mg of CZP CZP Anti-TNF
45mg of UST UST Anti-IL
50 mg of GOL GOL Anti-TNF
40mg of ADA ADA Anti-TNF
5 mg/kg of INF INF Anti-TNF
25mg of ETN ETN Anti-TNF
30mg of APR APR APR
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for all functional parameters were reported from the models. These differ by outcome, and further details
are presented in Methods. Treatment effects were expressed in relation to placebo. Owing to the sparse
evidence imposing a high level of uncertainty over estimates of functional parameters, point estimates are
medians throughout. Some models assumed exchangeability across treatments within a class, that is,
different treatments of the same class were assumed to be similar, rather than equal. Within such models
we reported the relative effectiveness estimates for each treatment (called shrunken estimates), rather than
the class means, allowing us to represent any residual differences across treatments.
The validity of a NMA depends on an assumption of homogeneity/exchangeability between all the trials
included in the network [i.e. that there are no essential differences between the methods, populations and
interventions being studied, and that any differences are a result of chance (as in a standard meta-analysis)].
The lack of homogeneity/exchangeability between studies involving one of the treatments of interest and
studies involving the other treatments of interest may generate inconsistency. Checking for consistency in
the current network was not possible because of the lack of trials that directly compare active agents. Our
examination of the study details and patient characteristics (see Chapter 3, Characteristics of the randomised
controlled trials included in the systematic review of short-term efficacy) identified that the trials of the
newer agents (SEC, CZP, UST and APR) included biologic-experienced patients as well as biologic-naive
patients. Given that it is evident from large observational data sets (see Chapter 3, Review of anti-tumour
necrosis factor patient registry studies) that efficacy response rates in biologic-experienced patients are
lower than in biologic-naive patients, it was considered inappropriate to conduct an all-patients NMA for
any outcome, and that, instead, biologic-naive and biologic-experienced patients should be analysed
separately. Therefore, separate analyses (separate networks) for treatment-naive and treatment-experienced
patients were constructed for each of the four outcomes: one each for PsARC, HAQ-DI conditional on
PsARC, PASI 50, 75 and 90, and ACR 20, 50 and 70 responses. A summary of the trials reporting data on
each of these outcomes is presented in Table 39. It should be noted that the NICE scope112 for the present
appraisal subdivides biologic-naive patients into those who have not responded to one cDMARD and those
who have not responded to two cDMARDs. However, sufficient data were not available for these further
levels of subgroup analysis.
APR 30 mg
PLA
UST 45 mg
SEC 300 mgSEC 150 mg
INF 5 mg/kg
GOL 50 mg
ETN 25 mg
CZP
PALACE 160RAPID-PsA47
Mease et al., 200454
Mease et al., 200053
GO-REVEAL50
IMPACT51
IMPACT 252
FUTURE 248
FUTURE 248
PSUMMIT 158
PSUMMIT 259,66
ADA 40 mg
ADEPT55
Genovese et al., 200756
SPIRIT-P157,67
PALACE 261
PALACE 365
FIGURE 7 Network of evidence (not outcome or subgroup specific). PLA, placebo.
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TABLE 39 Evidence on PsARC, HAQ-DI conditional on PsARC, PASI and ACR, by trial
Trial
Publication
year
Active
treatment
Outcome
PsARC
HAQ-DI score conditional on
PsARC PASI 50, PASI 75 and PASI 90 ACR 20, ACR 50 and ACR 70
Naive Experienced
Time
point
(weeks) Naive Experienced
Time
point
(weeks) Naive Experienced
Time
point
(weeks) Naive Experienced
Time
point
(weeks)
FUTURE 248 2015 SEC Yes Yes 12 Yes Yes 12 Yes Yes 12 Yes Yes 12
RAPID-PsA47 2014 CZP Yes Yesa 12 Yes Yesa 12 Yes Yesa 12 Yes Yesa 12
PSUMMIT 158,66 2013 UST Yes 24 Yesb 24 Yes 12 Yes 12
PSUMMIT 259,66 2014 UST Yes Yes 24 Yes 24 Yes Yes 12 Yes 12
GO-REVEAL50 2009 GOL Yes 14 Yes 14 Yes 14 Yes 14
Genovese et al.,
200756
2007 ADA Yes 12 Yes 12 Yes 12
ADEPT55 2005 ADA Yes 12 Yes 12 Yes 12 Yes 12
IMPACT 252 2005 INF Yes 14 Yes 14 Yes 14 Yes 14
IMPACT51 2005 INF Yes 16 Yes 16 Yes 16 Yes 16
Mease et al.,
200454
2004 ETN Yes 12 Yes 12 Yes 12
Mease et al.,
200053
2000 ETN Yes 12 Yes 12 Yes 12
PALACE 160,61 2014 APR Yes 16 Yes 16 Yes 16 Yes 16
PALACE 261,65 2014 APR Yes 16 Yes 16 Yes 16 Yes 16
PALACE 361,65 2014 APR Yes 16 Yes 16 Yes 16 Yes 16
SPIRIT-P157,67 2015 ADA Yes 12 Yes 12
a CZP treatment-experienced data not included in the NMA as the definition of treatment-experienced patients in this trial was different from that in other trials (see Chapter 3,
Characteristics of the randomised controlled trials included in the systematic review of short-term efficacy).
b Pooled data.
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As discussed in Chapter 3, Evaluating the secukinumab and certolizumab pegol trial results in comparison
with other treatments, another important difference between the included trials is the observed results in the
placebo arms, particularly for PsARC (see Table 40), PASI outcomes (see Table 50) and ACR (see Table 56).
Our investigations on trial designs and patient characteristics did not identify any clear reasons for such
differences, other than that placebo response rates appear to have increased over time. This observation
(termed placebo creep) has been made in several other areas of clinical research and its impact on indirect
treatment comparisons has been discussed.113 In the current review, across all trials, the PsARC placebo
response rates are high, but are much higher in more recently conducted trials, and this has implications
when interpreting unadjusted effect estimates. This is because the ceilings (maximum values) of RRs are
limited by baseline response rates. For example, in the FUTURE 2 trial,48 the placebo response rate for PsARC
in the biologic-naive subgroup was (confidential information has been removed), which meant that the
maximum possible RR would be (confidential information has been removed); this maximum result is lower
than some of the actual RRs for other biologics (see Table 40). Higher placebo rates therefore appear to dilute
effect estimates somewhat. This is also demonstrated by the examining the RRs moving up the ACR outcome
thresholds from ACR 20 to ACR 70, which generally increase (see Table 29). However, it is not clear exactly
how these varying placebo rates will affect treatment effects when calculated using ORs. The evidence
synthesis  which was based on ORs  therefore explored a potential relationship between baseline risk and
relative effectiveness. The NMA explored scenarios where a metaregression on baseline risk (i.e. placebo
response) was implemented for PsARC, PASI and ACR outcomes, which imposes an interaction effect
between baseline risk and relative effectiveness.114 Further details of these analyses are presented below.
Given that HAQ-DI scores are modelled conditional on PsARC response, such an interaction effect was
deemed to be less relevant, and a metaregression model was not implemented on HAQ-DI.
Psoriatic Arthritis Response Criteria response
Subpopulation: biologic naive
Data
For the biologic-naive population, trial-specific PsARC response data were available from 14 trials47,48,5056,5861,65,66
of nine active treatments (150mg of SEC, 300mg of SEC, CZP, UST, GOL, ADA, INF, ETN and APR), and all
treatments were compared with placebo (Table 40).
The nine active treatments were categorised into three classes (anti-TNF, anti-IL and APR). Outcome data
for GOL, INF and APR at 1416 weeks, and for UST at 24 weeks, were included in the analysis and
assumed equivalent to outcomes at 12 weeks. The inclusion of the 24-week PsARC data for UST was
based on an assumption that they fairly reflected the 12-week results (subgroup results for PsARC at
12 weeks in the PSUMMIT 2 trial59,66 were not available, although 12-week data for the full population
were available); this issue is discussed further in Appendix 3, Data used for the ustekinumab (PSUMMIT)
trials. The trial-specific data included in the PsARC response analysis are presented in Table 40.
Methods
The NMA implemented separate models for the pooling of treatment effects and of placebo responses.
We first implemented a model with independent treatment effects across treatments. Then a number of
alternative models were implemented to explore the possibility of placebo response, and, within this,
whether or not there was similarity between treatment effects for treatments of the same class.
Exploring placebo response as a treatment effect modifier
An examination of individual trial results suggests that studies presenting higher placebo rates report lower
relative effectiveness estimates (see Appendix 3, Detailed methods for the biologic-naive subpopulation).
In addition, recent trials, which evaluate newer treatments, also tend to show higher placebo response rates.
For example, a recent study on 300 mg of SEC showed a placebo response rate of 46% (the FUTURE 2
trial48), which is much higher than that reported in an earlier study evaluating ETN, of 23% (Mease et al.53).
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TABLE 40 Summary of trial-specific data in the biologic-naive subpopulation for PsARC response
Trial Treatment arm
PsARC response
OR (95% CI) RR (95% CI)
Treatment arms Placebo
ra nb % ra nb %
FUTURE 248 300mg of SEC Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
3.19 (1.80 to 5.66) 1.59 (1.17 to 2.15)
FUTURE 248 150mg of SEC Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
3.17 (1.77 to 5.67) 1.59 1.17 to 2.16)
RAPID-PsA47 CZP Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
2.98 (2.00 to 4.44) 1.61 (1.28 to 2.04)
PSUMMIT 158 UST 115 205 56 77 206 37 2.14 (1.51 to 3.03) 1.50 (1.21 to 1.86)
PSUMMIT 259,66 UST 24 43 56 16 42 38 2.05 (0.96 to 4.40) 1.47 (0.92 to 2.34)
GO-REVEAL50 GOL 107 146 73 24 113 21 10.17 (6.13 to 16.88) 3.45 (2.39 to 4.99)
Genovese et al., 200756 ADA 26 51 51 14 51 27 2.75 (1.29 to 5.86) 1.86 (1.10 to 3.13)
ADEPT55 ADA 94 153 61 42 162 26 4.55 (2.97 to 6.97) 2.37 (1.77 to 3.16)
IMPACT 252 INF 77 100 77 27 100 27 9.05 (5.39 to 15.20) 2.85 (2.03 to 4.01)
IMPACT51 INF 39 52 75 11 52 21 11.18 (5.17 to 24.19) 3.55 (2.05 to 6.13)
Mease et al., 200454 ETN 73 101 72 32 104 31 5.87 (3.57 to 9.65) 2.35 (1.72 to 3.21)
Mease et al., 200053 ETN 26 30 87 7 30 23 21.36 (8.05 to 56.68) 3.71 (1.91 to 7.21)
PALACE 160,61 APR 78 168 46 50 168 30 2.05 (1.35 to 3.10) 1.56 (1.17 to 2.07)
PALACE 261,65 APR 78 162 48 53 159 33 1.86 (1.23 to 2.80) 1.44 (1.10 to 1.90)
PALACE 361,65 APR 88 167 53 46 169 27 2.98 (1.97 to 4.51) 1.94 (1.46 to 2.58)
a Number of PsARC responders.
b Number randomised.
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Our investigations regarding trial designs and patient characteristics did not identify a clear reason for such
differences, although placebo response rates appear to have increased over time. We investigated the effect
of placebo response as a potential treatment effect modifier. It should be noted that the source of any
relationship between placebo response and treatment effect is unclear, and the reader should interpret the
results carefully and with caution.
To account for the differences in placebo response rates across the trials, a metaregression was undertaken.
The baseline risk estimated for each trial within the synthesis model was used as the adjustment covariate.
This allows for uncertainty in the estimation of baseline risk to be considered in the adjustment alongside
any correlation with the log-ORs. Note that the baseline risk is expressed as the log-odds of PsARC response
in the placebo arm. As typical of metaregression, the relationship between the treatment effect and baseline
risk is defined by an interaction term (beta).
Within the independent treatment-effects analysis, beta is estimated by comparing the treatment effects
across multiple studies on the same treatment with different placebo response rates. Within the evidence
base, not all treatments present with multiple trials. Thus, only a subset of treatments contribute evidence
to estimate beta: ADA (ADEPT55 and Genovese et al.56), ETN (Mease et al.53,54) and APR (the PALACE 1,60,61
PALACE 261,65 and PALACE 361,65 trials). This limitation in the evidence base meant that the beta had to be
assumed to be independent of treatment (i.e. equal for all treatments). Moreover, the evidence base also
showed that studies on the same treatment report reasonably similar placebo response rates. This may
limit the validity of inferences over beta. For example, the Genovese et al.56 and ADEPT55 studies report
placebo response rates of 27% and 26%, respectively, whereas across the whole set of studies the
placebo response range from 21% to (confidential information has been removed).
As inferences on beta are drawn from differences between trials, the smallest difference in placebo rates
corresponds to the maximum possible influential difference in reported treatment effects. The two trials on
ADA (ADEPT55 and Genovese et al.56) illustrate this perfectly: the small (1%) difference in placebo response
is associated with a 10% difference in response rate in the treatment group (from 51% to 61%). These
data are thus influential to estimates of beta. Of the studies that contribute to inferences on beta, two
trials have the smallest sample size of the whole set of trials: Mease et al.53 (ETN) and Genovese et al.56
(ADA). Given this, a sensitivity analysis excluding both Mease et al.53 and Genovese et al.56 was performed
and effects on the estimate of beta ascertained (see Appendix 3, Detailed methods for the biologic-naive
subpopulation for a more detailed account of the methods).53,56
Exploring treatment effects as class
In the context of an adjusted model for placebo response, we explored the possibility of there being
class effects. Three different class groupings were considered: all treatments as a single class; all biologics
as a class with APR separate; and, to reflect the pharmacology, anti-TNFs grouped, ILs grouped and APR
separate. Additionally, for the last two groupings, we explored two within-class assumptions: assuming
treatments within a class to have equal effectiveness and, alternatively, that treatments within a class have
similar (exchangeable) effectiveness. Fixed effects across studies were assumed for all models. We did not
consider models assuming exchangeability between classes.
Summary of all treatment effect models explored
All models implemented for the evidence synthesis of PsARC response are presented in Table 41. The
models are numbered for ease of reference. Details of the models are presented in Appendix 3, Detailed
methods for the biologic-naive subpopulation.
Model A1 considers the effectiveness of treatments as independent of each other. Model B1 considers the
relative effectiveness of the alternative treatments as independent of each other, but that they all depend
on the response in the placebo arm. Models C1, C2 and C3 consider the treatments as equal in terms of
their effectiveness within class, but dependent on the effect of the placebo arm. Models D1 and D2
assume the treatments to have a similar, but not equal, effectiveness that is dependent on the effect of
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the placebo arm; this model introduces more flexibility than assuming treatment effects to be equal
(models C2 and C3), but does not fully assume treatments to differ as in model A1. It allows for
differences between the effectiveness of treatments that we may not be able to explain but that we
should consider.
As stated earlier, sensitivity analysis around the adjustment for placebo response were performed: sets of
analyses (models A1, B1, C1, C2, C3, D1 and D2) were conducted for PsARC response, excluding the
Mease et al.53 and Genovese et al.56 trials.
Network meta-analysis results
Treatment effect models
Table 42 presents results of the treatment effects of PsARC response on the log-odds scale. Results are
presented for all the alternative models with measures of goodness of fit. There were no issues with
convergence. More detailed results of the models (A1, B1, C1, C2, C3, D1 and D2) are presented in
Appendix 3, Detailed results for the biologic-naive subpopulation (ORs as well as log-odds, together with
means, medians and 95% CIs are presented).
The unadjusted model A1 indicates an appropriate model fit (with residual deviance close to the number
of data points informing the model). The placebo response-adjusted model B1 fits well compared with the
unadjusted model A1 [it presents a smaller deviance information criterion (DIC) and residual deviance, but
not significantly so, as the difference in DIC is < 5 points].115 Model B1 imposes an association between the
log-odds of placebo response and treatment effect. The estimated beta implies that a trial with a higher
odds of a placebo response is expected to report smaller treatment effects. Consider 300 mg of SEC in
unadjusted model A1: the treatment effect is evaluated at 1.178, but the studies on this treatment have a
higher log-odds of placebo response than those on other anti-TNFs. The treatment effects reported in the
adjusted model assume all treatments were trialled with the same baseline risk. Thus, after adjustment
TABLE 41 Key assumptions of models implemented for the evidence synthesis of PsARC response
Sets of analysis Study Treatment Metaregression Class
A1 FE Independent No baseline adjustment No class effect
B1 FE Independent Common interaction
term with log-odds of
response in placebo arm
No class effect
C1 FE Equal | class Common interaction
term with log-odds of
response in placebo arm
Independent class effect:
class= {all treatments}
C2 FE Equal | class, remaining
treatments independenta
Independent class effect:
class= APR independent
{all remaining biologics}
C3 FE Equal | class, remaining
treatments independenta
Independent class effect:
class= {anti-TNFs, ILs};
APR independent
D1 FE Exchangeable | class,
remaining treatments
independenta
Common interaction
term with log-odds of
response in placebo arm
Independent class effect:
class= APR independent
{all other biologics}
D2 FE Exchangeable | class,
remaining treatments
independenta
Independent class effect:
class= {anti-TNFs, ILs};
APR independent
FE, fixed effect.
a APR independent.
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TABLE 42 Network meta-analysis results of PsARC response: log-ORs (median) of treatments analysed (including the studies of Genovese et al.56 and Mease et al.53) in the
biologic-naive subpopulation
Placebo-adjusted metaregression No Yes Yes Yes Yes Yes Yes
Treatment Ind Ind = | class = | class = | class ∼ | classa ∼ | classa
Class No No {All} {APR, other} {IL, TNF, APR} {APR, other} {ILs ,TNFs, APR}
Log-odds placebo A1 r B1 r C1 r C2 r C3 r D1 r D2 r
300mg of SEC 0.16 1.178 5 2.110 1 1.844 3 1.833 3
150mg of SEC 0.16 1.175 6 2.104 2 1.285 2 1.839 4 1.822 4
UST 0.51 0.758 9 1.187 7 1.197 8 1.174 8
CZP 0.28 1.094 7 1.837 5 1.278 1 1.565 1 1.722 5 1.716 5
GOL 1.32 2.339 1 1.619 6 1.692 6 1.712 6
ADA 1.02 1.401 4 1.081 8 1.648 1 1.201 7 1.201 7
INF 1.15 2.296 2 1.870 4 1.853 2 1.875 1
ETN 0.99 2.043 3 1.917 3 1.856 1 1.872 2
APR 0.85 0.813 8 0.765 9 0.756 2 0.779 3 0.769 9 0.771 9
Beta (mean)  1.471 0.498 1.692 1.061 1.264 1.225
Residual devianceb 29.9 27.2 59.24 46.8 47.5 27.8 27.9
DIC 193.1 190.5 N/Ac 203.8 199.1 190.0 190.3
= | class, equal class effect; ∼ | class, exchangeable class effect; ind, independent treatment effect; N/A, not applicable; pD, posterior mean of the deviance minus the deviance of the
posterior means; r, ranking of treatments according to point estimates.
a Shrunken estimates.
b Compared with 27 data points.
c N/A as the model C1 does not fit well and estimated lower posterior mean of the deviance than the deviance of the posterior means, which resulted in a negative pD and a lower DIC,
therefore we only use residual deviance as model fit statistics for model C1.
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with the placebo response in model B1, the treatment effect estimate for 300 mg of SEC is higher (2.110).
This is why the results (and rankings) generated by model B1 are very different from the observed trial
results and results generated by the model A1.
Although the assumptions imposed by the placebo-adjusted model may be difficult to justify, or counteract,
the limitations in the evidence base that underlie inferences also limit interpretation. First, the distinction
between treatment effects and placebo effect is unclear. This is because newer treatments tested under
higher placebo response rates show lower treatment effects, whereas older treatments tested under lower
placebo response rates show higher treatment effects. There is also limited evidence on the effects of
different placebo response rates for the newer treatments (SEC and CZP), as these drugs were studied in a
single trial each.
We have further explored treatment effects as class. Model C1, which assumes that all treatments are
equal, does not fit well with the existing data as it shows a much increased residual deviance. Models C2
and C3, which assume treatment equal within their class (model C2 separates APR from other drugs and
model C3 separates ILs, anti-TNFs and APR), also do not fit well with the existing data, resulting in higher
residual deviance and DIC. Models D1 and D2, however, relax the assumption of equality and apply a class
effect where treatments within a class are assumed to be similar, not equal. These models fit equally well
when compared with model B1 (similar DIC and residual deviance).
In all models exploring treatment effects as a class, the interaction term (beta) is negative. Among the
best-fitting models (B1, D1 and D2), the more negative interaction term is observed in model B1. The
interaction terms are similar between models D1 and D2.
In sensitivity analyses, we explored the effect of excluding the studies of Genovese et al.56 and Mease et al.53
on the placebo interactions (see Appendix 3, Detailed results for the biologic-naive subpopulation for details).
The results showed that the beta is still negative, although of lower absolute value.53,56
Preferred models
The unadjusted model A1 fits the data as well as any of the other models and generates results that reflect
the observed results of individual trials. Alternatively, we considered a model adjusted for placebo response.
Despite no clear rationale for why placebo response rate should affect the treatment effect, when allowing
for such an association (model B1), lower treatment effects are expected with higher placebo response
rates. The results (and rankings) attained with model B1 are very different to those evaluated in model A1,
and depend on the credibility of the association assumed. Regarding possible class effects, the analyses found
that an assumption of equal class effect for the treatments does not produce a better-fitting model (models
C1, C2 and C3) than assuming independent treatment effects (models A1 and B1) or similar treatment
effects (models D1 and D2). There was little difference in goodness-of-fit statistics (DIC and residual deviance)
between models D1 and D2, and we consider the exchangeable class effect model (D2), which utilised two
classes (anti-IL and anti-TNF) with APR separate, to be the most clinically plausible.53,56 Hence, we consider
models A1 and D253,56 to be our preferred models for the economic model in Chapter 6. Given the limited
effect in sensitivity analysis, the Genovese et al.56 and Mease et al.53 studies were included in the
preferred models.
A comparison of these analyses with those presented in the company submissions (CSs; Novartis and
UCB Pharma) and those in the previous MTA (Rodgers et al.33) is presented in Appendix 3, Comparison
of the network meta-analysis of Psoriatic Arthritis Response Criteria responses in the company submissions
(Novartis and UCB Pharma), a previous multiple technology appraisal (Rodgers et al.) and the current
Assessment Group.
Table 43 presents the probability and ORs for PSARC response from these preferred models.
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The NMA that does not adjust for the placebo response finds that SEC is more effective than CZP, and
both are more effective than UST and APR, but both are somewhat less effective than all comparator
anti-TNFs. After adjusting for the unexplained increase in placebo rates seen in more recent trials (and,
hence, of newer agents), and under a class effect that allows for exchangeability for treatments within
each class, the probability of a response with SEC remains slightly higher than with CZP and both remain
more effective than UST and APR, but now their probability of response is similar to, or only slightly less
than, that of the anti-TNF comparators.
These results indicate that, although SEC and CZP are effective in terms of the PsARC outcome, the
relative effectiveness of these biologics compared with ETN, ADA, GOL, UST and INF and with each other,
is uncertain. Both agents do seem to be more effective than APR.
Subpopulation: biologic experienced
For the biologic-experienced population, trial-specific PsARC response data were available from three
trials for three active treatments (300 mg of SEC, CZP and UST), all compared with placebo.47,48,59,66
However, the data from the CZP trial were not included in the analysis, as the RAPID-PsA trial excluded
patients with primary failures of a prior anti-TNF (i.e. no response within the first 12 weeks of treatment)
from being recruited in its biologic-experienced population and so is not comparable to the other two
trials. The data included in the NMA for treatment-experienced patients are presented in Table 44.
The NMA conducted for the synthesis of data in the biologic-experienced population is equal to that
implemented in the treatment-naive population: treatment effects are assumed to be independent and the
model assumed fixed effects across trials. The evidence for the biologic-experienced subpopulation was
sparse. The results of the analysis are presented in the Table 45. The result shows that the probability of a
PsARC response is higher with SEC than with UST, but the CrIs overlap and the difference is likely to be
insignificant. The results are comparable to the observed data (compare Tables 44 and 45) and consistent
with those of the biologic-naive subpopulation (compare Tables 43 and 45).
TABLE 43 Network meta-analysis results: probability of PsARC response and ORs by treatments in the
biologic-naive subpopulation
Treatment
Not adjusted for placebo response,
independent treatment (model A1)
Adjusted for placebo response, class effects
assumeda (model D2)
Probability, median
(95% CrI) OR, median (95% CrI)
Probability, median
(95% CrI) OR, median (95% CrI)
Placebo 0.31 (0.26 to 0.36) 0.31 (0.26 to 0.36)
300 mg of SEC 0.59 (0.40 to 0.76) 3.25 (1.56 to 6.89) 0.73 (0.57 to 0.86) 6.25 (3.15 to 13.31)
150 mg of SEC 0.59 (0.40 to 0.76) 3.24 (1.54 to 6.96) 0.73 (0.57 to 0.86) 6.18 (3.10 to 13.30)
UST 0.49 (0.38 to 0.60) 2.13 (1.49 to 3.07) 0.59 (0.48 to 0.70) 3.24 (2.25 to 4.86)
CZP 0.57 (0.44 to 0.69) 2.99 (1.88 to 4.81) 0.71 (0.60 to 0.81) 5.56 (3.59 to 9.11)
GOL 0.82 (0.71 to 0.90) 10.37 (5.87 to 18.98) 0.71 (0.58 to 0.81) 5.54 (3.23 to 9.06)
ADA 0.64 (0.53 to 0.75) 4.06 (2.70 to 6.21) 0.60 (0.49 to 0.69) 3.33 (2.30 to 4.70)
INF 0.81 (0.71 to 0.89) 9.93 (5.91 to 17.06) 0.74 (0.63 to 0.83) 6.52 (4.18 to 10.04)
ETN 0.77 (0.65 to 0.86) 7.71 (4.53 to 13.58) 0.74 (0.64 to 0.82) 6.50 (4.38 to 9.85)
APR 0.50 (0.41 to 0.59) 2.26 (1.73 to 2.94) 0.49 (0.41 to 0.57) 2.16 (1.76 to 2.64)
a Shrunken estimates presented here.
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Health Assessment Questionnaire-Disability Index changes conditional
on Psoriatic Arthritis Response Criteria response/non-response
Subpopulation: biologic naive
Data
For the biologic-naive population, HAQ-DI changes conditional on PsARC responses were available for nine
active treatments (150 mg of SEC, 300 mg of SEC, CZP, UST, GOL, ADA, INF, ETN and APR) from 13 trials
(see Table 39).47,48,5052,5456,5861,65,66 The data for HAQ-DI change conditional on PsARC response are presented
in Table 46.
Outcome data for GOL and INF at 1416 weeks, and for UST at 24 weeks, were included in the analysis
and assumed equivalent to outcomes at 12 weeks. The rationale for the inclusion of the 24-week data for
UST is discussed in Appendix 3, Data used for the ustekinumab (PSUMMIT) trials. The observed data
indicate that HAQ-DI changes conditional on PsARC response do vary by treatment, ranging between
(confidential information has been removed) (300 mg of SEC, FUTURE 2 trial48) and 0.290 (APR, PALACE 3
trial61,65). The observed HAQ-DI changes conditional on PsARC non-response in treatments range
between (confidential information has been removed) (150 mg of SEC, FUTURE 2 trial48) and 0.049
(GOL, GO-REVEAL trial50).
For the placebo arms, the observed HAQ-DI changes conditional on PsARC response and non-response
differ between trials [ranging between (confidential information has been removed) (FUTURE 2 trial48) and
0.160 (IMPACT 252) for response, and from (confidential information has been removed) (RAPID-PsA
trial47) to 0.070 (IMPACT 252) for non-response].
The observed HAQ-DI changes conditional on PsARC response and non-response with treatments are
greater than with placebo in all trials.
Methods
We consider three models to estimate the HAQ-DI changes conditional on PsARC responder or non-responder
status. A detailed description of the model and underlying assumptions are presented in Appendix 3, Detailed
methods for the biologic-naive subpopulation. The model E1 considers that treatments are independent
and considers fixed effects across studies. Models E2 and E3 apply a class effect comprising three groups:
anti-TNFs, ILs and APR. This class effect reflects the best-fitting class effect model for PsARC (see Network
meta-analysis results). The model E2 assumes that the treatments are similar within class (exchangeable)
and considers fixed effects across studies; and model E3 considers that the treatments are equal within class
and considers fixed effects across studies.
TABLE 45 Network meta-analysis results of PsARC response: probability of a PsARC response, ORs and treatment
effects on a log-scale in the biologic-experienced subpopulation
Treatment
Probability of PsARC response,
median (95% CrI) OR, median (95% CrI)
Treatment effects (log-odds),
median (95% CrI)
Placebo 0.266 (0.19 to 0.36) 1.013 (1.48 to 0.58)
300 mg of SEC 0.686 (0.41 to 0.88) 6.033 (2.15 to 18.39) 1.797 (0.77 to 2.91)
UST 0.566 (0.35 to 0.76) 3.559 (1.68 to 7.76) 1.279 (0.53 to 2.07)
Residual deviancea 4.07
DIC 24.62
a Compared four data points.
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TABLE 46 The HAQ-DI changes conditional on PsARC response and non-response by trials and treatments in the biologic-naive subpopulation: observed data
Trial Treatment
HAQ-DI changes conditional on PsARC response HAQ-DI changes conditional on PsARC non-response
Treatment arm Placebo arm Treatment arm Placebo arm
Mean SE Mean SE Mean SE Mean SE
FUTURE 248 150mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
FUTURE 248 300mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
RAPID-PsA47 CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
PSUMMIT 1 +
PSUMMIT 258,59,66
UST 0.487 0.05 0.260 0.04 0.097 0.05 0.001 0.03
GO-REVEAL50 GOL 0.424 0.07 0.286 0.05 0.049 0.06 0.023 0.02
ADEPT55 ADA 0.500 0.05 0.313 0.08 0.120 0.05 0.026 0.04
Genovese et al.,
200756
ADA 0.423 0.08 0.177 0.06 0.150 0.09 0.057 0.05
IMPACT 252 INF 0.580 0.06 0.160 0.10 0.110 0.06 0.070 0.04
IMPACT51 INF 0.650 0.09 0.270 0.14 0.200 0.09 0.020 0.05
Mease et al., 200454 ETN 0.635 0.06 0.258 0.01 0.196 0.07 0.002 0.04
PALACE 160,61 APR 0.460 0.05 0.320 0.07 0.070 0.05 0.000 0.04
PALACE 261,65 APR 0.330 0.06 0.220 0.07 0.120 0.05 0.010 0.04
PALACE 361,65 APR 0.290 0.05 0.250 0.06 0.080 0.05 0.000 0.03
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Network meta-analysis results
The results are presented as absolute changes in HAQ-DI score in relation to baseline (Table 47). More
detailed results are presented in Appendix 3, Detailed results for the biologic-naive subpopulation.
The model fit statistics (DIC) indicate that neither class effect model (E2 or E3) is a better fit for the data
than the unadjusted, independent treatments model (E1). The class effect models had similar fits, but the
one that allowed exchangeability within classes (E2) was considered to be the most clinically plausible.
For the purposes of the economic model, in Chapter 6, models E1 and E2 were the preferred models.
The results from the two preferred models are similar. The results from the unadjusted independent
treatment effects model found that significant reductions in mean HAQ-DI score were achieved with response
to all nine treatments and response to placebo. However, patients who responded to placebo achieved a
lower level of improvement in the HAQ-DI score than those who responded to active treatment. Furthermore,
the improvement in response to placebo is below the minimally important difference for PsA of 0.35.116
The median conditional on response HAQ-DI change was highest with INF and ETN, followed by 300 mg
of SEC, but 150 mg of SEC and CZP were worse than all treatments except for APR.
Subpopulation: biologic experienced
For the biologic-experienced population, HAQ-DI changes conditional on PsARC responses were available
for three active treatments (300 mg of SEC, CZP and UST) from three trials.47,48,59,66 However, the data from
the CZP trial were not included in the analysis as the biologic-experienced population in the RAPID-PsA
trial is not comparable to that in the other two trials48,59,66 (see Psoriatic Arthritis Response Criteria
response, Subpopulation: biologic experienced). The data included in the NMA for treatment-experienced
patients are presented in Table 48.
Outcome data at 24-week were included in the analysis and assumed equivalent to outcomes at 12 weeks
[see Appendix 3, Data used for the ustekinumab (PSUMMIT) trials]. The observed data indicate that, as in
the treatment-naive subgroup, HAQ-DI changes conditional on PsARC response do vary by treatments.
The observed HAQ-DI changes conditional on PsARC response and non-response in placebo arms differ
between trials. The observed HAQ-DI changes conditional on PsARC response and non-response with
treatments are greater than placebo in all trials.
The NMA conducted for the synthesis of data in the biologic-experienced population is equal to that
implemented in the treatment-naive population: treatment effects are assumed to be independent and the
model assumed fixed effects across trials. No class effect assumption was made for this subgroup analysis.
The results are presented as absolute changes in HAQ-DI score in relation to baseline (Table 49). These
results are generally comparable with the observed estimates from the primary studies.
The results from the independent treatment effects model found that significant reductions in mean HAQ-DI
score were achieved with response to SEC and UST, and response to placebo. As for the biologic-naive
patients, those who responded to placebo achieved a lower level of improvement in the HAQ-DI score than
those who responded to active treatments. Furthermore, the improvement in responders to placebo is
below the minimally important difference for PsA of 0.35.116
Psoriasis Area and Severity Index response
Subpopulation: biologic naive
Data
For the biologic-naive population, PASI response data were available for nine active treatments (150 mg of
SEC, 300 mg of SEC, CZP, UST, GOL, ADA, INF, ETN and APR) from 13 trials4767 (see Table 2). A brief
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TABLE 47 Network meta-analysis results of HAQ-DI score changes (median) conditional on PsARC response and non-response in the biologic-naive subpopulation
Treatment
Independent treatment
Exchangeable | class
{ILs, TNFs, APR} Equal | class {ILs, TNFs, APR}
PsARC response vs. non-response
FE FE FE
E1 E2a E3
Study
PsARC
response
PsARC
non-response
PsARC
response
PsARC
non-response
PsARC
response
PsARC
non-response E1 rb E2a rb E3 rb
Placebo 0.26 0.26 0.25 0.26 10 0.26 10 0.25 4
150mg of SEC 0.39 0.08 0.44 0.09 0.31 8 0.35 8
300mg of SEC 0.55 0.05 0.51 0.08 0.47 0.08 0.49 1 0.43 3 0.39 1
UST 0.49 0.10 0.48 0.09 0.39 4 0.39 4
CZP 0.43 0.07 0.47 0.12 0.36 6 0.35 7
GOL 0.44 0.06 0.49 0.11 0.52 0.13 0.38 5 0.37 5 0.39 1
ADA 0.49 0.13 0.50 0.13 0.36 7 0.37 6
INF 0.66 0.20 0.60 0.14 0.46 2 0.46 1
ETN 0.64 0.20 0.59 0.14 0.44 3 0.45 2
APR 0.36 0.09 0.36 0.09 0.36 0.09 0.27 9 0.27 9 0.27 3
DIC 126.0 133.0 131.4
FE, fixed effect.
a Shrunken estimates.
b Ranking of treatments according to point estimates.
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TABLE 48 The HAQ-DI score changes conditional on PsARC response and non-response by trials and treatments in the biologic-experienced subpopulation: observed data
Trial Treatment
HAQ-DI changes conditional on PsARC response HAQ-DI changes conditional on PsARC non-response
Treatment arm Placebo arm Treatment arm Placebo arm
Mean SE Mean SE Mean SE Mean SE
FUTURE 248 300mg of SEC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
PSUMMIT 259,66 UST 0.315 0.11 0.146 0.09 0.007 0.13 0.010 0.05
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summary of PASI responses in different trials is presented in Table 50. Outcomes at 14 and 16 weeks were
included in the analysis and assumed to be equivalent to outcomes at 12 weeks. Data from the 12-week
time point were used for the two PSUMMIT trials. Not all patients who were randomised to trials were
eligible for the PASI evaluation, and the proportion of PASI-evaluable patients differed between trials,
ranging between 42% and 84% in treatment arms and between 31% and 87% in placebo arms. All trials
reported PASI 50 and PASI 75, except the PSUMMIT 2 and SPIRIT-P1 (Study of Ixekizumab in Participants
With Active Psoriatic Arthritis) trials,57,59,66,67 which did not report PASI 50. A few trials did not report PASI
90 (i.e. the PALACE trials,60,61,65 Mease et al.53 and PSUMMIT 259,66).
Methods
The NMA for PASI utilised a framework of analysis that evaluated the probability of PASI responses in
different categories of PASI thresholds (50/75/90) within a single model:117 the single model included all
categories of PASI and generated a single effect estimate for each treatment and also probabilities of
achieving PASI 50, PASI 75 and PASI 90.
Reflecting the analyses on PsARC, alternative assumptions were tested in two analyses. The first analysis
assumed independent treatment effects and did not include any metaregression for placebo effects (model
F1). As the number of trials to inform each treatment effect was small, a fixed-effect model was used.
In a second analysis, we explored the impact on treatment effects of adjusting for placebo responses
[i.e. baseline effects (metaregression model)]. As can be seen in Table 50, there were large differences
between trials for PASI responses in the placebo arms, ranging between 0% (in IMPACT51) and 27%
(in RAPID-PsA47). The IMPACT51 had a very small sample size and reported 0% response in the placebo arm
and 100% response in the treatment arm, which lead to very extreme values for placebo adjustment.
Therefore, IMPACT51 could not be included in the metaregression analysis. Unlike the analysis for PsARC,
for PASI, we did not assume a class effect as the evidence from individual trials does not support such an
assumption. Table 51 presents the key assumptions for the models implemented for the PASI response.
The detailed model assumptions are presented in Appendix 3, Detailed methods for the biologic-naive
subpopulation.
Model F1 considers that treatments are independent of each other and assumes fixed effects on cut-off
points/thresholds. Model G1 considers the same assumption as model F1, but IMPACT51 was excluded
from the analysis. Model G2 assumes that treatments are independent of each other, but treatment effects
are adjusted with the trial-specific baseline effects assuming a common interaction term (beta).
Network meta-analysis results
Table 52 presents the results of the treatment effects for the PASI responses estimated from the three
models with measures of goodness of fit. There were no issues with convergence.
TABLE 49 Network meta-analysis results of evidence synthesis of HAQ-DI changes conditional on PsARC response
and non-response in biologic-experienced subpopulation
Treatment
HAQ-DI changes in PsARC response in
relation to PNR
HAQ-DI changes in PsARC non-response in
relation to PNR
Mean Median 95% CrI Mean Median 95% CrI
Placebo/baseline effect 0.134 0.134 0.288 to 0.021
300mg of SEC 0.385 0.385 0.624 to 0.145 0.431 0.430 0.880 to 0.014
UST 0.320 0.320 0.552 to 0.086 0.003 0.002 0.269 to 0.274
DIC 8.10
PNR, placebo non-responder.
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TABLE 50 Summary of trial-specific data in the biologic-naive subpopulation for PASI response outcome
Trial Treatment
PASI evaluated:
n (%) of patients
randomised to
treatment
PASI responses in treatment arm, n (%) PASI evaluated:
n (%) of patients
randomised to
placebo
PASI responses in placebo arm, n (%)
PASI 50 PASI 75 PASI 90 PASI 50 PASI 75 PASI 90
FUTURE 248 300mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
FUTURE 248 150mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
RAPID-PsA47 CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
PSUMMIT 158 UST 145 (71) 89 (61) 56 (39) 28 (19) 146 (71) 31 (21) 13 (9) 6 (4)
GO-REVEAL50 GOL 109 (75) 63 (58) 44 (40) 22 (20) 79 (70) 7 (9) 2 (3) 0 (0)
ADEPT55 ADA 69 (45) 50 (72) 34 (49) 21 (30) 69 (43) 10 (14) 3 (4) 0 (0)
IMPACT 252 INF 83 (83) 68 (82) 53 (64) 34 (41) 87 (87) 8 (9) 2 (2) 0 (0)
IMPACT51 INF 22 (42) 22 (100) 15 (68) 8 (36) 16 (31) 0 (0) 0 (0) 0 (0)
Mease et al. 200053 ETN 19 (63) 8 (42) 5 (26) NA 19 (63) 4 (21) 0 (0) NA
PALACE 160,61 APR 82 (49) 36 (44) 18 (22) NA 68 (40) 11 (16) 3 (4) NA
PALACE 261,62 APR 77 (48) 33 (43) 17 (22) NA 74 (47) 10 (14) 2 (3) NA
PALACE 361,65 APR 90 (54) 38 (42) 20 (22) NA 89 (53) 22 (25) 7 (8) NA
SPIRIT-P157,67 ADA 68 (67) NA 23 (34) 15 (22) 67 (63) NA 5 (7) 1 (1)
PSUMMIT 259,66 UST 36 (84) NA 17 (47) NA 30 (71) NA 1 (3) NA
NA, not available.
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The results of models G1 and F1 are similar, except for a small effect on the estimate of effect for INF;
therefore, model F1 is the preferred unadjusted model, as it does not exclude any trial evidence. In model
G2, the DIC and residual deviance are lower than in model G1, indicating that the model fits well with the
existing data and the data support the assumption of adjustment with baseline effects.
Table 53 shows the probability of achieving PASI 50, PASI 75 and PASI 90 from the preferred treatment-
unadjusted and -adjusted model in the biologic-naive population.
TABLE 51 Summary of models implemented for evidence synthesis of the PASI response
Sets of
analyses Study Treatment Metaregression
Thresholds
(i.e. cut-off
points)
Baseline effect for
metaregression
F1 FE Independent No baseline adjustment FE 
G1 FE Independent No baseline adjustment FE 
G2 FE Independent Common interaction term with
baseline effect
FE Adjusted with trial-specific
baseline effects
FE, fixed effect.
TABLE 52 Network meta-analysis results of the PASI response: treatment effects (median) on a probit scale in the
biologic-naive subpopulation
Placebo-adjusted metaregression No No Yes
Treatments Independent Independent Independent
Cut-off points FE FE FE
F1 ra G1 ra G2 ra
Placebo 1.024  0.983  1.015 
300mg of SEC 1.936 2 1.932 2 1.864 1
150mg of SEC 1.870 3 1.865 3 1.798 2
CZP 0.875 7 0.873 7 1.424 4
UST 1.134 6 1.131 6 1.342 6
GOL 1.645 4 1.635 4 1.141 7
ADA 1.477 5 1.476 5 1.422 5
INF 2.412 1 2.276 1 1.798 2
ETN 0.798 8 0.797 8 0.849 8
APR 0.749 9 0.748 9 0.815 9
Beta   1.310
Residual deviance 76.6b 62.5c 58.4c
DIC 318.9 297.2 293.7
FE, fixed effect.
a Ranking of treatments according to point estimates.
b Compared 65 data points.
c Compared 61 data points.
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The results of the unadjusted NMA for the PASI, as a single outcome or as separate categorical variables,
show that all treatments are more effective than placebo. The difference between treatments is uncertain,
with wide CrIs that mostly overlap with each other. The results show that patients taking INF have the
highest probability of achieving PASI 50, PASI 75 and PASI 90 responses. However, after adjustment for
placebo, 300 mg of SEC has the highest probability of response. The probabilities for CZP changed
between the models. It appears to be less efficacious than all other treatments, except APR and ETN, in
achieving PASI responses in the unadjusted model. However, in the adjusted model, it appears to be more
efficacious than GOL, UST, APR and ETN, and similar to ADA. The estimated probabilities from the analysis
reflect fairly closely those from the primary studies, indicating that the model fits the data well.
Subpopulation: biologic experienced
For the biologic-experienced population, trial-specific PASI response data were available for three active
treatments (300 mg of SEC, CZP and UST) from three trials,47,48,59,66 but, as for the other outcomes, the
data from the CZP trial were not included in the analysis as the biologic-experienced population in the
RAPID-PsA trial47 is not comparable to the population in the other two trials48,59,66 (see Psoriatic Arthritis
Response Criteria response, Subpopulation: biologic experienced). The data included in the NMA for the
treatment-experienced patients are presented in Table 54.
In the FUTURE 2 trial,48 only a small proportion of patients were eligible for the PASI evaluations; 33% in
the treatment arm and 34% in the placebo arm. The small sample size and associated lack of events in
this placebo arm increase uncertainty in the analysis.
A NMA was conducted under the same specification as used in model F1 (independent treatments,
unadjusted biologic-naive analysis). Because the data were sparse, no adjustment was undertaken for this
subgroup analysis. The results of the analysis are presented in Table 55.
TABLE 53 Network meta-analysis results of the PASI response: probability of achieving PASI 50, PASI 75 and PASI 90
in the biologic-naive subpopulation
Treatment
Independent treatment, median probability of achieving response (95% CrI)
Unadjusted for placebo response (model F1) Adjusted for placebo response (model G2)
PASI 50 PASI 75 PASI 90 PASI 50 PASI 75 PASI 90
Placebo 0.153
(0.13 to 0.18)
0.054
(0.04 to 0.07)
0.015
(0.01 to 0.02)
0.155
(0.12 to 0.19)
0.055
(0.04 to 0.07)
0.016
(0.01 to 0.02)
300 mg of SEC 0.819
(0.61 to 0.94)
0.627
(0.38 to 0.84)
0.405
(0.19 to 0.67)
0.801
(0.62 to 0.91)
0.604
(0.40 to 0.78)
0.384
(0.21 to 0.58)
150 mg of SEC 0.801
(0.59 to 0.93)
0.603
(0.36 to 0.82)
0.380
(0.18 to 0.63)
0.783
(0.60 to 0.90)
0.579
(0.38 to 0.75)
0.359
(0.19 to 0.54)
CZP 0.441
(0.31 to 0.59)
0.231
(0.14 to 0.36)
0.097
(0.05 to 0.18)
0.657
(0.50 to 0.82)
0.429
(0.29 to 0.63)
0.231
(0.13 to 0.41)
UST 0.544
(0.44 to 0.65)
0.317
(0.23 to 0.42)
0.149
(0.09 to 0.22)
0.627
(0.52 to 0.74)
0.398
(0.30 to 0.52)
0.207
(0.14 to 0.31)
GOL 0.732
(0.58 to 0.86)
0.514
(0.35 to 0.68)
0.297
(0.17 to 0.47)
0.548
(0.36 to 0.70)
0.322
(0.17 to 0.48)
0.154
(0.07 to 0.27)
ADA 0.675
(0.55 to 0.78)
0.448
(0.32 to 0.58)
0.242
(0.15 to 0.36)
0.657
(0.54 to 0.76)
0.429
(0.32 to 0.55)
0.231
(0.15 to 0.33)
INF 0.918
(0.84 to 0.96)
0.789
(0.67 to 0.88)
0.593
(0.44 to 0.73)
0.782
(0.61 to 0.88)
0.578
(0.39 to 0.73)
0.358
(0.20 to 0.52)
ETN 0.411
(0.15 to 0.72)
0.209
(0.05 to 0.50)
0.084
(0.01 to 0.29)
0.434
(0.20 to 0.69)
0.227
(0.08 to 0.47)
0.095
(0.02 to 0.26)
APR 0.391
(0.31 to 0.49)
0.195
(0.14 to 0.27)
0.077
(0.05 to 0.12)
0.420
(0.33 to 0.52)
0.216
(0.16 to 0.30)
0.090
(0.06 to 0.14)
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TABLE 54 Summary of trial-specific data in the biologic-experienced subpopulation for PASI response outcome
Trial Treatment
PASI evaluated:
n (%) of patients
randomised to
treatment
PASI responses in treatment arm, n (%) PASI evaluated:
n (%) of patients
randomised to
placebo
PASI responses in placebo arm, n (%)
PASI 50 PASI 75 PASI 90 PASI 50 PASI 75 PASI 90
FUTURE 248 300mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
PSUMMIT
259,66
UST 44 (73) NA 14 (32) NA 50 (81) NA 1 (2) NA
NA, not available.
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The result shows that the probability of achieving a PASI response in all categories is much higher with SEC
than with UST, although the estimates are highly uncertain, with wide CrIs that overlap with each other.
The results are fairly comparable with observed data.
American College of Rheumatology response
Subpopulation: biologic naive
Data
For the biologic-naive population, evidence on ACR response was available for nine active treatments
(150 mg of SEC, 300 mg of SEC, UST, CZP, GOL, ADA, INF, ETN and APR) from 15 trials.47,48,5061,6567
A brief summary of the ACR responses in the different trials is presented in Table 56. Outcomes at 14 and
16 weeks were included in the analysis and assumed to be equivalent to outcomes at 12 weeks. All 15 trials
reported all three categories of ACR response (20/50/70).
Methods
As ACR is, like PASI, a categorical variable (ACR 20, ACR 50 and ACR 70), the NMA for ACR utilised a
similar framework of analysis to that used to estimate the probability of PASI responses: all categories of
ACR were within a single model which generated a single effect estimate for each treatment and also
probabilities of achieving an ACR 20, ACR 50 and ACR 70.
Analogously to the analyses on PsARC, sets of alternative analyses were conducted for ACR response
outcomes. We explored the effect of differences in trial-specific placebo responses on treatment effect
by undertaking a metaregression. In the context of an adjusted model for placebo response, we explored
the possibility of there being class effects. Three different class groupings were considered: all treatments
as a single class; all biologics as a class with APR separate; and, to reflect the pharmacology, anti-TNFs
grouped, ILs grouped and APR separate. In addition, we explored two within-class assumptions: assuming
treatments within a class to have equal effectiveness and, alternatively, assuming that those treatments
within a class have similar (exchangeable) effectiveness. Fixed effects across studies were assumed for all
models. We have not considered models assuming exchangeability between classes.
TABLE 55 Network meta-analysis results of the PASI response: probability of achieving PASI 50, PASI 75, PASI 90
and treatment effects in the biologic-experienced subpopulation
Treatment/parameter
Treatment effects on a
probit scale, median
(95% CrI)
Response, median probability of achieving response (95% CrI)
PASI 50 PASI 75 PASI 90
Placebo 1.354 (0.59 to 2.19) 0.088 (0.01 to 0.28) 0.012 (0.00 to 0.06) 0.002 (0.00 to 0.02)
300 mg of SEC 2.509 (4.01 to 1.23) 0.875 (0.46 to 1.00) 0.598 (0.23 to 0.89) 0.365 (0.08 to 0.75)
UST 1.659 (2.73 to 0.83) 0.628 (0.29 to 0.89) 0.279 (0.07 to 0.61) 0.120 (0.01 to 0.42)
PASI 50 
PASI 75 0.870 (0.28 to 1.84)
PASI 90 1.484 (0.70 to 2.56)
Residual deviancea 5.99
DIC 26.75
 not available.
a Compared six data points.
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TABLE 56 Summary of trial-specific data in the biologic-naive subpopulation for ACR response outcome
Trial Treatment
ACR responses
Treatment arm Placebo arm
n
a
ACR 20 ACR 50 ACR 70
n
a
ACR 20 ACR 50 AC 70
r
b
% r
b
% r
b
% r
b
% r
b
% r
b
%
FUTURE 2
48
300mg of SEC Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
FUTURE 2
48
150mg of SEC Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
PSUMMIT 1
58
UST 205 85 41 38 19 8 4 206 44 21 11 5 3 1
PSUMMIT 2
59,66
UST 43 17 40 5 12 3 7 42 8 19 3 7 1 2
RAPID-PsA
47
CZP Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
GO-REVEAL
50
GOL 146 74 51 44 30 18 12 113 10 9 2 2 1 1
Genovese et al., 2007
56
ADA 51 20 39 13 25 7 14 51 8 16 1 2 0 0
ADEPT
55
ADA 153 88 58 54 35 30 20 162 23 14 6 4 1 1
SPIRIT-P1
57,67
ADA 101 52 51 30 30 18 18 106 33 31 5 5 0 0
IMPACT 2
52
INF 100 58 58 36 36 15 15 100 11 11 3 3 1 1
IMPACT
51
INF 52 34 65 24 46 15 29 52 5 10 0 0 0 0
Mease et al., 2004
54
ETN 101 60 59 38 38 11 11 104 16 15 4 4 0 0
Mease et al., 2000
53
ETN 30 22 73 15 50 4 13 30 4 13 1 3 0 0
PALACE 1
60,61
APR 168 64 38 27 16 7 4 168 32 19 10 6 2 1
PALACE 2
61,65
APR 162 52 32 17 10 2 1 159 30 19 8 5 1 1
PALACE 3
61,65
APR 167 68 41 25 15 6 4 169 31 18 14 8 4 2
a Number randomised.
b Number of ACR responses.
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Summary of all treatment effect models explored
All models implemented for the evidence synthesis of an ACR response are presented in Table 57. Detailed
coding of the models is presented in Appendix 3, Detailed methods for the biologic-naive subpopulation.
Model H1 considers that the treatments are independent of each other. Model I1 considers the relative
effectiveness of the alternative treatments as independent of each other, but that they all depend on the
response in the placebo arm. Model J1 considers the treatments as equal in terms of their effectiveness,
but dependent on the effect of the placebo arm. Models J2 and J3 consider the treatments as equal in
terms of their effectiveness within class, but dependent on the effect of the placebo arm. Models K1 and
K2 assume the treatments to have a similar, but not equal, effectiveness and to be dependent on the
effect of the placebo arm.
Network meta-analysis results
Table 58 presents the results of the treatment effects for ACR responses estimated from the seven models
with measures of goodness of fit. There were no issues with convergence.
The placebo response-adjusted model I1 fits well compared with the unadjusted model H1 (smaller DIC
and residual deviance), but is not significantly better. In addition, the results (rankings) generated by
model I1 are very different from the observed trial results. Models J1, J2 and J3 do not fit well with the
existing data, resulting in a significantly higher residual deviance and DIC. Both models K1 and K2 fit as
well as the unadjusted model H1 (similar DIC and residual deviance).
Among all the placebo response-adjusted models, models I1, K1 and K2 show similar DIC and residual
deviance, which means that these three models fit the existing data equally well, although not significantly
better than the unadjusted model.
The interaction term (beta) is negative in all models, which means that higher placebo response rates in
trials are associated with higher treatment effects, demonstrating that adjustment for heterogeneity in the
placebo responses across trials was required. The interaction term varies between models, but is similar
between models K1 and K2.
TABLE 57 Key assumptions of models implemented for evidence synthesis of ACR response
Sets of
analysis Study Treatment Metaregression Class
H1 FE Independent No baseline adjustment No class effect
I1 FE Independent Common interaction term
with baseline effect
No class effect
J1 FE Equal | class Common interaction term
with baseline effect
Independent class effect: class = {all
treatments}
J2 FE Equal | class, remaining
treatments independenta
Independent class effect: class = APR
independent {all remaining biologics}
J3 FE Equal | class, remaining
treatments independenta
Independent class effect: class =
{anti-TNFs, ILs}; APR independent
K1 FE Exchangeable | class, remaining
treatments independenta
Common interaction term
with baseline effect
Independent class effect: class = APR
independent {all other biologics}
K2 FE Exchangeable | class, remaining
treatments independenta
Independent class effect: class =
{anti-TNFs, ILs}; APR independent
FE, fixed effect.
a APR independent.
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Preferred models
The unadjusted model, H1, fits the data as well as any of the other models and generates results that reflect
the observed results. Considering the placebo-adjusted models, model I1-generated results (rankings) are
very different from the observed trial results and the results generated by model H1. Using an assumption
of equal class effect for the treatments does not produce a better-fitting model (models J1, J2, J3) than
assuming independent treatment effects (models H1, I1), or similar (exchangeable) treatment effects
(models K1, K2). In addition, there was a little difference in the goodness-of-fit statistics (DIC and residual
deviance) between models K1 and K2, and we consider the exchangeable class effect model, which utilised
two classes (anti-ILs and anti-TNFs) with APR separate, to be the most clinically plausible. Hence, our
preferred models are models H1 and K2. Note that the economic model uses PsARC; thus, these results
were not implemented in the economic model in Chapter 6.
Table 59 presents the probabilities of achieving ACR 20, ACR 50 and ACR 70 responses in a biologic-naive
population from the preferred models, H1 and K2.
The results of the unadjusted NMA for ACR, as a single outcome or as separate categorical variables,
show that all treatments are more effective than placebo. The difference between treatments is uncertain,
with wide CrIs that mostly overlap with each other. The results show that patients taking INF have the
highest probability of achieving ACR 20, ACR 50 and ACR 70 responses. The probabilities for SEC are
TABLE 58 Network meta-analysis results of ACR response: treatment effects (median) on a probit scale in a
biologic-naive subpopulation
Placebo-adjusted
metaregression
No Yes Yes Yes Yes Yes Yes
Treatments Ind Ind = | class
{all}
= | class
{APR, other}
= | class {ILs,
TNFs, APR}
∼ | classa
(APR, other)
∼ | classa (ILs,
TNFs, APR)
Cut-off points FE FE FE FE FE FE FE
H1 rb I1 rb J1 rb J2 rb J3 rb K1 rb K2 rb
Placebo 0.952 0.961 0.882 0.966 0.966 0.963 0.961
300mg of SEC 0.914 6 1.397 2 1.274 2 1.236 3
150mg of SEC 0.932 5 1.415 1 1.094 1 1.095 1 1.283 1 1.246 2
UST 0.570 8 0.722 8 0.750 8 0.732 8
CZP 0.811 7 1.265 3 0.830 1 1.193 5 1.176 5
GOL 1.429 2 0.918 7 1.010 7 1.040 7
ADA 1.072 4 1.126 6 0.609 2 1.121 6 1.124 6
INF 1.617 1 1.212 5 1.246 3 1.269 1
ETN 1.362 3 1.214 4 1.215 4 1.228 4
APR 0.509 9 0.592 9 0.610 2 0.014 3 0.581 9 0.576 9
Beta (mean) 1.276 1.327 1.627 1.621 1.099 1.018
Residual
deviancec
120.0 119.1 156.1 148.3 148.3 120.0 120.4
DIC 482.22 480.94 511.66 503.43 503.37 480.90 481.1
= | class, equal class effect; ∼ | class, exchangeable class effect; FE, fixed effect; ind, independent treatment effect.
a Shrunken estimates.
b Ranking of active treatments according to point estimates.
c Compared with 92 data points.
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lower than those for INF, ETN, GOL and ADA. After adjustment for placebo, the probabilities for 300 mg
of SEC and 150 mg of SEC increase and are very similar to those for INF. The probabilities of achieving
ACR 20, ACR 50 and ACR 70 responses with CZP varied between the models: in the unadjusted model
the probabilities were higher than only those for APR and UST, but after adjustment they were also higher
than those for GOL, ADA and UST.
Subpopulation: biologic experienced
For the biologic-experienced population, trial-specific ACR response data were available for three
active treatments (300 mg of SEC, CZP and UST) from three trials,47,48,59,66 but, as for the other outcomes,
the data from the CZP trial were not included in the analysis as the biologic-experienced population in the
RAPID-PsA trial is not comparable to the populations of the other two trials.48,59,66 The data included in the
NMA for treatment-experienced patients are presented in Table 60.
The NMA model was similar to model H1: independent treatment effects in the biologic-naive
subpopulation. Owing to the lack of data, no adjustment was undertaken for this subgroup analysis.
The results of the analysis are presented in Table 61 and show that the probabilities of achieving an ACR
response in all categories are slightly higher with UST than with SEC, although the differences are
insignificant. The results are fairly comparable to the observed data (compare Tables 60 and 61).
TABLE 59 Network meta-analysis results of ACR response: probability of achieving ACR 20, ACR 50 and ACR 70
responses in a biologic-naive subpopulation
Treatment
Not adjusted for placebo response,
independent treatment (model H1)
Adjusted for placebo response, class effects
assumeda (model K2)
ACR 20,
median
(95% CrI)
ACR 50,
median
(95% CrI)
ACR 70,
median
(95% CrI)
ACR 20,
median
(95% CrI)
ACR 50,
median
(95% CrI)
ACR 70,
median
(95% CrI)
Placebo 0.17
(0.15 to 0.19)
0.05
(0.04 to 0.06)
0.01
(0.01 to 0.02)
0.17
(0.15 to 0.19)
0.05
(0.04 to 0.06)
0.01
(0.01 to 0.02)
300 mg of SEC 0.49
(0.33 to 0.64)
0.24
(0.14 to 0.38)
0.09
(0.04 to 0.18)
0.61
(0.46 to 0.75)
0.35
(0.22 to 0.50)
0.16
(0.08 to 0.27)
150 mg of SEC 0.49
(0.34 to 0.65)
0.25
(0.14 to 0.39)
0.10
(0.04 to 0.19)
0.61
(0.46 to 0.75)
0.35
(0.22 to 0.51)
0.16
(0.08 to 0.27)
UST 0.35
(0.27 to 0.44)
0.15
(0.10 to 0.21)
0.05
(0.03 to 0.08)
0.41
(0.34 to 0.49)
0.19
(0.14 to 0.25)
0.07
(0.04 to 0.10)
CZP 0.44
(0.34 to 0.55)
0.21
(0.14 to 0.30)
0.08
(0.04 to 0.13)
0.58
(0.49 to 0.69)
0.33
(0.24 to 0.43)
0.14
(0.09 to 0.22)
GOL 0.68
(0.55 to 0.80)
0.43
(0.30 to 0.57)
0.21
(0.12 to 0.33)
0.53
(0.40 to 0.66)
0.28
(0.18 to 0.40)
0.11
(0.06 to 0.19)
ADA 0.55
(0.47 to 0.62)
0.29
(0.23 to 0.36)
0.12
(0.09 to 0.17)
0.56
(0.50 to 0.63)
0.31
(0.26 to 0.37)
0.13
(0.10 to 0.17)
INF 0.75
(0.65 to 0.83)
0.50
(0.39 to 0.62)
0.27
(0.18 to 0.38)
0.62
(0.51 to 0.72)
0.36
(0.26 to 0.47)
0.17
(0.10 to 0.24)
ETN 0.66
(0.55 to 0.76)
0.40
(0.29 to 0.52)
0.19
(0.12 to 0.29)
0.61
(0.51 to 0.69)
0.35
(0.27 to 0.43)
0.16
(0.11 to 0.21)
APR 0.33
(0.27 to 0.39)
0.13
(0.10 to 0.17)
0.04
(0.03 to 0.06)
0.35
(0.30 to 0.41)
0.15
(0.12 to 0.19)
0.05
(0.03 to 0.07)
a Probabilities estimated from the shrunken estimates.
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TABLE 60 Summary of trial-specific data in a biologic-experienced subpopulation for ACR response outcome
Trial Treatment
ACR responses
Treatment arm Placebo arm
n
ACR 20 ACR 50 ACR 70
n
ACR 20 ACR 50 ACR 70
1.1.1 r % 1.1.2 r % r % 1.1.3 r % 1.1.4 r % 1.1.5 r %
FUTURE 2
48
2, 300mg of SEC Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
PSUMMIT 2
59,66
3, UST 60 23 38 9 15 4 7 62 9 15 1 2 0 0
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Limitations
Data were sparse; there were few studies in each treatment [a maximum of three studies in two
treatments (ADA5557,67 and APR60,61,65)]. For this reason, we were not able to fit random-effect models,
especially when considering placebo adjustment. Hence, fixed-effect models were used in all analyses.
Summary of findings of relative efficacy from network meta-analysis
The NMA was conducted to formally investigate the relative efficacy of SEC and CZP and the other active
comparators. Analyses were conducted on four outcomes: PsARC, HAQ-DI conditional on PsARC response,
PASI and ACR. Analyses were not run for the full-trial populations because of the heterogeneity across
trials, but instead were performed separately for the biologic-naive and biologic-experienced subgroups.
The data suggest the rate of placebo response to be a potential source of heterogeneity within the
biologic-naive population networks, despite there being no clear rationale for such an effect. For this
reason, we explored models that adjust for the placebo response, alongside unadjusted models.
Biologic-naive patients
In terms of PsARC response, the results indicated that, although SEC and CZP are effective, the relative
effectiveness of these biologics compared with ETN, ADA, GOL and INF, and with each other, is uncertain,
although both agents do seem to be more effective than APR.
In terms of HAQ-DI conditional on PsARC response, the results from the preferred adjusted model were
similar to the independent treatment effect analysis. The results from the unadjusted independent
treatment effects model showed that significant reductions in mean HAQ-DI score were achieved with
response to all nine treatments and response to placebo, although the improvement in response to
placebo is below the minimum clinically significant threshold for PsA of 0.35.116 The median HAQ-DI score
change was highest with INF and ETN, followed by 300 mg of SEC, but 150 mg of SEC and CZP were
worse than all treatments except for APR.
The results of the unadjusted NMA for PASI, as a single outcome or as separate categorical variables,
indicated that all treatments were more effective than placebo. The difference between treatments was
uncertain, with wide CrIs that mostly overlap with each other. The results showed that patients treated
with INF have the highest probability of achieving PASI 50, PASI 75 and PASI 90 responses. However, after
TABLE 61 Network meta-analysis results of ACR response: probability of achieving ACR 20, ACR 50 and ACR 70
responses, and treatment effects in a biologic-experienced subpopulation
Treatment/parameter
Treatment effects
on a probit scale,
median (95% CrI)
ACR response, median probability (95% CrI)
ACR 20 ACR 50 ACR 70
Placebo 1.06 (0.76 to 1.38) 0.14 (0.08 to 0.22) 0.03 (0.01 to 0.06) 0.01 (0.00 to 0.02)
300 mg of SEC 0.71 (1.36 to 0.08) 0.36 (0.19 to 0.57) 0.11 (0.04 to 0.25) 0.03 (0.01 to 0.11)
UST 0.85 (1.34 to 0.37) 0.42 (0.26 to 0.59) 0.14 (0.06 to 0.27) 0.05 (0.01 to 0.12)
ACR 20 
ACR 50 0.85 (0.62 to 1.13)
ACR 70 1.47 (1.10 to 1.92)
Residual deviancea 11.33
DIC 45.85
a Compared 11 data points.
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adjustment for placebo, 300 mg of SEC has the highest probability of response. The probabilities for CZP
changed between the models. It appears to be less efficacious than all other treatments, except APR and
ETN, in achieving PASI responses in the unadjusted model. However, in the adjusted model, CZP appears
to be more efficacious than GOL, UST, APR and ETN, and similar to ADA.
Similarly, for ACR responses, differences between treatments were uncertain, with wide CrIs that mostly
overlapped with each other. The unadjusted results suggested that patients taking SEC or CZP had lower
probabilities of a response than those for INF, ETN, GOL and ADA. After adjustment for placebo response,
the probabilities of a response for both SEC and CZP increased; those for SEC were very similar to those
for INF.
Biologic-experienced patients
The evidence for the biologic-experienced subpopulation is very sparse with only two trials evaluating two
treatments. Hence, only two treatments (SEC and UST) could be included in these analyses. The results
showed that, across all outcomes analysed, both SEC and UST were significantly more effective than
placebo. Most of the results suggested SEC may be better than UST, although the results were uncertain
with wide overlapping CrIs.
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Chapter 5 Assessment of existing cost-effectiveness
evidence
The purpose of this section is to review the existing evidence on the cost-effectiveness of CZP and SECwithin their marketing authorisations for treating active PsA in adults for whom DMARDs have been
inadequately effective. The review includes published cost-effectiveness studies and the CSs from Novartis
(SEC) and UCB Pharma (CZP). The review also includes a broader assessment of published decision-analytic
models for relevant comparators. The differences in the model structures and assumptions used across
the studies are examined to identify any important differences in approaches and areas of remaining
uncertainty. The findings from the review also provide the basis for the development of a new
decision-analytic model reported in Chapter 6.
Methods
To identify published economic evidence for CZP and SEC, a broad range of studies was considered for
inclusion in the assessment of cost-effectiveness, including economic evaluations conducted alongside
trials, modelling studies and analyses of administrative databases. Only full economic evaluations that
compared two or more options and considered both costs and consequences (including cost-effectiveness,
costutility and costbenefit analyses) were included.
A broader review of economic evidence for the comparator treatments (INF, ETN, ADA, GOL and UST) was
also undertaken. The objective was to summarise the modelling approaches, and assumptions, employed
in previous studies, and to identify any important differences that may have arisen since the previous MTA
(TA19933). As the focus of the broader review related to modelling approaches and assumptions, only
decision-analytic modelling studies were included. The broader review also provides an important basis
to identify common areas and potential differences between the approaches previously used for the
comparator treatments and those employed by UCB Pharma and Novartis for the specific technologies
being considered in this appraisal. The broader review also helped inform the conceptualisation of the de
novo model presented in Chapter 6.
The following databases were searched for relevant published literature: Cochrane Controlled Trials
Register, EMBASE, Health Economic Evaluations Databases, MEDLINE, National Research Register, NHS
Economic Evaluation Database (NHS EED), PsycINFO and the SCI. The full details of the main search
strategy for this review are presented in Appendix 4. The searches for CZP and SEC for PsA were not
restricted by date. The searches for the broader comparator review were date restricted to identify studies
published since the previous MTA report for ADA, ETN and INF (TA19933). Additional hand-searching of
related TAs (TA199,33 TA220118 and TA34066) was also undertaken. Two reviewers assessed all obtained
titles and abstracts for inclusion, with any discrepancies resolved by discussion.
In addition, Novartis and UCB Pharma submitted evidence on the cost-effectiveness of CZP and SEC.
These submissions were reviewed and the approaches and findings compared with those found in the
review of previously published studies. The quality of the cost-effectiveness studies for CZP and SEC was
also assessed according to a checklist updated from that developed by Drummond et al.119
Results
Identified published studies
No previously published cost-effectiveness studies of SEC for PsA were identified. Two conference abstracts
were identified evaluating the cost-effectiveness of CZP for PsA in Greece and Romania.120,121 Further
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details were not provided on request from the corresponding authors and so these abstracts were
subsequently excluded from further consideration. Given the lack of previously published studies, only the
CSs are considered for SEC and CZP.
The systematic search of published literature identified nine studies3336,66,122124 that met the inclusion
criteria for the cost-effectiveness review for the broader set of comparators. From the nine studies, seven
UK studies were identified.3336,66,122 Three of the UK studies were reports from the independent AG/ERG
for the previous NICE appraisals of ETN, INF and ADA (TA19933), GOL (TA220118) and UST (TA34066). A
further three studies were the subsequent journal publications based on the reports for TA199,122 TA22034
and TA340.35 The final UK study identified was a more recent study that aimed to update the systematic
review, synthesis and model previously conducted as part of TA199.122 This study was funded by Pfizer.36
Of the two non-UK studies, one evaluated the cost-effectiveness of UST for PsA in Russia123 and the other
evaluated the cost-effectiveness of a mixture of biologic treatments to treat moderatesevere PsA in Germany.124
Both of these studies were available only as conference abstracts. Further details were requested from the
authors but were not provided and hence these two studies were excluded from the review.
Review of the existing published cost-effectiveness studies
The review starts with an overview of the seven UK studies identified in relation to the broader set of
comparators and then considers the de novo analyses submitted by the companies for SEC and CZP.
Summary of published studies for comparator treatments
Of the seven published studies included in the broader review of comparators,3336,66,122 six were directly
related to three previous NICE TAs: TA199,33 TA220118 and TA340.66 All of these publications employed a
similar modelling approach to that originally proposed by Rodgers et al.33 for TA199 (hereafter referred to
as the York model). The only study identified that was not directly related to a previous NICE TA was that
by Cawson et al.36 This study also used a very similar approach to the previous York model. Hence, the
main differences between these studies lie in relation to the comparators and associated evidence base
which have altered since TA199, rather than in terms of major structural differences. As the provenance of
the modelling approach used in all these studies can be related back to the York model, only the York
model is described in full in the following section. The key differences in the other published studies are
subsequently summarised.
Summary of the York model (TA199)
The York model is a cohort Markov model (Figure 8), built using the R software package (The R Foundation for
Statistical Computing, Vienna, Austria). The model was developed to estimate the costs and quality-adjusted
life-years (QALYs) of three biologics (ETN, INF or ADA), over a lifetime horizon (40 years), compared with
palliative care alone. The model adopts the perspective of the UK NHS and Personal Social Services. The price
year assumed for costs is 2008/9 and the annual discount rate is 3.5%,125 for both costs and QALYs.
The model structure is based on an understanding of the disease process and how this should be modelled
to determine cost-effectiveness.126 The model is based on a two part structure:
1. initial response period (short-term model used to determine initial response rate and treatment
continuation decision)
2. post-response period [longer-term model used to characterise the natural history of the disease
(i.e. without biologics) and the impact of biologics while on therapy and when therapy is stopped].
Patients receiving biologics and who meet the response criteria during the initial response period continue
on their biologic treatment in the post-response period. Biologics are withdrawn in non-responders and
these patients are assumed to move on to palliative care alone. Changes in the HAQ-DI and PASI scores
are used to quantitatively model the short- and longer-term cost and quality-of-life implications (estimated
using QALYs) of the use of biologics versus palliative care alone.
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A – withdrawn from biologic j
B – continue on biologic j with response of arthritis but not of psoriasis
C – continue on biologic j with response of both arthritis and psoriasis
N – no treatment
p.m. – probability of mortality (any cause)
p.w. – probability of withdrawal from biologic after first 3 months
Nodes 
     chance node
     terminal node (death from any cause)
     Markov node
No PsARC
Biologic j
N
PsARC
PASI 75
No PASI 75
PASI 75
No PASI 75
C
B
B
A
C
A
A
A
PASI 75 only: 
withdrawn from 
biologic j
Response of neither: 
withdrawn from 
biologic j
Response of both: 
continue on 
biologic j
Response of PsARC
only: continue on 
biologic j
N
A
p.m.
p.m.
p.m.
p.w.
p.w.
p.m.
p.m.
A
Cycle 1
Months 1–3
Cycle 2
Months 3–6
FIGURE 8 Schematic of the York model.33
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Initial (primary) response to the drug is defined using PsARC for joints and the PASI 75 for psoriasis, based
on BSR127 and British Association of Dermatologists128 guidelines. As two response variables are considered
(PsARC and PASI), there are four possible outcomes in the initial response period: (1) skin response only;
(2) joints response only; (3) response of both; and (4) response of neither. In the base-case analysis,
only joint (PsARC) response is used to determine treatment continuation. Alternative response rules are
explored in separate scenarios: skin (PASI 75) response only, and response for both measures (PsARC and
PASI 75).
The time point for the assessment of response is assumed to occur at around 3 months or between 12
and 16 weeks. Although differences in the recommended time points for assessing initial response were
identified by the authors based on the licences and between guideline-making bodies, a common time
point was subsequently assumed. This was justified based on the authors conclusions that there appeared
to be a lack of a clinically meaningful difference in the biologics response rates for joint disease or
psoriasis between approximately 12 and 24 weeks.
In the decision model, the change in HAQ-DI score compared with baseline is conditional on whether or
not a PsARC response was achieved and the specific biologic treatment received. During the initial
3-month response period, the model assumes that patients on biologics have some improvement in their
HAQ-DI score, even if they do not reach the PsARC threshold. Patients who do not achieve the required
level of response during the first 3 months are withdrawn from therapy, and are assumed to follow the
same HAQ-DI score trajectory after withdrawal as patients who had palliative care only.
The model assumes that patients who achieve a PASI 75 response will gain at least a 75% improvement
in psoriasis compared with baseline PASI score. Patients who do not achieve a PASI 75 response will also
have some proportionate gain in PASI score while they continue taking a biologic, although this will be less
than a 75% improvement. The distribution of PASI scores observed in the trials was reflected within the
model by utilising the PASI 50, PASI 75 and PASI 90 data to determine the change in PASI score for PASI
75 responders and non-responders.
Following an initial response to biologic therapy, the model assumed that patients maintain the initial
improvement in HAQ-DI score for the remaining period of time on that therapy. This assumption was
justified based on evidence from an elicitation exercise with clinical experts and supported by data on
HAQ-DI and HRQoL from biologics registers and radiographic information supplied by the manufacturers of
biologics. It was also assumed that patients maintain the improvement in PASI score while on biologic therapy.
The model assumes that no patients withdraw as a result of AEs in the first 3 months. The authors noted
that, as responses in the RCTs are reported on an ITT basis, including withdrawal during the first 3 months
would constitute double counting. The model includes an ongoing risk of withdrawal from biologic
therapy over the longer term as a result of a lack of continuing efficacy (secondary non-response), AEs or
other reasons. The rate of withdrawal after 3 months is assumed to be independent of the HAQ-DI and
PASI scores, to be independent of whether the initial response was for both psoriasis and arthritis or just
arthritis and to be constant over time.
On withdrawal of a biologic treatment, it is assumed that the mean PASI returns to its initial score at
baseline (rebound equal to initial gain). The authors acknowledged that there was more uncertainty about
change in HAQ-DI score associated with withdrawal (rebound). In the base-case analysis it is assumed that
rebound is equal to initial gain. Other scenarios (rebound less than initial gain and rebound equal to
natural history) were explored using sensitivity analyses.
Patient characteristics in the York model
Table 62 shows the baseline characteristics used in the York model. Patients were assumed to fulfil the
BSR guidelines and criteria specified for commencing biologics (i.e. that their PsA has not responded to
adequate trials of at least two standard DMARDs, administered either individually or in combination).
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The model cohort is assumed to be aged 47 years at the start of the model, and it is assumed that at least
7 years has passed since the diagnosis of PsA, based on the average characteristics of participants in the
included RCTs. The mean baseline HAQ-DI score at the start of the model is assumed to be 1.05 units and
patients are assumed to have mildmoderate psoriasis with a PASI score of 7.5 units, based on the average
HAQ-DI and PASI baseline scores in the RCTs. The mean body weight is assumed to be between 60 and
80 kg based on the mean adult weight of the general population for men and women.
Alternative subgroups were explored in scenario analyses based on different baseline HAQ-DI and
PASI scores:
l an alternative, more severe HAQ-DI of 1.8 units, which is the mean HAQ-DI score of patients entering
the BSRBR83
l no skin involvement, with a PASI score of 0 units (Smith et al.128 stated that 50% of patients with PsA
starting biologics in clinical practice would have mild or no skin involvement)
l moderatesevere psoriasis, with a PASI score of 12.5 units (Smith et al.128 stated that 25% of patients
with PsA starting biologics in clinical practice would have a baseline PASI of > 10 units).
Choice of intervention and comparators in the York model
Infliximab, ETN, ADA and palliative care were included, reflecting the licensed biologic treatments available
when TA199122 was conducted. Palliative care was assumed to represent conventional care without
biologic treatment.
Sequencing of treatments in the York model
In the base-case analysis, patients who are withdrawn from treatment (primary non-response or secondary
withdrawal) were assumed to receive palliative care alone. A separate exploratory scenario assessed the
cost-effectiveness of a further biologic treatment used as a second line of therapy (biologic experienced),
if the first biologic is withdrawn. This scenario considered two subgroups: failure of first biologic as a result
of AEs and failure because of efficacy.
In the absence of RCT data on these subgroups, treatment response and withdrawal rates for these
subgroups were estimated from observational data for RA patients from the BSRBR. In the case of a patient
who failed first-line therapy because of a lack of efficacy, the RR of failing the second-line therapy because
of a lack of efficacy increases by 2.7 (95% CI 2.1 to 3.4). If a patient fails first-line therapy because of an
AE, then the risk of failing the second-line therapy for AEs increases by 2.3 (95% CI 1.9 to 2.9).
Natural history of psoriatic arthritis in the York model
Psoriatic arthritis is a progressive disease and patients with untreated PsA may have persistent inflammation
and progressive joint damage (see Chapter 2). This was reflected in the York model by applying a constant
rate of HAQ-DI increase to patients receiving palliative care alone (Figure 9). The increase in HAQ-DI score
was applied to characterise the natural history of HAQ-DI (i.e. without biologic treatment) and was
TABLE 62 Baseline patient characteristics used in the York model
Characteristic Assumed value
Age (years) 47
Weight (kg) 6080
Baseline HAQ-DI score (units) 1.05
Baseline PASI score (units) 7.5
SD, standard deviation.
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estimated as 0.018 units in a 3-month cycle, based on data from the NOAR. Figure 9 graphically shows how
the HAQ-DI progression assumptions (on and off treatment) were applied in the York model.
For the psoriasis component of PsA, it was assumed that the PASI score does not worsen over time
(off treatment), which was stated to be consistent with clinical evidence.
Sources and synthesis of effectiveness data in the York model
The effectiveness of the alternative treatments was estimated using a NMA. The network of evidence was
based on six trials that have a common comparator (placebo).33 Three different synthesis models were
specified to allow relevant outcomes for the economic model to be synthesised: PsARC response at
1216 weeks; change in HAQ-DI score conditional on a PsARC response; and the probability of achieving
PASI 50, PASI 75 and PASI 90 responses.
In the decision model, the change in HAQ-DI score compared with baseline is conditional on PsARC
response status. It is uncertain whether the change in HAQ-DI score is the same for all PsARC treatment
responders (TRs) or depends on the particular biologic treatment received. In the base case, the change in
HAQ-DI score depended on PsARC response and the individual biologic treatment, whereas alternative
scenarios (i.e. HAQ-DI score change the same for all PsARC responders) were assessed within the
sensitivity analysis.
A placebo or expectation effect, which is the improvement reported for patients in the placebo arms of the
RCTs, is uncertain and may not be reproducible in clinical practice. In the base case, the mean change in
HAQ-DI score across the placebo arms of the RCTs was discounted from the change in HAQ-DI score for
patients using biologics. This was applied in the decision model by deducting the change in HAQ-DI score
in the placebo arm, weighted by the PsARC response in that arm, from the HAQ-DI score change in
the treatment arm. A similar adjustment is made for the expected change in PASI score. An alternative
scenario was conducted assuming that the response rate to treatment in the RCTs is fully generalisable to
general practice and, therefore, no adjustment for placebo/expectancy effects is made.
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FIGURE 9 Illustration of the progression of arthritis for a patient successfully maintained on a biologic, a patient
without a biologic and a patient who withdraws at 5 years, as implemented in the York model.33
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Data on time to withdrawal from first biologic were separately synthesised using a meta-analysis of five
European registry studies, one of which was the UK BSRBR.83 The estimated annual probability of withdrawing
from the biologic treatment after the first cycle is 0.165; therefore, patients who achieve an initial PsARC
response will, on average, remain on biologic drugs for just over 6 years in the model (1/0.165= 6.06 years).
This was assumed to be identical for all biologics.
The base-case model uses a published estimate of the additional mortality risk in PsA (Wong et al.12).
Sources of utility data used in the York model
Quality-adjusted life-years were determined by estimating health utilities as a function of HAQ-DI and PASI.
The York model used an equation based on an ordinary least squares regression of patient-level data from
one of the companies (Wyeth) submitting evidence for TA199.122 It was stated that similar results were
obtained from separate trials across each of the three companies, indicating that the relationship between
HAQ-DI, PASI and utility appears stable across independent clinical trials. Equation 1 shows the algorithm
used in the base-case analysis of the York model:
Expected utility = 0:897− 0:298 × HAQ− 0:004 × PASI. (1)
Summary of resource utilisation and costs data used in the York model
The costs of acquiring the drugs and of their administration and monitoring were obtained from the BSR
guidelines for the use of biologics and national prices and tariffs. The base case assumes that vial sharing is
not permitted for INF and, therefore, separate scenarios regarding the use of three or four vials per patient
were considered according to different weight assumptions.
Health-care costs increase with severity of both arthritis and psoriasis. Health state costs associated
with HAQ-DI were derived from data from a UK-based study by Kobelt et al.129 including 916 patients
suffering from RA and followed up for between 5 and 9 years. Direct health-care resources were collected
prospectively for all patients for hospitalisations, surgical interventions and RA medications. Based on this
study, Bansback et al.130 separately applied a linear regression model to estimate the relationship between
HAQ-DI score and resource use (Equation 2). The regression estimates were subsequently reduced by 15%
to account for expenditure on DMARDs and to avoid double counting other drug acquisition costs which
were separately estimated.
Direct cost per 3-month period = 342 + 103:5 × HAQ-DI. (2)
As the Kobelt et al.129 study includes only RA patients, separate costs were estimated for treating
mildmoderate psoriasis in patients who do not use biologics, or who do not respond to biologics, from
NHS unit costs of phototherapy and a UK RCT. For patients with moderate or severe psoriasis, costs were
obtained from a Dutch RCT (see Hartman et al.131) and adjusted to UK price levels. These costs were
assigned to patients based on whether or not a PASI 75 response was achieved (Table 63).
TABLE 63 Psoriasis (PASI) costs applied in the York model
State
Level of psoriasis, 3-month cost (£)
Mild–moderate Moderate–severe
On anti-TNF-α with PASI 75 response 16 16
On anti-TNF-α without PASI 75 response 198 566
Not on anti-TNF-α therapy 198 566
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Cost-effectiveness results from the York model
The summary results from the York model are those which are reported in the Final Appraisal Determination
document for TA199.132 The results of the base-case model reported that INF was the most effective strategy
taking into account both joint and skin effects (QALYs = 7.3), followed by ETN (QALYs = 7.0) and ADA
(QALYs = 6.6). In terms of costs, INF was the most costly treatment (£88,442), followed by ETN (£74,841)
and ADA (£68,638). The incremental cost-effectiveness ratio (ICER) for ETN compared with palliative
care was £17,853 per QALY. The ICER for INF compared with ETN was around £44,326 per QALY. ADA
was extendedly dominated. Of the three biologic therapies, ETN had the highest probability of being
cost-effective at a threshold between £20,000 (probability = 44%) and £30,000 (probability = 48%)
per QALY.
The results of the subgroup analysis showed that biologics appear slightly less cost-effective if the baseline
HAQ-DI score is 1.8 (high), although the ICER for ETN remained below £20,000 per QALY. In patients with
a negligible baseline psoriasis (i.e. PASI = 0 units), ETN was the most cost-effective strategy, with an ICER
of £18,512 per QALY compared with palliative care. The ICER of INF versus ETN increased to £64,744 per
QALY and ADA remained extendedly dominated. However, for a cohort in which the baseline PASI
score was moderate to severe (PASI of 12.5 units rather than 7.5 units), ADA was no longer extendedly
dominated. The ICER of ADA versus palliative care was £16,310 per QALY. The ICER of ETN versus ADA
was £19,319 per QALY and the ICER of INF versus ETN was £27,778 per QALY.
In the scenario considering the cost-effectiveness of biologics, used as a second course of therapy after a
first biologic has failed for PsA patients with mildmoderate skin disease, the ICERs depend on which drug
was used as first-line therapy and is therefore ineligible for use as second line. For patients failing ETN,
ADA has an ICER of < £20,000 and INF is around £25,000 per QALY. The ICERs were reported to be
broadly similar for people whose PsA failed to respond to first-line therapy because of adverse effects and
those whose disease failed first-line therapy because of inefficacy.
Summary of key differences in modelling approaches from other published studies
As described in Summary of published studies for comparator treatments, following the development of the
York model for TA199,33 three further models were developed comparing different sets of interventions.
The model developed for TA22070 compared ETN, INF, ADA, GOL and palliative care in a biologic-naive
population. The model developed for TA34066 compared ETN, INF, ADA, GOL, UST and palliative care in
biologic-naive and biologic-experienced populations. The model developed by Cawson et al.36 compared
ETN, INF, ADA, GOL and palliative care in a biologic-naive population.
The model structure used in each of the three models is broadly the same as the York model. There were
some minor variations in the duration of the response period, in particular extending this up to 24 weeks
in TA22070 to reflect the longer response period for UST in line with its licence, but generally all models
have a similar underlying structure and use PsARC as the main response measure.
One key difference between the models concerns the different sets of interventions that have been
compared. The sequence of published studies closely follows the licensing of additional TNF-α inhibitors after
TA19933 (GOL) and new biologic alternatives (UST). As a result, the scope of each study has been extended
to include these additional licensed treatments. With the exception of the UST (TA34066), the majority of
studies have focused on evaluating the relative cost-effectiveness of the alternative TNF-α inhibitors in a
biologic-naive population and all have been consistent in assuming that biologics are started only following
the failure of at least two DMARDs (individually or in combination, in line with BSR guidelines). However, as
one of the RCTs for UST included patients with and without prior exposure to TNF-α inhibitors, the decision
problem for TA34066 was subsequently broadened to reflect these different populations. For the TNF-α
inhibitor-exposed (experienced) population, UST was compared with conventional management only,
because at the time of the submission there were no RCTs of TNF-α inhibitors in this population. Analyses
were based on clinical effectiveness evidence from the TNF-α inhibitor-exposed subpopulation of the
PSUMMIT 2 trial.
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As new interventions have been included, subsequent modelling studies have been based on revised NMAs
incorporating new RCT evidence for the interventions being assessed in each appraisal (GOL in TA22070 and
UST in TA34066). However, the synthesis approaches and methodologies applied across the studies remains
consistent with that applied in the York model. The only exception to this is the comparison of UST with
conventional care in the TNF-α inhibitor-exposed subpopulation, which was based on subgroup results from
the PSUMMIT 2 trial. For this subpopulation a NMA was not considered feasible because of the lack of RCT
evidence for the comparator treatments.
The main approaches to estimating longer-term costs and QALYs employ similar methodologies and
assumptions across the studies identified. The main difference in relation to costs concerns the link to PASI.
Estimates of PASI costs applied in the GOL and UST appraisals (TA22070 and TA34066) were derived from a
clinician survey and used to estimate the expected difference in cost per additional unit change in PASI
score. This contrasts with the approach used in the York model, which distinguished costs on the basis of
PASI 75 response. Although different utility algorithms have been applied in each of the models (TA22070
and TA34066 used patient-level data from each companys trials), these have reported similar coefficients
for HAQ-DI and PASI to those applied in the York model. All studies have also routinely reported results
based on the utility estimates used in the York model in separate scenarios.
With the exception of TA220 (GOL),70 all models have used the same assumptions and data sources to
model the natural history and progression of PsA [i.e. assuming a constant PASI score and a linear increase
(worsening) of HAQ-DI score over time]. In TA220 (GOL)70 and TA340,66 the annual rate of change per year
was derived from an alternative source, the Leeds NESPAR study. However, the estimate is broadly similar
to the estimate applied in the York model and other published models (0.0719 per year compared with
0.077 per year in the York model). All published studies have used the same estimate (16.5% per annum)
concerning longer-term withdrawal of biologic treatment due to lack of efficacy.
Comparison of cost-effectiveness results from published models
Given the different interventions and effectiveness data utilised in each of the models, it is not surprising
that each generates different costs and QALYs, resulting in different ICERs for the various options being
compared (Table 64). However, there appeared a number of findings which were consistent across the
separate studies. Consistently, ETN appeared to represent the most cost-effective strategy based on fully
incremental ICER calculations, with an ICER ranging between £16,426 and £17,853 per additional QALY
versus palliative (i.e. conventional) care. In addition, INF was reported to be the most effective and costly
strategy with the exception of TA220,70 where INF was reported to have the same effectiveness as ETN.
There is greater variation across the studies in terms of the ICERs reported for INF versus palliative care
than for other comparisons. The ICERs for INF versus palliative range between £20,789 and £40,943 per
QALY. These differences appear largely as a result of differences in assumptions related to dosing for INF
based on body weight. In all fully incremental comparisons, treatments other than ETN and INF were
reported to be either dominated or extendedly dominated. The majority of studies reported that the ICER
for INF versus ETN (the next less effective and non-dominated strategy) ranged between £44,326 and
£268,107 per QALY. In contrast, INF was reported to be dominated by ETN in TA220 (i.e. same
effectiveness but higher cost).70
Technology Appraisal 340 included a separate analysis of a biologic-experienced population for UST.
In this analysis UST was reported to be cost-effective compared with BSC (ICER around £25,000) in the
biologic-experienced/-ineligible population. UST was subsequently approved by NICE for this population,
highlighting the importance of considering the impact of broader treatment pathways for PsA for
future studies.
Analysis of subgroups, according to psoriasis involvement, has been consistently done via deterministic
sensitivity analysis in TA199, TA220 and TA340, specifying a negligible or more severe PASI score.
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Critique of company submissions
Two de novo economic models were submitted by the companies (Novartis and UCB Pharma) as part of
this TA. The main features of the models are summarised in Table 65 and critiqued in the sections
following this. Quality assessment checklists for the two submissions are presented in Appendix 5.
Model structure and assumptions
The two company models have a similar structure to the York model, reflecting both the initial short-term
(response period) and long-term (maintenance) phases (Figures 10 and 11). Within the short-term response
period, treatment response is assessed within a decision tree in the Novartis submission, and within a
Markov cohort model in the UCB Pharma submission. Both submissions characterise the long-term phase
(modelled via changes in HAQ-DI and PASI scores) using a Markov cohort model. This longer-term phase is
40 years in the Novartis model and 50 years in the UCB Pharma model. Both models are built in Microsoft
Excel® (Microsoft Corporation, Redmond, WA, USA).
TABLE 64 Summary of cost-effectiveness results from the published studies and NICE TAs
NICE TA and published studies
aTA199:33 Rodgers
et al.33 and Bojke et al.122
aTA220:70 Cummins
et al.133 and Yang et al.34
aTA340:66 Craig et al.66 and
O’Connor et al.35 Cawson et al.36
Only fully incremental
ICERs presented. The ICER
of ETN compared with
palliative care was
£17,853 and the ICER of
INF compared with ETN
was £44,326 per QALY.
ADA is extendedly
dominated
Pairwise ICERs presented
vs. palliative care and fully
incremental comparisons
presented
Pairwise ICERs presented vs.
palliative care and fully
incremental comparisons
presented. Separate analyses
presented for TNF-α inhibitor-naive
and TNF-α inhibitor-experienced
populations. ERG alternative
model estimates presented below
including UST PAS
Pairwise ICERs presented
vs. palliative care and
fully incremental
comparisons presented
Of the three biologic
therapies, ETN has the
highest probability of
being cost-effective at a
threshold between
£20,000 and £30,000 per
QALY
Pairwise ICERs vs. palliative
care (company corrected):
l ADA= £18,824
l GOL= £19,993
l ETN= £17,177
l INF= £23,578
Pairwise ICERs vs. palliative care 
naive (ERG alternative model
including UST PAS):
l UST= £21,857
l ADA= £29,915
l ETN= £17,809
l GOL = £19,213
l INF = £40,943
Pairwise ICERs vs.
palliative care:
l ADA= £17,222
l GOL= £17,435
l ETN= £16,426
l INF = £20,789
Fully incremental ICERs:
l ETN vs. palliative
care= £17,177
per QALY
l ADA and GOL
extendedly dominated
l INF dominated by ETN
Fully incremental ICERs  naive
(ERG alternative model including
UST PAS):
l ETN vs. palliative
care= £17,809 per QALY
l INF vs. ETN = £268,107
per QALY
l UST and GOL dominated
l ADA extendedly dominated
Fully incremental ICERs:
l ETN vs. palliative
care= £16,426
per QALY
l INF vs. ETN =
£62,527 per QALY
l GOL dominated
l ADA extendedly
dominated
Experienced patients (ERG
alternative model including UST
PAS):
l UST vs. palliative
care= £25,393 per QALY
PAS, Patient Access Scheme.
a ICERs reported for TA199, TA220 and TA340 based on the preferred assumptions of the committee from Final Appraisal
Determination documents.
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TABLE 65 Summary of the Novartis and UCB Pharma models
Feature
CS
Novartis UCB Pharma
Comparators These are specified according to the
subpopulations considered:
1. Biologic naive (one prior DMARD):
150 mg of SEC, SoC (25 mg per
week of MTX)
2. Biologic naive (two or more prior
DMARDs): 150 mg of SEC, CZP,
ADA, ETN, INF, GOL and SoC
3. Biologic experienced: 300 mg of
SEC, CZP, UST and SoC
These are specified according to the subpopulations
considered:
1. Biologic naive (one prior DMARD): CZP, cDMARD
2. Biologic naive (one or more prior DMARDs): CZP,
150 mg of SEC, ADA, ETN, INF, GOL
3. Biologic experienced: CZP, 300 mg of SEC, UST and a
mix of treatments defined as MTX, other cDMARDs
and palliation (antirheumatics)
Model structure Short-term (3-month) decision tree,
leading into a long-term (40-year)
Markov cohort model
Cohort Markov model. Three periods:
1. short term, in which the initial response to treatment is
determined (12 or 24 weeks depending on the
treatment
2. treatment continuation (up to 36 weeks post
initial response)
3. long-term (50 years)
Response at 3 months defined using
both PsARC and PASI 75. Responders
enter the maintenance phase and can
switch to SoC as a result of death or
withdrawal from treatment
PsARC is used to determine response. Responders enter
the maintenance phase and can switch to another
treatment as a result of loss of efficacy or for other
reasons. Initial non-responders switch to the next line of
treatment immediately after the initial period
Disease progression, through PASI and
HAQ-DI, are linked to costs and utilities.
For patients on treatment, HAQ-DI and
PASI scores remain constant from
12 weeks
Disease progression, through PASI and HAQ-DI, is linked
to costs and utilities. For patients on treatment, HAQ-DI
and PASI scores remain constant. For patients who
withdraw from treatment, PASI score rebounds back to
the baseline value in the cycle after stopping active
treatment, but HAQ-DI score rebounds to a worse position
For patients who withdraw from
treatment, PASI and HAQ-DI scores
both rebound back to the baseline
value in the cycle after stopping active
treatment. Patients on SoC experienced
a linear increase in their HAQ-DI score
of 0.018 units for each cycle
Patients on SoC experienced a linear increase in their
HAQ-DI score of 0.018 units for each cycle
Sequencing Not addressed in the base-case analysis.
Included as a scenario in which patients
move to a subsequent basket of
biologics before switching to SoC. This
was applied only in the anti-TNF-naive
population
Full sequence model of biologics followed by the mix
of palliation, the sequence differs based on the
subpopulation, ranging from one line to three lines of
treatments. Switching can only occur in the first 4 years,
after which patients remain on treatment indefinitely,
accounting for mortality
Patient inputs Homogeneous cohort using average
characteristics from the FUTURE 2
trial:48 baseline HAQ-DI
score = (confidential information has
been removed); baseline PASI
score = (confidential information has
been removed). These baseline values
were applied to each of the three
subpopulations
Homogeneous cohort using average characteristics from
the RAPID-PsA trial:47
l Biologic naive (one prior DMARD): baseline HAQ-DI
score= (confidential information has been removed);
baseline PASI score= (confidential information has
been removed)
l Biologic naive (one or more prior DMARDs: for
anti-TNF-naive population baseline HAQ-DI
score= 1.29 units; baseline PASI score= 11.58 units
l Biologic experienced: baseline HAQ-DI score= 1.37 units;
baseline PASI score= (confidential information has
been removed)
continued
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Although both submissions share a similar underlying structure, there are important differences in the
base-case approaches of each company in terms of the definition and timing of the response assessment:
l In the UCB Pharma base-case model, response is defined in terms of PsARC alone. The base case also
assumes that PsARC response is assessed at 24 weeks both for CZP and for all other comparators.
The use of 24 weeks contrasts with previously published studies reviewed for the comparator treatments,
which have consistently assumed that this assessment would occur at around 3 months (1216 weeks).
The main exception in previous studies has been for UST, for which a 24-week time point has been
used, in accordance with its marketing authorisation. The justification provided by UCB Pharma for
choosing a common time point of 24 weeks for all treatments was based on the European League
Against Rheumatism (EULAR) Treat to Target 2013 recommendations, which state that a maximum
of 6 months is recommended for reaching the treatment target. However, the submission from UCB
Pharma also notes that that the same recommendations also advise that therapy should be adapted
earlier than 6 months if no significant reduction in disease activity is observed. The UCB Pharma
submission does not explicitly discuss the proportion of patients in whom its therapy would be adapted
earlier than the 24-week time point, nor is there any discussion of the potential biases that could arise
by assuming that therapy is adapted only after 24 weeks. However, a separate scenario in which the
initial response was assessed at 12 weeks both for CZP and for other comparators (including UST)
was explored as part of a scenario analysis. Patients are then further stratified according to PASI 75
response/no PASI 75 response. This stratification is not assumed in the base case to alter the decision
to continue treatment, but allows alternative cost and utility assumptions to be applied according to
PsARC response status.
TABLE 65 Summary of the Novartis and UCB Pharma models (continued )
Feature
CS
Novartis UCB Pharma
Sources of
effectiveness
evidence and
synthesis
See Sources and synthesis of
effectiveness and Appendix 6
See Sources and synthesis of effectiveness and Appendix 6
Sources of cost
data
MIMS 2016134 and BNF 2015135 for
acquisition costs and doses required
for treatments. PSSRU136 and NHS
Reference Costs 2014 to 2015137 for
administration and monitoring costs
MIMS 2016134 and BNF 2015135 for acquisition costs
and doses required for treatments. PSSRU136 and NHS
Reference Costs 2014 to 2015137 for administration and
monitoring costs
Health state costs were estimated
based on Kobelt et al.129
Health state costs were estimated based on Poole et al.138
Utilities Algorithm derived from patient-level
data of FUTURE 248 in which utility is a
function of HAQ-DI, PASI, age, sex and
anti-TNF response state
Algorithm derived from patient-level data of the
RAPID-PsA trial47 in which utility is a function of
HAQ-DI and PASI
The algorithm from the York model
was also applied in a scenario analysis
The algorithm from the York model was also applied in a
scenario analysis
BNF, British National Formulary; MIMS, online and print prescribing database for health professionals; PSSRU, Personal
Social Services Research Unit; SoC, standard of care.
FIGURE 10 Overview of the UCB Pharma model structure. (Confidential information has been removed.)
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l In the Novartis model, patients are defined as responders if both a PsARC and PASI 75 response are
achieved at 12 weeks (or 24 weeks for UST). The model also includes additional scenarios in which
either PASI or PsARC only is used to determine a patients initial response. Although the company
notes that the SEC Summary of Product Characteristics recommends a 16-week assessment point, a
12-week time point is assumed for SEC based on consistency with BSR/British Health Professionals in
Rheumatology guidelines and previous NICE appraisals.
In both models, HAQ-DI score changes are based on a treatment-specific rate of change conditional on
PsARC response status. However, important differences were evident between the companies, in the
approaches and assumptions applied in their models:
l In the UCB Pharma model, HAQ-DI score change for CZP is based on the week 4 data from the
RAPID-PsA trial. UCB Pharma justifies this assumption on the basis that the RAPID-PsA trial47 showed
minimal further change in HAQ-DI score between weeks 4 and 24. In the absence of HAQ-DI data over
time for the other comparators, a similar assumption was made for the comparators. An alternative
Biologic
treatment
Alive
Responder To Markov
maintenance
treatment
To Markov SoC
To Markov SoC
To Markov death
Non-responder
Dead
Start 
treatment
(a)
SoC
Maintenance
treatment
(b)
SoC
Death
FIGURE 11 Overview of the Novartis model structure. (a) Decision tree structure; and (b) Markov model structure
(base case). SoC, standard of care.
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assumption was explored as part of a scenario analysis in which the highest rate of change (or best)
HAQ-DI score change for the comparators is achieved only at 24 weeks. These assumptions are applied
in the UCB Pharma model to the treatment response period (24 weeks in the base case). Beyond
24 weeks, it is also assumed that there is continued improvement in HAQ-DI score up to week 36 post
initial response. UCB Pharma justifies this additional period of HAQ-DI score improvement based on
continued improvement over this period observed in the RAPID-PsA trial.47 In the absence of data, a
similar assumption is applied to all the comparators. After 36 weeks it is assumed that HAQ-DI score
remains constant for patients for the remainder of the period on treatment. Figure 12 illustrates the
separate intervals over which different assumptions are applied for patients responding to biological
treatment in the UCB Pharma submission.
l In the Novartis model, HAQ-DI score change data were derived directly from data reported during the
12- to 16-week time period included in its main NMA and were assumed to remain constant from
12 weeks onwards for patients who remained on treatment. This approach is consistent with the
assumption made in the previous York model.
In both models the change in PASI score is derived from the distribution of PASI responses. The approaches
followed by each company are consistent with the approach and assumptions of the York model.
The two submissions also account for the correlation between PASI 75 and PsARC using a similar method
to the York model. However, both companies source data on the correlation coefficients from their own
trial data as opposed to the data used in the York model.
Both submissions also incorporate an adjustment to HAQ-DI and PASI scores in order to account for
possible placebo or expectation effects in order to generalise the treatment effects from the RCTs to
routine practice. The methods of adjustment follow the same approach as the York model, by reducing
the change in HAQ-DI score for biologics by the weighted average of change in HAQ-DI score for PsARC
responders and non-responders across the standard of care (SoC) arm. A similar approach is followed for
PASI. Consequently, SoC patients were not assumed to experience any HAQ-DI or PASI score improvement
in the models.
The Novartis model assumes that, when a treatment is withdrawn, patients rebound to their baseline
HAQ-DI score (i.e. rebound equal to gain) and that their HAQ-DI score continues to deteriorate in line with
the natural history of HAQ-DI (i.e. a constant monthly rate of HAQ-DI deterioration). In contrast, the UCB
Pharma submission assumes that the HAQ-DI trajectory of patients switching to a subsequent treatment
initially rebounds to a higher (i.e. worse) HAQ-DI value than the original baseline.
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FIGURE 12 Illustration of HAQ-DI score change for patients responding to a biologic treatment in the UCB
Pharma model.
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The two submissions include a sex-specific multiplier effect for PsA mortality. The Novartis submission
applied the RRs reported in Wong et al.12 (1.65 and 1.59 for men and women, respectively) to life tables
from the general population. The impact of these multiplier effects was assessed by removing the effects
in a scenario analysis. In the UCB Pharma submission, a standardised mortality ratio of 1.36 was applied
for males and females.14 This represents an updated analysis of the cohort from Wong et al.12
Intervention and comparators
According to the BSR guidelines, biologic treatments should be considered for patients with active PsA
who have inadequately responded to two previous conventional disease-modifying antirheumatic drugs.127
However, in accordance with the NICE scope112 and the licences for SEC and CZP, the two submissions
have addressed three different subpopulations, including the one prior non-biologic DMARD population.
The three subpopulations specified in the NICE scope are:
1. subpopulation 1 (biologic naive, one prior DMARD): people who have received one prior non-biologic
DMARD
2. subpopulation 2 (biologic naive, two or more prior DMARDs): people whose disease has not responded
adequately to at least two prior non-biologic DMARDs
3. subpopulation 3 (biologic experienced or contraindicated): people whose disease has not responded
adequately to non-biologic DMARDs and not adequately responded to biological therapies (including
ETN, ADA, INF and GOL), or for whom biologic therapies are contraindicated.
There are two areas where the CSs appear to deviate from the specified NICE scope.112 First, subpopulation
2 is subsequently defined by UCB Pharma as all biologic-naive people. Hence, subpopulation 2 is presented
by UCB Pharma as an expansion of subpopulation 1 (i.e. representing one or more prior DMARDs). In
contrast, the Novartis submission specifies subpopulation 2 in accordance with the NICE scope (i.e.
inadequate response to at least two DMARDs). Second, both companies focus on the biologic-experienced
population for subpopulation 3. Hence, neither company separately considers people in whom biologic
therapies (including ETN, ADA, INF and GOL) are contraindicated.
The interventions and comparators in both submissions are specified separately for each of the three
subpopulations. Conceptually there are important differences between the submissions in terms of the
scope of the models and the approaches used to model the interventions and comparators:
l The UCB Pharma model has been developed to assess the cost-effectiveness of the interventions in
the context of a treatment pathway and, hence, explicitly considers subsequent treatment lines by
modelling separate sequences. The length and composition of the sequences differ across each of the
three subpopulations.
l The base-case model from Novartis for each subpopulation focuses on each specific point in the pathway
(i.e. the point that a decision to initiate a new intervention would be made for each subpopulation) and
does not attempt to formally model the sequences of subsequent treatments. Instead, the impact of
further treatment and associated sequences is explored as part of a separate scenario and is presented as
an exploratory analysis. Novartis justifies this approach given the limitations in the data available to model
sequencing of treatments and the lack of formal guidelines concerning the order in which biologics
should be used sequentially.
The interventions and comparators in each subpopulation are summarised in Figure 13 (UCB Pharma) and
Figure 14 (Novartis). The figures illustrate the different approaches employed by the companies and the
focus on the entire pathway (sequences and different lines) in the UCB Pharma submission compared with
the approach used by Novartis in its base case.
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Subpopulation 1: biologic naive (one prior DMARD)
In the UCB Pharma model, two sequences are compared in subpopulation 1:
1. sequence 1: first line (CZP)→ second line (TNF)→ third line (UST)→ last line (mix)
2. sequence 2: first line (cDMARD)→ second line (TNF)→ third line (UST)→ last line (mix).
The sequences differ in terms of the first-line therapy (CZP or cDMARDs) and the subsequent lines of
therapies (up to three further lines) in both sequences are assumed to be identical. Primary and secondary
failures to first-line therapy are assumed to move onto a second-line treatment comprising a mixture of
four TNF-α inhibitors (ETN, INF, ADA and GOL). The mixture of the four TNF-α inhibitors is modelled
assuming an equal market share (25%) and costs and outcomes are estimated as the weighted sum.
Following failure of the mixture of TNFs, patients are assumed to move onto UST as a third-line treatment
before moving onto the last line (mix). The last line (mix) is defined as a mixture of cDMARDs (base case:
MTX = 58.8%, leflunomide = 1.5%, sulfasalazine, 2.9% MTX sodium) and palliation (34.6%).
The UCB Pharma submission states that, although SEC is also a relevant comparator in this subpopulation
(i.e. a third sequence starting with SEC), the lack of published clinical evidence specifically on the one prior
DMARD subpopulation precluded SEC from being formally included.
In the Novartis model, the intervention assessed in subpopulation 1 is 150 mg of SEC and the comparator
is SoC (defined as 100% use of MTX, dose 25 mg per week). Similarly, the lack of published clinical
evidence specifically on the one prior DMARD subpopulation precluded CZP from being formally included
in the Novartis submission. Following primary or secondary treatment failure of SEC, patients are assumed
to move to SoC (MTX) without further biologic treatment.
Although 300mg of SEC is the licensed dose for biologic-experienced patients with concomitant
moderatesevere psoriasis, Novartis stated three reasons why the 300-mg dose was included for biologic-
naive patients (subpopulations 1 and 2):
1. the use of 300 mg of SEC for moderatesevere psoriasis is already recommended based on a separate
appraisal in this indication
2. no comparator data for biologic-naive PsA patients with concomitant moderatesevere psoriasis were
reported to be available
3. the subgroup of biologic-naive patients with concomitant moderatesevere psoriasis in the FUTURE 2
trial48 was too small to appropriately inform model inputs.
Subpopulation 2: biologic naive (one or more prior DMARDs, UCB Pharma; two or more
prior DMARDs, Novartis)
In the UCB Pharma model, three main sequences are compared in subpopulation 2:
1. sequence 1: first line (CZP)→ second line (UST)→ last line (mix)
2. sequence 2: first line (TNF)→ second line (UST)→ last line (mix)
3. sequence 3: first line (SEC)→ second line (UST)→ last line (mix).
The sequences start with CZP, other TNF-α inhibitors (ETN, INF, ADA and GOL) or SEC. In contrast to
subpopulation 1, the four other TNF-α inhibitors are evaluated as alternative first-line treatments. Hence,
sequence 2 actually comprises four separate sequences with ETN, INF, ADA or GOL specified as the
first-line treatment. The six sequences assessed in subpopulation 2 are thus:
1. sequence 1: first line (CZP)→ second line (UST)→ last line (mix)
2. sequence 2: first line (ETN)→ second line (UST)→ last line (mix)
3. sequence 3: first line (INF)→ second line (UST)→ last line (mix)
4. sequence 4: first line (ADA)→ second line (UST)→ last line (mix)
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5. sequence 5: first line (GOL)→ second line (UST)→ last line (mix)
6. sequence 6: first line (SEC)→ second line (UST)→ last line (mix).
Primary and secondary failures to first-line treatment are assumed to subsequently move onto UST before
moving onto mix (similarly defined as in subpopulation 1 as a mixture of cDMARDs and palliation).
The UCB Pharma model does not separately model the 150- and 300-mg doses of SEC for subpopulation
2. Instead, a single SEC sequence is modelled based on a weighted approach according to prevalence
of moderatesevere plaque psoriasis in subpopulation 2 and assuming that 53.7% of patients would
have a PASI score of > 10 units at baseline. The proportion used as the basis for weighting is referenced to
an academic-in-confidence study and no further details are reported. The weighting is discussed only in
the context of costing and, hence, it is unclear whether or not the efficacy estimates for SEC were
similarly weighted.
In the Novartis model, the treatment assessed in subpopulation 2 is 150 mg of SEC and five TNF-α
inhibitors (CZP, ETN, INF, ADA and GOL). Primary and secondary failures are assumed to subsequently
move onto SoC without biologic therapy (100% use of MTX, dose 25 mg per week).
The Novartis submission also considers a separate scenario (exploratory analysis) for subpopulation 2 in
which it is assumed that patients can move onto a mixed biologic therapy, prior to moving to SoC.
The mixed biologic treatment therapy comprises a mix of all biologics other than that received at first line.
This mixed strategy is assigned a weighted average efficacy, costs and AE incidence rates. The weights
assumed are not formally specified, but appear to be based on a similar approach to that taken by UCB
Pharma (i.e. assuming each has the same market share). Two scenarios were considered in which either
the same first-line efficacy is assumed for the mixed biologic therapy or a 20% decline in efficacy for
HAQ-DI, PsARC and PASI response while on second-line therapy.
Available biosimilars for ETN and INF are also included in the two submissions as part of separate
scenario analyses.
Subpopulation 3: biologic experienced
In the UCB Pharma model, four sequences are compared in subpopulation 3:
1. sequence 1: first line (CZP)→ last line (mix)
2. sequence 2: first line (300 mg of SEC)→ last line (mix)
3. sequence 3: first line (UST)→ last line (mix)
4. sequence 4: first line (mix).
In common with the other subpopulations, the sequences for subpopulation 3 differ in terms of the first-line
therapy (CZP, 300 mg of SEC, UST or mix), and the subsequent line of therapy (mix  comprising a mixture
of cDMARDs and palliative care) is assumed to be identical. The SEC sequence is modelled based on the
300-mg dose in accordance with the licensed dose for biologic-experienced patients.
In the Novartis model, the intervention assessed in subpopulation 3 is 300 mg of SEC, and UST and SoC
are included as separate comparators. The Novartis submission does not discuss why CZP is not included as
a separate comparator for subpopulation 3. Following primary or secondary treatment failure of SEC or
UST, patients are assumed to move to SoC without further biologic treatment (i.e. MTX).
Patient characteristics
The UCB Pharma submission uses the RAPID-PsA trial47 and specifies different baseline characteristics for
the three subpopulations. In the Novartis submission, baseline characteristics were reported to be similar
across subgroups in the FUTURE 2 trial48 and, hence, the same values were assigned to all patient
characteristics apart from PASI score.
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Tables 66 and 67 report the values applied in the two company models. The subpopulations are broadly
similar in terms of age and weight; however, there are some differences in terms of baseline HAQ-DI and
PASI scores assumed across the separate models. The UCB Pharma submission applies an increasing
baseline mean HAQ-DI score across subpopulations 13, which contrasts with the same HAQ-DI score
applied across the three subpopulations in the Novartis submission. There appears to be more variation in
the baseline PASI scores between the submissions, with mean PASI scores assumed to be > 10 units and
≤ 10 units, respectively, in the UCB Pharma and Novartis submissions for each of the subpopulations.
The differences in the mean PASI scores appear to be an important source of variation between the two
submissions. By assuming a mean PASI score of > 10 units, the UCB Pharma base-case results relate to an
average PsA patient with concomitant moderatesevere psoriasis (i.e. ≥ 3% of BSA affected and a PASI
score of > 10 units). In contrast, the Novartis base-case results relate to an average PsA patient with
concomitant mildmoderate psoriasis (≥ 3% of BSA affected and a PASI score of ≤ 10 units). These
differences are likely to have an impact on subsequent costs and outcomes, most importantly in terms of
the appropriate dosing and costs assumed for SEC (i.e. 150 or 300 mg depending on the presence and
severity of concomitant psoriasis) in the naive subpopulations (i.e. subpopulations 1 and 2).
The UCB Pharma submission presents separate deterministic sensitivity analyses based on different PASI
scores. These sensitivity analyses were presented for two alternative baseline PASI scores (0 and 12.5 units).
These sensitivity analyses essentially reflect separate subgroups without concomitant psoriasis (mean PASI
score= 0 units), and a subgroup with concomitant moderatesevere psoriasis (mean PASI score = 12.5 units).
The Novartis model does not present separate subgroup results or sensitivity analyses in relation to the
baseline PASI score.
TABLE 66 Baseline characteristics in subpopulations 1–3 (UCB Pharma)
Feature
Subpopulation
1 2 3
Age (years), mean Confidential information has been removed 47 49
% female Confidential information has been removed 55.6 53.8
Weight (kg), mean (SD) Confidential information has been removed 84 (18) 87 (20)
HAQ-DI score (units), mean Confidential information has been removed 1.29 1.37
PASI score (units), mean Confidential information has been removed 11.58 12.04
SD, standard deviation.
TABLE 67 Baseline characteristics in subpopulations 1–3 (Novartis)
Feature
Subpopulation
1 2 3
Age (years), mean 47.96 47.96 47.96
% female 51.6 51.6 51.6
Weight (kg), mean (SD) 87.11 (19.66) 87.11 (19.66) 87.11 (19.66)
HAQ-DI score (units), mean Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
PASI score (units), mean Confidential information
has been removed
Confidential information
has been removed
Confidential information
has been removed
SD, standard deviation.
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Given that PASI is directly observable and because the severity of concomitant psoriasis means that different
SEC dosages are appropriate for the separate subgroups (i.e. 150 mg of SEC for naive patients without
concomitant psoriasis or with concomitant mildmoderate psoriasis and 300mg of SEC for experienced
patients and for naive patients with concomitant moderatesevere psoriasis), it would appear more appropriate
for both companies to have more explicitly modelled the three specific subgroups within each of the
subpopulations as opposed to assuming a single average PsA patient or cohort. These three subgroups are:
1. PsA without concomitant psoriasis
2. PsA with concomitant mildmoderate psoriasis (≥ 3% of BSA and a PASI score of ≤ 10 units)
3. PsA with concomitant moderatesevere psoriasis (≥ 3% of BSA and a PASI score of > 10 units).
Withdrawal from treatment and the natural history of psoriatic arthritis
Following treatment failure and withdrawal, the Novartis submission assumes that patients HAQ-DI and
PASI scores will revert to the original baseline values, which is consistent with the rebound equal to gain
approach previously applied in the York model. In contrast, the UCB Pharma submission assumes that the
HAQ-DI score trajectory of patients switching to a subsequent treatment initially rebounds to a higher
(i.e. worse) HAQ-DI value than the original baseline. The value assumed for rebound is equal to the baseline
value plus the HAQ-DI score change for the previous treatments PsARC non-responders. Furthermore,
when switching from the second to the third line of treatment, this rebound increases further, representing
the baseline plus the previous two treatments change in HAQ-DI score for non-PsARC responders. For
example, in a treatment sequence addressing subpopulation 1, the baseline HAQ-DI score is assumed to be
(confidential information has been removed); on switching to the second line of treatment, this initially
increases to (confidential information has been removed), and increases further to (confidential information
has been removed) and (confidential information has been removed). The UCB Pharma submission does not
include any discussion or justification for this approach.
The natural progression of PsA (i.e. in the absence of biologic treatments), in terms of increasing the
HAQ-DI score, is reflected in both models using the approach adopted in the York model. The two models
assume that the HAQ-DI score linearly increases over time by 0.018 units every 3 months until it reaches
the maximum, 3 units. This increasing HAQ-DI score is applied in conventional treatment arms of both
models and to patients who subsequently move on to conventional (i.e. non-biologic) treatment.
Both the UCB Pharma and Novartis models consider the possibility that patients who initially respond to
treatment may subsequently withdraw from treatment in the longer-term model. Based on safety and
tolerability data from the FUTURE 1 and 2 trials (see Chapter 4),46,48 the Novartis submission derived the
discontinuation rates for patients receiving 150 and 300 mg of SEC. This was (confidential information
has been removed) and (confidential information has been removed) for the first year and (confidential
information has been removed) and (confidential information has been removed) for subsequent years
(applied until the end of the model). These values were used for all comparators in the base case and
alternative values were examined in sensitivity analysis, in which withdrawal rate values were derived from
different trials (Table 68 shows these values).
TABLE 68 Discontinuation rates applied in sensitivity analysis (Novartis)
Time
point
Treatment, annual discontinuation rate (%)
150mg of SEC 300mg of SEC CZP ETN ADA INF GOL UST
Year 1 Confidential information
has been removed
Confidential information
has been removed
15.1 15.6 15.0 13.9 29.5 26.1
Year 2+ Confidential information
has been removed
Confidential information
has been removed
15.1 15.6 15.0 8.5 29.5 11.3
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The UCB Pharma model assumes an annual discontinuation rate of 16.5% for all biologic treatments.
This figure is consistent with the assumption and data used to inform the York model. A further assumption
was also included in the UCB Pharma model such that if a patient continued on a therapy for at least
48 months there would be no risk of longer-term withdrawal beyond this time point. This assumption was
justified as a result of the lack of data reporting long-term withdrawal rates.
Sources and synthesis of effectiveness
The main clinical outcomes included in the company models were PsARC and PASI (50, 75 and 90)
response, and HAQ-DI score changes conditional on PsARC response. The sources and assumptions of the
effectiveness evidence used in the base case of each of the economic models are summarised in detail in
Appendix 6. A brief overview is provided below and is specifically focused on the relationship between the
meta-analyses undertaken by each company and the specific inputs and assumptions applied to each
subpopulation within the economic models.
Subpopulation 1: biologic naive (one prior DMARD)
For the biologic-naive (one prior DMARD) subpopulation, both companies used the results from post hoc
subgroup analyses of the naive subgroup (one prior DMARD) from either the RAPID-PsA (UCB Pharma)47
or FUTURE 2 (Novartis)48 trials to inform PsARC and PASI responses and conditional HAQ-DI scores.
Subpopulation 2: biologic naive (one or more prior DMARDs, UCB Pharma; two or more
prior DMARDs, Novartis)
The PsARC and PASI responses were derived directly from the estimates of the separate NMAs undertaken
by each company. The patients used for subpopulation for each NMA differed. The UCB Pharma estimates
were derived from a NMA based on trials (or relevant subgroups) of biologic-naive patients only. In the
absence of subgroup data for SEC for biologic-naive patients, UCB Pharma included a separate assumption
that the effectiveness of SEC (confidential information has been removed). In contrast, Novartis used the
results from its NMA based on the overall population (i.e. including both naive and experienced patients
for some trials) results for all treatments.
A variety of different sources and assumptions were used to inform HAQ-DI change scores, including
results from the NMA, external published estimates and assumptions.
Subpopulation 3: biologic experienced
There were important differences in the approaches and assumptions used by each company for
subpopulation 3. The UCB Pharma model included PsARC and PASI response estimates for CZP and SoC
directly from a subgroup of biologic-experienced patients from the RAPID-PsA trial47 and then applied
separate assumptions for 300 mg of SEC and UST. In contrast, Novartis assumed a common reduction
in the efficacy of biologic-experienced patients based on a comparison between biologic-naive and
biologic-experienced subgroups in the FUTURE 2 trial. The efficacy reductions were subsequently applied
to the all-population NMA. The following reductions were applied:
l PsARC reduced by (confidential information has been removed)%
l PASI 5074 reduced by (confidential information has been removed)%
l PASI 7589 reduced by (confidential information has been removed)%
l PASI 9099 reduced by (confidential information has been removed)%.
For HAQ-DI change scores, the UCB Pharma model derived data for CZP and SoC directly from the
biologic-experienced subgroup of the RAPID-PsA trial47 and used separate assumptions for UST and
300 mg of SEC. Novartis assumed the same change scores as applied to subpopulation 2.
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Sources of utility data
The two manufacturers submissions present separate utility algorithms derived from patient data in the
FUTURE248 (Novartis) and RAPID-PsA47 (UCB Pharma) trials. These algorithms are estimated to determine
the independent contribution of HAQ-DI and PASI scores to health utilities.
Table 69 shows the parameters used in each submission, alongside the values used in the York model.
The Novartis algorithm, in addition to HAQ-DI and PASI, also includes age, sex and the baseline utility as
explanatory variables, together with the response status for anti-TNF treatment. This implies that a different
algorithm was defined according to PsARC response status. The algorithm also accounts for the decline in
utility over time by including age as a covariate. Both submissions also used the algorithm adopted by the
York model within a separate scenario analysis. The UCB Pharma and York algorithms are broadly consistent;
however, the Novartis algorithm predicts a much smaller coefficient for HAQ-DI score (0.172 units as
opposed to 0.298 units in the York algorithm and 0.258 units in the UCB Pharma model). This implies a
much smaller utility decrement for a unit increase in HAQ-DI score.
Summary of resource utilisation and costs data
In both models, resource use and costs were categorised in terms of drug acquisition, administration and
monitoring and associated health state costs (i.e. according to HAQ-DI and PASI scores). In both models,
it was assumed that DMARDs were used concomitantly with all biologic treatments (58% using MTX in
the UCB Pharma model and 100% using MTX in the Novartis model). AE costs were included only in the
Novartis model.
Drug acquisition costs
Both models estimated the acquisition costs for CZP based on the Patient Access Scheme currently under
approval. There were differences in the approaches and costs used by the companies for SEC. In the
Novartis model, the acquisition costs for 150 and 300 mg of SEC were based on the Patient Access
Scheme for SEC. The Novartis model also evaluated only the 300-mg dose for the biologic-experienced
subpopulation and the 150-mg dose for subpopulations 1 and 2 for reasons previously outlined. In the
TABLE 69 Utility algorithms used in the CSs
Parameter
Submission
York model (SE)Novartis: FUTURE 248 (SE) UCB Pharma: RAPID-PsA47 (SE)
Intercept Confidential information has
been removed
Confidential information has
been removed
0.897 (0.006)
HAQ-DI score Confidential information has
been removed
Confidential information has
been removed
0.298 (0.006)
PASI total score Confidential information has
been removed
Confidential information has
been removed
0.004 (0.0003)
EQ-5D coefficient Confidential information has
been removed
N/A N/A
Anti-TNF therapy status (anti-TNF naive was used as the reference for anti-TNF therapy status)
Inadequate responder Confidential information has
been removed
N/A N/A
Sex (female was used as the reference)
Male Confidential information has
been removed
N/A N/A
Age (years) Confidential information has
been removed
N/A N/A
N/A, not applicable.
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UCB Pharma model, the acquisition costs for SEC were based on the list prices and a weighted cost was
estimated for subpopulations 1 and 2 based on the 150- and 300-mg doses, based on the proportion of
patients assumed to have concomitant moderatesevere psoriasis.
Both companies used national list prices [British National Formulary (BNF)139 and an online and print
prescribing database for health professionals (MIMS)] for other comparators and incorporated existing
Patient Access Schemes for UST and GOL. In addition, both companies used a similar approach to estimating
acquisition costs for INF by assuming a normal distribution of weights to determine the required number of
vials based on patient-level data in the FUTURE 248 [mean 87.11 kg, standard deviation (SD) 19.66 kg] and
RAPID-PsA47 (mean 84.34 kg, SD 18.77 kg) trials. The drug acquisition costs for biosimilars in both submissions
were sourced from MIMS (in 2016) and were approximately 90% of the price of the originator product.
Drug administration and monitoring costs
In terms of drug administration costs, the Novartis model assumed a half-day inpatient visit for each
infusion for INF (£326.46). For all other (subcutaneously administered) biologics, resource use associated
with administration was based on a single 30-minute session with a specialist community nurse in the first
3-month period in order to train patients in self-administration (£37.50). No administration costs were
assumed for MTX.
In contrast, the UCB Pharma model assumed a cost of £159 for each infusion for INF based on the cost of
delivering a simple parenteral chemotherapy (first attendance). For all other (subcutaneously administered)
biologics and MTX, the UCB Pharma model assumed a cost of £43 based on the cost of a 1-hour nurse
visit at a GP practice.
Although the two submissions included the same laboratory tests for monitoring PsA patients, there were
differences in the costs that are applied for these. In the UCB Pharma submission, monitoring costs were
defined as laboratory tests and estimated at £117.60 for the first 3 months and £21 for the subsequent
3 months. The monitoring costs for biologics applied in the Novartis model were lower, at £79 for the first
3 months and £4.20 for the subsequent 3 months.
Adverse events
Only the Novartis submission included the resource costs of AEs. These comprised the costs of TB reactivation
(£3054) and other serious infections (£1527), based on the approach used for a separate NICE appraisal for
ankylosing spondylitis (see TA383104).
Health Assessment Questionnaire-Disability Index and Psoriasis Area and Severity
Index costs
In the Novartis submission, HAQ-DI and PASI costs were estimated using the same approach as the York
model (uprated to 2016 costs). Table 70 shows the inputs used by Novartis and the previous estimates
used in the York model.
TABLE 70 Health Assessment Questionnaire-Disability Index and PASI costs applied in the Novartis model
Input
Cost (£)
UnitYork model Novartis model
Intercept 233 255.78 Per 3 months
Cost per HAQ-DI score change 103 113.07 Per 1-unit change per 3 months
Health states
Uncontrolled psoriasis (PASI < 75 units) 198 217.36 Per 3 months
Controlled psoriasis (PASI ≥ 75 units) 16 17.56 Per 3 months
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In the UCB Pharma submission, health state costs for HAQ-DI and PASI were derived from a separate study
by Poole et al.138 The Poole et al.138 study utilised data from a sample of PsA patients from the BSRBR to
develop a multivariate model estimating disease severity from parameters routinely available in primary
care data. The multivariate model was subsequently applied to routine data from The Health Improvement
Network (THIN) to link to treatment and resource costs. These costs include costs of drugs, contacts with a
GP and other health-care professionals, tests, hospital outpatient attendances and inpatient admissions.
The relationship between disease severity and costs, based on HAQ-DI score, was then estimated using a
generalised linear model. Table 71 shows the coefficients from the generalised linear model.
Annual costs applied in the model were estimated using the following regression:
Annual costs = Exp(Intercept + HAQ-DI coefficient × HAQ-DI score + Age coefficient × Age
+ Interaction coefficient × HAQ-DI score × Age).
(3)
An adjustment was applied in the UCB Pharma model to avoid double counting prescription costs, which
accounted for 38% of the total costs in the Poole et al.138 study. Hence, HAQ-DI costs were assumed to be
62% of the total costs. The final costs were then uprated to 2015 values.
The UCB Pharma submission stated that, since the costs from Poole et al.138 included all medical resource
use for PsA patients, adding additional PASI-related costs would result in double counting. Consequently,
PASI-related costs were not included in the model base case. A sensitivity analysis including PASI-related
costs was undertaken based on the method used in the York model, with costs uprated to 2015 values.
Cost-effectiveness results from the company submissions
Subpopulation 1: biologic naive (one prior DMARD)
The base-case (deterministic) results for subpopulation 1 are reported in Tables 72 (UCB Pharma model)
and 73 (Novartis model). The UCB Pharma model reports an ICER of £23,666 per QALY based on the
comparison of a sequence starting with CZP and a separate sequence starting with cDMARDs. The
Novartis model reports an ICER of £12,189 per QALY based on a comparison of 150 mg of SEC versus
TABLE 71 Health Assessment Questionnaire-Disability Index and PASI costs applied in the UCB Pharma model
Coefficient Mean SE
Intercept 3.537 0.010
HAQ-DI coefficient 2.048 0.006
Age coefficient 0.026 0.000
Interaction coefficient, for interaction between HAQ-DI and age −0.012 0.000
TABLE 72 Base-case results for subpopulation 1 (biologic naive, one prior DMARD): the UCB Pharma submission
Treatment Total cost (£) Total QALYs
Incremental
cost (£)
Incremental
QALYs ICER (£)
cDMARDs Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed

CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
23,666
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SoC. Neither company included both CZP and SEC as relevant comparators in this subpopulation and
hence direct comparisons of CZP and SEC are not possible in this subpopulation.
There appear to be large differences in the total costs and QALYs reported for the comparator treatment
across the separate models. This may be partly explained by the different model time horizons (50 years in
the UCB Pharma model and 40 years in the Novartis model), the inclusion of subsequent lines of biologic
therapy and the different sources of cost data for HAQ-DI and PASI. The UCB Pharma submission reports
higher incremental costs and QALYs for CZP relative to the comparator treatment than does the Novartis
submission for 150 mg of SEC.
Subpopulation 2: biologic naive (one or more prior DMARDs, UCB Pharma; two or more
prior DMARDs, Novartis)
The base-case (deterministic) results for subpopulation 2 are reported in Tables 74 (UCB Pharma model)
and 75 (Novartis model). The UCB Pharma model reports that CZP dominates all the other treatments,
including SEC. In contrast, the Novartis model reports that 150 mg of SEC dominates all the other
treatments with the exception of SoC (less costly and less effective than 150 mg of SEC) and INF (more
costly and more effective than 150 mg of SEC). The ICER of 150 mg of SEC versus SoC is reported in the
Novartis submission to be £10,549 per QALY and the ICER of INF versus 150 mg of SEC is £220,558
per QALY.
TABLE 73 Base-case results for subpopulation 1 (biologic naive, one prior DMARD): the Novartis submission
Treatment Total costs (£) Total QALYs
Incremental
costs (£)
Incremental
QALYs ICER (£)
SoC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed

150mg of SEC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
12,189
TABLE 74 UCB Pharma’s base-case ICER results for subpopulation 2 (biologic naive, one or more prior DMARDs)
Treatment Total cost (£) Total QALYs
Incremental costs
vs. next least costly
intervention (£)
Incremental QALYs
vs. next least costly
intervention
ICER vs. next least
costly intervention (£)
CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed

ADA Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed
Dominated
GOL Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed
Dominated
ETN Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed
Dominated
SEC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed
Dominated
INF Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed
Dominated
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As both companies included both CZP and SEC as relevant comparators in this subpopulation, a direct
comparison between the submissions is possible for subpopulation 2. Both companies report their own
treatment to be the most cost-effective treatment at conventional cost-effectiveness thresholds and both
report that their specific treatment dominates the other. The contrasting conclusions could arise from
several important differences previously noted, including (1) different NMA approaches (i.e. the use of
24-week data by UCB Pharma in the base case vs. 12- to 16-week data from Novartis); (2) different
acquisition costs and dosages assumed for SEC (weighted estimate for SEC based on list price costs of
150 mg of SEC and 300 mg of SEC in the UCB Pharma submission vs. Patient Access Scheme price for
150 mg of SEC assumed in the Novartis submission); (3) inclusion of subsequent lines of biologic therapy in
the UCB Pharma submission; and (4) different sources of cost data for HAQ-DI and PASI and different
model horizons.
As the UCB Pharma model did not present comparisons against a strategy of no biologic therapy, it is difficult
to determine the external validity of the results presented for the comparator treatments. In contrast, the
Novartis submission presents both fully incremental ICERs and pairwise ICERs versus SoC. The presentation of
the pairwise ICERs versus SoC provides an important basis to consider issues of cross-validation based on the
consistency of the findings for the comparator treatments and those reported from the broader comparator
review presented earlier in Chapter 5. It is notable that the ICERs reported for the comparator treatments
(ADA, ETN, GOL and INF) in the Novartis submission appear higher (i.e. less favourable) than reported in
previous studies. Indeed, none of these comparator treatments would appear to be cost-effective versus SoC
at conventional cost-effectiveness thresholds. The reason for this difference and implications in terms of
external validity is not discussed in the Novartis submission.
TABLE 75 Novartis’ base-case ICER results for subpopulation 2 (biologic naive, two or more prior DMARDs)
Treatment Total cost (£) Total QALYs
Incremental
costs vs. SoC
(£)
Incremental
QALYs vs. SoC
ICER vs. SoC
(QALYs) (£)
ICER vs. next
least costly
intervention
(£)
SoC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
 
150mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
10,549 10,549
CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
28,432 Dominated by
SEC
ETN Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
31,280 Dominated by
SEC
GOL Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
33,802 Dominated by
SEC
ETN Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
32,706 Dominated by
SEC
INF Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
53,223 220,558
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Subpopulation 3: biologic experienced
The base-case (deterministic) results for subpopulation 3 are reported in Tables 76 (UCB Pharma model)
and 77 (Novartis model). The UCB Pharma model reports that CZP dominates UST and 300 mg of SEC. The
least costly and least effective non-dominated treatment in the UCB Pharma model is mix (i.e. a mixture of
cDMARDs and palliative care). The ICER of CZP versus mix is reported to be £8894 per QALY. In contrast,
the Novartis model reports that 300 mg of SEC extendedly dominates CZP and UST. The ICER of 300 mg
of SEC versus SoC is reported to be £27,562 per QALY.
Similar to the conclusions reported for subpopulation 2, both companies report their own treatment to be
the most cost-effective treatment at conventional cost-effectiveness thresholds and both report that their
specific treatment either dominates (UCB Pharma model) or extendedly dominates (Novartis model)
the other.
TABLE 76 UCB Pharma’s base-case ICER results for subpopulation 3 (biologic experienced)
Treatment Total cost (£) Total QALYs
Incremental costs
vs. next least costly
alternative (£)
Incremental QALYs
vs. next least costly
intervention
ICER vs. next least
costly intervention
(£)
Mix Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed

CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed
8894
UST Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed
Dominated by CZP
300mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has been
removed
Confidential
information has been
removed
Dominated by CZP
TABLE 77 Novartis’ base-case ICER results for subpopulation 3 (biologic experienced)
Treatment Total cost (£) Total QALYs
Incremental
costs vs. SoC
(£)
Incremental
QALYs vs. SoC
ICER vs. SoC
(QALYs) (£)
ICER vs. next
least costly
intervention
(£)
SoC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
 
CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
29,538 Extendedly
dominated
UST Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
37,228 Extendedly
dominated
300mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
27,562 27,562
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The Novartis submission, again, presents both fully incremental ICERs and pairwise ICERs versus SoC for
subpopulation 3. Although pairwise comparisons versus the non-biologic comparator (mix) are not presented
in the UCB Pharma submission, these can be estimated for UST versus mix from the data reported in its ICER
results table. As with subpopulation 2, these provide an opportunity to consider issues of cross-validation in
terms of the consistency of findings for one of the comparator treatments (UST) considered in the broader
review. The ICER for UST versus SoC is reported to be £37,228 per QALY in the Novartis submission, indicating
that UST is not cost-effective compared with SoC at conventional cost-effectiveness thresholds. Again, this
appears inconsistent with previous studies reporting the cost-effectiveness of UST in a biologic-experienced
population, and the reasons and possible implications in terms of external validity are not discussed in the
Novartis submission. One possible explanation is the different approaches used in the Novartis submission
for the experienced population (i.e. applying a common reduction in the efficacy rate to all treatments
based on a comparison between the biologic-naive and biologic-experienced subgroups based on the
FUTURE 2 trial48 data, as opposed to using the actual subgroup data reported for UST). The pairwise
comparison for UST versus mix, estimated from the results presented in the UCB Pharma results table,
results in an ICER of £28,068 per QALY. This appears reasonably consistent with the ICER reported in
TA34035 for UST (£25,393 per QALY).
Relevance of submitted cost-effectiveness evidence for National
Institute for Health and Care Excellence decision-making: summary
and motivation for de novo model
The CSs are the only studies that directly assess the decision problem in relation to the new interventions
[i.e. the positioning of these treatments within the pathway for PsA (biologic-naive and biologic-experienced
populations)]. Although the studies, in relation to the broader comparators, are helpful in terms of
highlighting similarities and possible differences between the approaches being applied by the separate
companies and those previously used for previous TA appraisals, they are not directly relevant to the
evaluation of SEC and CZP.
In general, the structure and approaches of both models were similar in many key respects to the York
model conducted for TA19933 (ETN, ADA and INF). The main differences were:
l The timing of the initial response period was assumed to be 24 weeks in the UCB Pharma submission
and 3 months (i.e. 1216 weeks) in both the Novartis submission (with the exception of UST) and
the York model. The justification provided by Novartis for assuming 3 months for the initial response
period was to ensure consistency with previous NICE appraisals and BSR/British Health Professionals in
Rheumatology guidelines and to maximise the data included in the NMA. UCB Pharma justified the
24-week period based on 2011 EULAR guidelines, although results were also reported as part of
separate sensitivity analysis assuming a 3-month response period.
l The definition of response in the Novartis base case (PsARC and PASI) differed from that used in the
base-case approaches by both UCB Pharma and the previous York model (PsARC only). The Novartis
submission presented a separate sensitivity analysis assuming that response was assessed using just
PsARC, and this reported only minor differences from its base case.
l The UCB Pharma base case focused on sequences and the incorporation of subsequent lines of
treatments as opposed to presenting this as a separate exploratory scenario (Novartis and York models).
l In common with the York model, the Novartis model assumed that the HAQ-DI score gain reported at
3 months was the maximum reduction achieved on treatment and assumed no further change (i.e.
increase or decrease) beyond this period for patients while they remained on this treatment. In contrast,
the UCB Pharma model employed different assumptions during the initial 9-month treatment (i.e. that the
highest rate of change is obtained at 4 weeks, but further improvements in HAQ-DI score are possible
during a period of 9 months for a responding patient who remains on treatment). After 9 months, the
UCB Pharma model assumed no further change beyond this period for patients while they remained on
this treatment.
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l Assumptions related to the rebound effect on HAQ-DI score following treatment withdrawal. The UCB
Pharma submission assumes that a patients HAQ-DI score rebounds to a worse position than the
original baseline value when they switch to the next treatment. Both the Novartis and York models
assume that a patients HAQ-DI score rebounds to its original baseline value.
l The Novartis and UCB Pharma submissions include additional subpopulations (subpopulations 1 and 3),
based on the broader scope for the appraisal of SEC and CZP compared with the scope of TA199.33
l The Novartis submission estimates costs associated with HAQ-DI and PASI based on the same sources
and assumptions previously used in the York model. In contrast, the UCB Pharma submission based
costs on a separate study by Poole et al.138 and justified this on the basis that the use of a PsA
population was more appropriate than deriving costs based on a RA population and employing
separate assumptions for PASI costs.
l Although UCB Pharma assumed the same annual withdrawal rate as the York model (16.5% per
annum), the UCB Pharma submission applied this only to the first 4 years of a treatment. Thereafter it
was assumed that no patient would withdraw. This assumption was justified by UCB Pharma based on
the lack of longer-term evidence reported for withdrawal. Novartis utilised withdrawal data from its
trial population (FUTURE 2 trial48) and applied a (confidential information has been removed) per
annum rate for the first year and (confidential information has been removed) for subsequent years.
l By assuming a mean PASI score of > 10 units, the UCB Pharma base-case results relate to an average
PsA patient with concomitant moderatesevere psoriasis (i.e. ≥ 3% of BSA affected and a PASI score
of > 10 units). In contrast, the Novartis base-case results relate to an average PsA patient with
concomitant mildmoderate psoriasis (≥ 3% of BSA affected and a PASI score of ≤ 10 units), similar to
the base case in the York model. Both the UCB Pharma and York model also presented separate
sensitivity analyses based on different PASI scores, which reflected subgroups of PsA patients without
concomitant psoriasis and with concomitant moderatesevere psoriasis. Separate sensitivity and
scenario analyses were not presented in the Novartis submission.
l The time horizon was assumed to be 40 years in the Novartis and York models and 50 years in the
UCB Pharma model.
As highlighted in Results, drawing robust conclusions from the results reported from the separate companies
is challenging given the differences noted in the approaches and data sources employed. Comparisons in
subpopulation 1 are not possible as neither company included the other treatment in their comparisons. The
difficulty of comparing results across subpopulations 2 and 3 are further hampered by the different assumptions
made concerning the dosage of SEC included and in both subpopulations 2 and 3 based on the use of list
prices for SEC in the UCB Pharma submission and Patient Access Scheme prices in the Novartis submission.
Assessments of cross-validity were possible for subpopulations 2 and 3 based on the Novartis results
presented for comparator treatment and those reported in previous studies. The results from the Novartis
model did not appear consistent with the cost-effectiveness reported for the comparator treatment
assessed in previous NICE TAs (see TA199,33 TA220133 and TA34035). A discussion of possible reasons for
this difference was not provided in the Novartis submission. An assessment of cross-validity was possible
only in terms of subpopulation 3 for the UCB Pharma submission. Here the reported ICER appeared
reasonably consistent for the main comparator treatment (UST) and the ICER reported in the previous NICE
TA (TA34035).
Given the different approaches and assumptions employed by the companies, there remains considerable
uncertainty regarding the cost-effectiveness of both SEC and CZP in each of the subpopulations and potential
implications for the NHS. These differences make it challenging to draw robust conclusions from the current
submissions, particularly given the contradictory findings reported for several of the subpopulations in terms
of the relative cost-effectiveness of SEC and CZP. Furthermore, neither company incorporated the full range
of interventions and comparators as stated in the NICE scope112 across all three subpopulations. The following
chapter describes the development of a de novo model that attempts to address several areas of remaining
uncertainty and to apply a consistent basis for evaluating the cost-effectiveness of the full range of
interventions and comparators as stated in the NICE scope112 across all three subpopulations.
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Chapter 6 Independent economic assessment
Introduction
The review of published models, and the CSs, show that the underlying structure used to model the
cost-effectiveness of treatments for PsA has remained largely unaltered since the previous York model
for TA199.33 Despite the similarity observed across studies in terms of the model structure, important
differences were identified in terms of associated assumptions and data sources. None of these can be
considered unequivocally superior to the others; however, there are a number of issues with each of the
currently available models (see Chapter 5, Relevance of submitted cost-effectiveness evidence for National
Institute for Health and Care Excellence decision-making: summary and motivation for de novo model).
In terms of the previous York model, this does not consider all of the subpopulations defined in the NICE
scope112 for this assessment. Currently available guidance, issued by NICE on the use of biologics in PsA,140
recommends that patients try two cDMARDs over a 6-month period before they can be considered for
biologic treatment in accordance with current BSR guidelines. However, as defined in the NICE scope for
this appraisal, three subpopulations need to be considered:
1. subpopulation 1 (biologic naive, one prior DMARD)
2. subpopulation 2 (biologic naive, two or more prior DMARDs)
3. subpopulation 3 (biologic experienced or contraindicated).
The two CSs consider these three subpopulations in their economic models; however, neither includes the
full range of relevant treatments for all of the subpopulations and neither specifically considers patients
contraindicated to existing biologic treatments.
In modelling the cost-effectiveness of available treatments, it is also important to consider the possibility
that patients may switch to another active treatment, following primary failure (non-response) or secondary
withdrawal (initial response with later withdrawal due to AE or loss of efficacy). Therefore, a key objective
of the de novo model is to assess the cost-effectiveness of SEC and CZP for PsA within possible sequences
of available treatments.
Methods
Overview
A decision-analytic model was developed to estimate the cost-effectiveness of SEC and CZP compared with
other relevant comparators, including ETN, INF, ADA, GOL, UST and BSC for the treatment of adult PsA. BSC
is defined as a mix of cDMARDs and usual care (see Choice of intervention and comparators). A different set
of comparators are defined according to each subpopulation of interest (see Patient characteristics).
The cost-effectiveness model takes the form of a Markov cohort model with 3-monthly cycles, developed
using R programing language (see Appendix 7 for the full model code). A lifetime horizon (40 years) is
assumed. A half-cycle correction was not applied as the cycle length is 3 months, which is relatively short
and, therefore, half-cycle correction is unlikely to be required.119
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Although the model shares a number of important characteristics with the previous York model, several
significant changes have also been implemented. These include:
l The base-case model attempts to replicate real-world clinical practice, in terms of incorporating
subsequent biologic treatments following a primary lack of response or secondary failure. Ignoring
these subsequent treatment lines and/or assuming patients move directly onto BSC following failure of
an initial biologic treatment, could result in overly optimistic estimates of cost-effectiveness of new (and
more effective) interventions. This may arise because the consequences of treatment failure are likely
to be overstated compared with real-world clinical practice, as additional treatment options remain
which are more cost-effective than BSC alone. Although exploratory scenarios were considered in the
previous York model in relation to treatment sequences, the formal inclusion of further lines of
treatment within the base model necessitated significant amendments to the previous R code.
l The model now includes the three subpopulations specified in the NICE scope112 for this appraisal.
l Rather than presenting a single base case reflecting an average PsA patient, heterogeneity in terms
of baseline PASI score is now formally addressed by presenting results for three distinct subgroups
within each subpopulation: (1) PsA without concomitant psoriasis; (2) PsA with concomitant
mildmoderate psoriasis (≥ 3% of BSA and a PASI score of ≤ 10 units); and (3) PsA with concomitant
moderatesevere psoriasis (≥ 3% of BSA and a PASI score of > 10 units). Differences in baseline PASI
score were previously considered in the previous York model as part of a sensitivity analysis. However,
as the decision problem differs across the specific subgroups as a result of the different licensed
dosages of SEC, it was considered more appropriate to model these subgroups separately.
Outcomes are expressed using QALYs.141 The QALY provides a summary measure combining estimates of
the remaining length of life (life-years) and its associated quality. QALYs are derived from health-related
utilities by multiplying a utility value (quality of life) by the time spent with this utility (length of life).
Utility values are generated from the main clinical outcomes of the disease, HAQ-DI reflecting the arthritis
component and PASI representing the psoriasis element (see Sources of utility data). These clinical scores
(HAQ-DI = 03 units and PASI = 072 units) represent the health states of the model and are also
associated with health-care resource use and costs (see Health state costs).
The parameters of the model were obtained from published literature, data reported in the CSs and the results
of the evidence synthesis in Chapter 4. The model adopts a NHS and Personal Social Services perspective.
A price year of 2016 is assumed and a 3.5% annual discount rate is applied to costs and QALYs.125
Probabilistic sensitivity analysis (PSA) was conducted as is reported separately from the deterministic results.
Model structure and assumptions
Figure 15 illustrates the model structure. The structure remains largely unchanged since the previous
York model (see Figure 8). However, in the updated York model, patients who withdraw from an initial
treatment during cycle 1 because of a lack of response or as a result of AEs (or later cycles for patients
who initially respond) are assumed to be eligible to receive further treatments prior to moving to BSC.
The subsequent treatment lines are defined separately for each of the three subpopulations (see Choice of
intervention and comparators).
Patients enter the model and receive one of the treatments or BSC, relevant to each particular subgroup.
Patients remain on treatment for 3 months (13 weeks), after which, if they respond, defined using PsARC,
they continue on the treatment; otherwise they move to BSC or another biologic treatment, if the
sequence allows.
The PsARC response data reported in the clinical trials (see Chapter 4) dichotomise patients into two
groups: responders and non-responders (as a result of lack of efficacy or AEs). In accordance with current
BSR guidelines (and to ensure consistency with previous NICE TAs), only PsARC response is used to
determine continuation on treatment. PsARC responders/non-responders are further stratified according
to PASI response status, to provide a more granular assessment of utilities and costs. PsARC and PASI
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No PsARC A
Cycle 1
Months 1–3
Cycle 2
Months 3–6
Biologic j1
BSC
N
PASI 75 only:
withdrawn from
biologic j1 to j2 or
BSC
Response of neither:
withdrawn from
biologic j1 to j2 or
BSC 
PASI 75
No PASI 75
PASI 75
No PASI 75
p.m.
B
C
A
Response of both:
continue on 
biologic j1
p.w.
p.m.
B
A
p.m.
p.w.
A
p.m.
PsARC
p.m.
C
A
A
Response of PsARC
only: continue on
biologic j1
A – withdrawn from biologic j1 to j2 or BSC
B – continue on biologic j1 with response of arthritis but not of psoriasis
C – continue on biologic j1 with response of both arthritis and psoriasis
N – no treatment
p.m. – probability of mortality (any cause)
p.w. – probability of withdrawal from biologic after first 3 months
Nodes 
     chance node
     terminal node (death from any cause)
     Markov node
FIGURE 15 Overview of the model structure.
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responses are assumed to be correlated. For consistency, the same correlation coefficient (0.4) applied in
the previous York model is assumed. This value is also assumed to apply across all subpopulations,
subgroups and individual treatments.
The PASI changes observed in the clinical trials are categorised according to the proportion of patients
who achieve at least 50%, 75% and 90% improvement in their baseline PASI score (PASI 50, PASI 75 and
PASI 90, respectively). The calculation of the expected improvement in PASI score for PASI 75 responders
and non-responders is equivalent to the approach used in the previous York model.33 That is, the new
model also assumes that patients who achieve a PASI 75 response will gain at least a 75% improvement in
psoriasis compared with baseline PASI score, with some achieving a 90% improvement. Similarly, patients
who do not achieve a PASI 75 response may achieve PASI 50.
Functional capability, in terms of the arthritis component of the disease, is measured using the HAQ-DI.
A relationship between PsARC response and HAQ-DI score is explicitly considered in the current model.
The change in baseline HAQ-DI score is assumed to be conditional on PsARC response status. To ensure
that the treatment effect is reproducible in the clinical practice, an adjustment for the placebo or
expectation effect is applied within the new model. This adjustment follows the same methods employed
in the previous York model.
An individuals HAQ-DI and PASI score determine health state costs (in addition to treatment-related costs)
and QALYs; hence, the model tracks these clinical scores over time. The new model employs tunnel
states142 to reflect how long patients stay in a particular health state (HAQ-DI and PASI scores) and when
they move (switch to another treatment) (see Choice of intervention and comparators). The ability to build
multidimensional arrays, facilitated through the use of R, enables this functionality and the inclusion of
subsequent lines of treatments, either after the initial response period or during the longer-term period.143
After the treatment response period, responders are subject to an ongoing risk of withdrawal from
treatment as a result of lack of efficacy or the occurrence of AEs (modelled together as an overall risk
of withdrawal). HAQ-DI and PASI scores again change according to the second-line treatment received
and associated response status. It is assumed that PsARC responders continuing on treatment after the
initial 3-month response period maintain their improvement in HAQ-DI and PASI scores until subsequent
withdrawal (i.e. no progression in HAQ-DI and PASI scores). Once patients withdraw from treatment to
BSC, or to another biologic treatment, their HAQ-DI and PASI scores rebound to their baseline values
(see Withdrawal from treatment and the natural history of psoriatic arthritis).
A summary of data inputs used in the model is given in Table 78. These are described in detail in the
relevant sections that follow. The effectiveness data utilised in the model are shown separately in Table 79
in Sources of effectiveness data. The variable names in both tables follow those used in the R code,
reported in Appendix 7.
Patient characteristics
As discussed in Overview, the NICE scope112 for this appraisal specified three specific subpopulations of
interest, reflecting the various stages of the treatment pathway for adult PsA. These three subpopulations
are subsequently referred to as:
1. subpopulation 1: biologic naive, one previous cDMARD
2. subpopulation 2: biologic naive, two or more previous cDMARDs
3. subpopulation 3: biologic experienced.
Within subpopulation 3, the availability of evidence relating to CZP, necessitates the specification of a
further scenario analysis to address the subgroup of patients who have previously responded to biologic
treatment (primary responders), but who have subsequently withdrawn as a result of loss of efficacy or the
occurrence of an AE.
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In addition, in the NICE scope112 for this appraisal, a further population (subpopulation 4) contraindicated
to TNF-α inhibitors (including ETN, ADA, INF and GOL) was also considered for SEC. CZP was not
considered within the contraindicated population on the basis that, in patients in whom other TNF-α
inhibitors are contraindicated, CZP (a new TNF-α inhibitor) would probably also be contraindicated.
In the updated York model, separate versions of the model are specified, representing each of the three
main subpopulations. In the base case of each of these models, the baseline age is assumed to be 47 years
and mean baseline HAQ-DI score is 1.22 units. These values represent the average baseline characteristics
from the included trials (see Chapter 4). Baseline weight is required for administration of INF; however,
not all trials report these values. Here the weight distribution reported in the RAPID-PsA trial47 is used
(see Treatment costs).
TABLE 78 Summary of data inputs for the York model
Description
Variable
name Mean SE Source/appendix
Sex: male= 1, female = 0 Male 1
Baseline HAQ-DI score HAQ-DI0 1.22 Mean of RCTs (see Chapter 4)
Baseline age Age 47 Mean of RCTs (see Chapter 4)
Model time horizon cycles num_cycles 160 Clinical opinion
Cycle length, year Cl 0.25
Discount rate (per year) r 0.035 UK treasury144
Utility function intercept h0 0.897 0.006 Rodgers et al., 201133
Change in utility for a 1-unit change in HAQ-DI
score
h1 0.298 0.006
Change in utility for a 1-unit change in PASI
score
h2 0.004 0.0003
Interaction term HAQ-DI PASI h3 0 10 × E5
Change in HAQ-DI score while on treatment
per 3-month period
HAQ-DI1.d 0 Rodgers et al., 201133
Change in HAQ-DI score while not on
treatment per 3-month period
HAQ-DI1.w 0.018 0.007 Rodgers et al., 201133
Rebound in HAQ-DI score on withdrawal
(compared with HAQ-DI score at baseline)
(zero means rebound equal to initial gain)
loss.w 0 Assumption
Intercept of regression of log-mortality vs. age
in men
ln.R.g.m 10.25 0.046 Gompertz parameters
parameterising life table data
for England and Wales145
Intercept of regression of log-mortality vs. age
in women
ln.R.g.f 11.10 0.046
Change in log-mortality with additional year of
age in men aged > 40 years
a.g.m 0.094 0.0006
Change in log-mortality with additional year of
age in women aged > 40 years
a.g.f 0.101 0.0006
Standardised mortality ratio for PsA vs. general
population
SMRmen
SMRwomen
1.36 Ali et al., 200714
Log-withdrawal rate from biologics per year ln.long.yr 1.823 0.2044 Rodgers et al., 201133
Correlation between PASI 75 and PsARC rho.new 0.4 0.1 ADEPT55
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
© Queens Printer and Controller of HMSO 2017. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
139
As discussed in Chapter 5, it is also important to consider the impact of differences in baseline
characteristics, in terms of HAQ-DI and, particularly, PASI scores, and the impact that these differences
have on cost-effectiveness and the choice of optimal treatment. This is a particular issue in terms of
the severity of concomitant psoriasis, as 300 mg of SEC, as opposed to the standard dose of 150 mg of
SEC, is approved in patients with more severe psoriasis. To explore the impact of severity of the psoriasis
component of the disease on cost-effectiveness, separate analyses are presented according to three
concomitant psoriasis subgroups. Clinical opinion suggests that about 50% of patients who receive
biologic treatment have mild or minimal concomitant psoriasis (< 3% of BSA or a PASI score of < 2.5 units),
25% have mildmoderate concomitant psoriasis (a baseline PASI score between 2.5 and 10 units) and 25%
have moderatesevere concomitant psoriasis (a PASI score of > 10 units).128 These definitions have been
used as the basis for the three concomitant psoriasis subgroups formally considered here:
l no concomitant psoriasis, with a baseline PASI score of 0 units
l mildmoderate concomitant psoriasis, with a baseline PASI score of 7.3 units (the same value used in
the previous York model)
l moderatesevere concomitant psoriasis, with a baseline PASI score of 12.5 units (the same value used
as part of a separate sensitivity analysis presented in the previous York model).
In the absence of effectiveness data reported for these subgroups, an assumption is made that treatments
are similarly effective (in relative terms) for each subgroup within the separate subpopulations. Hence, the
differences in cost-effectiveness for these subgroups are driven entirely by the different baseline PASI
scores and the subsequent impact on costs and outcomes of these differences.
Baseline HAQ-DI scores are assumed the same across the separate subpopulations and PASI subgroups.
Differences in baseline HAQ-DI scores were considered in a separate sensitivity analysis based on estimates
reported in the UCB Pharma submission.
Choice of intervention and comparators
l In subpopulation 1, only SEC, CZP and BSC are included in accordance with the NICE scope.112 Based
on the licence of SEC, 150 mg of SEC is included for the no-concomitant PASI and mildmoderate PASI
subgroups in the naive populations and 300 mg of SEC for the severe psoriasis subgroup.
l In subpopulation 2, SEC, CZP and other TNF-α inhibitors (ETN, INF, ADA and GOL) are considered to be
relevant treatment alternatives in accordance with the NICE scope. BSC includes cDMARDs according
to the placebo response rates as observed in the trials and costs according to HAQ-DI and PASI
health states (see Health state costs). Again, in accordance with the licence of SEC, 150 mg of SEC is
evaluated for the no-concomitant PASI and mildmoderate PASI subgroups in the naive populations
and 300 mg of SEC for the severe psoriasis subgroup.
l In subpopulation 3, 300 mg of SEC, CZP, UST and BSC (as defined above) are regarded as relevant
treatment alternatives in accordance with the NICE scope.112 As previously stated, as the data available
for CZP inform only a subgroup of subpopulation 3, a separate analysis is conducted for CZP compared
with BSC (see Patient characteristics).
l In the additional contraindicated subpopulation (subpopulation 4), SEC, UST and BSC (as defined above)
are regarded as relevant treatment alternatives. An assumption is made for this subpopulation that
patients in whom TNF-α inhibitors are contraindicated are biologic naive and hence the effectiveness
data are derived from this population. In reality, it is recognised that contraindications (e.g. infection, TB
activation) may arise after a TNF-α inhibitor has been tried. However, for simplicity this analysis assumes
patients are biologic naive. Hence, in accordance with the licence of SEC, 150 mg of SEC is evaluated
for the no-concomitant PASI and mildmoderate PASI subgroups in the naive populations and 300 mg
of SEC for the severe psoriasis subgroup.
In accordance with the NICE scope112 for this appraisal, APR was not included as a comparator in any of
the subpopulations, as at the time this report was completed it had not been approved for use in adult
PsA by NICE.
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A key element of updating the previous York economic model is the formal incorporation of subsequent
lines of therapy assumed within the base case. Specifically, the updated model allows for patients to move
(switch) to a second treatment rather than to BSC as a result of primary non-response or secondary failure
of treatment. The model also allows third- and fourth-line treatments. This functionality is enabled in the R
by including tunnel states to track the HAQ-DI and PASI scores of patients who switch therapy. Tunnel
states are generated for every cycle in the model (160 cycles). Further tunnel states are generated within
this structure where patients can switch to a third and fourth treatment. This significantly increases the size
of the Markov structure compared with the previous York model.
The length of the treatment sequence depends on the subpopulation: subpopulation 1 (biologic naive, one
previous cDMARD) is eligible to receive three lines of treatment before moving to BSC; subpopulation 2
(biologic naive, two or more previous cDMARDs) is eligible to receive two lines of treatment before moving
to BSC; and subpopulation 3 (biologic experienced) is eligible to receive one treatment before moving to
BSC. Subpopulation 4 is assumed to be equivalent to subpopulation 3 in terms of sequencing, the only
difference being the use of 150 mg of SEC as opposed to 300 mg of SEC.
The sequences of treatments are shown in Figures 1618 for the main subpopulations 1, 2 and 3,
respectively. Only the biologic-naive populations are eligible to receive further active treatments once they
have failed on their initial treatment.
l In subpopulation 1, patients may be eligible to receive further biologics. ETN is assumed to be the next
biologic treatment as part of the overall sequence, on the basis that is it the lowest cost currently
approved biologic and because it was consistently reported to be more cost-effective than other TNFs
in previously published studies.33 Following failure of ETN, patients are assumed to receive UST before
moving onto BSC.
l In subpopulation 2, patients are assumed to subsequently receive UST (approved in the biologic-
experienced population) before moving onto BSC.
l Patients in subpopulation 3 are assumed to move to BSC after failure of 300 mg of SEC, UST or CZP
(secondary failures only).
Etanercept and INF are available as the originator products or biosimilars. The originator product of ETN is
ENBREL and the biosimilar version is Benepali (SB4, Biogen Idec Ltd, Maidenhead, UK). The originator product
of INF is REMICADE® (Janssen Pharmaceuticals/ Merck Sharp & Dohme) and the biosimilar versions are
Inflectra® (Hospira UK Ltd, Maidenhead, UK), Remsima (Napp Pharmaceuticals Ltd, Cambridge, UK) and SB2
(Samsung Bioepis Co. Ltd, Seoul, Korea). In each of the base-case scenarios, the list prices for the originator
products of ETN and INF are assumed. A separate analysis is presented using the prices of the biosimilar
products (see Appendix 8). The biosimilar analysis is restricted to subpopulation 2. In this separate analysis the
biosimilar versions are assumed to be equivalent to the originator products in terms of effectiveness.
Withdrawal from treatment and the natural history of psoriatic arthritis
As the psoriasis element of PsA is not progressive, it is assumed that PASI score does not increase over
time for patients receiving BSC. The arthritis element of PsA is assumed to be progressive, consistent with
the clinical evidence (see Chapter 4). Therefore, for patients not receiving biologic therapies, the HAQ-DI
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Sequence 1 SEC ETN UST BSC
Sequence 2 CZP ETN BSCUST
FIGURE 16 Treatment sequences in subpopulation 1.
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score is assumed to worsen over time, reflecting the decrease in functional capability as the arthritis
component of the disease progresses. In the absence of a more appropriate alternative identified in the
review of long-term open-label data (see Chapter 3, Open-label extension studies) and registry data
(see Chapter 3, Review of anti-tumour necrosis factor patient registry studies), the rate determined in
the previous York model, derived from the NOAR, was utilised in the updated York model. This rate of
0.018 units per 3-month cycle is assumed to be constant over time. Figure 12 shows the trajectory of
HAQ-DI scores over time, for patients receiving BSC alone.
For PsARC responders, there is a risk of withdrawal following the first cycle of the model (3 months).
This risk is due to AEs and loss of efficacy. Based on the previous York model, this probability is estimated
from a meta-analysis of registry data from several countries to be 1.823 (SE 0.2044) on the log-scale, or
exp(1.823 + 0.5 × 0.20442) = 0.165 per year. This probability of withdrawal (0.165 per year) is assumed to
be independent of HAQ-DI and PASI score in the model, relevant for all comparators and is constant over
time. Alternative scenarios were specified according to those reported in the CSs (see Scenario analyses).
Following withdrawal, the rebound of HAQ-DI and PASI scores is assumed to be equivalent to the gain.
This assumption is consistent with the previous York model (see Figure 12). The rebound effect is assumed
to happen immediately following withdrawal.
Sequence 3 BSC
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FIGURE 18 Treatment sequences in subpopulation 3.
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Sequence 2 CZP UST BSC
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FIGURE 17 Treatment sequences in subpopulation 2.
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Sources of effectiveness data
The effectiveness data applied in the economic model are derived from the NMA, reported separately in
Chapter 5. Three outcomes were included in the NMA to inform the economic model: (1) PsARC response,
(2) change in HAQ-DI score conditional on PsARC response and (3) PASI 50, PASI 75 and PASI 90 responses.
The NMA implemented separate models for the pooling of treatment effects and placebo responses. A
number of alternative models were implemented to explore the possibility of placebo response determining
the effectiveness of alternative treatments, and also whether or not there was similarity between treatment
effects for treatments of the same class. These are discussed in detail in Chapter 5. The following sections
specify the approaches used in the economic model for each of the three outcomes.
Psoriatic Arthritis Response Criteria response
Chapter 5 details the data available for PsARC response, for each of the comparators. The NMA
implemented seven alternative models for PsARC response in the naive populations (see Table 41).
Owing to data limitations, these could be specified only for all biologic-naive patients (i.e. not separately
for subpopulations 1 and 2). Of these seven models, two were considered to be the preferred models on
the basis of model fit, goodness-of-fit statistics and clinical plausibility. These are:
1. Model A1: no baseline adjustment. Assumes that the treatments are independent (fixed effect) and,
therefore, utilises the baseline and treatment effects as observed in the trial.
2. Model D2: a metaregression on baseline risk (placebo response). Treatments within a class have similar
(exchangeable) effectiveness and depend on the effect of the placebo arm. Shrunken estimates are
reported to account for the differences between treatments. The Genovese et al.56 and Mease et al.53
trials are included.
Results for the two preferred PsARC models, in the naive population, are presented in Table 43. These
show the median probabilities and ORs.
For the biologic-experienced population (subpopulation 3), it was not possible to conduct a metaregression
because of data limitations; therefore, only independent analysis estimates are available for this subpopulation
(model A1). As discussed in Patient characteristics, the data from the RAPID-PsA trial (CZP)47 were not
included in the analysis. Results for the biologic-experienced population are presented in Table 45. These
show the median probabilities and ORs.
Health Assessment Questionnaire-Disability Index changes conditional on Psoriatic
Arthritis Response Criteria response
Given that HAQ-DI scores are modelled conditional on PsARC response, modelling an interaction effect
between baseline and treatment effect was deemed to be less relevant, and a metaregression model was
not implemented on HAQ-DI (see Chapter 4, Health Assessment Questionnaire-Disability Index conditional
on Psoriatic Arthritis Response Criteria response/non-response). Instead, three models are implemented
in the biologic-naive populations (see Chapter 4, Health Assessment Questionnaire-Disability Index changes
conditional on Psoriatic Arthritis Response Criteria response/non-response, Subpopulation: biologic naive),
two of which model a class effect for treatments. Again, as a result of data limitations, these could be
specified only for all biologic-naive patients. Of these three models, two were considered to be the
preferred models on the basis of model fit, goodness-of-fit statistics and clinical plausibility. These are:
1. Model E1: no baseline adjustment. Assumes that the treatments are independent (fixed effect) and,
therefore, utilises the baseline and treatment effects as observed in the trial.
2. Model E2: no baseline adjustment. A class effect is applied comprising three groups: anti-TNFs, ILs and
APR. Treatments are similar within class (exchangeable) and there is a fixed effect across studies.
The results for the two preferred HAQ-DI change models, in the naive population, are presented in Table 47.
These show the absolute median changes (with a more negative number representing a larger HAQ-DI
score improvement).
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For the biologic-experienced population (subpopulation 3), it was not possible to determine a class effect;
therefore, only independent analysis estimates are available for this subpopulation (model E1). As discussed
in Chapter 4, Health Assessment Questionnaire-Disability Index conditional on Psoriatic Arthritis Response
Criteria response/non-response, the data from the RAPID-PsA trial (CZP)47 were not included in the analysis.
Results for the biologic-experienced population are presented in Table 49. These show the absolute
median/mean HAQ-DI score changes.
Psoriasis Area and Severity Index 50, 75 and 90 responses
Chapter 5 details the data available for PASI response, for each of the comparators. The NMA utilised a
framework of analysis that evaluated the probability of PASI responses in different categories of PASI
thresholds (50/75/90) within a single model. For the economic model this was used to determine the
probabilities of achieving PASI 50, PASI 75 and PASI 90.
The NMA implemented three alternative models for PASI response in the naive populations (see Table 51).
Owing to data limitations, these could be specified only for all biologic-naive patients. Of these three
models, two were considered to be the preferred models on the basis of model fit, goodness-of-fit
statistics and clinical plausibility. These are:
1. Model F1: no baseline adjustment. Assumes that treatments are independent and fixed effect on
cut-off points/thresholds.
2. Model G2: common interaction term with baseline effect. Assumes that treatments are independent, but
treatment effects are adjusted with the trial-specific baseline effects assuming a common interaction term.
The results for the two preferred PASI response models, in the naive population, are presented in Table 53.
These show the median probabilities for PASI 50, PASI 75 and PASI 90.
For the biologic-experienced population (subpopulation 3), it was not possible to determine a class effect;
therefore, only independent analysis estimates are available for this subpopulation (model F1). As discussed
in Chapter 4, Psoriasis Area and Severity Index Psoriasis Area and Severity Index response, the data from
the RAPID-PsA trial (CZP)47 were not included in the analysis. Results for the biologic-experienced
population are presented in Table 55. These show the median/mean probabilities and ORs.
Combinations of evidence synthesis estimates utilised in the economic model
As discussed in the sections above, results are available for two alternative evidence synthesis models, for
each of the three outcomes (PsARC response, change in HAQ-DI score conditional on PsARC response and
PASI 50, PASI 75 and PASI 90 responses). The economic model utilises two combinations of these results
for PsARC response, HAQ-DI score conditional on PsARC response and PASI response. These are:
l independent analysis: PsARC response (model A1), HAQ-DI conditional on PsARC response (model E1)
and PASI response (model F1)
l metaregression: PsARC response (model D2), HAQ-DI conditional on PsARC response (model E2) and
PASI response (model G2).
Table 79 presents the effectiveness data used in the updated York model. The clinical effectiveness results
reported in Chapter 4 are, on the whole, reported as medians. The economic model instead utilises the
means from the NMA. The means represent the most appropriate values for the economic model in order
to inform a decision regarding the expected cost-effectiveness of competing treatments.
Correlation between Psoriatic Arthritis Response Criteria and Psoriasis Area and Severity
Index responses
Although treatment continuation is determined by PsARC response, the model needs to consider the
proportion of those patients who achieve PASI 75 together with PsARC, as this cohort has a different PASI
score, and hence incurs different costs and QALYs. Based on previously published models and the CSs,
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TABLE 79 Effectiveness data utilised in the economic model
Parameter Name Value Source
Placebo responses for biologic-naive population: treatment effects from the independent analysis
Probability of a PsARC response p.psarc.plac2 0.3073 See Chapter 4
Change in HAQ-DI score given a PsARC
response
HAQ-DI.resp.plac2 0.2629
Probability of a PASI 50 response p.pasi.50.plac2 0.153
Probability of a PASI 75 response p.pasi.75.plac2 0.054
Probability of a PASI 90 response p.pasi.90.plac2 0.015
Placebo responses for biologic-naive population: treatment effects from the metaregression
Probability of a PsARC response p.psarc.plac2 0.3073 See Chapter 4
Change in HAQ-DI score given a PsARC
response
HAQ-DI.resp.plac2 0.2579
Probability of a PASI 50 response p.pasi.50.plac2 0.155
Probability of a PASI 75 response p.pasi.75.plac2 0.055
Probability of a PASI 90 response p.pasi.90.plac2 0.016
Placebo responses for biologic-experienced population: treatment effects from the independent analysis
Probability of a PsARC response p.psarc.plac3 0.268 See Chapter 4
Change in HAQ-DI score given a PsARC
response
HAQ-DI.resp.plac3 0.134
Probability of a PASI 50 response p.pasi.50.plac3 0.103
Probability of a PASI 75 response p.pasi.75.plac3 0.012
Probability of a PASI 90 response p.pasi.90.plac3 0.004
Description Variable name
Treatment
ETN INF ADA GOL CZP
150mg
of SEC
300mg
of SEC
Treatments’ input data for biologic-naive population: treatment effects from the independent analysis
Probability of a
PsARC response
psarc2 0.77 0.8114 0.6421 0.8168 0.5697 0.5849 0.5870
Change in HAQ-DI
score in the first
3 months given no
PsARC response
HAQ-DI.noresp2 0.20 0.1966 0.1344 0.0634 0.0683 0.0825 0.0535
Change in HAQ-DI
score in the first
3 months given a
PsARC response
HAQ-DI.resp2 0.6407 0.66 0.4889 0.4385 0.4284 0.3947 0.5472
Probability of a PASI
50 response
p.pasi.50_2 0.411 0.918 0.675 0.732 0.441 0.801 0.819
Probability of a PASI
75 response
pasi75_2 0.209 0.789 0.448 0.514 0.231 0.603 0.627
Probability of a PASI
90 response
p.pasi.90_2 0.084 0.593 0.242 0.297 0.097 0.380 0.405
continued
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a positive correlation between the two main responses in the model, PsARC and PASI 75, is included in
the base-case model. The correlation coefficient value used in the model is 0.4, taken from the analysis
conducted as part of the previous York model.
Table 80 shows the effect of treatment, in terms of PsARC and PASI 75 response probabilities, utilising the
results from the evidence synthesis model performing independent analysis. The positive correlation
columns account for the correlation between these two outcomes to generate the proportion of patients
achieving joint only and joint plus skin improvement together. The no correlation columns assume
independence between the two responses (no correlation coefficient applied). The no correlation columns
TABLE 79 Effectiveness data utilised in the economic model (continued )
Description Variable name
Treatment
ETN INF ADA GOL CZP
150mg
of SEC
300mg
of SEC
Treatments’ input data for biologic-naive population: treatment effects from the metaregression
Probability of a
PsARC response
psarc2 0.74 0.74 0.60 0.71 0.71 0.73 0.73
Change in HAQ-DI
score in the first
3 months given no
PsARC response
HAQ-DI.noresp2 0.15 0.15 0.13 0.11 0.12 0.09 0.08
Change in HAQ-DI
score in the first
3 months given a
PsARC response
HAQ-DI.resp2 0.59 0.60 0.50 0.48 0.47 0.43 0.51
Probability of a PASI
50 response
p.pasi.50_2 0.43 0.77 0.66 0.54 0.66 0.77 0.79
Probability of a PASI
75 response
pasi75_2 0.24 0.57 0.43 0.32 0.44 0.57 0.60
Probability of a PASI
90 response
p.pasi.90_2 0.11 0.36 0.23 0.16 0.24 0.36 0.39
Description Variable name
Treatment
CZP 300mg of SEC UST
Treatments’ input data for biologic-experienced population: treatment effects from the independent analysis
Probability of a
PsARC response
Psarc3 Confidential
information has
been removed
0.674 0.562
Change in HAQ-DI
score in the first
3 months given no
PsARC response
HAQ-DI.noresp3 Confidential
information has
been removed
0.4295 0.0015
Change in HAQ-DI
score in the first
3 months given a
PsARC response
HAQ-DI.resp3 Confidential
information has
been removed
0.3838 0.32
Probability of a PASI
50 response
p.pasi.50_3 0.56 0.875 0.628
Probability of a PASI
75 response
pasi75_3 0.41 0.598 0.279
Probability of a PASI
90 response
p.pasi.90_3 0.19 0.365 0.12
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are shown only for illustration here, as these values are not employed in the updated York model.
Assuming a positive correlation between PsARC and PASI (the assumption in the updated York model), ETN
has the highest probability of a joint only response and INF the lowest probability of a joint only response.
For both a joint and skin response, INF has the highest probability and CZP the lowest probability.
Table 81 also shows the effect of treatment, in terms of PsARC and PASI 75 response probabilities, but
instead utilises the evidence synthesis outcomes based on metaregression. There are some differences
between the independent probabilities and the metaregression probabilities, reflecting the adjustments
made to the relative effectiveness of treatments using class effect shrunken estimates in the metaregression,
as opposed to relative treatments effects as observed in the trials in the independent analysis (see Chapter 4).
Assuming a positive correlation between PsARC and PASI, again ETN has the highest probability of a joint
only response; however, 300 mg of SEC has the lowest probability of a joint only response. For both a joint
and skin response, 300 mg of SEC has the highest and ETN has the lowest probability.
TABLE 80 Probabilities of PsARC and PASI 75 responses at 3 months: independent analysis
Treatment
Evidence synthesis
Correlation
Positive No
PsARC PASI 75
Joints only
(PsARC)
Joints and skin
(PsARC+ PASI)
Joints only
(PsARC)
Joints and skin
(PSARC+ PASI)
ETN 0.770 0.227 0.525 0.245 0.595 0.175
INF 0.811 0.785 0.110 0.701 0.175 0.637
ADA 0.642 0.449 0.259 0.384 0.354 0.288
GOL 0.817 0.514 0.320 0.497 0.397 0.420
CZP 0.570 0.236 0.351 0.218 0.435 0.134
150mg of SEC 0.585 0.600 0.138 0.447 0.234 0.351
300mg of SEC 0.587 0.623 0.126 0.461 0.221 0.366
USTa 0.486 0.319 0.238 0.248 0.331 0.155
a Values for UST refer to 6 months.
TABLE 81 Probabilities of PsARC and PASI 75 responses at 3 months: metaregression, shrunken estimates
Treatment
The evidence synthesis
outcome
Correlation
Positive No
PsARC PASI 75
Joints only
(PsARC)
Joints and skin
(PsARC+ PASI)
Joints only
(PsARC)
Joints and skin
(PsARC+ PASI)
ETN 0.740 0.238 0.489 0.251 0.564 0.176
INF 0.740 0.573 0.229 0.511 0.316 0.424
ADA 0.594 0.430 0.241 0.353 0.338 0.256
GOL 0.706 0.323 0.393 0.313 0.478 0.228
CZP 0.710 0.436 0.310 0.399 0.400 0.309
150mg of SEC 0.728 0.575 0.222 0.507 0.309 0.419
300mg of SEC 0.730 0.600 0.205 0.525 0.292 0.438
USTa 0.589 0.401 0.256 0.333 0.353 0.237
a Values for UST refer to 6 months.
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Mortality
All-cause mortality is incorporated by applying a risk of death during each model cycle. The mortality
risk is not assumed to be structurally related to response or treatments received. Instead a common excess
mortality risk is assumed for all PsA patients compared with general population mortality risks. The general
population mortality risk is obtained from life tables for England and Wales and is specified separately for
males and females, although the model averages across these as it does not generate results separately
for males and females. Similar to the previous York model, a Gompertz function was fitted to life table
data (see Table 78). The excess mortality risk associated with PSA is modelled assuming a HR of 1.3614
compared with the general population. This value is based on an updated analysis of the same source
used in the previous York model and hence employs a different estimate from the one previously assumed.
Sources of utility data
Health utility is measured as a function of HAQ-DI and PASI. A separate search was undertaken to identify
alternative utility algorithms (see Appendix 9). In the absence of finding any published sources reporting
alternative algorithms to the one applied in the previous York model, the same algorithm was used. This
algorithm is based on a linear function relating the expected utility to HAQ-DI and PASI. The same utility
function is applied to all subpopulations, subgroups and treatments.
Figure 19 shows the trajectories of utility according to a patients HAQ-DI score over time, for BSC,
remaining on treatment and treatment withdrawal at 5 years.
The equation below shows this relationship:
Expected Utility = 0:897− 0:298 × HAQ-DI− 0:004 × PASI. (4)
The utility function provided by one of the companies (Novartis) includes coefficients, namely baseline
EQ-5D score, which cannot be utilised easily in the current model structure. UCB Pharma used a similar
function to the previous York model but with a smaller coefficient for PASI (0.001 rather than 0.004).
Given that this algorithm is very similar to the previous York model, separate scenarios, using alternative
utility algorithms are not considered.
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FIGURE 19 Utility corresponding to alternative HAQ-DI trajectories.
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Sources of resource utilisation and costs data
Costs in the model are determined from the treatment costs (acquisition, administration and monitoring)
and changes in health service utilisation driven by disease status (HAQ-DI and PASI scores). The resource
use assumptions and costs applied to each of these categories are discussed in the sections below. Further
searches were conducted to identify alternative sources of health state costs. The searches and results are
described in Appendix 10.
Treatment costs
Table 82 shows the treatment-related costs applied in the updated York model. These costs are based on
the list prices for SEC and CZP (biosimilar costs and Patient Access Scheme prices are used in the separate
analysis). Costs are presented for the first and subsequent cycles and in terms of annual costs.
Each of the existing models (published and CSs) presents different resource use assumptions and unit costs,
which are used to cost drug treatment, administration and monitoring of patients. Different assumptions have
been used regarding the dosing of drugs and resource use for administration and monitoring (see Chapter 5,
Summary of resource utilisation and costs data in the York model and Chapter 5, Summary of resource
utilisation and costs data). The current York model sought to specify the most appropriate resource use
associated with drug acquisition, administration and monitoring patients for each of the treatment options.
The resource use items from the previous York model33 have been updated for ETN, INF and ADA,
reflecting evidence from a recent appraisal in ankylosing spondylosis.104 The assumptions regarding
resource use for GOL have been taken from the GOL STA,70 and the assumptions regarding the resource
use for UST have been taken from the UST STA.35 The resource use for SEC and CZP has been derived
using the Summary of Product Characteristics, MIMS, clinical advice and BSR guidelines. The treatments
dosing schedules were obtained from the Summary of Product Characteristics found on the Electronic
Medicines Compendium website.
The dose for INF was determined by a patients weight, that is, 5 mg for each 1 kg. These weights were
derived using the weight distribution reported in the RAPID-PsA trial.47 All assumptions made regarding
resource use have been validated with the clinical expert for this appraisal.
Table 83 summarises the drug acquisition, administration and monitoring costs used in the updated York
model. Further details of these costs are given in the sections below.
Drug acquisition
Table 84 shows the number of vials assumed for each treatment, during the first cycle (the loading phase)
and subsequent cycles. In the loading phase, 400 mg of CZP is given at weeks 0, 2 and 4. Subsequently,
200 mg is given every 2 weeks. Patients receive MTX (7.5 mg) alongside CZP, in accordance with the
licence. For patients with mildmoderate psoriasis, the recommended dose of SEC is 150 mg, with initial
dosing at weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at week 4. For patients
with moderatesevere psoriasis, or those who are biologic experienced, the recommended dose is 300 mg,
with initial dosing at weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at week 4.
Each 300-mg dose is given as two subcutaneous injections of 150 mg.
TABLE 82 Intervention-related costs applied in the updated York model
Time period
Treatment cost (£)
ETN INF ADA GOL CZP 150mg of SEC 300mg of SEC UST
First cycle 2541 7887 2506 2498 3784 4475 8741 4503
Subsequent cycles 2336 3672 2301 2293 2149 1832 3661 2151
Annual cost 9549 18,902 9409 9377 10,232 9972 19,722 10,957
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For the other treatments, the following assumptions were made:
l Six and a half vials of ADA are assumed given in every 3-month cycle. This does not represent vial
sharing; instead the total yearly numbers of vials is equally divided by each 3-month (13-week) cycle.
l Twenty-six vials of ETN are assumed given in the first cycle (two 25-mg prefilled syringes per week),
followed by 26 vials for all subsequent cycles.
l GOL is given as a 50-mg dose once a month. In patients with a body weight of > 100 kg who do not
achieve an adequate clinical response after three or four doses, the dose of GOL can be increased to
100 mg once a month. The company (Janssen Pharmaceuticals) provides this double dose at the same
price as the 50-mg dose as part of an approved Patient Access Scheme.
l UST is given as an initial dose of 45 mg, followed by a 45-mg dose 4 weeks later, and then every
12 weeks thereafter. Alternatively, 90 mg may be used in patients with a body weight of > 100 kg.
Similarly, the company (Janssen Pharmaceuticals) offers this double dose at an equivalent price as part
of an approved Patient Access Scheme.
TABLE 83 Summary of drug acquisition, administration and monitoring costs used in economic model
Treatment
Cost (£)
First cycle (13 weeks) Subsequent cycles
Acquisition Administration Monitoring Total Acquisition Administration Monitoring Total
ETN 2332 43 166 2541 2332 0 4 2336
INF 7147 574 166 7887 3395 273 4 3672
ADA 2297 43 166 2506 2297 0 4 2301
GOL 2289 43 166 2498 2289 0 4 2293
CZP 3575 43 166 3784 2145 0 4 2149
150mg of SEC 4266 43 166 4475 1828 0 4 1832
300mg of SEC 8532 43 166 8741 3656 0 4 3661
UST 4294 43 166 4503 2147 0 4 2151
TABLE 84 Number of vials administered for each treatment
Treatment
Number of vials
First cycle Subsequent cycles
ETN 26 26
INF Weight based Weighted based
ADA 6.5 6.5
GOL 3 3
CZP 10 6
150mg of SEC 7 3
300mg of SEC 7 3
UST 2 1
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Infliximab is given at 0, 2 and 6 weeks, then every 8 weeks, with the number of vials administered at each
time point determined by the patients weight. Baseline weight is taken from the weight distribution
reported in the RAPID-PsA trial.47 Table 85 shows the proportion of patients in each weight category in the
RAPID-PsA trial47 and the number of INF vials required.
The drug acquisition costs used in the current York model are shown in Table 86. The acquisition costs of
the drugs represent the list prices in the base-case analysis. The list prices are taken from the BNF139 and
MIMS.134 An analysis utilising non-list prices (biosimilar costs), for some of the comparators, is presented in
Appendix 8. Biosimilar costs used are presented in Appendix 8. A separate analysis is also presented using
the Patient Access Scheme prices for CZP and SEC as part of a separate and confidential appendix.
A separate acquisition cost was not applied to BSC and, therefore, the cost of BSC is assumed to be
entirely captured in terms of health state costs. These represent the full HAQ-DI costs (without discounting
the prescribing costs) and the uncontrolled psoriasis costs (see Health state costs).
Drug administration
For all treatments, other than INF, an administration cost was applied only on the first cycle, therefore
assuming self-administration in the subsequent cycles. This was assigned a cost of a 1-hour nurse visit in a GP
practice (£43) (Personal Social Services Research Unit; PSSRU136). INF requires intravenous (i.v.) infusion and,
therefore, the administration cost for INF was assumed to represent the cost of delivering simple parenteral
chemotherapy at first attendance (£159; reference costs 2015137). These costs are the same as those used in
the UCB Pharma model. The administration costs assumed in the updated model are shown in Table 87.
TABLE 85 Distribution of weights used to determined INF vials required
Patient’s weight (kg) Number of vials required Dose (mg) Proportion of population
20 1 100 0.0003
40 2 200 0.0087
60 3 300 0.0878
80 4 400 0.3105
100 5 500 0.3898
120 6 600 0.1740
140 7 700 0.0273
160 8 800 0.0015
TABLE 86 Acquisition costs used in the updated York model
Treatment Cost (£; 2016) Source
INF (100-mg vial): Inflectra/Remsima 419.62 MIMS134
ETN (25-mg syringe): ENBREL 89.50 MIMS134
ADA (40-mg syringe): Humera 352.14 MIMS134
GOL (50-mg syringe; 100-mg syringe): SIMPONI 762.97; 1525.94 MIMS134
UST (45-mg syringe; 90-mg syringe) 2147; 2147 MIMS134
SEC (150-mg syringe) 609.39 MIMS134
CZP (200-mg syringe) 357.50 MIMS134
MTX (7.5 mg) 0.30 BNF139
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Initiation and monitoring
A summary of the initiation and monitoring resource use assumptions is reported Table 88. The resource
use assumptions for laboratory testing for biologic treatment initiation and monitoring have been sourced
from the previous York model and updated using the Hospital and Community Health Service Pay and
Prices Index from the PSSRU.137 These conform to guidelines from the BSR127 for the use of biologics.
Psoriatic arthritis patients on biologic therapy are assumed to undertake a series of tests at treatment
initiation and at 3 months when assessing initial treatment response [i.e. a full blood count, erythrocyte
sedimentation rate (ESR) test, liver function test, urea and electrolytes test]. Additional testing is assumed
to be conducted once during the initial period (i.e. chest radiography, TB Heaf test, antinuclear antibody
test and a double-stranded deoxyribonucleic acid test). Patients on biologics are also assumed to visit a
specialist (rheumatologist) twice during the initial 3-month period (at treatment initiation and when
assessing a response). The cost of a rheumatologist visit was applied only in the first cycle. The assumption
that subsequent visit costs would be encapsulated within health state costs and has been applied in similar
appraisals104 and in the company models. The cost of a rheumatology visit was taken from the NHS
Reference Costs 2014 to 2015.137
Health state costs
In order to generate an estimate of the lifetime costs for each of the treatments, estimates of resource use
and costs associated with HAQ-DI and PASI are required. As reported in Chapter 5, the previous York
model used separate studies and assumptions to estimate HAQ-DI- and PASI-related costs.
A search of the published literature was undertaken to identify alternative published evidence regarding
the resource use and costs associated with the management of PsA in the UK (see Appendix 11). The only
TABLE 87 Administration costs used in the updated York model
Method of administration
Cost (£)
First cycle Subsequent cycles
Subcutaneously 43 
Intravenously 159 159
TABLE 88 Initiation and monitoring resource use and costs
Item
Initiation and monitoring costs (£) Frequency
First cycle Subsequent cycles First cycle Subsequent cycles
Full blood count 6.18 1.54 2 0.5
ESR test 6.11 1.53 2 0.5
Liver function test 1.56 0.39 2 0.5
Urea and electrolytes test 2.86 0.72 2 0.5
Chest radiography 27.11 0.00 1 0
TB Heaf test 9.03 0.00 1 0
Antinuclear antibody test 4.81 0.00 1 0
Double-stranded DNA test 4.81 0.00 1 0
Specialist visit 103.53 0.00 1 0
Total 166.01 4.18
DNA, deoxyribonucleic acid; ESR, erythrocyte sedimentation rate.
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other published source identified in the search that specifically reported estimates of costs according to
HAQ-DI and/or PASI was the study from Poole et al.138 This study was used in the UCB Pharma submission
and was previously described in Chapter 5.
The alternative approaches identified, which could be used to estimate HAQ-DI and PASI costs, represent
an important area of remaining uncertainty. One potential advantage of the Poole et al.138 study is that
the estimates according to HAQ-DI score are derived from a sample of PsA patients as opposed to a sample
of RA patients. However, Poole et al.138 noted important differences in the authors predictions, with
markedly higher costs predicted for equivalent HAQ-DI scores for PsA patients than those previously reported
for RA patients. Although the authors of the Poole et al.138 study stated that this could indicate important
differences in the economic burden associated with PsA compared with RA, they also acknowledged that the
differences might simply be attributed to differences in methods and/or the requirement to predict HAQ-DI
score in the THIN data set using a separate regression model from the BSRBR. A number of further
limitations were also noted in Poole et al.,138 including (1) the predicted HAQ-DI score did not cover the full
range (03 units) and applying the generalised linear model to predict for the full range could result in
substantial errors, particularly for the more severe event of the range; and (2) PASI data were not available in
either the BSBR or THIN data. These additional limitations are particularly important in the context of the
current model, as HAQ-DI predictions are required across the full range of HAQ-DI scores and that separate
PASI subgroups are modelled.
Having identified important differences in the predictions based on the separate sources and noting the
potential limitations identified in the Poole et al.138 study, the final HAQ-DI costs were based on the same
function used in the previous York model, with costs uprated to current prices. This assumption also
ensures consistency across the separate NICE TAs. Despite some concerns with the Poole et al.138 study,
the fact that it provides the only source of costs specific to PsA makes it potentially relevant for the
updated York model. The use of the Poole et al.138 study is therefore explored as a separate scenario
(see Scenario analyses).
The costs according to HAQ-DI scores address only the arthritis component of PsA; therefore, additional
costs were required to capture the psoriasis element of the disease. The current York model addresses
three subgroups according to psoriasis severity (see Patient characteristics). It was assumed patients
without concomitant psoriasis would not incur additional psoriasis-related costs. In the absence of
identifying any other relevant UK costing studies to inform PASI estimates for the mildmoderate and
moderatesevere PASI subgroups, the same sources as in the previous York model were assumed and the
same assumptions were made. Hence, the costs assumed for treating mildmoderate psoriasis in patients
who do not use biologics or who do not respond to biologics (PASI 75) were based on NHS unit costs of
phototherapy137 and a UK RCT.146 Similarly, for patients with moderate or severe psoriasis, costs were
based on a Dutch RCT adjusted to UK price levels (see Hartman et al.131). Costs from the previous York
model were uprated to the current price year (2016).
The psoriasis-related costs applied to PASI 75 non-responders and for patients not receiving biologics are
shown in Table 89 for each of the psoriasis subgroups.
TABLE 89 Costs (£) assigned for PASI 75 non-responders and patients not receiving biologics
Cost
Psoriasis subgroups
Without psoriasis Mild to moderate Moderate to severe
Baseline PASI score 0.0 7.3 12.5
Uncontrolled psoriasis 0.0 223 638
Controlled psoriasis (PASI 75 response) 0.0 18 18
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Scenario analyses
As described in Patient characteristics, a further subgroup of subpopulation 3 was considered as part of a
separate scenario analysis. This separate scenario is presented to reflect that the data reported for CZP
in biologic-experienced patients are applicable only to patients who initially responded to the previous
biologic therapy (i.e. secondary failure of treatment), and are is not directly comparable to the data for UST
and SEC ,which include primary and secondary treatment failures. This separate scenario includes only CZP
and BSC. Other subgroups, in terms of extent of psoriasis (measured using PASI), are presented as part of
the base-case analysis.
In addition, a number of scenarios are specified to explore the robustness of some of the assumptions
made in the model, focusing on key areas where these deviate from assumptions made in the CSs:
l Applying an alternative cost function from Poole et al.138
l Alternative assumptions regarding withdrawals. Two scenarios were specified: (1) the withdrawal rate
for SEC is assumed to be 50% of the base-case value from year 2; and (2) all treatments are associated
with a withdrawal rate equivalent to 50% of the base-case values from year 5. The first withdrawal
scenario is similar to the assumption made in the Novartis model, in which lower withdrawal rates are
reported for SEC in the second year of treatment. The second withdrawal scenario was undertaken to
assess the robustness of the results to assumptions made regarding the constant rate of withdrawal
applied in the model. Given the lack of longer-term data to inform an alternative, time-dependent
withdrawal rate, an assumption was made that patients who remained on therapy at 5 years would no
longer be at risk of subsequent withdrawals. This is similar to the assumption made in the UCB Pharma
model, but not as extreme in that patients are still permitted to withdraw albeit at a reduced rate and
from a slightly later time point (5 years as opposed to 4 years).
l Baseline HAQ-DI score according to subpopulation. Equivalent to the separate baseline HAQ-DI scores
assumed in the UCB Pharma model, three separate baseline scores were applied according to the
subpopulation: (confidential information has been removed) for subpopulation 1, (confidential
information has been removed) for subpopulation 2 and (confidential information has been removed)
for subpopulation 3.
Analytic methods
The expected costs and QALYs of the alternative treatment strategies are determined for each
subpopulation and PASI subgroup and the relative cost-effectiveness of the strategies is then compared
using standard decision rules, estimating ICERs as appropriate.147 The ICER examines the additional cost
that one strategy incurs over another and compares this with the additional benefits. The ICER estimate
represents the additional cost required to generate one additional unit of health outcome (QALY). When
more than two strategies are being compared, the ICERs are calculated using the following process:
l The strategies are ranked in terms of mean QALYs (from the least effective to the most effective).
l If a strategy is more costly and less effective than any previous strategy, then this strategy is said to be
dominated and is excluded from the calculation of the ICERs.
l The ICERs are calculated for each successive alternative, from the least effective to the most effective;
if the ICER for a given strategy is higher than that of any more effective strategy, then this strategy is
ruled out on the basis of extended dominance.
l Finally, the ICERs are recalculated, excluding any strategies that are ruled out by principles of
dominance or extended dominance.
The resulting ICERs then provide the basis for establishing which strategy appears optimal based on
cost-effectiveness considerations, that is, which strategy (or strategies) appears to provide good value for
money to the NHS. Guidance from NICE suggests that an incremental cost per additional QALY of around
£20,00030,000 is considered to represent an appropriate threshold to establish value for money to
the NHS.125
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In addition to determining which strategy appears optimal based on fully incremental comparisons of all
treatments simultaneously, separate pairwise ICERs are presented for each treatment versus BSC alone.
These pairwise ICERs are helpful in informing assessments of cross-validity (i.e. providing a comparable
basis to compare particular treatments with previously published results). These comparisons may also be
informative if strategies are ruled out from the fully incremental calculations based on differences between
treatments that are not considered clinically or economically significant. In this situation, comparing the
pairwise ICERs for each individual treatment with a common comparator may provide further information
to inform subsequent decisions.
The model was run several times, once for the main base-case analysis (for each subpopulation and PASI
subgroup) and then for a number of alternative scenarios to consider alternative assumptions related to
key aspects of the base-case approach (see Scenario analysis). Given the large number of subpopulation,
subgroup and scenario combinations, it has not been possible to conduct PSA, although this functionality
is included in the model.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis is used to assess the implications of parameter uncertainty (the imprecision
with which input parameters are estimated), in terms of the estimates of cost-effectiveness. The uncertainty
in each parameter was represented using a probability distribution and the PSA was carried out using Monte
Carlo simulation. The rate of change of the HAQ-DI score while not on treatment was assigned a gamma
distribution to ensure that values are strictly positive. All other uncertain parameters were assigned normal
distributions using the mean and SE. The treatment effect parameters used in the model, PsARC response,
conditional change in HAQ-DI score and PASI responses, utilise the convergence diagnostic and output
analysis (CODA) output from the evidence synthesis models (see Sources of effectiveness data).
This analysis reflects the decision uncertainty associated with the optimal treatment. PSA generates
distributions (20,000 iterations) of total costs and QALYs, and shows the probability that a treatment is
cost-effective at thresholds of £20,000 and £30,000. This was performed for the three subpopulations,
defined by the patients position in the treatment pathway, and also on the three subgroups of
concomitant psoriasis severity.
This analysis utilised the two evidence synthesis outputs: the independent and the metaregression analyses.
Given the mathematically intensive operations, represented by 20,000 iterations for each version of the model,
the computation time is a major challenge. This may potentially reach 2 months on a desktop machine.
Therefore, there was a need to run the probabilistic model on the University of Yorks supercomputer. This
necessitated some flexibility in the code allowing the model to be run in parallel on hundreds of processors
within the supercomputer.
Results
Results of the base-case cost-effectiveness analysis
According to the three main subpopulations (biologic naive, one prior or two or more prior DMARDs;
and biologic experienced), results for three separate concomitant psoriasis subgroups (baseline PASI
score = 0, 7.5 or 12.5) are presented and discussed in the following sections. For ease of presentation and
interpretation, individual ICER tables are presented only for the independent analysis from the evidence
synthesis in the main body of the report and summary tables used to compare with the results based on
metaregression approach. Individual ICER tables based on the metaregression are also reported separately
in Appendix 12.
All results presented in Results are based on the list prices for SEC and CZP and the originator products for
INF and ETN. Results are presented for the base-case models, according to subpopulation and psoriasis
subgroup, for the scenarios as specified and the PSA. A separate confidential appendix is included which
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incorporates the confidential Patient Access Scheme prices for CZP and SEC. Scenarios including biosimilar
prices are also presented separately in Appendix 8.
Subpopulation 1: biologic naive (one prior DMARD)
The cost-effectiveness results for subpopulation 1 are shown for the three subgroups according to the level
of concomitant psoriasis (moderatesevere psoriasis, mildmoderate psoriasis and no concomitant
psoriasis) in Tables 9092.
In the moderatesevere psoriasis subgroup (Table 90), 300 mg of SEC is the most effective strategy
(QALYs = 8.52), followed by CZP (QALYS = 8.38) and BSC (QALYs = 5.31). In terms of costs, 300 mg of
SEC is also the mostly costly strategy (£179,692) followed by CZP (£159,951) and BSC (£95,965). Based on
the fully incremental ICERs, the ICER of CZP compared with BSC is £20,870 per QALY and the ICER of
300 mg of SEC compared with CZP is £134,783 per QALY.
The individual pairwise ICERs for CZP and 300 mg of SEC compared with BSC are £20,870 and £26,064
per QALY, respectively.
In the mildmoderate psoriasis group (Table 91), 150 mg of SEC is the most effective strategy
(QALYs = 8.69), followed by CZP (QALYs = 8.68) and BSC (QALYs = 5.68). In terms of costs, CZP is now
the most costly strategy (£135,946), followed by 150 mg of SEC (£132,500) and BSC (£67,000). Based on
the fully incremental ICERs, CZP is dominated by 150 mg of SEC. The ICER of 150 mg of SEC compared
with BSC is £21,772 per QALY.
The individual pairwise ICERs for CZP and 150 mg of SEC compared with BSC are £23,052 and £21,772
per QALY, respectively.
In the no concomitant psoriasis subgroup (Table 92), CZP is the most effective strategy (QALYs = 9.074),
followed by 150 mg of SEC (QALYs = 9.067) and BSC (QALYs = 6.188). In terms of costs, CZP is also the
most costly strategy (£122,832), followed by 150 mg of SEC (£120,303) and BSC (£51,436). Based on
the fully incremental ICERs, the ICER for 150 mg of SEC compared with BSC is £23,928 per QALY and the
ICER of CZP compared with 150 mg of SEC is £346,785 per QALY.
TABLE 90 Treatment effects from the independent analysis for moderate–severe psoriasis, subpopulation 1: fully
incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next-best
option (£)
ICER vs. BSC
(£)
BSC 95,965 5.312    
CZP 159,951 8.377 63,987 3.066 20,870 20,870
300mg of SEC 179,692 8.524 19,741 0.146 134,783 26,064
TABLE 91 Treatment effects from the independent analysis for mild–moderate psoriasis, subpopulation 1: fully
incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next best
option (£)
ICER vs. BSC
(£)
BSC 67,000 5.676    
CZP 135,946 8.667   Dominateda 23,052
150mg of SEC 132,500 8.685 65,500 3.009 21,772 21,772
a See Analytic methods.
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The individual pairwise ICERs for 150 mg of SEC and CZP compared with BSC are £23,928 and £24,774
per QALY, respectively.
There are a number of important differences evident across the separate concomitant psoriasis subgroups
for subpopulation 1. Mean costs are higher (and mean QALYs lower) for all treatments depending on the
presence and severity of concomitant psoriasis, demonstrating the important contribution of psoriasis to
costs and HRQoL, and to subsequent ICER estimates. The difference in mean QALYs between SEC and
CZP is greatest in the moderatesevere psoriasis subgroup, with 300 mg of SEC reported to be the most
effective strategy. The difference appears largely attributable to the higher average PASI responses
(PASI 50, PASI 75 and PASI 90), estimated for 300 mg of SEC compared with CZP from the independent
evidence synthesis. The differences in PASI outcomes become less important as the severity of concomitant
psoriasis is reduced and the differences are now based on comparisons between 150 mg of SEC and CZP.
The difference in QALYs between 150 mg of SEC and CZP is subsequently reduced in the mildmoderate
psoriasis subgroup (QALY difference still in favour of 150 mg of SEC), and reduced again in the subgroup
with no concomitant psoriasis (QALY difference now in favour of CZP). As the influence of PASI outcomes
is reduced, the differences in both the PsARC response rate and the HAQ-DI change scores conditional
on PsARC response between the treatments become more important. Although the PsARC response rate
was estimated to be marginally higher for 150 mg of SEC than CZP (probability = 0.58 vs. 0.57), marginally
higher conditional HAQ-DI changes were then estimated for CZP than 150 mg of SEC (0.43 vs. 0.39). In
the no concomitant psoriasis subgroup, in which differences in PASI response are no longer relevant, the
higher conditional HAQ-DI score assumed for CZP appears to offset the higher PsARC response rate for
150 mg of SEC. However, subsequent differences in QALY outcomes appear minor between 150 mg of
SEC and CZP (0.007 QALYs in favour of CZP).
In terms of the pairwise ICERs reported versus BSC, the ICERs for CZP vary between £20,870 (moderatesevere
psoriasis) and £24,744 (no concomitant psoriasis) per QALY across the psoriasis subgroups. The ICERs for SEC
range from £23,052 (mildmoderate psoriasis) to £26,064 per QALY (moderatesevere psoriasis). The ICERs
versus BSC for SEC do not follow the same pattern as for CZP (i.e. more favourable ICERs as severity of
concomitant psoriasis increases), as a result of the different dosages assumed for SEC and the higher cost of
300mg of SEC assumed in the moderatesevere psoriasis subgroup.
Table 93 illustrates the differences between the independent analysis and the metaregression evidence
synthesis for each of the subgroups in subpopulation 1 (full results are presented in Appendix 12). The
pairwise ICERs for each of the treatments compared with BSC are presented along with the optimal
(or most cost-effective) treatment strategy determined based on the fully incremental ICER comparisons
at thresholds of £20,000 and £30,000 per QALY.
In summary, the differences in the pairwise ICERs estimated using the alternative synthesis models have only
a minor effect. Furthermore, the optimal treatment remains consistent across the two evidence synthesis
approaches using a threshold of £30,000 per QALY. At a threshold of £20,000 the optimal treatment
changes in the moderatesevere subgroup. CZP is now the most cost-effective treatment as its ICER
compared with BSC now falls below the threshold (£19,908), based on the results of the metaregression.
TABLE 92 Treatment effects from the independent analysis for no concomitant psoriasis, subpopulation 1: fully
incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next best
option (£) ICER vs. BSC (£)
BSC 51,436 6.188    
150mg of SEC 120,303 9.067 68,866 2.878 23,928 23,928
CZP 122,832 9.074 2529 0.007 346,785 24,744
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Subpopulation 2: biologic naive (two or more prior DMARDs)
The cost-effectiveness results for subpopulation 2 are reported according to the level of concomitant
psoriasis (moderatesevere psoriasis, mildmoderate psoriasis and no concomitant psoriasis) in
Tables 9496.
As discussed in Choice of intervention and comparators, it is assumed that, after failing the first biologic
treatment, patients move (switch) to UST as a second-line treatment before moving to BSC. In the
moderatesevere subgroup (Table 94), 300 mg of SEC treatment is compared in this population, as
opposed to 150 mg of SEC, as the licence for SEC states that a 300-mg dose is appropriate for patients
with severe psoriasis (PASI score of > 10 units). The cost-effectiveness results for this subgroup show that
300 mg of SEC is dominated by other comparators (ADA, GOL and ETN), as it incurs higher costs and
results in fewer QALYs. CZP is extendedly dominated (by a linear combination of ADA and BSC). Of the
remaining non-dominated alternatives, the ICER of ADA versus BSC is £20,074 per QALY, the ICER of GOL
versus ADA is £20,976 per QALY, the ICER of ETN versus GOL is £21,215 per QALY and the ICER of INF is
£131,716 per QALY.
TABLE 93 Summary of differences between independent and metaregression approaches, subpopulation 1
NMA approach
ICERs vs. BSC (£)
Optimal treatment strategy at
a threshold of
CZP 150mg of SEC 300mg of SEC £20,000 £30,000
Moderatesevere psoriasis
Independent analysis 20,870  26,064 BSC CZP
Metaregression 19,908  27,033 CZP CZP
Mildmoderate psoriasis
Independent analysis 23,052 21,772  BSC 150mg of SEC
Metaregression 22,446 21,287  BSC 150mg of SEC
No concomitant psoriasis
Independent analysis 24,744 23,928  BSC 150mg of SEC
Metaregression 24,388 23,408  BSC 150mg of SEC
TABLE 94 Treatment effects from the independent analysis for moderate–severe psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£)
ICER vs. BSC
(£)
BSC 95,965 5.312    
CZP 137,240 7.226   Extendedly
dominateda
21,564
300mg of SEC 157,086 7.379   Dominateda 29,569
ADA 138,109 7.411 42,144 2.100 20,074 20,074
GOL 142,850 7.637 4741 0.226 20,976 20,161
ETN 144,585 7.719 1735 0.082 21,215 20,197
INF 167,126 7.890 22,541 0.171 131,716 27,599
a See Analytic methods.
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The individual pairwise ICERs for CZP and 300 mg of SEC compared with BSC are £21,564 and £29,569
per QALY, respectively.
Table 95 shows the results for the mildmoderate psoriasis subgroup. In this subgroup CZP is the least
effective biologic treatment, generating 7.537 QALYs, whereas INF generates the highest QALYs (8.161).
Fully incremental analysis shows that CZP is dominated by 150 mg of SEC, GOL is dominated by ETN, and
ADA is extendedly dominated (linear combination of 150 mg of SEC and ETN). Of the remaining non-
dominated alternatives, the ICER of 150 mg of SEC versus BSC is £22,032 per QALY, the ICER of ETN
versus 150 mg of SEC is £23,256 per QALY and the ICER of INF versus ETN is £193,063 per QALY.
The individual pairwise ICERs for CZP and 150 mg of SEC compared with BSC are £24,103 and £22,032
per QALY, respectively.
For the no concomitant psoriasis subgroup (PASI score = 0) (Table 96), INF maintains its position as the most
effective treatment (8.543 QALYs), whereas 150 mg of SEC is now the least effective option. As expected
in this subgroup, the ICERs versus BSC increase compared with the mildmoderate and severe psoriasis
subgroups, as a result of the benefits being driven entirely by HAQ-DI as opposed to a combination of
HAQ-DI and PASI. The incremental cost-effectiveness analysis shows that GOL is dominated by ETN and
150 mg of SEC, and CZP and ADA are extendedly dominated. Of the non-dominated alternatives, the ICER
of ETN versus BSC is £23,833 per QALY and the ICER of INF versus ETN is £324,502 per QALY.
The individual pairwise ICERs for CZP and 150 mg of SEC compared with BSC are £26,105 and £24,773
per QALY, respectively.
Table 97 summarises the differences between the independent analysis and the metaregression evidence
synthesis for each of the separate psoriasis subgroups within subpopulation 2 (full results are available in
Appendix 12). The pairwise ICERs for each of the treatments compared with BSC are presented along with
the optimal (or most cost-effective) treatment at thresholds of £20,000 and £30,000 per QALY, using the full
incremental results. Although there are only minimal differences in the pairwise ICERs, in this subpopulation
the optimal treatment alters across the two evidence synthesis approaches. Both approaches accord in terms
of the optimal strategy at a threshold of £20,000 for the mildmoderate and no concomitant psoriasis
subgroups. In the moderatesevere subgroup, the ICER for CZP (compared with BSC  its next best) falls
below £20,000; therefore, at this threshold it represents the optimal treatment. Using the metaregression
estimates, CZP, as opposed to ETN, represents the most cost-effective option at a threshold value of £30,000
per QALY in the moderatesevere psoriasis group. The optimal treatment switches from ETN to 150 mg of
TABLE 95 Treatment effects from the independent analysis for mild–moderate psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£)
ICER vs. BSC
(£)
BSC 67,000 5.676    
CZP 111,856 7.537   Dominateda 24,103
150mg of SEC 108,508 7.560 41,508 1.884 22,032 22,032
ADA 114,039 7.708   Extendedly
dominateda
23,149
GOL 119,624 7.923   Dominateda 23,419
ETN 119,326 8.025 10,818 0.465 23,256 22,274
INF 145,569 8.161 26,243 0.136 193,063 31,616
a See Analytic methods.
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SEC in the mildmoderate and non-concomitant psoriasis subgroups. These differences are driven by the
increased relative effectiveness of CZP and 150 mg of SEC in the metaregression approach (see Chapter 4).
Subpopulation 3: biologic experienced
Tables 98100 present the results for subpopulation 3 for the moderatesevere, mildmoderate and no
concomitant psoriasis subgroups, respectively. Only an independent analysis is available for this subpopulation,
because of the smaller number of data available (see Sources of effectiveness data). In this subpopulation,
300mg of SEC is considered as a relevant comparator, alongside UST and BSC. The clinical trial data for UST
and 300 mg of SEC come from a mix of biologic-experienced patients: those who have not responded to
biologic treatment (primary non-responders) and those who have responded but subsequently failed the
treatment (secondary failures). CZP is not included in this model as only patients who had a primary response
to a biologic treatment (secondary failures) were included in the RAPID-PsA trial.47 Primary non-responders
were explicitly excluded from this trial and, therefore, the population represents a separate subgroup of the
TABLE 97 Summary of differences between independent and metaregression approaches, subpopulation 2
NMA approach
ICERs vs. BSC (£)
Optimal treatment
strategy at a
threshold of
CZP
150mg
of SEC
300mg
of SEC ADA GOL ETN INF £20,000 £30,000
Moderatesevere psoriasis
Independent analysis 21,564  29,569 20,074 20,074 20,197 27,599 BSC ETN
Metaregression 19,923  30,456 20,092 20,767 20,552 29,138 CZP CZP
Mildmoderate psoriasis
Independent analysis 24,103 22,032  23,149 23,419 22,274 31,616 BSC ETN
Metaregression 22,939 21,177  23,130 23,408 22,750 32,703 BSC 150mg
of SEC
No concomitant psoriasis
Independent analysis 26,105 24,773  25,532 25,951 23,883 34,930 BSC ETN
Metaregression 25,275 23,768  25,485 25,475 24,460 35,689 BSC 150mg
of SEC
TABLE 96 Treatment effects from the independent analysis for no concomitant psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next best
option (£)
ICER vs. BSC
(£)
BSC 51,436 6.188    
150mg of
SEC
95,632 7.972   Extendedly dominateda 24,773
CZP 98,060 7.974   Extendedly dominateda 26,105
ADA 100,893 8.125   Extendedly dominateda 25,532
GOL 106,895 8.325   Dominateda 25,951
ETN 105,592 8.456 54,156 2.268 23,883 23,883
INF 133,664 8.543 28,071 0.087 324,502 34,930
a See Analytic methods.
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overall biologic-experienced subpopulation (those that have previously had a response). The results for CZP are
presented separately in Results of subgroup analysis: biologic-experienced secondary failures.
Table 98 shows the results of the moderatesevere psoriasis subgroup. The most effective and expensive
treatment is 300 mg of SEC, generating greater QALYs than UST (6.632 vs. 6.334 QALYs) and incurring
higher costs (£143,534 vs. £118,127). In the fully incremental analysis, the ICER of UST versus BSC is
£21,684 per QALY and the ICER of 300 mg of SEC is £85,013 per QALY.
The individual pairwise ICER for 300 mg of SEC compared with BSC is £36,013.
Table 99 shows the results of the mildmoderate psoriasis subgroup. In this subgroup, 300 mg of SEC is
the most effective and expensive treatment, generating more QALYs than UST (6.945 vs. 6.666) and
incurring higher costs (£118,564 vs. £91,246). In the fully incremental analysis, the ICER of UST versus BSC
is £24,510 per QALY and the ICER of 300 mg of SEC versus UST is £97,713 per QALY.
The individual pairwise ICER for 300 mg of SEC compared with BSC is £40,639.
Table 100 shows the results of non-evaluable psoriasis subgroup The most effective and expensive
treatment is 300 mg of SEC, generating more QALYs than UST (7.384 vs. 7.132 QALYs) and incurring
higher costs (£104,973 vs. £76,712). In the fully incremental analysis, the ICER of UST versus BSC is
£26,797 per QALY and the ICER of 300 mg of SEC versus UST is £111,927 per QALY.
The individual pairwise ICER for 300 mg of SEC compared with BSC is £44,774.
TABLE 99 Mild–moderate psoriasis, subpopulation 3: fully incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£)
ICER vs. BSC
(£)
BSC 67,000 5.676    
UST 91,246 6.666 24,246 0.989 24,510 24,510
300mg of SEC 118,564 6.945 27,318 0.280 97,713 40,639
TABLE 98 Moderate–severe psoriasis, subpopulation 3: fully incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£)
ICER vs. BSC
(£)
BSC 95,965 5.312    
UST 118,127 6.334 22,162 1.022 21,684 21,685
300mg of SEC 143,534 6.632 25,407 0.299 85,013 36,013
TABLE 100 No concomitant psoriasis, subpopulation 3: fully incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£)
ICER vs. BSC
(£)
BSC 51,436 6.188    
UST 76,712 7.132 25,275 0.943 26,797 26,797
300mg of SEC 104,973 7.384 28,261 0.252 111,927 44,774
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Subpopulation 4: TNF-α inhibitors contraindicated
As described in Patient characteristics, a separate scenario is required for patients in whom existing TNF-α
inhibitors (INF, ETN, ADA and GOL) are contraindicated. These patients are likely to be a combination of
biologic-naive and biologic-experienced patients who have experienced a significant AE. SEC, UST and
BSC were included as comparators. CZP was not included as it was assumed that other TNF-α inhibitors,
including CZP, would also be contraindicated in these patients. As described in Sources of effectiveness
data, in the absence of effectiveness data specific to these patients, the analysis was undertaken using
the naive populations from the SEC and UST trials. Only an independent analysis is available for this
subpopulation, because of the smaller number of data available (see Sources of effectiveness data).
Table 101 shows the results of the moderatesevere psoriasis subgroup. The most effective and expensive
treatment is 300 mg of SEC, generating more QALYs than UST (6.530 vs. 6.274 QALYs) and incurring
higher costs (£137,936 vs. £115,216). In the fully incremental analysis, the ICER of UST versus BSC is
£19,969 per QALY and the ICER of 300 mg of SEC versus UST is £89,302 per QALY.
The individual pairwise ICER for 300 mg of SEC compared with BSC is £34,445.
Table 102 shows the results of the mildmoderate psoriasis subgroup. The most effective treatment is
150 mg of SEC, generating more QALYs than UST (6.739 vs. 6.613 QALYs). It incurs lower costs than UST
(£87,559 vs. £88,280). In the fully incremental analysis, UST is dominated by 150 mg of SEC. The ICER of
150 mg of SEC versus BSC is £19,349 per QALY.
Table 103 shows the results of the no concomitant psoriasis subgroup. The most effective and expensive
treatment is 150 mg of SEC, generating more QALYs than UST (7.190 vs. 7.088 QALYs) and incurring
higher costs (£73,798 vs. £73,717). In the fully incremental analysis, UST is extendedly dominated by
150 mg of SEC. The ICER of 150 mg of SEC compared with BSC is £22,334 per QALY.
TABLE 101 Moderate–severe psoriasis, subpopulation 4, contraindicated: fully incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£)
ICER vs. BSC
(£)
BSC 95,965 5.312    
UST 115,216 6.276 19,252 0.964 19,969 19,969
300mg of SEC 137,936 6.530 22,720 0.254 89,302 34,445
TABLE 102 Mild–moderate psoriasis, subpopulation 4, contraindicated: fully incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£)
ICER vs. BSC
(£)
BSC 67,000 5.676    
UST 88,280 6.613 Dominateda   22,708
150mg of SEC 87,559 6.739 20,558 1.063 19,349 19,349
a See Analytic methods.
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
162
Results of the scenario analyses
As discussed in Scenario analyses, a number of scenario analyses were conducted to explore the impact
of various model assumptions. These scenarios were conducted for the three main subpopulations and
were intended to accord with assumptions and data employed in the CSs. These scenarios therefore aid
comparison across the models (see Scenario analyses).
Details of the scenarios are given in Scenario analyses. First, baseline HAQ-DI score is specified according
to the subpopulation of interest. Second, the costs assigned according to HAQ-DI score were taken from
Poole et al.138 as opposed to Kobelt et al.129 Third, two alternative withdrawal scenarios were specified.
The results of these alternative scenarios are summarised in Tables 104106 for each of the three main
subpopulations. The pairwise ICERs for each of the treatments compared with BSC are presented along with
the optimal (or most cost-effective) treatment at thresholds of £20,000 and £30,000 per QALY, using the
fully incremental ICERs. List prices are used in all of these scenarios. Independent analyses from the evidence
synthesis are also employed throughout. The HAQ-DI costs and withdrawal scenarios are specified for only
subpopulations 2 and 3. The full results for these scenarios are presented in Appendix 13.
Table 104 illustrates the differences between the base case and the alternative scenarios for each of the
concomitant psoriasis subgroups in subpopulation 1. The optimal treatment is consistent across the two
scenarios, base case and using a subpopulation-specific baseline HAQ-DI score. In the moderatesevere
subgroup, the optimal treatment is BSC at a threshold of £20,000 and CZP at a threshold of £30,000. In the
mildmoderate and no concomitant subgroups, the optimal treatment is BSC at a threshold of £20,000 and
150mg of SEC at a threshold of £30,000. The lower ICERs for SEC in these two subgroups are driven by the
lower acquisition costs of the 150-mg dose than of the 300-mg dose used in the moderatesevere subgroup.
TABLE 103 No concomitant psoriasis, subpopulation 4, contraindicated: fully incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£)
ICER vs. BSC
(£)
BSC 51,436 6.188    
UST 73,717 7.088   Extendedly
dominateda
24,781
150mg of SEC 73,798 7.190 22,362 1.001 22,334 22,334
a See Analytic methods.
TABLE 104 Summary of differences between base-case models and alternative scenarios, subpopulation 1
Scenario
ICERs vs. BSC (£)
Optimal treatment strategy at
a threshold of
CZP 150mg of SEC 300mg of SEC £20,000 £30,000
Moderatesevere psoriasis
Base case 20,870  26,064 BSC CZP
Baseline HAQ-DI by subpopulation 20,709  25,873 BSC CZP
Mildmoderate psoriasis
Base case 23,052 21,772  BSC 150mg of SEC
Baseline HAQ-DI by subpopulation 22,874 21,604  BSC 150mg of SEC
No concomitant psoriasis
Base case 24,744 23,928  BSC 150mg of SEC
Baseline HAQ-DI by subpopulation 24,543 23,732  BSC 150mg of SEC
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Table 105 illustrates the differences between the base case and the alternative scenarios for each of the
subgroups in subpopulation 2. Aside from the use of the HAQ-DI costs reported by Poole et al.,138 the
optimal treatment is consistent across all scenarios, BSC at a threshold of £20,000 and ETN at a threshold
of £30,000. Using the Poole et al.138 costs significantly reduces the ICERs for all treatments relative to BSC,
as it estimates a much higher cost for BSC. As a result, ETN, as opposed to BSC, is considered to be the
most cost-effective treatment at a threshold of £20,000. At a threshold of £30,000, ETN remains the
optimal treatment despite the reduced ICERs for all the treatments.
Table 106 illustrates the differences between the base case and the alternative scenarios for each of the
subgroups in subpopulation 3. Like subpopulation 2, aside from the use of the Poole et al.138 costs, the
optimal treatment is consistent across all scenarios: BSC at a threshold of £20,000 and UST at a threshold
of £30,000. Using the Poole et al.138 costs significantly reduces the ICERs for all treatments relative to BSC,
as it estimates a much higher cost for BSC (see Appendix 13, Alternative Health Assessment Questionnaire-
Disability Index costs from Poole et al.). As a result, UST, as opposed to BSC, is considered to be the most
cost-effective treatment at a threshold of £20,000. At a threshold of £30,000, UST remains the optimal
treatment, despite the reduced ICERs across all treatments.
TABLE 105 Summary of differences between base-case models and alternative scenarios, subpopulation 2
Scenario
ICERs vs. BSC (£)
Optimal
treatment
strategy at a
threshold of
CZP
150mg
of SEC
300mg
of SEC ADA GOL ETN INF £20,000 £30,000
Moderatesevere psoriasis
Base case 21,564  29,569 20,074 20,074 20,197 27,599 BSC ETN
Baseline HAQ-DI by
subpopulation
21,809  29,877 20,295 20,384 20,409 27,866 BSC ETN
Poole et al.138 HAQ-DI
costs
3115  13,500 3069 3244 2842 13,036 ETN ETN
Withdrawal scenario 1 21,560  30,461 20,074 20,161 20,197 27,599 BSC ETN
Withdrawal scenario 2 21,791  29,562 20,406 20,545 20,555 27,750 BSC ETN
Mildmoderate psoriasis
Base case 24,103 22,032  23,149 23,419 22,274 31,616 BSC ETN
Baseline HAQ-DI by
subpopulation
24,395 22,294  23,418 23,687 22,514 31,938 BSC ETN
Poole et al.138 HAQ-DI
costs
3205 1698  3171 3358 2913 13,526 ETN ETN
Withdrawal scenario 1 24,107 21,291  23,153 23,418 22,274 31,616 BSC ETN
Withdrawal scenario 2 24,459 22,267  23,623 23,946 22,734 31,911 BSC ETN
No concomitant psoriasis
Base case 26,105 24,773  25,532 25,951 23,883 34,930 BSC ETN
Baseline HAQ-DI by
subpopulation
26,444 25,096  25,851 26,267 24,150 35,311 BSC ETN
Poole et al.138 HAQ-DI
costs
3341 1794  3328 3531 3018 14,279 ETN ETN
Withdrawal scenario 1 26,117 24,219  25,542 25,951 23,883 34,930 BSC ETN
Withdrawal scenario 2 26,570 25,138  26,129 26,604 24,427 35,352 BSC ETN
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Results of subgroup analysis: biologic-experienced secondary failures
As discussed in Subpopulation 3: biologic experienced, the RAPID-PsA trial47 includes only experienced
patients who had a primary response to a biologic treatment (secondary failures), representing a specific
subgroup of the overall biologic-experienced subpopulation. In the absence of data for other comparators
for this subgroup, the comparison is restricted to CZP and BSC. The results for this subgroup of biologic-
experienced patients are presented in Tables 107109.
In the biologic-experienced subgroup including only secondary failures, the ICERs of CZP versus BSC are
£16,573, £19,113 and £20,973 for moderatesevere, mildmoderate and no concomitant psoriasis
patients, respectively.
TABLE 106 Summary of differences between base-case models and alternative scenarios, subpopulation 3
Scenario
ICERs vs. BSC (£) Optimal treatment strategy at a threshold of
UST 300mg of SEC £20,000 £30,000
Moderatesevere psoriasis
Base case 21,685 36,013 BSC UST
Baseline HAQ-DI by subpopulation 22,309 26,926 BSC UST
Poole et al.138 HAQ-DI costs 2778 20,154 UST UST
Withdrawal scenario 1 21,685 35,876 BSC UST
Withdrawal scenario 2 21,829 36,276 BSC UST
Mildmoderate psoriasis
Base case 24,510 40,639 BSC UST
Baseline HAQ-DI by subpopulation 25,239 41,721 BSC UST
Poole et al.138 HAQ-DI costs 2870 20,981 UST UST
Withdrawal scenario 1 24,510 40,749 BSC UST
Withdrawal scenario 2 24,763 41,081 BSC UST
No concomitant psoriasis
Base case 26,797 111,927 BSC UST
Baseline HAQ-DI by subpopulation 27,638 46,057 BSC UST
Poole et al.138 HAQ-DI costs 3010 22,264 UST UST
Withdrawal scenario 1 26,797 45,105 BSC UST
Withdrawal scenario 2 27,142 45,389 BSC UST
TABLE 107 Moderate–severe psoriasis, subpopulation 4, secondary failures: fully incremental cost-effectiveness analysis
Treatment Cost (£) QALY Incremental cost (£) Incremental QALY ICER vs. BSC (£)
BSC 95,965 5.312   
CZP 121,314 6.841 25,349 1.530 16,573
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Results from the probabilistic sensitivity analysis
Results for the three main subpopulations (biologic naive with one prior DMARD, biologic naive with two
or more prior DMARDs and biologic experienced), and for three separate concomitant psoriasis subgroups
(baseline PASI score = 0, 7.5 or 12.5), are presented and discussed in the following sections. For ease of
presentation and interpretation, only tables for the independent analysis from the evidence synthesis are
presented in the main body of the report, and summary tables are used to compare with the results based
on metaregression approach.
All results presented in Results are based on the list prices for SEC and CZP and the originator products for
INF and ETN. A separate confidential appendix is included which incorporates the Patient Access Scheme
prices for CZP and SEC.
In each of the 15 versions of the model, the expected model outputs are not equal to the output
evaluated at the expected values of the parameters of the model [deterministic analysis (DA)], showing that
the model is non-linear.
Subpopulation 1: biologic naive (one prior DMARD)
The probabilistic cost-effectiveness results for subpopulation 1 are shown for the three subgroups
according to the level of concomitant psoriasis (moderatesevere psoriasis, mildmoderate psoriasis and no
concomitant psoriasis) in Tables 110112.
Table 110 shows that the means from the PSA imply the same optimal treatment (CZP) as the DA. The
probability that CZP is cost-effective at a threshold of £20,000 is 0.39. At a threshold of £30,000 this
increases to 0.53. Using the metaregression results increases the likelihood of CZP being cost-effective to
0.46 at a £20,000 threshold and to 0.63 at a £30,000 threshold.
In the mildmoderate psoriasis group (Table 111), again the cost-effectiveness results from the means of
the PSA are similar to the results obtained from the DA; 150 mg of SEC represents the optimal treatment
at a threshold between £20,000 and £30,000. This is highly uncertain; the probability that CZP is cost-
effective at threshold of £20,000 is 0.17. At a threshold of £30,000 this increases to 0.30. Using the
metaregression results again produces similar results.
In the no concomitant psoriasis subgroup (Table 112), the probabilistic results again imply the same
optimal treatment (150 mg of SEC). The probability that 150 mg of SEC is cost-effective at a threshold of
£20,000 is 0.28. This increases to 0.45 at a threshold of £30,000. Using metaregression analysis gives very
similar results.
TABLE 109 No concomitant psoriasis, subpopulation 4, secondary failures: fully incremental cost-effectiveness analysis
Treatment Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER vs. BSC (£)
BSC 51,436 6.188   
CZP 81,447 7.622 30,011 1.433 20,937
TABLE 108 Mild–moderate psoriasis, subpopulation 4, secondary failures: fully incremental cost-effectiveness analysis
Treatment Cost (£) QALYs Incremental cost (£) Incremental QALYs ICER vs. BSC (£)
BSC 67,000 5.676   
CZP 95,470 7.166 28,470 1.490 19,113
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Table 113 illustrates the differences between the independent analysis and the metaregression evidence
synthesis for each of the subgroups in subpopulation 1 using the means from the PSA. The pairwise ICERs
for each of the treatments compared with BSC are presented along with the optimal (or most cost-effective)
treatment strategy determined based on the fully incremental ICER comparisons at thresholds of £20,000
and £30,000 per QALY.
In summary, the differences in the pairwise ICERs estimated using the alternative synthesis models have
only a minor effect. Furthermore, the optimal treatment remains consistent across the two evidence
synthesis approaches using a threshold of £30,000 per QALY. At a threshold of £20,000 the optimal
treatment is BSC, unlike the DA results. The ICER for CZP compared with BSC now is beyond the threshold
(£20,621) based on the results of the metaregression.
TABLE 110 Treatment effects from the independent analysis for moderate–severe psoriasis, subpopulation 1: fully
incremental cost-effectiveness PSA
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs.
next best
option (£)
Pairwise
ICER vs.
BSC (£)
Probability of
being cost-effective
at a threshold of
£20,000 £30,000
BSC 95,849 5.363     0.51 0.20
CZP 160,096 8.363 64,247 3.000 21,417 21,417 0.39 0.53
300mg of
SEC
179,594 8.661 19,498 0.298 65,416 25,394 0.10 0.26
TABLE 111 Treatment effects from the independent analysis for mild–moderate psoriasis, subpopulation 1: fully
incremental cost-effectiveness PSA
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs.
next best
option (£)
Pairwise
ICER vs.
BSC (£)
Probability of
being cost-effective
at a threshold of
£20,000 £30,000
BSC 66,885 5.727     0.46 0.20
CZP 135,999 8.653 69,114 2.926 Dominated 23,621 0.17 0.30
150mg of
SEC
132,284 8.822 3714 0.168 21,136 21,136 0.37 0.50
TABLE 112 Treatment effects from the independent analysis for no concomitant psoriasis, subpopulation 1: fully
incremental cost-effectiveness PSA
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs.
next best
option (£)
Pairwise
ICER vs.
BSC (£)
Probability of
being cost-effective
at a threshold of
£20,000 £30,000
BSC 51,321 6.239     0.59 0.26
CZP 122,839 9.061 71,518 2.822 Dominated 25,342 0.13 0.29
150mg of
SEC
120,028 9.204 2810 0.142 23,177 23,177 0.28 0.45
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Subpopulation 2: biologic naive (two or more prior DMARDs)
The means from the PSA for subpopulation 2 are reported according to the level of concomitant psoriasis
(moderatesevere psoriasis, mildmoderate psoriasis and no concomitant psoriasis) in Tables 114116.
In the moderatesevere subgroup (Table 114), the PSA results imply a different optimal treatment from the
DA results; it switches from ETN to GOL. This is driven by the skewed nature of the PASI 75 data. Figure 20
shows that the PASI 75 data for ETN have the widest variation, with the mean having greater value than the
median, indicating that the data are rightly skewed. PASI 75 response plays a more important role in this
subgroup than in those with the mildmoderate or no concomitant psoriasis.
There is a high degree of uncertainty around the choice of optimal treatment (GOL); the probability that GOL is
cost-effective is 0.20 at a threshold of £20,000 and 0.23 at a threshold of £30,000. Using the metaregression
estimates reduces the difference between the QALYs for GOL and ETN, making ETN within the threshold of
TABLE 113 Summary of differences for the PSA results between independent and metaregression approaches,
subpopulation 1
NMA approach
ICERs vs. BSC (£)
Optimal treatment strategy
at a threshold of
CZP 150mg of SEC 300mg of SEC £20,000 £30,000
Moderatesevere psoriasis
Independent analysis 21,417  25,394 BSC CZP
Metaregression 20,621  26,766 BSC CZP
Mildmoderate psoriasis
Independent analysis 23,621 21,136  BSC 150mg of SEC
Metaregression 23,280 20,993  BSC 150mg of SEC
No concomitant psoriasis
Independent analysis 25,342 23,177  BSC 150mg of SEC
Metaregression 25,334 23,090  BSC 150mg of SEC
TABLE 114 Treatment effects from the independent analysis for moderate–severe psoriasis, subpopulation 2: fully
incremental cost-effectiveness PSA
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs.
next best
option (£)
Pairwise
ICER vs.
BSC (£)
Probability of being
cost-effective at a
threshold of
£20,000 £30,000
BSC 95,849 5.363     0.26 0.10
CZP 137,306 7.255 41,457 1.893 Extendedly
dominated
21,906 0.13 0.11
ADA 138,117 7.494 811 0.239 Extendedly
dominated
19,831 0.16 0.16
300mg of
SEC
156,926 7.531 18,809 0.036 Dominated 28,176 0.03 0.07
GOL 142,645 7.753 14,281 0.223 19,577 19,577 0.20 0.23
ETN 144,518 7.800 1873 0.047 39,854 19,968 0.21 0.26
INF 166,776 8.075 22,257 0.275 81,064 26,153 0.01 0.08
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£30,000 at £25,886 per QALY compared with GOL. Again, this decision is highly uncertain; probability of
being cost-effective is 0.20 and 0.25 at a threshold of £20,000 and £30,000, respectively.
Table 115 shows the results for the mildmoderate psoriasis subgroup. In this subgroup, the optimal
treatment (ETN) is consistent for the PSA and DA results. The probability that ETN is cost-effective is 0.13
at a threshold of £20,000 and 0.22 at a threshold of £30,000. Using the metaregression estimates
increases the decision uncertainty associated with ETN and makes 150 mg of SEC the optimal treatment
within a threshold of £30,000 and with a probability of being cost-effective of 0.21.
For the no concomitant psoriasis subgroup (PASI score = 0) (Table 116), the choice of optimal treatment
(ETN) is consistent across the PSA and DA results. The probability that ETN is cost-effective is highly
uncertain, with a probability of 0.12 at a threshold of £20,000 and of 0.22 at a threshold of £30,000.
Using metaregression switches the optimal treatment (see Table 8). The uncertainty associated with the
optimal treatment (150 mg of SEC) is somewhat less uncertain, the probability being 0.19.
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FIGURE 20 Range of values and distributions for PASI 75 response for the treatments.
TABLE 115 Treatment effects from the independent analysis for mild–moderate psoriasis, subpopulation 2: fully
incremental cost-effectiveness PSA
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs.
next best
option (£)
Pairwise
ICER vs.
BSC (£)
Probability of being
cost-effective at a
threshold of
£20,000 £30,000
BSC 66,885 5.727     0.28 0.13
CZP 111,852 7.567 44,967 1.839 Dominated 24,446 0.14 0.12
150mg of SEC 108,252 7.712 3600 0.145 20,844 20,844 0.20 0.18
ADA 113,980 7.791 5728 0.079 Extendedly
dominated
22,819 0.11 0.13
GOL 119,349 8.040 5369 0.248 Dominated 22,691 0.13 0.18
ETN 119,168 8.107 181 0.068 27,619 21,969 0.13 0.22
INF 145,152 8.346 25,985 0.238 108,986 29,893 0.00 0.05
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Table 117 summarises the differences between the independent analysis and the metaregression evidence
synthesis for each of the separate psoriasis subgroups within subpopulation 2. Although there are only
minimal differences in the pairwise ICERs in this subpopulation, the optimal treatment alters across the two
evidence synthesis approaches. In the moderatesevere subgroup, it switches from ETN to GOL because of
the skewness of the PASI 75 data for ETN. In the mildmoderate and no concomitant subgroups, the
optimal treatment switches from ETN to 150 mg of SEC. These differences are driven by the increased
relative effectiveness of 150 mg of SEC in the metaregression approach.
TABLE 116 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 2: fully
incremental cost-effectiveness PSA
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs.
next best
option (£)
Pairwise
ICER vs.
BSC (£)
Probability of being
cost-effective at a
threshold of
£20,000 £30,000
BSC 51,321 6.239     0.33 0.16
CZP 98,022 8.004 46,701 1.765 Dominated 26,461 0.14 0.13
150mg of SEC 95,329 8.123 2693 0.119 23,356 23,356 0.19 0.17
ADA 100,800 8.208 5471 0.085 Extendedly
dominated
25,129 0.10 0.13
GOL 106,585 8.441 5785 0.233 Dominated 25,095 0.11 0.16
ETN 105,389 8.538 1196 0.097 24,248 23,517 0.12 0.22
INF 133,214 8.726 27,826 0.188 148,259 32,932 0.00 0.03
TABLE 117 Summary of differences for the PSA results between independent and metaregression approaches,
subpopulation 2
NMA approach
ICERs vs. BSC (£)
Optimal treatment
strategy at a
threshold of
CZP
150mg
of SEC
300mg
of SEC ADA GOL ETN INF £20,000 £30,000
Moderatesevere psoriasis
Independent analysis 21,906  28,176 19,831 19,577 19,968 26,153 BSC GOL
Metaregression 20,256  29,289 19,812 20,038 20,285 27,411 BSC ETN
Mildmoderate psoriasis
Independent analysis 24,446 20,844  22,819 22,691 21,969 29,893 BSC ETN
Metaregression 23,279 20,262  22,752 22,543 22,406 30,690 BSC 150mg
of SEC
No concomitant psoriasis
Independent analysis 26,461 23,356  25,129 25,095 23,517 32,932 BSC ETN
Metaregression 25,630 22,675  25,023 24,484 24,052 33,391 BSC 150mg
of SEC
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Subpopulation 3: biologic experienced
Tables 118120 present the results for subpopulation 3 for the moderatesevere, mildmoderate and no
concomitant psoriasis subgroups. Similar to the DA results, in the moderatesevere subgroup, UST is the
optimal treatment at thresholds of £20,000 and £30,000. The probability of UST being cost-effective at a
threshold of £20,000 is 0.48. This increases to 0.50 using a threshold of £30,000.
Table 119 shows the results for the mildmoderate psoriasis subgroup. The optimal treatment remains
UST, with the probability that it is cost-effective at a threshold of £20,000 being 0.45. This increases to
0.49 at a threshold of £30,000.
Table 120 shows the results of non-evaluable psoriasis subgroup. In this subgroup, again, the choice of
optimal treatment (UST) is consistent across the PSA and DA. The probability that UST is cost-effective at a
threshold of £20,000 is 0.43 and at a threshold of £30,000 is 0.49.
TABLE 119 Mild–moderate psoriasis, subpopulation 3: fully incremental cost-effectiveness PSA
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs.
next best
option (£)
Pairwise
ICER vs.
BSC (£)
Probability of being
cost-effective at a
threshold of
£20,000 £30,000
BSC 66,885 5.727     0.47 0.36
UST 90,719 6.935 23,835 1.208 19,731 19,731 0.45 0.49
300mg of SEC 118,576 6.950 27,857 0.014 1,961,907 42,295 0.07 0.14
TABLE 118 Moderate–severe psoriasis, subpopulation 3: fully incremental cost-effectiveness PSA
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs.
next best
option (£)
Pairwise
ICER vs.
BSC (£)
Probability of being
cost-effective at a
threshold of
£20,000 £30,000
BSC 95,849 5.363     0.44 0.34
UST 117,666 6.605 21,817 1.242 17,571 17,571 0.48 0.50
300mg of SEC 143,629 6.636 25,964 0.032 818,886 37,524 0.09 0.16
TABLE 120 No concomitant psoriasis, subpopulation 3: fully incremental cost-effectiveness PSA
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs.
next best
option (£)
Pairwise
ICER vs.
BSC (£)
Probability of being
cost-effective at a
threshold of
£20,000 £30,000
BSC 51,321 6.239     0.50 0.38
300mg of SEC 104,944 7.389 53,624 1.150 Dominated 46,617 0.07 0.13
UST 76,152 7.400 28,792 0.010 21,394 21,394 0.43 0.49
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
© Queens Printer and Controller of HMSO 2017. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
171
Summary of the model results
The current York model specifies three main subpopulations according to the position in the pathway
of treatment:
1. subpopulation 1: biologic naive, one previous cDMARD
2. subpopulation 2: biologic naive, two or more previous cDMARDs
3. subpopulation 3: biologic experienced.
For subpopulation 3, CZP was excluded on the basis that data were available for only a subset of biologic-
experienced patients (see Patient characteristics and Choice of intervention and comparators). A separate
scenario was conducted for secondary failures as a result of the availability of data for CZP. This scenario
includes only CZP versus BSC.
Three subgroups are also specified within each of the three subpopulations. These subgroups refer to the
severity of concomitant psoriasis:
1. no concomitant psoriasis
2. mildmoderate concomitant psoriasis
3. moderatesevere concomitant psoriasis.
A fourth subpopulation is also specified, which defines a population in which TNF-α inhibitors are
contraindicated (subpopulation 4). A number of scenarios are specified to explore the robustness of some
of the assumptions made in the model: rate of withdrawals beyond the first cycle and source of costs
relating to HAQ-DI. In addition, separate analyses were conducted using biosimilar prices for ETN and INF
and Patient Access Scheme prices for CZP and SEC.
Base-case results
Under base-case assumptions and using the independent analysis from the evidence synthesis, the results
for each of the three subpopulations can be summarised as:
l For subpopulation 1:
¢ CZP is likely to be the optimal treatment in the moderatesevere psoriasis group (ICER = £20,870
compared with BSC). The individual pairwise ICER for 300 mg of SEC compared with BSC is
£26,064 per QALY.
¢ In the mildmoderate psoriasis group, CZP is dominated by 150 mg of SEC, which has an ICER of
£21,772 compared with BSC. The individual pairwise ICER for CZP compared with BSC is £23,052
per QALY.
¢ In the no concomitant psoriasis subgroup, CZP is no longer dominated by 150 mg of SEC;
however, its ICER is substantial compared with 150 mg of SEC (£346,785). The ICER for 150 mg of
SEC increases to £23,928, compared with BSC. The individual pairwise ICER for CZP compared
with BSC is £24,774 per QALY.
l For subpopulation 2:
¢ ETN is likely to be the optimal treatment in the moderatesevere subgroup, with an ICER of
£21,210 compared with GOL. The individual pairwise ICERs for CZP and 300 mg of SEC compared
with BSC are £21,564 and £29,569 per QALY, respectively.
¢ For the mildmoderate psoriasis subgroup, again ETN appears to be the optimal treatment, with an
ICER of £23,256 compared with 150 mg of SEC. The individual pairwise ICERs for CZP and 150 mg
of SEC compared with BSC are £24,103 and £22,032 per QALY, respectively.
¢ For the no concomitant psoriasis subgroup, the ICERs increase for all treatments. ETN is likely
to be the optimal treatment in this subgroup, with an ICER of £23,883 compared with BSC.
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The individual pairwise ICERs for CZP and 150 mg of SEC compared with BSC are £24,103 and
£22,032 per QALY, respectively.
l For subpopulation 3:
¢ UST is likely to be the optimal treatment for the moderatesevere psoriasis subgroup, with an ICER
of £21,684 compared with BSC. The individual pairwise ICER for 300 mg of SEC compared with
BSC is £36,013 per QALY.
¢ In the mildmoderate psoriasis subgroup, the ICER for UST compared with BSC increases to
£24,510. The individual pairwise ICER for 300 mg of SEC compared with BSC is £40,639 per QALY.
¢ In the non-evaluable psoriasis subgroup, UST is likely to be the optimal treatment, at thresholds
below £30,000, with an ICER of £26,797 compared with BSC. The individual pairwise ICER for
300 mg of SEC compared with BSC is £44,774 per QALY.
For subpopulations 1 and 2, separate effectiveness results are also available utilising a metaregression
approach. The differences between the independent analysis and the metaregression can be summarised as:
l In subpopulation 1 the use of the metaregression evidence has a minimal impact on the pairwise ICERs;
however, at a threshold of £20,000 the optimal treatment changes in the moderatesevere subgroup.
CZP is now likely to be the most cost-effective treatment, as its ICER, compared with BSC, falls below
the threshold (£19,908).
l In subpopulation 2, again, there are only minimal differences in the pairwise ICERs; however, the
optimal treatment is not consistent across the two evidence synthesis approaches. Both approaches
accord in terms of the optimal strategy at a threshold of £20,000 for the mildmoderate and no
concomitant subgroups. In the moderatesevere subgroup, the ICER for CZP (compared with BSC  its
next best) falls below £20,000, therefore at this threshold it represents the optimal treatment. Using
the metaregression estimates, CZP, as opposed to ETN, represents the most cost-effective optimal
treatment at a threshold value of £30,000 per QALY in the moderatesevere psoriasis group. In
addition, the optimal treatment switches from ETN to 150 mg of SEC in the mildmoderate and no
concomitant psoriasis subgroups.
In the contraindicated subgroup (subpopulation 4):
l UST appears to the most cost-effective treatment in moderatesevere psoriasis patients, with an ICER
of £19,969 compared with BSC. The individual pairwise ICER for 300 mg of SEC compared with BSC is
£34,445 per QALY.
l In mildmoderate psoriasis patients, UST is dominated by 150 mg of SEC. Compared with BSC, 150 mg
of SEC has an ICER of £19,349.
l In the no concomitant psoriasis patients, UST is extendedly dominated by 150 mg of SEC. Compared
with BSC, 150 mg of SEC has an ICER of £22,334.
In the biologic-experienced subgroup, including only secondary failures, CZP seems to be the cost-effective
treatment compared with BSC, with ICERs of £16,573, £19,113 and £20,973 for moderatesevere,
mildmoderate and no concomitant psoriasis patients, respectively.
Results using biosimilar prices
When using biosimilar prices for ETN and INF in subpopulation 2, the ICERs for ETN compared with BSC
and for INF compared with ETN decrease. The ICER for ETN compared with its next best alternative (BSC)
in the moderatesevere subgroup falls below the threshold of £20,000; therefore, at this threshold, using
the biosimilar prices for ETN, the optimal treatments switches from BSC to ETN. For the mildmoderate
and no concomitant psoriasis subgroups the optimal treatments remains unchanged.
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Scenario results
A number of scenarios were specified to explore the sensitivity of results to some of the assumptions made
in the model. Alternative scenarios were specified for the three main subpopulations, although withdrawal
scenarios and the use of Poole et al.138 costs were conducted only for subpopulations 2 and 3. List prices
and originator products (ETN and INF) are used in all of these scenarios. Independent analyses from the
evidence synthesis are also employed throughout. The results can be summarised as:
l In subpopulation 1, the optimal treatment is consistent across the two scenarios, base case and using a
subpopulation-specific baseline HAQ-DI score.
l In subpopulation 2, aside from the use of the Poole et al.138 HAQ-DI costs, the optimal treatment is
consistent across all scenarios. Using the Poole et al.138 costs significantly reduces the ICERs for all
treatments relative to BSC, as it estimates a much higher cost for BSC. As a result, ETN, as opposed to
BSC, is identified to be the most cost-effective treatment at a threshold of £20,000 per QALY. At a
threshold of £30,000 per QALY, ETN remains the optimal treatment despite the reduced ICERs for all
the treatments.
l In subpopulation 3, aside from the use of the Poole et al.138 costs, the optimal treatment is consistent
across all scenarios. Using the Poole et al.138 costs significantly reduces the ICERs for all treatments
relative to BSC, as it estimates a much higher cost for BSC. As a result, UST, as opposed to BSC, is
considered to be the most cost-effective treatment at a threshold of £20,000 per QALY. At a threshold
of £30,000 per QALY, UST remains the optimal treatment despite the reduced ICERs across all
treatments.
Probabilistic sensitivity analysis
l In all subpopulations and subgroups according to level of psoriasis, the PSA demonstrates considerable
decision uncertainty regarding the optimal treatment, at both £20,000 and £30,000 thresholds.
l The ICERs are broadly consistent between the deterministic and the means of the PSA. Although there
are only small differences in the ICER, the optimal treatment does change in a few instances:
¢ in subpopulation 1, at a threshold of £20,000 the optimal treatment is BSC, unlike the
deterministic results, where either CZP or SEC are optimal
¢ in subpopulation 2 the optimal treatment changes in the moderatesevere subgroup, from ETN in
the deterministic results to GOL in the means of the PSA.
External validation of results
Comparison of updated York model results with company model results
In the absence of a list price analysis from either of the companies, it is not possible to make direct
comparisons between the updated York model results and those from the Novartis and UCB Pharma
submissions. In general, the structure and approaches of both company models were similar in many key
respects to the updated York model and models developed as part of previous appraisals. However, as
highlighted in Chapter 5, further challenges arise when trying to make comparisons between the results of
the updated York model, similar to those we faced when trying to make comparisons between the CSs,
given the differences identified in the approaches and data sources employed. On this basis we consider
that direct comparisons between the ICER results would not be sufficiently meaningful.
The main advantage of the York model is that it facilitates a more consistent basis for evaluating CZP
and SEC by ensuring comparability in methods and inputs (including prices). In addition, the York model
attempts to include all relevant treatments within each subpopulation and more explicitly considers issues
around the appropriate dosing for SEC by undertaking separate subgroup analyses based on the presence
and severity of concomitant psoriasis.
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Comparison of updated York model results with published models’ results
It is possible to compare some of the results of the updated York model with those from previously published
models, namely the three models developed as part of previous appraisals in this area (TA199,33 TA220133
and TA34035), and a published update of the previous York model by Cawson et al.36 (see Table 3). This
comparison is somewhat restricted by the more limited scope in previously published models. In TA199,33
TA220133 and Cawson et al.,36 only subpopulation 2 was considered. TA34035 also included an analysis for
subpopulations 3 and 4 together [experienced and contraindicated (termed ineligible)]. All previously
published models looked at the extent of concomitant psoriasis; however, this was included only as limited
scenario analyses and full results are only available for the average severity of psoriasis: mildmoderate. It is
also noted that none of the previously published models included the comparators CZP or SEC.
In terms of the results for subpopulation 2, the ICERs for ETN versus the next best treatment are broadly
consistent across the updated York model and the four published models (£16,426 in Cawson et al.36 to
£23,256 in the updated York model, mildmoderate psoriasis subgroup). For subpopulation 3, TA34035
included a separate analysis of a biologic-experienced/contraindicated population for UST. In this analysis,
the ICER for UST compared with BSC was £25,393. This result is very similar to those from subpopulation 3
of the updated York model results, in which the ICER for UST compared with BSC, in the mildmoderate
psoriasis subgroup, is £24,510. In the contraindicated subgroup (subpopulation 4 of the York model), in
mildmoderate psoriasis patients, the ICER for UST compared with BSC is again broadly consistent at
£22,708. In the full incremental analysis for this subpopulation, however, UST is dominated by 150 mg of
SEC and 150 mg of SEC has an ICER of £19,349 compared with BSC.
Discussion of the York model
The previous York model has been updated for this appraisal. This includes an update of the evidence
used to populate the model and a number of updates to the model structure and assumptions.
Specifically, the updated York model differs from the previous York in several respects:
l The model now incorporates subsequent biologic treatments following primary lack of response or
secondary failure.
l The model now includes the three subpopulations specified in the NICE scope112 for this appraisal.
l Rather than presenting a single base case reflecting an average PsA patient, heterogeneity in terms of
baseline PASI score is now formally addressed by presenting results for three distinct subgroups within
each subpopulation.
In addition, the updated York model includes the comparators CZP and SEC and considers the cost-
effectiveness of these treatments in each of the subpopulations. The updated York model also considers
several key uncertainties: the acquisition cost of SEC and CZP (list or Patient Access Scheme prices); the
products for ETN and INF (originator or biosimilar); the source algorithm used to link progression in HAQ-DI
score to costs; and assumptions regarding the longer-term rate of withdrawal for primary responders.
The model utilises all currently available evidence to generate estimates of clinical effectiveness using NMA.
Alternative models are specified for the NMA, and a more limited set of models is chosen on the basis of
model fit, goodness-of-fit statistics and clinical plausibility. These alternative models (independent analysis
and metaregression) are each used in the economic model and the sensitivity of model results to these
alternative evidence synthesis models assessed.
Using list prices, SEC and CZP are likely to be considered cost-effective only in subpopulation 1 (biologic
naive, one prior DMARD). In subpopulation 2, ETN is likely to be the optimal treatment across all psoriasis
subgroups and, in subpopulation 3, UST is likely to be the optimal treatment across all psoriasis subgroups.
The cost-effectiveness results are, however, sensitive to a number of assumptions made in the model,
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namely the choice of NMA model used to determine clinical effectiveness and the algorithm used to link
HAQ-DI score to health state costs.
The updated York model also has a number of limitations, which have largely been imposed by a lack of
available data to inform aspects of the model. First, subpopulation 1 includes only the comparators CZP,
SEC and BSC, as per the NICE scope.112 It is recognised, however, that there may be other comparators
relevant for this subpopulation. In particular, patients who have received only one prior DMARD may be
eligible to receive a second DMARD. It was not possible within the scope of this appraisal to assess the
evidence for DMARDs and, therefore, include this as a formal comparator in this subpopulation. The
extremely low cost of DMARDs (7.5 mg of MTX is £0.30) makes it likely that these would be considered
cost-effective in this population. In addition, the licences for the other biologic treatments (ETN, INF, ADA
and GOL) do not preclude their use in the one-DMARD population and, therefore, these could be
considered to be relevant comparators in subpopulation 1. Indeed, this subpopulation appears to not have
been considered in previously published models, largely because the scope of these models has closely
followed existing BSR guidelines and criteria for commencing biologic treatments (i.e. that the PsA has
not responded to adequate trials of at least two standard DMARDs, administered either individually or in
combination), as opposed to reflecting important differences in the licences of existing biologic treatments
and those for SEC and CZP.
Second, the clinical effectiveness evidence synthesised in the NMA does not differentiate between
subpopulations 1 and 2 as a result of the limited data availability. This means that it was possible to
differentiate these two populations only on the basis of the comparators included and the subsequent
treatments received following primary failure or secondary withdrawal. Related to this, the subpopulation
1 analysis makes the assumption that ETN is the next treatment received, following failure of 150 mg of
SEC or CZP. It is likely that other treatments could be used as second line in this population. Owing to the
large number of possible treatment sequences for subpopulation 1, it was not feasible as part of this
appraisal to determine the optimal sequence for all potential treatments. Modelling multiple lines of
biologic treatments would also require evidence on any degradation effect for subsequent lines. Such
evidence is sparse in PsA and that which exists does not consider the full set of biologic treatments
considered in this appraisal.
Finally, it has not been possible to update a number of the assumptions in the York model, specifically the
rate of withdrawal for primary responders, the progression in HAQ-DI score for those receiving treatment,
and the progression of HAQ-DI score for those remaining on treatment. These assumptions rely on non-
experimental data and, unfortunately, within the time constraints of this appraisal, it was not possible to
gain access to registry data to update these assumptions, although attempts to do so were made.
Given these uncertainties and possible limitations, and the lack of direct head-to-head evidence for the
alternative treatments, the results from the fully incremental cost-effectiveness analyses should be carefully
considered alongside the separate pairwise comparisons presented against BSC. The significant efficacy of
all biologic treatments was evident in the important QALY differences reported compared with BSC alone.
In contrast, differences between the alternative biologic therapies were much less significant and, in some
instances, may not be clinically meaningful. Hence, there remains considerable uncertainty in relation to
defining an optimal treatment or pathway of care. The PSA also demonstrates considerable decision
uncertainty regarding the optimal treatment, at both £20,000 and £30,000 thresholds.
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Chapter 7 Assessment of factors relevant to the
NHS and other parties
The potential extra cost to the NHS of providing SEC and CZP to adult patients with PsA is unclear,as the prevalence of UK PsA patients in subpopulation 1 is somewhat uncertain.
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Chapter 8 Discussion
Statement of principal findings
The systematic review of the efficacy of SEC, CZP and relevant comparator therapies in patients with PsA
identified an evidence base of generally high-quality randomised trials. The results of the pivotal randomised
trials of SEC (FUTURE 2 trial48) and CZP (RAPID-PsA trial47) demonstrated their short-term efficacy for treating
PsA. When considering the whole-trial populations, both SEC and CZP were associated with statistically
significant improvements in all key clinical outcomes. At 3 months, patients taking SEC were around six
times more likely to be ACR 50 responders  an important clinical outcome to patients  than patients
taking placebo. Patients taking CZP were around three times more likely to be ACR 50 responders than
placebo patients. Clinically important improvements in activities of daily living (assessed using the HAQ-DI)
were also evident for both therapies, particularly in patients who were PsARC responders. In addition, both
SEC and CZP significantly improved measures of HRQoL and the resolution of enthesitis and dactylitis.
However, when the populations from these two trials were split into subgroups based on previous biologic
experience, results for the biologic-experienced subgroups became difficult to interpret. This was as a result
of both the low numbers of placebo patients (and placebo events) and the differences in placebo response
rates across subgroups; it was therefore not possible to make robust conclusions about the relative efficacy
of SEC and CZP across these subgroups.
Subgroup results from PsA patients recruited to trials of patients with quite severe psoriasis suggested SEC
may be particularly efficacious in treating the psoriasis symptoms of PsA.
The results from open-label trial extension studies that radiographically assessed joint damage indicated
that, after 2 years of treatment, CZP effectively reduced disease progression, with benefits being similar
to those observed in the open-label studies for the other biologics. For SEC, fewer result details were
available at 2 years, although results also indicated effective reduction in radiographic disease progression.
Meaningful treatment comparisons of longer-term data for other outcomes were difficult to undertake
because of the variation in both time points assessed and in methodological approaches used for data
analyses (confidential information has been removed).
The trials identified to inform a comparison of SEC and CZP with other biologics were performed across a
15-year period and variation in placebo response was evident for some important outcomes, with larger
placebo response rates seen in the more recent trials. Furthermore, there was important heterogeneity
across trials with regard to patients previous use of a biologic therapy: subgroups of biologic-experienced
patients were recruited only in more recent trials. Our NMAs were therefore performed on the biologic-
naive and biologic-experienced subgroups separately, and included models which adjusted for, and
explored, the different rates of placebo response across trials.
The NMA results  both adjusted and unadjusted  demonstrated that, in biologic-naive patients, SEC and
CZP were more effective than placebo in terms of achieving PsARC and ACR responses. There was though
some uncertainty regarding the relative effectiveness of SEC and CZP when compared with each other
and with all other biologics: they had fairly similar effectiveness when compared with the other anti-TNFs,
although they were possibly slightly more effective than UST. However, both SEC and CZP appeared to be
more effective than APR. In terms of psoriasis outcomes in biologic-naive patients, treatment with SEC and
INF resulted in the best PASI results when compared with other therapies, although the differences for
most comparisons were not statistically significant.
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The median HAQ-DI score change, conditional on a PsARC response, was highest with INF and ETN,
followed by 300 mg of SEC, but 150 mg of SEC and CZP were worse than all treatments except for APR.
Only three trials recruited biologic-experienced patients: one each of SEC, CZP and UST. Unfortunately.
data from the CZP trial had to be excluded from the NMAs because this trial included a more restricted
biologic-experienced population, which was not comparable to the biologic-experienced populations in the
other two trials. The NMA results showed that the probabilities of PsARC and ACR responses with SEC and
UST were quite similar, as was the change in HAQ-DI score in PsARC responders. Patient numbers were
particularly limited for the biologic-experienced PASI analyses, as they were based on a subgroup (prior use
of a biologic) of a subgroup (psoriasis on ≥ 3% of BSA), so estimates from the NMA were highly uncertain.
However, the results suggested that the probabilities of achieving PASI responses were higher for SEC than
for UST.
Results from studies of patient registries that recorded biologic use suggested that, although patients
benefit from a second or further anti-TNFs, the expected benefit from anti-TNFs diminishes after switching,
with a reduced chance of response and reduced drug survival. The paucity of observational data on the
natural history of PsA meant that it was difficult to produce accurate estimates of yearly disease
progression rates in patients not taking anti-TNFs.
Results from three systematic reviews of AEs suggested that CZP was associated with statistically
significantly more SAEs and serious infections than placebo. SEC was not included in these systematic
reviews of AEs, probably as a result of the limited availability of data at the time. Although the safety data
for SEC appear promising, the fairly small number of trials for which data are currently available means
that there is still some uncertainty regarding its safety.
Strengths and limitations of the assessment
Strengths
The systematic review was performed using transparent, reproducible and robust methods. Our
comprehensive searches therefore sought to identify all relevant published and unpublished trials, which
minimised the possibility of publication or language biases affecting the review results. The possibility of
reviewer errors and biases affecting this assessment was minimised by performing review processes in
duplicate. A thorough evaluation of the risk of bias in each randomised trial was performed. We conducted
many NMAs to investigate the relative efficacy of all the comparator agents. Additionally, and in order to
improve the methodological similarity of the trial data included in our analyses, we successfully obtained
previously unpublished data relating to two key trials (for which manufacturer submission data were
not available).
A further key strength of our review was the breadth of its scope: in addition to randomised trials we
included other types of study, such as non-randomised trial extension studies, registry studies of patients
taking anti-TNFs, systematic reviews and other large studies of adverse effects of anti-TNFs and studies of
the natural history of PsA. Our review was reported based on the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement.
The updated York model confers several advantages over current published cost-effectiveness studies,
namely the inclusion of the three subpopulations according to the position in the pathway of treatment,
the explicit consideration of the severity of concomitant psoriasis and the modelling of subsequent
treatments following primary non-response or secondary failure. Like the company models, the updated
York model includes the comparators CZP and SEC. In addition, it considers the cost-effectiveness of these
treatments in each of the subpopulations and more explicitly considers issues around the appropriate
dosing for SEC by undertaking separate subgroup analyses based on the presence and severity of
concomitant psoriasis.
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The updated York model also considers several key uncertainties: the acquisition cost of SEC and CZP
(list or Patient Access Scheme prices); the products for ETN and INF (branded or biosimilars); the source
algorithm used to link progression in HAQ-DI score to costs; and assumptions regarding the longer-term
rate of withdrawal for primary responders.
The model utilises all currently available evidence to generate estimates of clinical effectiveness using a
NMA. Alternative models are specified for the NMA, and a more limited set of models is chosen on the
basis of model fit, goodness-of-fit statistics and clinical plausibility. These alternative models (independent
analysis and metaregression) are each used in the economic model and the sensitivity of model results to
these alternative evidence synthesis models assessed. The York model facilitates a more consistent basis for
evaluating CZP and SEC by ensuring comparability in methods and inputs.
Limitations
Data from randomised, fully blinded populations were available only for up to around 3 or 4 months for
most of the trials included in our review (after which patients could cross over to active treatments); much
of the RCT evidence was therefore quite short term in nature. Some of the earlier trials were also limited
by small sample sizes (increasing the possibility of results being attributable to chance, rather than being
attributable to treatment). The variation in placebo responses over time was also a limitation of the
available data, although we sought to address this in our NMAs (using metaregression adjustments).
Although we also evaluated long-term results from studies that were not RCTs, data from such studies
may have been affected by biases or confounding and often either key method details were absent from
publications or methods were found to be suboptimal. Much less reliability and certainty could therefore
be ascribed to the results obtained from these other studies.
As discussed previously, the updated York model does have a number of limitations, which have largely
been imposed by a lack of available data to inform aspects of the model.
Of particular note is the fact that subpopulation 1 includes only the comparators CZP, SEC and BSC,
as per the NICE scope.112 It is recognised, however, that there may be other comparators relevant for this
subpopulation. In particular, patients who have received only one prior DMARD may be eligible to receive a
second DMARD. It was not possible within the scope of this appraisal to assess the evidence for DMARDs
and, therefore, include this as a formal comparator in this subpopulation. In addition, the licences for the
other biologic treatments (ETN, INF, ADA and GOL) do not appear to preclude their use in the one-DMARD
population and, therefore, these could be considered to be relevant comparators in subpopulation 1.
Indeed, this subpopulation appears to not have been considered in previous models, largely because the
scope of these models has closely followed existing BSR guidelines and criteria for commencing biologic
treatments (i.e. that the PsA has not responded to adequate trials of at least two standard DMARDs,
administered either individually or in combination), as opposed to reflecting important differences in the
licences of existing biologic treatments and those for SEC and CZP.
Uncertainties
l The magnitude of SEC and CZP treatment effects in biologic-experienced patients is uncertain because
the trial subgroup sample sizes were small, and the subgroup in the CZP trial was not appropriately
representative of the biologic-experienced population that would be seen in clinical practice.
l The limitations and variations in the design and reporting of long-term studies means that there is
uncertainty whether or not there are differences in efficacy and safety between the different therapies
in the long term.
l The long-term impact of SEC and CZP (and other anti-TNFs) on other important outcomes, such as
cardiovascular disease and mortality, is uncertain.
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The cost-effectiveness results are potentially sensitive to a number of assumptions made in the model,
namely the choice of NMA model used to determine clinical effectiveness and the algorithm used to link
HAQ-DI score to health state costs. Given these uncertainties and the lack of direct head-to-head evidence
for the alternative treatments, the results from the fully incremental cost-effectiveness analyses should also
be considered alongside the separate pairwise comparisons presented against BSC. The significant efficacy
of all biologic treatments was evident in the important QALY differences reported, compared with BSC
alone. In contrast, differences between the alternative biologic therapies were much less significant and in
some instances may not be clinically meaningful. Hence, there remains considerable uncertainty in relation
to defining an optimal treatment or pathway of care. Indeed, the PSA demonstrates considerable decision
uncertainty regarding the optimal treatment, at both £20,000 and £30,000 thresholds.
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Chapter 9 Conclusions
A lthough the NMAs were based on data from high-quality randomised trials, heterogeneity across trialsmeant that the analyses had to be performed in biologic-naive and biologic-experienced subpopulations
separately, and also needed to include models which adjusted for the different rates of placebo response
evident across trials. The NMA results for the biologic-naive subpopulation indicated that, although SEC
and CZP were effective across all outcomes after 3 months therapy, their relative effectiveness compared
with ETN, ADA, GOL and INF and with each other was uncertain (the rankings of treatment varied with
outcome and analysis). However, both agents did seem consistently more effective than APR. The results
also indicated that SEC and INF were the most effective in terms of treating psoriasis (PASI response). Only
SEC and UST could be included in the analyses of the biologic-experienced subpopulation. The results
showed that, across all outcomes analysed, both SEC and UST were significantly more effective than
placebo. Most of the results suggested that SEC may be better than UST. However, the patient numbers in
this subpopulation were quite low; the results were therefore uncertain (with wide overlapping CrIs).
The results from open-label trial extension studies which radiographically assessed joint damage suggest
that both CZP and SEC effectively reduce disease progression. Published systematic reviews of AEs have
suggested CZP is associated with statistically significantly more SAEs and serious infections than placebo.
Although the safety data for SEC appear promising, the fairly small number of trials for which data are
currently available means that there is still some uncertainty regarding its safety.
Economic modelling found that these new biologics can be considered a cost-effective use of NHS
resources when compared with the other therapies currently recommended by NICE for treating PsA.
Which treatment is most cost-effective depends on which previous treatments a patient has tried and not
responded to, the severity of the psoriasis symptoms, and the price of the treatment. Some of the studys
results were somewhat limited because not enough relevant clinical trial data were available.
Implications for service provision
l The clinical evidence indicates that SEC and CZP are only two of a number of effective treatments for
the treatment of active PsA.
l For patients with PsA and significant psoriasis, SEC may be one of the more effective biologic
treatments.
l The limited long-term evidence suggests some beneficial impact of radiographic disease progression.
Suggested research priorities
l Adequately powered randomised trials are needed to inform the clinical effectiveness of biologics in
biologic-experienced populations.
l Future trials should consider using newer composite disease outcome measures which have recently
been developed for PsA, such as the Composite Psoriatic arthritis Disease Activity Index, the PsA
disease activity score, the Disease Activity index for PSoriatic Arthritis (DAPSA) and minimal
disease activity.
l Further research is required to better elucidate the impact of biologics on radiographic disease
progression and HAQ-DI score in the long term. This requires the use of real-world data.
l With the continuing introduction of new biologic drugs and continued collection of data through
biologic registries, further analysis of the data to investigate patterns of drug switching and the
long-term effectiveness and safety of biologics is warranted. Radiographic outcomes should be
evaluated given the significance of radiographic damage as a measure of disease progression and
treatment effects.
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l Although randomised head-to-head trials  which directly compare different biologics  would yield
very useful results, their design and recruitment strategies may require very careful thought. Different
biologics are administered at different rates and time points; therefore, to achieve adequate blinding,
patients would need both their randomised treatment injections and placebo injections corresponding
to the comparator biologic regimen (i.e. patients would receive many more injections than would be
needed if they took a biologic outside a trial). When considering this, together with the known benefits
of biologics, and the likely large trial population that would be needed to detect efficacy differences
between different biologics, consideration of trial recruitment and compliance issues should be key
when conducting pilot studies. INF is delivered intravenously so would be even more difficult to study
in a head-to-head blinded trial.
l Larger-scale, longer-term studies are required to determine the HRQoL impact of response to treatment
and changes in functional capacity (measured using HAQ-DI) and psoriasis (measured using PASI).
These should include the full range of PsA severities.
l Larger-scale studies are required to determine the cost implications of response to treatment and
changes in functional capacity (measured using HAQ-DI) and psoriasis (measured using PASI). These
should be undertaken in a PsA population and include the full range of PsA severities.
CONCLUSIONS
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Appendix 1 Database search strategies
MEDLINE
Via Ovid: http://ovidsp.ovid.com/
Date range searched: 1946 to November week 3 2015.
Date searched: 1 December 2015.
Records retrieved: 712.
The Cochrane highly sensitive search strategy for identifying randomised trials in Ovid MEDLINE: sensitivity
maximising version was used to limit retrieval to clinical trials (lines 2535).148
The search was updated on 28 April 2016 and retrieved 749 records.
Search strategy
1. Arthritis, Psoriatic/ (4144)
2. (psoria$ adj2 (arthrit$ or arthropath$)).ti,ab. (6043)
3. 1 or 2 (6887)
4. (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7).af. (763)
5. 3 and 4 (53)
6. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (88)
7. 3 and 6 (18)
8. (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5).af. (431)
9. (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$).ed. (4,809,341)
10. 3 and 8 and 9 (89)
11. (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9).af. (92)
12. (2014$ or 2015$).ed. (1,668,230)
13. 3 and 11 and 12 (22)
14. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (536)
15. (2012$ or 2013$ or 2014$ or 2015$).ed. (3,233,078)
16. 3 and 14 and 15 (86)
17. (inflectra or remsima or CT-P13).af. (17)
18. 3 and 17 (1)
19. (etanercept or enbrel or 185243-69-0).af. (5831)
20. (infliximab or remicade or 170277-31-3).af. (9674)
21. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (4205)
22. 19 or 20 or 21 (14,458)
23. (2009$ or 2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$).ed. (5,535,938)
24. 3 and 22 and 23 (650)
25. randomized controlled trial.pt. (417,039)
26. controlled clinical trial.pt. (92,231)
27. randomized.ab. (308,924)
28. placebo.ab. (159,456)
29. drug therapy.fs. (1,860,741)
30. randomly.ab. (218,795)
31. trial.ab. (321,356)
32. groups.ab. (1,376,975)
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33. or/25-32 (3,513,844)
34. exp animals/ not humans/ (4,152,952)
35. 33 not 34 (2,995,700)
36. 5 or 7 or 10 or 13 or 16 or 18 or 24 (765)
37. 35 and 36 (712)
Key
/ = indexing term [medical subject heading (MeSH) heading].
exp = exploded indexing term (MeSH heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
af = terms in any field.
ed = entry date  date added to the database.
pt = publication type.
fs = floating subheading.
adj = terms next to each other (order specified).
adj2 = terms within two words of each other (any order).
MEDLINE In-Process & Other Non-Indexed Citations
Via Ovid: http://ovidsp.ovid.com/
Date range searched: 30 November 2015.
Date searched: on 1 December 2015.
Records retrieved: 157.
The search was updated on 28 April 2016 and retrieved 168 records.
Search strategy
1. Arthritis, Psoriatic/ (0)
2. (psoria$ adj2 (arthrit$ or arthropath$)).ti,ab. (655)
3. 1 or 2 (655)
4. (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7).af. (126)
5. 3 and 4 (16)
6. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (45)
7. 3 and 6 (10)
8. (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5).af. (97)
9. 3 and 8 (13)
10. (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9).af. (45)
11. 3 and 10 (25)
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12. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (148)
13. 3 and 12 (36)
14. (inflectra or remsima or CT-P13).af. (19)
15. 3 and 14 (0)
16. (etanercept or enbrel or 185243-69-0).af. (542)
17. (infliximab or remicade or 170277-31-3).af. (994)
18. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (631)
19. 16 or 17 or 18 (1560)
20. 3 and 19 (97)
21. 5 or 7 or 9 or 11 or 13 or 15 or 20 (157)
Key
/ = indexing term (MeSH heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
af = terms in any field.
adj = terms next to each other (order specified).
adj2 = terms within two words of each other (any order).
Cochrane Central Register of Controlled Trials
Via Wiley Online Library: http://onlinelibrary.wiley.com/
Issue 11 of 12, November 2015.
Date searched: 1 December 2015.
Records retrieved: 225.
The strategy below was used to search CENTRAL and CDSR.
The search was updated on 28 April 2016 and retrieved 249 records from CENTRAL.
Search strategy
#1 MeSH descriptor: [Arthritis, Psoriatic] this term only (199)
#2 (psoria* near/2 (arthrit* or arthropath*)):ti,ab,kw (560)
#3 #1 or #2 (560)
#4 (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7):ti,ab,kw (191)
#5 #3 and #4 (24)
#6 (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6):ti,ab,kw (124)
#7 #3 and #6 (28)
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#8 (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5):ti,ab,kw Publication Year from
2010 to 2015 (210)
#9 #3 and #8 (40)
#10 (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9):ti,ab,kw Publication Year
from 2014 to 2015 (35)
#11 #3 and #10 (21)
#12 (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0):ti,ab,kw Publication Year
from 2012 to 2015 (102)
#13 #3 and #12 (39)
#14 (inflectra or remsima or CT-P13):ti,ab,kw (15)
#15 #3 and #14 (4)
#16 (etanercept or enbrel or 185243-69-0):ti,ab,kw Publication Year from 2009 to 2015 (577)
#17 (infliximab or remicade or 170277-31-3):ti,ab,kw Publication Year from 2009 to 2015 (655)
#18 (adalimumab or humira or D2E7 or (D2 next E7) or 331731-18-1):ti,ab,kw Publication Year from
2009 to 2015 (722)
#19 #16 or #17 or #18 (1551)
#20 #3 and #19 (116)
#21 #5 or #7 or #9 or #11 or #13 or #15 or #20 (250)
#22 #5 or #7 or #9 or #11 or #13 or #15 or #20 in Cochrane Reviews (Reviews and Protocols) and
Trials (228)
Note that 228 results at line #22 include Cochrane Reviews or Protocols as well as trials from CENTRAL.
Key
MeSH descriptor = indexing term (MeSH heading).
* = truncation.
ti,ab,kw = terms in either title or abstract or keyword fields.
near/2 = terms within two words of each other (any order).
next = terms are next to each other.
Cochrane Database of Systematic Reviews
Via Wiley Online Library: http://onlinelibrary.wiley.com/
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Issue 12 of 12, December 2015.
Date searched: 1 December 2015.
Records retrieved: three.
See above under CENTRAL for search strategy used.
The search was updated on 28 April 2016 and retrieved three records from CDSR.
Database of Abstracts of Reviews of Effects
Via: www.crd.york.ac.uk/CRDWeb/
Date range searched: inception to 31 March 2015.
Date searched: 1 December 2015.
Records retrieved: 13.
The strategy below was used to search DARE and NHS EED.
As DARE and NHS EED were no longer receiving new records after 31 March 2015 these searches were
not updated.
Search strategy
1 MeSH DESCRIPTOR Arthritis, Psoriatic 55
2 ((psoria* NEAR2 (arthrit* or arthropath*))) 88
3 (((arthrit* or arthropath*) NEAR2 psoria*)) 68
4 (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7) 33
5 (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6) 7
6 (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5) where LPD from 1 January 2010 to
31 March 2015
31
7 (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9) where LPD from 1 January 2014 to
31 March 2015
1
8 (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0) where LPD from 1 January 2012 to
31 March 2015
22
9 (inflectra or remsima or CT-P13) 5
10 (etanercept or enbrel or 185243-69-0) where LPD from 1 January 2009 to 31 March 2015 137
11 (infliximab or remicade or 170277-31-3) where LPD from 1 January 2009 to 31 March 2015 204
12 (adalimumab or humira or D2E7 or D2-E7 or 331731-18-1) where LPD from 1 January 2009 to 31 March 2015 152
13 #1 OR #2 OR #3 92
14 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 321
15 #13 AND #14 39
16 (#13 AND #14) in DARE 13
17 (#13 AND #14) in NHS EED 8
18 (#13 AND #14) in HTA 18
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Key
l MeSH DESCRIPTOR = indexing term (MeSH heading).
l * = truncation.
l NEAR2 = terms within two words of each other (order specified).
EMBASE
Via Ovid: http://ovidsp.ovid.com/
Date range searched: 1974 to 2015 November 30.
Date searched: 1 December 2015.
Records retrieved: 639.
A search strategy developed by Lefebvre et al. to limit retrieval of studies to RCTs was used
(see lines 3852).149
The search was updated on 28 April 2016 and retrieved 744 records.
Search strategy
1. psoriatic arthritis/ (13,050)
2. (psoria$ adj2 (arthrit$ or arthropath$)).ti,ab. (11,246)
3. 1 or 2 (15,353)
4. certolizumab pegol/ (3506)
5. (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7).af. (4212)
6. 4 or 5 (4212)
7. 3 and 6 (548)
8. secukinumab/ (601)
9. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (679)
10. 8 or 9 (679)
11. 3 and 10 (199)
12. golimumab/ (2969)
13. (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5).af. (3054)
14. 12 or 13 (3054)
15. (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$).em. (8,021,136)
16. 3 and 14 and 15 (708)
17. apremilast/ (456)
18. (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9).af. (490)
19. 17 or 18 (490)
20. (2014$ or 2015$).em. (3,442,925)
21. 3 and 19 and 20 (170)
22. ustekinumab/ (2445)
23. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (2559)
24. 22 or 23 (2559)
25. (2012$ or 2013$ or 2014$ or 2015$).em. (6,165,443)
26. 3 and 24 and 25 (565)
27. (inflectra or remsima or CT-P13).af. (123)
28. 3 and 27 (21)
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29. etanercept/ (21,668)
30. (etanercept or enbrel or 185243-69-0).af. (22,500)
31. infliximab/ (33,968)
32. (infliximab or remicade or 170277-31-3).af. (34,643)
33. adalimumab/ (18,932)
34. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (19,317)
35. or/29-34 (47,513)
36. (2009$ or 2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$).em. (9,378,944)
37. 3 and 35 and 36 (3116)
38. random$.ti,ab. (1,044,993)
39. factorial$.ti,ab. (26,816)
40. crossover$.ti,ab. (55,631)
41. cross-over$.ti,ab. (24,911)
42. placebo$.ti,ab. (230,032)
43. (doubl$ adj blind$).ti,ab. (163,599)
44. (singl$ adj blind$).ti,ab. (16,962)
45. assign$.ti,ab. (278,181)
46. allocat$.ti,ab. (100,141)
47. volunteer$.ti,ab. (201,600)
48. Crossover Procedure/ (45,294)
49. double blind procedure/ (127,551)
50. Randomized Controlled Trial/ (392,436)
51. single blind procedure/ (21,379)
52. or/38-51 (1,651,603)
53. 7 or 11 or 16 or 21 or 26 or 28 or 37 (3624)
54. 52 and 53 (639)
55. animal/ (1,708,125)
56. exp animal experiment/ (1,900,985)
57. nonhuman/ (4,661,466)
58. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or
cats or bovine or sheep).ti,ab,sh. (5,213,728)
59. or/55-58 (7,584,705)
60. exp human/ (16,613,065)
61. human experiment/ (345,688)
62. 60 or 61 (16,614,514)
63. 59 not (59 and 62) (5,821,013)
64. 54 not 63 (639)
Key
/ = indexing term (Emtree heading).
exp = exploded indexing term (Emtree heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
af = all fields.
pt = publication type.
sh = subject heading field.
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adj2 = terms within two words of each other (any order).
em = entry week  date added to the database.
Health Technology Assessment database
Via: www.crd.york.ac.uk/CRDWeb/
Date range searched: inception to 31 March 2015.
Date searched: 1 December 2015.
Records retrieved: 18.
The search was updated on 28 April 2016 and retrieved 20 records.
Search strategy
1 MeSH DESCRIPTOR Arthritis, Psoriatic 55
2 ((psoria* NEAR2 (arthrit* or arthropath*))) 88
3 (((arthrit* or arthropath*) NEAR2 psoria*)) 68
4 (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7) 33
5 (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6) 7
6 (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5) where LPD from 1 January 2010 to
1 December 2015
31
7 (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9) where LPD from 1 January 2014 to
1 December 2015
4
8 (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0) where LPD from 1 January 2012 to
1 December 2015
28
9 (inflectra or remsima or CT-P13) 5
10 (etanercept or enbrel or 185243-69-0) where LPD from 1 January 2009 to 1 December 2015 176
11 (infliximab or remicade or 170277-31-3) where LPD from 1 January 2009 to 1 December 2015 267
12 (adalimumab or humira or D2E7 or D2-E7 or 331731-18-1) where LPD from 1 January 2009 to
1 December 2015
204
13 #1 OR #2 OR #3 92
14 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 403
15 #13 AND #14 46
16 (#13 AND #14) in HTA 18
Key
l MeSH DESCRIPTOR = indexing term (MeSH heading).
l * = truncation.
l NEAR2 = terms within two words of each other (order specified).
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PubMed
Via: www.ncbi.nlm.nih.gov/pubmed/
Date searched: 1 December 2015.
Records retrieved: 779.
The Cochrane highly sensitive search strategy for identifying randomised trials in PubMed sensitivity
maximising version was used to limit retrieval to clinical trials.148
The search was updated on 28 April 2016 and retrieved 844 records.
Search strategy
Search ((((((((((((Arthritis, Psoriatic[Mesh:noexp]) OR (psoria*[Title/Abstract] AND arthrit*[Title/Abstract]) OR
(psoria*[Title/Abstract] AND arthropath*[Title/Abstract]))) AND ((Certolizumab OR Cimzia OR CZP OR
CDP870 OR CDP-870 OR 428863-50-7)))) OR ((((Arthritis, Psoriatic[Mesh:noexp]) OR (psoria*[Title/
Abstract] AND arthrit*[Title/Abstract]) OR (psoria*[Title/Abstract] AND arthropath*[Title/Abstract]))) AND
((secukinumab OR Cosentyx OR AIN457 OR AIN-457 OR 1229022-83-6)))) OR ((((Arthritis, Psoriatic[Mesh:
noexp]) OR (psoria*[Title/Abstract] AND arthrit*[Title/Abstract]) OR (psoria*[Title/Abstract] AND arthropath*
[Title/Abstract]))) AND (((golimumab OR simponi OR CNTO148 OR CNTO-148 OR 476181-74-5)) AND
(2010/01/01[Date - Entrez] : 3000[Date - Entrez])))) OR ((((Arthritis, Psoriatic[Mesh:noexp]) OR (psoria*
[Title/Abstract] AND arthrit*[Title/Abstract]) OR (psoria*[Title/Abstract] AND arthropath*[Title/Abstract])))
AND (((apremilast OR otezla OR otezia OR CC10004 OR CC-10004 OR 608141-41-9)) AND (2014/01/
01[Date - Entrez] : 3000[Date - Entrez])))) OR ((((Arthritis, Psoriatic[Mesh:noexp]) OR (psoria*[Title/
Abstract] AND arthrit*[Title/Abstract]) OR (psoria*[Title/Abstract] AND arthropath*[Title/Abstract]))) AND
(((ustekinumab OR stelara OR CNTO1275 OR CNTO-1275 OR 815610-63-0)) AND (2012/01/01[Date -
Entrez] : 3000[Date - Entrez])))) OR ((((Arthritis, Psoriatic[Mesh:noexp]) OR (psoria*[Title/Abstract] AND
arthrit*[Title/Abstract]) OR (psoria*[Title/Abstract] AND arthropath*[Title/Abstract]))) AND ((inflectra OR
remsima OR CT-P13)))) OR ((((Arthritis, Psoriatic[Mesh:noexp]) OR (psoria*[Title/Abstract] AND arthrit*
[Title/Abstract]) OR (psoria*[Title/Abstract] AND arthropath*[Title/Abstract]))) AND (((((((etanercept OR
enbrel OR 185243-69-0))) AND (2009/01/01[Date - Entrez] : 3000[Date - Entrez]))) OR ((((infliximab OR
remicade OR 170277-31-3))) AND (2009/01/01[Date - Entrez] : 3000[Date - Entrez]))) OR ((((adalimumab
OR humira OR D2E7 OR D2-E7 OR 331731-18-1))) AND (2009/01/01[Date - Entrez] : 3000[Date -
Entrez])))))) AND ((((((((((randomized controlled trial[Publication Type]) OR controlled clinical trial[Publication
Type]) OR randomized[Title/Abstract]) OR placebo[Title/Abstract]) OR drug therapy[sh]) OR randomly[Title/
Abstract]) OR trial[Title/Abstract]) OR groups[Title/Abstract])) NOT (animals[mh] NOT humans[mh]))
Key
[Mesh] = exploded indexing term (MeSH heading).
[mh] = exploded indexing term (MeSH heading).
[Mesh:NoExp] = indexing term (MeSH heading) not exploded.
* = truncation.
[Title/Abstract]) = terms in either title or abstract fields.
[Publication Type] = terms in the publication type field.
[Date - Entrez] = date added to the database.
[sh] = subheading.
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Science Citation Index
Via Web of Science, Thomson Reuters: http://thomsonreuters.com/thomson-reuters-web-of-science/
Date range searched: 1900 to 28 November 2015.
Date searched: 1 December 2015.
Records retrieved: 712.
Strategy below was used to search SCI and the CPCI-S. As both databases were searched together the
records retrieved refer to results from both databases.
The search was updated on 28 April 2016 and retrieved 796 records from both databases.
Search strategy
# 27 712 #26 AND #25
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 26 1284 #18 OR #13 OR #11 OR #9 OR #7 OR #5 OR #3
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 25 5,529,680 #23 NOT #24
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 24 3,812,114 TS=(animal or animals or dog or dogs or hamster* or mice or mouse or rat or rats or bovine or
sheep or guinea*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 23 6,341,875 #22 OR #21 OR #20 OR #19
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 22 5,414,453 TS=(placebo* or random* or control* or prospectiv* or volunteer*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 21 486,891 TS=(clinic* SAME trial*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 20 227,219 TS=((singl* or doubl* or trebl* or tripl*) SAME (blind* or mask*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 19 1,143,892 TS=((study or studies) SAME design*)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 18 973 #17 AND #1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 17 13,195 #16 OR #15 OR #14
Indexes=SCI-EXPANDED, CPCI-S Timespan=2009-2015
# 16 4497 TS=(adalimumab or humira or D2E7 or (D2 NEAR/1 E7) or 331731-18-1)
Indexes=SCI-EXPANDED, CPCI-S Timespan=2009-2015
# 15 8564 TS=(infliximab or remicade or 170277-31-3)
Indexes=SCI-EXPANDED, CPCI-S Timespan=2009-2015
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# 14 4505 TS=(etanercept or enbrel or 185243-69-0)
Indexes=SCI-EXPANDED, CPCI-S Timespan=2009-2015
# 13 4 #12 AND #1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 12 48 TS=(inflectra or remsima or CT-P13)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 11 151 #10 AND #1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 10 632 TS=(ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0)
Indexes=SCI-EXPANDED, CPCI-S Timespan=2012-2015
# 9 61 #8 AND #1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 8 126 TS=(apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9)
Indexes=SCI-EXPANDED, CPCI-S Timespan=2014-2015
# 7 137 #6 AND #1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 6 594 TS=(golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5)
Indexes=SCI-EXPANDED, CPCI-S Timespan=2010-2015
# 5 54 #4 AND #1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 4 257 TS=(secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 3 101 #2 AND #1
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 2 1386 TS=(Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7)
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
# 1 9294 TS=(psoria* NEAR/2 (arthrit* or arthropath*))
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
* = truncation.
  = phrase search.
NEAR/2 = terms within two words of each other (any order).
SAME = terms within the same sentence.
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Ongoing, unpublished or grey literature search strategies
ClinicalTrials.gov
https://clinicaltrials.gov/
Date searched: 7 December 2015.
Records retrieved: 99.
The searches were updated on 28 April 2016 and retrieved 110 records.
Search strategy
1. Six studies found for: ((psoriatic arthritis OR psoriatic arthropathy) AND (Certolizumab OR Cimzia OR
CZP OR CDP870 OR CDP-870 OR 428863-50-7))
2. Eleven studies found for: ((psoriatic arthritis OR psoriatic arthropathy) AND (secukinumab OR
Cosentyx OR AIN457 OR AIN-457 OR 1229022-83-6))
3. Thirteen studies found for: (psoriatic arthritis OR psoriatic arthropathy) AND (golimumab OR simponi
OR CNTO148 OR CNTO-148 OR 476181-74-5) | received from 1 January 2010 to 7 December 2015
4. Two studies found for: (psoriatic arthritis OR psoriatic arthropathy) AND (apremilast OR otezla OR otezia
OR CC10004 OR CC-10004 OR 608141-41-9) | received from 1 January 2014 to 7 December 2015
5. Three studies found for: (psoriatic arthritis OR psoriatic arthropathy) AND (ustekinumab OR stelara OR
CNTO1275 OR CNTO-1275 OR 815610-63-0) | received from 1 January 2012 to 7 December 2015
6. Two studies found for: (psoriatic arthritis OR psoriatic arthropathy) AND (inflectra OR remsima OR
CT-P13)
7. Eighteen studies found for: (psoriatic arthritis OR psoriatic arthropathy) AND (etanercept OR enbrel
OR 185243-69-0) | received from 1 January 2009 to 7 December 2015
8. Eleven studies found for: (psoriatic arthritis OR psoriatic arthropathy) AND (infliximab OR remicade
OR 170277-31-3) | received from 1 January 2009 to 7 December 2015
9. Thirty-three studies found for: (psoriatic arthritis OR psoriatic arthropathy) AND (adalimumab OR
humira OR D2E7 OR D2-E7 OR 331731-18-1) | received from 1 January 2009 to 7 December 2015
Conference Proceedings Citation Index: Science
Via Web of Science, Thomson Reuters: http://thomsonreuters.com/thomson-reuters-web-of-science/
Date range searched: 1990 to 28 November 2015.
Date searched: 1 December 2015.
Records retrieved: 712.
See above under SCI for search strategy used. As both databases were searched together the records
retrieved refers to results from both databases.
The search was updated on 28 April 2016 and retrieved 796 records from both databases.
EU Clinical Trials Register
www.clinicaltrialsregister.eu/ctr-search/search
Date searched: 7 December 2015.
Records retrieved: 29.
The searches were updated on 28 April 2016 and retrieved two new records.
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Search strategy
1. Thirteen result(s) found for: (psoriatic arthritis OR psoriatic arthropathy) AND (Certolizumab OR
Cimzia OR CZP OR CDP870 OR CDP-870 OR 428863-50-7 OR secukinumab OR Cosentyx OR AIN457
OR AIN-457 OR 1229022-83-6 OR inflectra OR remsima OR CT-P13)
2. Four result(s) found for: (psoriatic arthritis OR psoriatic arthropathy) AND (golimumab OR simponi OR
CNTO148 OR CNTO-148 OR 476181-74-5) date limit 01/01/2010-07/12/2015
3. No result(s) found for: (psoriatic arthritis OR psoriatic arthropathy) AND (apremilast OR otezla OR
otezia OR CC10004 OR CC-10004 OR 608141-41-9) date limits  01/01/2014-07/12/2015
4. Three result(s) found for: (psoriatic arthritis OR psoriatic arthropathy) AND (ustekinumab OR stelara
OR CNTO1275 OR CNTO-1275 OR 815610-63-0) date limits 01/01/2012-07/12/2015
5. Nine result(s) found for: (psoriatic arthritis OR psoriatic arthropathy) AND (etanercept OR enbrel OR
185243-69-0 OR infliximab OR remicade OR 170277-31-3 OR adalimumab OR humira OR D2E7 OR
D2-E7 OR 331731-18-1) date limits 01/01/2009-07/12/2015
PROSPERO
www.crd.york.ac.uk/PROSPERO/
Date searched: 4 December 2015.
Records retrieved: 25.
Search: psoriatic arthritis in all fields.
The search was updated on 28 April 2016 and retrieved nine new records.
World Health Organization’s International Clinical Trials Registry Platform
www.who.int/ictrp/search/en/
Date searched: 7 December 2015.
Records retrieved: 113.
The searches were updated on 28 April 2016 and retrieved five new records.
Search strategy
1. Condition: (psoriatic arthritis OR psoriatic arthropathy) AND Intervention: (Certolizumab OR Cimzia OR
CZP OR CDP870 OR CDP-870 OR 428863-50-7 OR secukinumab OR Cosentyx OR AIN457 OR AIN-457
OR 1229022-83-6 OR inflectra OR remsima OR CT-P13)
Twenty-nine trials found.
2. Condition: (psoriatic arthritis OR psoriatic arthropathy) AND Intervention: (golimumab OR simponi OR
CNTO148 OR CNTO-148 OR 476181-74-5) limits 1 January 2010 to 7 December 2015
Sixteen trials found.
3. Condition: (psoriatic arthritis OR psoriatic arthropathy) AND Intervention: (apremilast or otezla or otezia
or CC10004 or CC-10004 or 608141-41-9) limits 1 January 2014 to 7 December 2015
No records found.
4. Condition: (psoriatic arthritis OR psoriatic arthropathy) AND Intervention: (ustekinumab or stelara or
CNTO1275 or CNTO-1275 or 815610-63-0) limits 1 January 2012 to 7 December 2015
Two trials found.
5. Condition: (psoriatic arthritis OR psoriatic arthropathy) AND Intervention: (etanercept OR enbrel OR
185243-69-0 OR infliximab OR remicade OR 170277-31-3 OR adalimumab OR humira OR D2E7 OR
D2-E7 OR 331731-18-1) limits 1 January 2009 to 7 December 2015
Eighty-six trials found.
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Extra searches for systematic reviews
As DARE ceased at the end of March 2015, searches for systematic reviews were carried out on MEDLINE
and EMBASE to ensure that any relevant systematic reviews were identified.
EMBASE
Via Ovid: http://ovidsp.ovid.com/
Date range searched: 1974 to 30 November 2015.
Date searched: 1 December 2015.
Records retrieved: 82.
The following strategy includes a search strategy designed to locate reviews for DARE in Ovid EMBASE
(see lines 35129).150
The search was updated on 28 April 2016 and retrieved 139 records.
Search strategy
1. psoriatic arthritis/ (13,050)
2. (psoria$ adj2 (arthrit$ or arthropath$)).ti,ab. (11,246)
3. 1 or 2 (15,353)
4. certolizumab pegol/ (3506)
5. (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7).af. (4212)
6. 4 or 5 (4212)
7. 3 and 6 (548)
8. secukinumab/ (601)
9. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (679)
10. 8 or 9 (679)
11. 3 and 10 (199)
12. golimumab/ (2969)
13. (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5).af. (3054)
14. 12 or 13 (3054)
15. 3 and 14 (806)
16. apremilast/ (456)
17. (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9).af. (490)
18. 16 or 17 (490)
19. 3 and 18 (231)
20. ustekinumab/ (2445)
21. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (2559)
22. 20 or 21 (2559)
23. 3 and 22 (754)
24. (inflectra or remsima or CT-P13).af. (123)
25. 3 and 24 (21)
26. etanercept/ (21,668)
27. (etanercept or enbrel or 185243-69-0).af. (22,500)
28. infliximab/ (33,968)
29. (infliximab or remicade or 170277-31-3).af. (34,643)
30. adalimumab/ (18,932)
31. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (19,317)
32. or/26-31 (47,513)
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33. 3 and 32 (4302)
34. 7 or 11 or 15 or 19 or 23 or 25 or 33 (4863)
35. systematic$ review$.ti,ab. (95,091)
36. systematic$ literature review$.ti,ab. (6884)
37. systematic review/ (98,895)
38. systematic review (topic)/ (13,418)
39. meta analysis/ (102,483)
40. meta analysis (topic)/ (23,719)
41. meta-analytic$.ti,ab. (5089)
42. meta-analysis.ti,ab. (92,607)
43. metanalysis.ti,ab. (351)
44. metaanalysis.ti,ab. (4420)
45. meta analysis.ti,ab. (92,607)
46. meta-synthesis.ti,ab. (333)
47. metasynthesis.ti,ab. (173)
48. meta synthesis.ti,ab. (333)
49. meta-regression.ti,ab. (4113)
50. metaregression.ti,ab. (569)
51. meta regression.ti,ab. (4113)
52. (synthes$ adj3 literature).ti,ab. (2047)
53. (synthes$ adj3 evidence).ti,ab. (5649)
54. (synthes$ adj2 qualitative).ti,ab. (939)
55. integrative review.ti,ab. (1084)
56. data synthesis.ti,ab. (10,020)
57. (research synthesis or narrative synthesis).ti,ab. (1100)
58. (systematic study or systematic studies).ti,ab. (9606)
59. (systematic comparison$ or systematic overview$).ti,ab. (2447)
60. (systematic adj2 search$).ti,ab. (14,698)
61. systematic$ literature research$.ti,ab. (172)
62. (review adj3 scientific literature).ti,ab. (1182)
63. (literature review adj2 side effect$).ti,ab. (11)
64. (literature review adj2 adverse effect$).ti,ab. (2)
65. (literature review adj2 adverse event$).ti,ab. (9)
66. (evidence-based adj2 review).ti,ab. (2599)
67. comprehensive review.ti,ab. (9891)
68. critical review.ti,ab. (13,722)
69. critical analysis.ti,ab. (6783)
70. quantitative review.ti,ab. (596)
71. structured review.ti,ab. (712)
72. realist review.ti,ab. (93)
73. realist synthesis.ti,ab. (61)
74. (pooled adj2 analysis).ti,ab. (10,726)
75. (pooled data adj6 (studies or trials)).ti,ab. (1727)
76. (medline and (inclusion adj3 criteria)).ti,ab. (13,602)
77. (search adj (strateg$ or term$)).ti,ab. (23,159)
78. or/35-77 (313,391)
79. medline.ab. (82,933)
80. pubmed.ab. (59,842)
81. cochrane.ab. (49,544)
82. embase.ab. (49,331)
83. cinahl.ab. (14,619)
84. psyc?lit.ab. (963)
85. psyc?info.ab. (11,667)
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86. lilacs.ab. (4162)
87. (literature adj3 search$).ab. (41,110)
88. (database$ adj3 search$).ab. (38,127)
89. (bibliographic adj3 search$).ab. (1761)
90. (electronic adj3 search$).ab. (13,296)
91. (electronic adj3 database$).ab. (18,556)
92. (computeri?ed adj3 search$).ab. (3348)
93. (internet adj3 search$).ab. (2745)
94. included studies.ab. (12,116)
95. (inclusion adj3 studies).ab. (10,022)
96. inclusion criteria.ab. (73,458)
97. selection criteria.ab. (23,235)
98. predefined criteria.ab. (1684)
99. predetermined criteria.ab. (980)
100. (assess$ adj3 (quality or validity)).ab. (62,963)
101. (select$ adj3 (study or studies)).ab. (56,413)
102. (data adj3 extract$).ab. (46,092)
103. extracted data.ab. (9890)
104. (data adj2 abstracted).ab. (5666)
105. (data adj3 abstraction).ab. (1428)
106. published intervention$.ab. (148)
107. ((study or studies) adj2 evaluat$).ab. (168,567)
108. (intervention$ adj2 evaluat$).ab. (9530)
109. confidence interval$.ab. (302,095)
110. heterogeneity.ab. (130,769)
111. pooled.ab. (71,894)
112. pooling.ab. (10,965)
113. odds ratio$.ab. (209,779)
114. (Jadad or coding).ab. (151,963)
115. evidence-based.ti,ab. (89,257)
116. or/79-115 (1,249,442)
117. review.pt. (2,121,803)
118. 116 and 117 (155,285)
119. review.ti. (354,800)
120. 116 and 119 (79,064)
121. (review$ adj10 (papers or trials or trial data or studies or evidence or intervention$ or evaluation$ or
outcome$ or findings)).ti,ab. (349,461)
122. (retriev$ adj10 (papers or trials or studies or evidence or intervention$ or evaluation$ or outcome$ or
findings)).ti,ab. (17,449)
123. 78 or 118 or 120 or 121 or 122 (648,468)
124. letter.pt. (918,884)
125. editorial.pt. (497,918)
126. 124 or 125 (1,416,802)
127. 123 not 126 (636,540)
128. (animal/ or nonhuman/) not exp human/ (4,935,282)
129. 127 not 128 (611,316)
130. 34 and 129 (558)
131. 2015$.em. (1,962,120)
132. 130 and 131 (82)
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Key
/ = indexing term (Emtree heading).
exp = exploded indexing term (Emtree heading).
$ = truncation.
? = optional wildcard  one or no characters.
ti,ab = terms in either title or abstract fields.
af = all fields.
pt = publication type.
sh = subject heading field.
adj2 = terms within two words of each other (any order).
em = entry week  date added to the database.
MEDLINE
Via Ovid: http://ovidsp.ovid.com/
Date range searched: 1946 to November week 3 2015.
Date searched: 1 December 2015.
Records retrieved: nine.
The following strategy includes a search strategy designed to locate reviews for DARE in Ovid MEDLINE
(see lines 2298).150
The search was updated on 28 April 2016 and retrieved 25 records.
Search strategy
1. Arthritis, Psoriatic/ (4144)
2. (psoria$ adj2 (arthrit$ or arthropath$)).ti,ab. (6043)
3. 1 or 2 (6887)
4. (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7).af. (763)
5. 3 and 4 (53)
6. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (88)
7. 3 and 6 (18)
8. (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5).af. (431)
9. 3 and 8 (104)
10. (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9).af. (92)
11. 3 and 10 (29)
12. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (536)
13. 3 and 12 (114)
14. (inflectra or remsima or CT-P13).af. (17)
15. 3 and 14 (1)
16. (etanercept or enbrel or 185243-69-0).af. (5831)
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17. (infliximab or remicade or 170277-31-3).af. (9674)
18. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (4205)
19. 16 or 17 or 18 (14,458)
20. 3 and 19 (1129)
21. 5 or 7 or 9 or 11 or 13 or 15 or 20 (1267)
22. systematic$ review$.ti,ab. (62,767)
23. meta-analysis as topic/ (15,063)
24. meta-analytic$.ti,ab. (3875)
25. meta-analysis.ti,ab,pt. (80,432)
26. metanalysis.ti,ab. (130)
27. metaanalysis.ti,ab. (1122)
28. meta analysis.ti,ab. (61,044)
29. meta-synthesis.ti,ab. (245)
30. metasynthesis.ti,ab. (143)
31. meta synthesis.ti,ab. (245)
32. meta-regression.ti,ab. (2799)
33. metaregression.ti,ab. (315)
34. meta regression.ti,ab. (2799)
35. (synthes$ adj3 literature).ti,ab. (1446)
36. (synthes$ adj3 evidence).ti,ab. (4369)
37. integrative review.ti,ab. (943)
38. data synthesis.ti,ab. (7556)
39. (research synthesis or narrative synthesis).ti,ab. (821)
40. (systematic study or systematic studies).ti,ab. (6891)
41. (systematic comparison$ or systematic overview$).ti,ab. (1891)
42. evidence based review.ti,ab. (1253)
43. comprehensive review.ti,ab. (6999)
44. critical review.ti,ab. (10,688)
45. quantitative review.ti,ab. (474)
46. structured review.ti,ab. (490)
47. realist review.ti,ab. (58)
48. realist synthesis.ti,ab. (44)
49. or/22-48 (164,741)
50. review.pt. (2,034,742)
51. medline.ab. (60,574)
52. pubmed.ab. (36,054)
53. cochrane.ab. (34,003)
54. embase.ab. (33,609)
55. cinahl.ab. (11,111)
56. psyc?lit.ab. (871)
57. psyc?info.ab. (7994)
58. (literature adj3 search$).ab. (27,401)
59. (database$ adj3 search$).ab. (26,195)
60. (bibliographic adj3 search$).ab. (1303)
61. (electronic adj3 search$).ab. (9505)
62. (electronic adj3 database$).ab. (11,568)
63. (computeri?ed adj3 search$).ab. (2654)
64. (internet adj3 search$).ab. (1771)
65. included studies.ab. (7960)
66. (inclusion adj3 studies).ab. (7019)
67. inclusion criteria.ab. (37,933)
68. selection criteria.ab. (21,191)
69. predefined criteria.ab. (1159)
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70. predetermined criteria.ab. (756)
71. (assess$ adj3 (quality or validity)).ab. (42,982)
72. (select$ adj3 (study or studies)).ab. (39,117)
73. (data adj3 extract$).ab. (31,055)
74. extracted data.ab. (7660)
75. (data adj2 abstracted).ab. (3467)
76. (data adj3 abstraction).ab. (878)
77. published intervention$.ab. (108)
78. ((study or studies) adj2 evaluat$).ab. (110,270)
79. (intervention$ adj2 evaluat$).ab. (6324)
80. confidence interval$.ab. (243,474)
81. heterogeneity.ab. (97,658)
82. pooled.ab. (48,633)
83. pooling.ab. (7960)
84. odds ratio$.ab. (161,734)
85. (Jadad or coding).ab. (123,582)
86. or/51-85 (846,853)
87. 50 and 86 (138,063)
88. review.ti. (262,483)
89. 88 and 86 (51,780)
90. (review$ adj4 (papers or trials or studies or evidence or intervention$ or evaluation$)).ti,ab. (105,599)
91. 49 or 87 or 89 or 90 (305,581)
92. letter.pt. (928,972)
93. editorial.pt. (379,192)
94. comment.pt. (631,763)
95. 92 or 93 or 94 (1,437,876)
96. 91 not 95 (297,485)
97. exp animals/ not humans/ (4,152,952)
98. 96 not 97 (287,212)
99. 21 and 98 (96)
100. 2015$.ed. (777,364)
101. 99 and 100 (9)
Key
/ = indexing term (MeSH heading).
exp = exploded indexing term (MeSH heading).
$ = truncation.
? = optional wildcard  one or no characters.
ti,a. = terms in either title or abstract fields.
af = terms in any field.
ed = entry date  date added to the database.
pt = publication type.
adj = terms next to each other (order specified).
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
© Queens Printer and Controller of HMSO 2017. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
217
Appendix 2 Inclusion and exclusion criteria of the
included studies
Study and drug Inclusion criteria Exclusion criteria
FUTURE 2;48 SEC l Active PsA with three or more tender and
swollen joints and met the CASPAR, despite
previous treatment with NSAIDs, DMARDs or
anti-TNFs
l Concomitant oral corticosteroids (≤ 10mg/day
prednisone or equivalent) and MTX
(≤ 25 mg/week) were allowed provided the
dose was stable for at least 2 weeks and at
least 4 weeks before randomisation
l Previously received biologic immunomodulating
agents, except for those targeting TNF
l Previously been treated with three or more
different TNF inhibitors
l Ongoing use of prohibited psoriasis
treatments/medications (e.g. topical
corticosteroids, ultraviolet therapy) at
randomisation [the following washout periods
were required to be observed: oral or topical
retinoids 4 weeks; photochemotherapy
4 weeks; phototherapy 2 weeks; topical skin
treatments (except in face, eyes, scalp, and
genital area during screening, only
corticosteroids with mild to moderate
potency) 2 weeks]
l Active, ongoing inflammatory diseases other
than PsA
l Active TB (patients with latent TB had to
commence treatment for latent TB before
study entry)
l A history of hepatitis B or C, human
immunodeficiency virus, or any active
systemic infection within the 2 weeks
before baseline
l History of ongoing, chronic or recurrent
infections, or evidence of active TB infection
l History of malignancy within the past 5 years
(except for basal cell carcinoma or actinic
keratosis that has been treated with no
evidence of recurrence in the past 3 months, in
situ cervical cancer or non-invasive malignant
colon polyps that had been removed)
l Underlying metabolic, haematological, renal,
hepatic, pulmonary, neurological, endocrine,
cardiac, infectious or gastrointestinal
conditions which, in the opinion of the
investigator, immunocompromised the
patient and/or placed the patient at
unacceptable risk for participation
l Pregnant or nursing (lactating) women and
women of child-bearing potential unwilling to
use effective contraception during the study
and for 16 weeks after stopping treatment
ERASURE;49,151
SEC
l Moderate and severe plaque-type psoriasis
diagnosed for at least 6 months
l Severity of psoriasis disease meeting all of the
following three criteria:
¢ PASI score of ≥ 12 units
¢ Investigators Global Assessment score
of ≥ 3
¢ total BSA affected of ≥ 10%
l Inadequate control by prior use of topical
treatment, phototherapy and/or
systemic therapy
l Current forms of psoriasis other than chronic
plaque-type psoriasis (e.g. pustular,
erythrodermic, guttate)
l Current drug-induced psoriasis
l Previous use of SEC or any drug that targets
IL-17 or the IL-17 receptor
l MTX, ciclosporin A,
corticosteroids, cyclophosphamide
l Significant medical problems such as
uncontrolled hypertension, congestive heart
failure or a condition that significantly
immunocompromises the subject
l Haematological abnormalities
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Study and drug Inclusion criteria Exclusion criteria
l History of an ongoing, chronic or recurrent
infectious disease, or evidence of
untreated TB
l History of lymphoproliferative disease or
history of malignancy of any organ system
within the past 5 years
l Pregnant or nursing (lactating) women
l Subjects not willing to limit ultraviolet light
exposure during the study
FIXTURE;49,151
SEC
l Moderate and severe plaque-type psoriasis
diagnosed for at least 6 months
l Severity of psoriasis disease meeting all of the
following three criteria:
¢ PASI score of ≥ 12 units
¢ Investigators Global Assessment score
of ≥ 3
¢ total BSA affected of ≥ 10%
l Inadequate control by prior use of topical
treatment, phototherapy and/or
systemic therapy
l Previous use of ETN
l Current forms of psoriasis other than chronic
plaque-type psoriasis (e.g. pustular,
erythrodermic, guttate)
l Current drug-induced psoriasis
l Previous use of SEC or any drug that targets
IL-17 or the IL-17 receptor
l MTX, ciclosporin A, corticosteroids,
cyclophosphamide
l Significant medical problems such as
uncontrolled hypertension, congestive heart
failure or a condition that significantly
immunocompromises the subject
l Haematological abnormalities
l History of an ongoing, chronic or recurrent
infectious disease, or evidence of
untreated TB
l History of lymphoproliferative disease or
history of malignancy of any organ system
within the past 5 years
l Pregnant or nursing (lactating) women
l Subjects not willing to limit ultraviolet light
exposure during the study
CLEAR;62,63 SEC l Moderate and severe plaque-type psoriasis
diagnosed for at least 6 months
l Patients eligible for systemic therapy with
inadequately controlled psoriasis
l Forms of psoriasis other than plaque-type
psoriasis
l Previous exposure to SEC, UST, or other
biologic drugs targeting IL-17A or IL-17
receptor A
aSPIRIT-P1;57,67
ADA
l Presents with established diagnosis of active
PsA for at least 6 months, and currently
meets CASPAR
l Active PsA defined as the presence of at least
three tender and at least three swollen joints
l Presence of active psoriatic skin lesion or a
history of plaque psoriasis
l Men must agree to use a reliable method of
birth control or remain abstinent during
the study
l Women must agree to use reliable birth
control or remain abstinent during the study
and for at least 12 weeks after stopping
treatment
l Current or prior use of biologic agents for
treatment of plaque psoriasis or PsA
l Inadequate response to four or more
cDMARDs
l Current use of more than one cDMARD
l Evidence of active inflammatory arthritic
syndromes or spondyloarthropathies other
than PsA
l Have participated in any study with IL-17
antagonists, including ixekizumab
l Serious disorder or illness other than PsA
l Serious infection within the last 3 months
l Breastfeeding or nursing (lactating) women
RAPID-PsA;47
CZP
l Active PsA for at least 6 months defined by
the CASPAR
l Active joint disease, defined as three or more
tender and swollen joints
An ESR of ≥ 28mm/hour (Westergren) or a CRP
concentration greater than the upper limit of
normal (7.9 mg/l)
l Have previously failed one or more DMARD
l Active psoriatic skin lesions or a documented
history of psoriasis
l Latent or active TB unless prophylactic
treatment of latent TB had begun ≥ 4 weeks
prior to baseline
l Chronic or clinically significant infections,
malignancy, or demyelinating disease of the
central nervous system
l Previous exposure to two or more biologics
or one or more TNF inhibitors for the
treatment of PsA or psoriasis, or primary
failure of a prior TNF inhibitor (defined as no
response within the first 12 weeks of
treatments with the anti-TNF) according to
investigator assessment
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Study and drug Inclusion criteria Exclusion criteria
l Concomitant MTX (≤ 25mg/week),
sulfasalazine (≤ 3 g/day), leflunomide
(≤ 20mg/day) or prednisone (≤ 10 mg/day)
were allowed provided the dose was stable
and started ≥ 28 days before the baseline visit
l Diagnosis of any other inflammatory arthritis
l The use of DMARDs other than MTX,
sulfasalazine, leflunomide, or intra-articular
corticosteroids, was prohibited within 28 days
of the baseline visit and during the trial
l Use of combinations of MTX, sulfasalazine
and leflunomide was not permitted
l Concurrent use of topical, systemic or
phototherapy treatments was not permitted
up to week 48 of the study
PALACE 1, 2,
3;60,61,65 APR
l Three or more tender and swollen joints
l CASPAR
l Stable dose (oral or parenteral MTX ≤ 25mg/
week; leflunomide ≤ 20mg/day ; sulfasalazine
≤ 2 g/day; or a combination) for at least
4 weeks before the screening visit
l Prednisone ≤ 10mg/day or equivalent for at
least 1 month
l NSAIDs ≥ 2 weeks
l At least one ≥ 2-cm plaque psoriasis lesionb
l Three or more agents for PsA (DMARDs or
biologics) or one or more anti-TNF
l History of or current
i. inflammatory rheumatic or autoimmune
joint disease other than PsA
ii. erythrodermic guttate or generalised
pustular psoriasis
iii. were functional class IV, defined by the
ACR Classification of Functional Status in
Rheumatoid Arthritis
iv. had used phototherapy or DMARDs other
than MTX, leflunomide or sulfasalazine
within 4 weeks of randomisation
v. had used ADA, ETN, GOL, INF, CZP or
tocilizumab within 12 weeks of
randomisation or alefacept or UST within
24 weeks of randomisation
vi. had prior treatment with APR
l Topical therapy for psoriasis within 2 weeks
l Patients with active TB or a history of
incompletely treated TB
PSUMMIT 2;59,66
UST
l ≥ 3 months (DMARD) therapy, ≥ 4 weeks
(NSAIDs) therapy and/or ≥ 8 (ETN, ADA, GOL,
CZP) or 14 (INF) continuous weeks
l ≥ 5/66 swollen and ≥ 5/68 tender joints
l A CRP concentration of ≥ 6.0 mg/l (modified
to ≥ 3.0 mg/l after study start, upper limit of
normal 10 mg/l)
l Active/documented history of plaque psoriasis
l Concomitant MTX was permitted if started
≥ 3 months prior to study start and at a stable
dose (≤ 25mg/week) for ≥ 4 weeks
l Have other inflammatory diseases, including
but not limited to RA, ankylosing spondylitis,
systemic lupus erythematosus or Lyme
disease
l Have used any therapeutic agent targeted at
reducing IL-12 or IL-23 agent or abatacept
l Have a medical history of latent or active
granulomatous infection, including TB,
histoplasmosis or coccidioidomycosis, prior
to screening
l Have any known malignancy or have a
history of malignancy (with the exception of
basal cell carcinoma, squamous cell
carcinoma in situ of the skin, or cervical
carcinoma in situ) that has been treated with
no evidence of recurrence, or squamous cell
carcinoma of the skin that has been treated
with no evidence of recurrence within
5 years of the beginning of the study
PSUMMIT 1;66
UST
l ≥ 5 tender and swollen joints, a CRP
concentration of ≥ 3.0 mg/l, documented
history of plaque psoriasis
l MTX ≤ 25 mg/week at least 3 months prior
l If currently not using MTX, must have not
received MTX for at least 4 weeks prior to the
first administration of the study agent
l Have other inflammatory diseases, including
but not limited to RA, ankylosing spondylitis,
systemic lupus erythematosus, or Lyme
disease
l Have used any therapeutic agent targeted at
reducing IL-12 or IL-23, including but not
limited to UST and briakinumab (ABT-874)
l Have used any biologic agents that are
targeted for reducing TNF-α, including but
not limited to INF, ETN, ADA and GOL
l Have a medical history of latent or active
granulomatous infection
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Study and drug Inclusion criteria Exclusion criteria
l Have any known malignancy or have a
history of malignancy (with the exception of
basal cell carcinoma, squamous cell
carcinoma in situ of the skin, or cervical
carcinoma in situ) that has been treated with
no evidence of recurrence, or squamous cell
carcinoma of the skin that has been treated
with no evidence of recurrence within
5 years of the beginning of the study
Atteno et al.,
2010;64 ETN vs.
ADA vs. INF
l Patients aged > 18 years with active PsA who
experienced an inadequate response to a
previous DMARD therapy
l CASPAR
l Previous usage of anti-TNF-α inhibitors
l The usage of DMARDs other than
sulfasalazine, MTX, azathioprine, and
leflunomide within 4 weeks of enrolment
l The usage of > 10mg prednisone daily
l Variation of dosage of NSAIDs or prednisone
within 2 weeks of enrolment
GO-REVEAL;50
GOL
l Three or more swollen joints and three
tender joints
l Negative rheumatoid factor, at least one
subset of PsA and the presence of plaque
psoriasis with a qualifying lesion at least 2 cm
in diameter
l Previous use of anti-TNF agents, rituximab,
natalizumab, or cytotoxic agents was
prohibited
l Stable doses of MTX, NSAIDs and
corticosteroids (prednisone 10mg/day)
were allowed
l Patients with latent TB could participate if they
were treated for latent TB prior to or
concurrent with administration of the
study agent
l No prior treatment with biologic anti-TNF
agents (INF, ETN, ADA)
l No treatment with alefacept or efalizumab
within 3 months prior to the first study
drug injection
l No DMARDs other than MTX, or
immunosuppressive drugs within 4 weeks
prior to the first study drug injection
Genovese et al.,
2007;56 ADA
l Three or more swollen and tender joints
l Plaque psoriasis
l Had received/receiving concomitant DMARD
therapy or had a history of DMARD therapy
with an inadequate response
l Prednisone ≤ 10mg/day and had been stable
l Stable dose of MTX ≤ 30mg/week and other
DMARDs except ciclosporin and tacrolimus
was allowed if within 4 weeks of the
baseline visit
l History of previous anti-TNF therapy
l Intra-articular injections or i.v. infusions of
corticosteroids within 4 weeks of baseline
l Topical psoriasis therapies within 2 weeks
of baseline
l Ultraviolet A phototherapy, using tanning
booth within 2 weeks
l Oral retinoids within 4 weeks
l Alefacept or siplizumab within 12 weeks
l Any other biologic or investigational therapy
within 6 weeks
l Currently using or likely to need
antiretroviral therapy
l Patients with persistent or severe infections
or a history of active TB, or who had an
active non-psoriatic skin disease
l Significant history of cardiac, renal,
neurological, psychiatric, endocrinological,
metabolic, or hepatic disease; neurological
symptoms suggestive of central nervous
systemic demyelinating disease; and a
history of malignancy other than carcinoma
in situ of the cervix or adequately treated
non-metastatic squamous or basal cell
skin carcinoma
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Study and drug Inclusion criteria Exclusion criteria
ADEPT;55 ADA l Three or more swollen and tender joints
l Patients required to have inadequate response
or intolerance to NSAIDs
l MTX was allowed only if it had been taken for
at least 3 months with the dosage stable for
at least 4 weeks prior to the baseline visit
l Treatment within 4 weeks of the baseline
visit with ciclosporin, tacrolimus, DMARDs
other than MTX or oral retinoids
l Topical treatments for psoriasis within
2 weeks of baseline, other than medicated
shampoos or low-potency topical steroids
l Concurrent treatment with MTX at dosages
> 30mg/week and/or corticosteroids in a
prednisone-equivalent dosage of > 10mg/day
l Anti-TNF therapy
l History of neurological symptoms suggestive
of central nervous system demyelinating
disease, a history of active TB or listeriosis, or
the presence of a severe infection requiring
hospitalisation or treatment with i.v.
antibiotics within 30 days or oral antibiotics
within 14 days of study entry
IMPACT;51 INF Diagnosed PsA for ≥ 6 months
l Previous failure of treatment with one or
more DMARDs
l Active arthritis with five or more tender and
swollen joints
An ESR of ≥ 28mm/hour, a CRP concentration
of ≥ 15mg/l, and/or morning stiffness lasting
≥ 45 minutes
l Negative results of serum tests for rheumatoid
factor and negative results for active or latent TB
l Patients were allowed to receive concomitant
therapy with one of the following DMARDs:
MTX (dosage of ≥ 15mg/week, with folic acid
supplementation), leflunomide, sulfasalazine,
hydroxychloroquine, intramuscular gold,
penicillamine, or azathioprine
l Standard topical treatments for psoriatic
lesions (e.g. topical steroids) were permitted
l Use of intramuscular or i.v. corticosteroids,
ciclosporin, or tacrolimus within 4 weeks of
screening and throughout the study
l Therapy with psoralen ultraviolet A
l Received any investigational drug within
3 months of screening or any previous
treatment with a monoclonal antibody or
fusion protein
IMPACT 2;52 INF l Diagnosed PsA for ≥ 6 months
l Active arthritis with five or more tender and
swollen joints
l CRP concentrations of at least 15 mg/l and/or
morning stiffness lasting ≥ 45 minutes
l Inadequate response to current or previous
DMARDs or NSAIDs
l Active plaque psoriasis with at least one
qualifying target lesion at least 2 cm
in diameter
l Negative test for rheumatoid factor in
their serum
l Concurrent use of topical or systemic drugs/
treatments for psoriasis was not permitted
during the study except low-potency topical
corticosteroids on the face or groin
l Evidence of latent or active TB
l Had chronic or clinically significant infection,
malignancy, or congestive heart failure; or if
they had used TNF-α inhibitors previously
l Concomitant MTX treatment ≥ 25mg/week
and > 10mg prednisone
l DMARDs (other than MTX) or intra-articular
corticosteroids within 4 weeks prior to
enrolment in the study and DMARD use
other than MTX was not allowed during
the trial
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Study and drug Inclusion criteria Exclusion criteria
Mease et al.
2004;54 ETN
l Active PsA with three or more swollen and
tender joints
l Inadequate response to NSAIDs
l Had at least one of the following clinical
subtypes of PsA: distal interphalangeal joint
involvement, polyarticular arthritis (absence
of rheumatoid nodules and presence of
psoriasis), arthritis mutilans, asymmetrical
peripheral arthritis, or ankylosing
spondylitis-like arthritis
l Plaque psoriasis with a qualifying lesion at
least 2 cm in diameter
Concomitant MTX, a stable dosage of
≤ 25mg/week and prednisolone ≤ 10mg/day
l Discontinued other DMARDs at least 4 weeks
before the study
l Phototherapy was discontinued at least
2 weeks before the study start. Oral
retinoids, topical vitamin A or D analogue
preparations, and dithranol were not
allowed. Topical therapies were permitted
on the scalp, axillae and groin only
l Significant concurrent medical diseases
including:
¢ diabetes mellitus requiring insulin
¢ uncompensated congestive heart failure
¢ myocardial infarction within 12 months
of screening visit
¢ unstable or stable angina pectoris
¢ uncontrolled hypertension
¢ severe pulmonary disease (requiring
medical or oxygen therapy)
¢ history of cancer (other than resected
cutaneous basal or squamous cell
carcinoma or in situ cervical cancer)
within 5 years of screening visit
¢ HIV positive, hepatitis B surface antigen
or hepatitis C positive
¢ RA, systemic lupus, scleroderma
or polymyositis
¢ any condition judged by the subjects
physician that would cause this study to
be detrimental to the subject
l Current or history of psychiatric disease that
would interfere with ability to comply with
the study protocol or give informed consent
l History of alcohol or drug abuse that would
interfere with ability to comply with the
study protocol
Mease et al.,
2000;53 ETN
l Active PsA with three or more swollen and
tender joints
l Inadequate response to NSAIDs
l Patients taking MTX (≤ 25mg/week) were
allowed to continue MTX if the dose was
stable for 4 weeks before study start and
remained stable throughout the study
l ≤ 10mg/day of prednisone, stable for at least
2 weeks before the first dose of study drug,
and maintained at a constant dose
throughout the study
l Evidence of skin conditions other than
psoriasis (such as eczema)
l Other DMARDs (except MTX) were
discontinued at least 2 weeks before
beginning the study drug and were not
allowed during the study
l Topical therapies and oral retinoids for
psoriasis were discontinued at least 2 weeks
before the baseline evaluation and
phototherapy was discontinued at least
4 weeks
HIV, human immunodeficiency virus.
a Ixekizumab is not a treatment of interest, which is excluded from the remaining of the report.
b PALACE 3 only.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
224
Appendix 3 Detailed evidence synthesis
Detailed evidence synthesis framework
The evidence synthesis was undertaken using WinBUGS (version 1.4.3). WinBUGS is a Bayesian analysis
software tool that, through the use of Markov chain Monte Carlo, calculates posterior distributions for the
parameters of interest given likelihood functions derived from data and prior probabilities (uninformative
priors were used throughout). There were few individual studies on each treatment; therefore, fixed-effect
models were used across studies in all analyses. Parameter estimates for all functional parameters were
reported from the models. These differ by outcome, and further details are presented in the subsections
that follow. Treatment effects were expressed in relation to placebo. Owing to the sparse evidence
imposing a high level of uncertainty over estimates of functional parameters, point estimates are medians
throughout. Some models assumed exchangeability across treatments within a class. Within such models
we reported the estimates for each treatment (called shrunken estimates), rather than the class medians,
allowing us to represent any residual differences across treatments.
All PsARC response, and HAQ-DI conditional on PsARC response, models were run for 20,000 iterations
after a burn-in of 30,000 on two chains. All PASI response and ACR response models were run for 20,000
iterations after a burn-in of 50,000 on two chains. The level of credibility used was 95% (i.e. 95% CrIs).
The DIC statistic, convergence and autocorrelation were all assessed and informed model selection.
Thinning was considered where autocorrelation was high. Model fit statistics are reported in the form of
DIC and residual deviance.
Data used for the ustekinumab (PSUMMIT) trials
The marketing authorisation for UST differs from that of the other biologics in terms of how long
treatment should be continued before clinicians should consider stopping treatment. Although the
recommendation for UST is for doctors to consider stopping treatment if there is no response after
28 weeks, for the other biologics the stopping time frames range between 12 and 16 weeks. However,
the PSUMMIT trials58,59,66 had an early escape crossover design at week 16, just like several other trials
included in the NMA (including the FUTURE 248 and RAPID-PsA trials47). Using the post-early escape
24-week data from the PSUMMIT trials but pre-early escape data from the other trials would introduce
methodological heterogeneity across treatments, which could potentially have implications on results.
With this in mind we obtained 12-week data for the PSUMMIT trials via the YODA project (see Chapter 3,
Methods for reviewing clinical effectiveness). Although biologic-naive and biologic-experienced subgroup
data were extracted for several relevant outcomes from the PSUMMIT clinical study reports, these
subgroup data were not available for PsARC at 12 weeks for PSUMMIT 2,59,66 although they were available
for the full population.
The data from YODA showed that results for the PsARC and HAQ-DI outcomes were very similar at 12 and
24 weeks in both PSUMMIT trials (Table 121).58,59,66 Conversely, the 12- and 24-week results appear
different for the PASI outcomes, particularly at the higher thresholds. A similar pattern of results (when
comparing 12 and 24 weeks) can be seen in the RAPID-PsA trial,47 but is less evident in the SEC FUTURE
2 trial48 (see Table 121). Some differences across treatments may be attributable to variations in analysis
approaches used with respect to non-responder imputations in early escapers. It was also noted that in
ADEPT,55 which was placebo controlled and blinded up to 24 weeks without early escape, there was
around a 10% increase in PASI 75 and PASI 90 response rates going from 12 to 24 weeks.
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Based on these observations, and to allow our analyses to include subgroup data from both PSUMMIT
trials,58,59,66 we used the 24-week PSUMMIT trial data for the analyses of PsARC and HAQ-DI, on the
assumption that they fairly reflected the 12-week results. For the analyses of PASI and ACR outcomes
(where the 12- and 24-week results differed), we used the 12-week data.
For completeness, and to allow comparison with the placebo groups and the 24-week data, the PsARC
and HAQ-DI 12-week data for the PSUMMIT trial full populations are as follows: PSUMMIT 1,58,66 PsARC
responders 121 of 205 for 45 mg of UST and 75 of 206 for placebo; HAQ-DI mean change from baseline
0.28 units (SD 0.487 units) for 45 mg of UST and 0.1 units (SD 0.384 units) for placebo; PSUMMIT 2,59,66
PsARC responders 54 of 103 for 45 mg of UST and 33 of 104 for placebo; HAQ-DI mean change from
baseline 0.21 units (SD 0.472 units) for 45 mg of UST and 0.07 units (SD 0.398 units) for placebo.
Psoriatic Arthritis Response Criteria response
Detailed methods for the biologic-naive subpopulation
Each trial reported the number of events (PsARC responses) in the placebo and the number of events
under treatments (rit), where i represents a trial (i = 1, . . . , 14) and t represents a treatment (t = 1, . . . , 10).
Across all models, it was assumed that that rit are binomially distributed, with probability parameter pit
representing the probability of an event (PsARC response) in treatment arm t of trial i. As the parameters
of interest, pit, are probabilities and, therefore, can take only values between 0 and 1, we modelled these
on the logit scale (log-odds). We implemented separate models for the pooling of treatment effects and of
placebo responses.
TABLE 121 The 12- and 24-week full population results across recent trials that used an early escape at 16 weeks
design
Trial and arm
Outcome
PsARC HAQ-DI (units)a PASI 50 PASI 75 PASI 90
12
weeks
24
weeks
12
weeks
24
weeks
12
weeks
24
weeks
12
weeks
24
weeks
12
weeks
24
weeks
FUTURE 2;48
150mg of SEC
69 Confidential
information has
been removed
NR 0.48 83 NR 53 43 33 33
FUTURE 2;48
300mg of SEC
72 Confidential
information has
been removed
NR 0.56 83 NR 59 63 39 49
RAPID-PsA;47
CZP 200mg
73 78 0.45 0.52 69 74 47 62 22 47
RAPID-PsA;47
CZP 400mg
66 77 0.39 0.43 63 72 47 61 20 36
PSUMMIT 1;58,66
45mg of UST
59 56 0.28 0.31 61 78 39 57 19 41
PSUMMIT 2;59,66
45mg of UST
52 55 0.21 0.21 64 68 39 51 20 30
NR, not reported.
a Change from baseline; results are % responders for all outcomes except HAQ-DI; for early escapers non-responder
imputations were used for all treatment groups in the FUTURE 2 and PSUMMIT trials but for the placebo group only in
the RAPID-PsA trial.
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Treatment effect models
The treatment effect model assumed the baseline and treatment effects to be additive on the logit scale
Logit(pit) = µi + δt. This means that log-ORs were pooled across trials. In the treatment effect models, the
baselines were considered trial specific (unconstrained). We implemented a set of alternative models in
what concerns the specification of treatment effects. We first explored a model with independent
treatment effects across treatments. We then explored the possibility of placebo response determining the
effectiveness of alternative treatments (with treatment effects still assumed independent). We also explored
whether or not there was similarity between treatment effects for treatments of the same class.
Exploring placebo response as a treatment effect modifier
The trial-specific data show that higher placebo rates are associated with lower relative effectiveness
estimates. Our investigations regarding trial designs and patient characteristics did not identify a clear
reason for such differences, although placebo response rates appear to have increased over time. We
investigated the effect of placebo response as a treatment effect modifier. It should be noted that the
source of any relationship between placebo response and treatment effect is unclear and the reader
should interpret the results carefully and with caution.
Figure 21 shows the relationships between trial-specific observed placebo responses and ORs on log-odds
scale in the biologic-naive population. Considering placebo response as a treatment effect modifier in the
independent treatment-effects analysis, only multiple studies of the same treatment (two or more studies)
can inform the placebo effect. Hence, treatments from the single trials (i.e. CZP, SEC and GOL) do not
contribute to the interaction in the independent treatment-effects analysis. In Figure 21, the solid lines
within the plot reflect the relationship between the trials of the same treatments. Those with a steeper
slope will indicate a stronger effect modification of placebo response (i.e. stronger association between
placebo response and treatment effects). The highest effects are seen between trials of ADA and ETN 
lines in green in Figure 21. Among the trials on ETN, the Mease et al. trial53 has the smallest number of
participants and the response rates in placebo and treatment arms are very different from other trials.
Similarly, the smallest trial of ADA (i.e. Genovese et al.56) reports a similar proportion of PRs but very
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FIGURE 21 The PsARC response in the biologic-naive subpopulation: plot of trial-specific observed log-odds of
placebo responses and ORs on log-scale (all 13 trials).
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different response to treatment compared with the ADEPT55 of ADA. Therefore, the Mease et al.53 and
Genovese et al.56 trials could contribute most (and possibly unreasonably so) to the estimation of
interaction term (beta). It should be noted that the effect of placebo is consistently negative across all trials
(i.e. higher placebo rates are associated with lower relative effectiveness estimates in the trial evidence).
Exclusion of both Mease et al.53 and Genovese et al.56 will probably result in a much less pronounced
placebo effect but it will still be negative.
Given the issue of heterogeneity in terms of unexplained differences in placebo response rates across the
trials, analyses were undertaken, including a metaregression adjusting for placebo response. We used the
baseline risk in each trial for the adjustment, taking into account the error in the estimation of baseline risk
and its correlation to the ORs.114 Sensitivity analyses excluding both the Mease et al.53 and Genovese et al.56
trials were performed. Note that the effect of excluding these studies will be more pronounced if
independent treatment effects are considered, rather than class effects. In the treatment effects as class
analysis, all treatments assume to have equal or similar treatment effects; therefore, all studies within the
class will contribute to the interaction term (compare dashed lines in Figures 21 and 22, in which all
biologics as a class was assumed). The metaregression model includes an interaction term between the
treatment effect (log-OR) and the trial-level estimate of placebo log-odds of response. By including such an
interaction term, analyses will assume that the relative effectiveness of each of the treatments is not
constant, but is associated with the response rate in the placebo arm. Treatment effects are no longer
independent of the placebo response, but will be predicted for a particular value for the response rate in
the placebo arm  usually the mean across the trials. The ranking of treatments is expected to differ from
that estimated in the primary analyses (without the metaregression being imposed). This is because if, for
example, the metaregression shows that trials with higher placebo response rates are associated with lower
treatment effects, then treatments such as SEC that have been trialled only under a high placebo response
will be predicted to have shown higher effectiveness in a different trial with a placebo response equal to the
mean observed across trials.
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FIGURE 22 The PsARC response in the biologic-naive subpopulation: plot of trial-specific observed log-odds of
placebo responses and ORs on log-scale (excluding Mease et al.53 and Genovese et al.56).
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Exploring treatment effects as class
In the context of an adjusted model for placebo response, we explored the possibility of there being class
effects. Three different class groupings were considered: all treatments as a single class; all biologics as a
class with APR separate; and, to reflect the pharmacology, anti-TNFs grouped, ILs grouped and APR
separate. In addition, we explored two within-class assumptions: assuming treatments within a class to
have equal effectiveness and, alternatively, that treatments within a class have similar (exchangeable)
effectiveness (described by a normal distribution with an estimated mean and variance). Fixed effects
across studies were assumed for all models. We have not considered models assuming exchangeability
between classes.
Summary of all treatment effect models explored
All models implemented for evidence synthesis of PsARC response are presented in Table 122. Detailed
coding of the models is presented in Table 123.
As stated earlier, sensitivity analyses around the adjustment for placebo response were performed: sets of
analyses (models A1, B1, C1, C2, C3, D1 and D2) were conducted for PsARC response excluding the
Mease et al.53 and Genovese et al.56 trials.
Placebo response synthesis model
To estimate baseline effect, the number of events in the placebo arm reported within each trial (ri1) was
assumed to be binomially distributed and the log-odds for placebo was pooled across trials. A random
effect was assumed between studies. The trial-specific effects for placebo PDi were estimated from a
common distribution PDi ∼ dnorm(mean,1/σ2). The random effect was defined using a mean and variance
parameters (mean and σ, respectively). Mean was assigned a non-informative normal prior distribution and
σ was assigned a uniform prior. Results of the analysis are presented in Detailed results for the biologic-
naive subpopulation.
TABLE 122 Key assumptions of models implemented for evidence synthesis of PsARC response
Sets of
analysis
Between-studies
assumption Treatment Metaregression Class
A1 FE Independent No baseline adjustment No class effect
B1 FE Independent Common interaction term
with log-odds of response
in placebo arm
No class effect
C1 FE Equal | class Common interaction term
with log-odds of response
in placebo arm
Independent class effect:
class = {all treatments}
C2 FE Equal | class, remaining
treatments independenta
Independent class effect:
class = APR independent
{all remaining biologics}
C3 FE Equal | class, remaining
treatments independenta
Independent class effect:
class = {anti-TNFs, ILs}; APR
independent
D1 FE Exchangeable | class,
remaining treatments
independenta
Common interaction term
with log-odds of response
in placebo arm
Independent class effect:
class = APR independent
{all other biologics}
D2 FE Exchangeable | class,
remaining treatments
independenta
Independent class effect:
class = {anti-TNFs, ILs}; APR
independent
FE, fixed effect.
a APR independent
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
© Queens Printer and Controller of HMSO 2017. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
229
TABLE 123 Description of models and underlying assumptions for PsARC response
Model A1 Model B1
Likelihood
r iteBinomial(pit ,nit )
Model
Logit(pit ) = µi + δt
Priors
δtednorm(0,0:000001),
µiednorm(0,0:000001)
Likelihood
r iteBinomial(pit ,nit )
Model
Logit(pit ) = µi + δt + β(µi − µ)
Priors
δtednorm(0,0:000001),
µiednorm(0,0:000001),
β
e
dnorm(0,0:000001)
Assumptions:
l baselines are unconstrained
l the treatments effects
are independent
l fixed effects between studies
Assumptions:
l baselines are unconstrained
l the treatments effects are independent
l fixed effects between studies
l common interaction term between studies
Models C1, C2 and C3 Models D1 and D2
Likelihood
r iteBinomial(pit ,nit )
Model
Logit(pit ) = µi + δt + β(µi − µ)
δt = δc
Priors
δcednorm(0,0:000001)
µiednorm(0,0:000001)
β
e
dnorm(0,0:000001)
Likelihood
r iteBinomial(pit ,nit )
Model
Logit(pit ) = µi + δt + β(µi − µ)
δtednorm(Classc, 1/γ
2)
Priors
Classcednorm(0,0:000001)
γ
e
dunif (0, 10)
µiednorm(0,0:000001)
β
e
dnorm(0,0:000001)
C1: class = {all biologics} D1: APR independent; class = {all other biologics}
C2: APR independent; class = {all other
biologics}
D2: class = {anti-TNFs, ILs}; APR independent
C3: class = {anti-TNFs, ILs}; APR
independent
Assumptions:
l baselines are unconstrained
l the treatments effects are equal
within class
l fixed effects between studies
l common interaction term
between studies
Assumptions:
l baselines are unconstrained
l a random effect is used to describe differences between treatments
(exchangeability is assumed)
l fixed effects between studies
l common interaction term between studies
Pooling of placebo effects
Likelihood :
rplaciedbin(pplaci,ni )
Model
Logit(pplaci ) = PDi
PDiednorm(Mean, 1/σ
2)
Priors :
Mean
e
dnorm(0,0:000001)
σ
e
duni(0,10)
In summary, this model assumes:
l common placebo effect
across studies
l random effects between studies
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Detailed results for the biologic-naive subpopulation
Summary results of Psoriatic Arthritis Response Criteria response
Tables 124 and 125 show summary results of PsARC response including and excluding the Genovese et al.56
and Mease et al.53 studies.
Detailed results of Psoriatic Arthritis Response Criteria response
Results of the baseline effects (placebo)
The mean baseline effect is estimated to be 0.81 (Table 126).
Results of treatment effects models
More detailed results of models A1, B1, C1, C2, C3, D1 and D2 are presented next.
TABLE 124 Results of PsARC response: log-ORs (median) of treatments analysed (including Genovese et al.56 and
Mease et al.53 studies) in the biologic-naive subpopulation
Metaregression No Yes Yes Yes Yes Yes Yes
Treatments Ind Ind = | class = | class = | class ∼ | classa ∼ | classa
Class No No {All} {APR,
other}
{ILs, TNFs,
APR}
{APR,
other}
{ILs, TNFs,
APR}
Log-odds
placebo A1 rb B1 rb C1 rb C2 rb C3 rb D1 rb D2 rb
300mg of
SEC
0.16 1.178 5 2.110 1 1.844 3 1.833 3
150mg of
SEC
0.16 1.175 6 2.104 2 1.285 2 1.839 4 1.822 4
UST 0.51 0.758 9 1.187 7 1.197 8 1.174 8
CZP 0.28 1.094 7 1.837 5 1.278 1 1.565 1 1.722 5 1.716 5
GOL 1.32 2.339 1 1.619 6 1.692 6 1.712 6
ADA 1.02 1.401 4 1.081 8 1.648 1 1.201 7 1.201 7
INF 1.15 2.296 2 1.870 4 1.853 2 1.875 1
ETN 0.99 2.043 3 1.917 3 1.856 1 1.872 2
APR 0.85 0.813 8 0.765 9 0.756 2 0.779 3 0.769 9 0.771 9
Beta (mean)  1.471 0.498 1.692 1.061 1.264 1.225
Residual deviancec 29.9 27.2 59.2 46.8 47.5 27.8 27.9
DIC 193.1 190.5 148.0 203.8 199.1 190.0 190.3
= | class, equal class effect; ∼ | class, exchangeable class effect; ind, independent.
a Shrunken estimates.
b Ranking of treatments according to point estimates.
c Compared with 27 data points.
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Results including Genovese et al. and Mease et al. studies
The results of the models A1, B1, C1, C2, C3, D1 and D2, including the Genovese et al.56 and Mease
et al.53 studies, are presented in Tables 127133.
Results of analysis assuming treatments are independent including all studies (Table 127).
Metaregression results including all studies
Results of analysis assuming treatments are independent (Table 128).
TABLE 125 Results of PsARC response: log-ORs (median) of treatments analysed (excluding Genovese et al.56 and
Mease et al.53 studies) in the biologic-naive subpopulation
Metaregression No Yes Yes Yes Yes Yes Yes
Treatments Ind Ind = | class = | class = | class ∼ | classa ∼ | classa
Class No No {All} {APR,
other}
{IL, TNF,
APR}
{APR,
other}
{ILs, TNFs,
APR}
Log-odds
placebo A1 rb B1 rb C1 rb C2 rb C3 rb D1 rb D2 rb
300mg of
SEC
0.16 1.176 5 1.928 2 1.775 2 1.682 4
150mg of
SEC
0.16 1.169 6 1.914 3 1.259 2 1.766 3 1.674 5
UST 0.51 0.757 9 1.099 8 1.179 8 1.127 8
CZP 0.28 1.092 7 1.686 6 1.665 6 1.640 6
GOL 1.32 2.341 1 1.761 5 1.294 1 1.577 1 1.680 1 1.729 4 1.778 2
ADA 1.05 1.526 4 1.251 7 1.344 7 1.377 7
INF 1.15 2.301 2 1.953 1 1.864 1 1.897 1
ETN 0.80 1.784 3 1.781 4 1.725 5 1.748 3
APR 0.85 0.814 8 0.772 9 0.761 2 0.781 3 0.773 9 0.777 9
Beta (mean)  1.149 1.680 1.481 0.903 1.131 1.018
Residual deviancec 23.6 22.6 52.2 38.2 36.3 22.3 22.8
DIC 169.8 168.7 147.9 177.8 176.0 167.0 167.7
= | class, equal class effect; ∼ | class, exchangeable class effect; ind, independent.
a Shrunken estimates.
b Ranking of treatments according to point estimates.
c Compared with 23 data points.
TABLE 126 Result of PsARC response: baseline effect (log-odds) in the biologic-naive subpopulation
Baseline (placebo) Mean Median 95% CrI
Baseline effect 0.814 0.812 1.023 to 0.611
0.290 0.277 0.102 to 0.550
Including Genovese et al.56 and Mease et al.53 studies.
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Results of analyses assuming treatments as class (Tables 129–133).
Results excluding Genovese et al. and Mease et al. studies
The results of the models A1, B1, C1, C2, C3, D1 and D2, excluding the Genovese et al.56 and Mease
et al.53 studies, are presented in Tables 134140.
The results of analysis assuming treatments are independent excluding the Genovese et al.56 and Mease
et al.53 studies (Table 134).
TABLE 127 Results of model A1: treatment effects (treatment, independent; studies, fixed effect)
Treatment
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
300mg of SEC 3.499 3.246 1.559 to 6.886 1.181 1.178 0.444 to 1.930
150mg of SEC 3.503 3.239 1.540 to 6.955 1.179 1.175 0.432 to 1.939
UST 2.172 2.134 1.489 to 3.070 0.759 0.758 0.398 to 1.122
CZP 3.082 2.985 1.880 to 4.813 1.096 1.094 0.631 to 1.571
GOL 10.890 10.370 5.865 to 18.980 2.343 2.339 1.769 to 2.943
ADA 4.159 4.059 2.703 to 6.212 1.403 1.401 0.994 to 1.827
INF 10.330 9.931 5.914 to 17.060 2.299 2.296 1.777 to 2.837
ETN 8.063 7.712 4.529 to 13.580 2.047 2.043 1.510 to 2.609
APR 2.276 2.255 1.733 to 2.941 0.813 0.813 0.550 to 1.079
Residual deviancea 29.86
DIC 193.148
a Compared 27 data points.
TABLE 128 Results of model B1: treatment effects (metaregression; treatment, independent; studies, fixed effect)
Treatment
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
300mg of SEC 10.560 8.251 3.244 to 26.790 2.142 2.110 1.177 to 3.288
150mg of SEC 10.410 8.196 3.174 to 26.980 2.135 2.104 1.155 to 3.295
UST 3.441 3.276 2.117 to 5.752 1.201 1.187 0.750 to 1.750
CZP 7.024 6.277 3.166 to 14.980 1.861 1.837 1.153 to 2.707
GOL 5.360 5.049 2.000 to 10.400 1.593 1.619 0.693 to 2.342
ADA 2.989 2.947 1.745 to 4.404 1.067 1.081 0.557 to 1.483
INF 6.702 6.488 3.345 to 11.120 1.856 1.870 1.207 to 2.408
ETN 7.018 6.804 4.026 to 11.250 1.914 1.917 1.393 to 2.420
APR 2.160 2.150 1.684 to 2.691 0.763 0.765 0.521 to 0.990
Beta 1.471 1.459 2.769 to 0.216
Residual deviancea 27.17
DIC 190.495
a Compared 27 data points.
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TABLE 130 Results of model C2: treatment effects (metaregression; treatment, APR = independent, other
biologics = equal | class; studies, fixed effect)
Treatment/parameter
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
Biologics as class (excluding APR) 4.805 4.782 4.099 to 5.657 1.566 1.565 1.411 to 1.733
APR 2.142 2.130 1.676 to 2.670 0.755 0.756 0.516 to 0.982
Beta 1.692 1.666 2.406 to 1.122
Residual deviancea 46.83
DIC 203.806
a Compared 27 data points.
TABLE 131 Results of model C3: treatment effects [metaregression; treatment, APR = independent, equal | class
(ILs, anti-TNFs); studies, fixed effect, including all studies]
Treatment/parameter
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
ILs as class 3.755 3.616 1.880 to 6.573 1.273 1.285 0.631 to 1.883
Anti-TNFs as class 5.238 5.195 4.036 to 6.710 1.648 1.648 1.395 to 1.904
APR 2.194 2.179 1.726 to 2.751 0.779 0.779 0.546 to 1.012
Beta 1.061 1.025 1.864 to 0.462
Residual deviancea 47.54
DIC 199.129
a Compared 27 data points.
TABLE 129 Results of model C1: treatment effects (metaregression; treatment, equal | class; studies, fixed effect)
Treatment/parameter
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
Biologics as class 3.612 3.589 2.730 to 4.648 1.275 1.278 1.004 to 1.537
Beta 0.498 0.523 3.711 to 2.483
Residual deviancea 59.24
DIC 147.961
a Compared 27 data points.
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TABLE 133 Results of model D2: treatment effects [metaregression; treatment, APR = independent, exchangeable |
class (ILs, anti-TNFs); studies: fixed effect, including all studies]
Treatment
OR Predicted mean distribution
Shrunken or independent
treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
300mg of SEC 5.521 4.982 2.326 to
11.920
1.618 1.597 0.315 to 3.016 1.841 1.833 1.146 to 2.588
150mg of SEC 1.832 1.822 1.133 to 2.588
UST 1.180 1.174 0.809 to 1.580
CZP 5.546 5.340 3.112 to 9.147 1.671 1.673 0.424 to 2.891 1.722 1.716 1.278 to 2.209
GOL 1.707 1.712 1.173 to 2.204
ADA 1.199 1.201 0.834 to 1.548
INF 1.874 1.875 1.430 to 2.306
ETN 1.874 1.872 1.476 to 2.287
APR 2.172 2.162 1.763 to 2.638 0.770 0.771 0.567 to 0.970
γa 0.491 0.437 0.193 to 1.107
Beta 1.225 1.227 2.039 to 0.393
Residual
devianceb
27.92
DIC 190.342
a Variance parameter for the random effect across biologics (excluding APR).
b Compared 27 data points.
TABLE 132 Results of model D1: treatment effects (metaregression; treatment, APR = independent, other
biologics = exchangeable | class; studies, fixed effect, including all studies)
Treatment
OR Predicted mean distribution
Shrunken or independent
treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
300mg of SEC 5.331 5.206 3.675 to 7.737 1.657 1.647 0.653 to 2.714 1.859 1.844 1.343 to 2.456
150mg of SEC 1.853 1.839 1.332 to 2.451
UST 1.202 1.197 0.885 to 1.538
CZP 1.731 1.722 1.342 to 2.165
GOL 1.689 1.692 1.233 to 2.122
ADA 1.197 1.201 0.861 to 1.509
INF 1.854 1.853 1.462 to 2.254
ETN 1.859 1.856 1.481 to 2.258
APR 2.166 2.157 1.765 to 2.609 0.768 0.769 0.568 to 0.959
γa 0.437 0.398 0.187 to 0.924
Beta 1.264 1.261 1.917 to 0.633
Residual
devianceb
27.76
DIC 189.961
a Variance parameter for the random effect across biologics (excluding APR).
b Compared 27 data points.
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Metaregressions results excluding Genovese et al. and Mease et al. studies
Results of analysis assuming treatments are independent (Table 135).
Results of analyses assuming treatments as class (Tables 136–140).
TABLE 134 Results of model A1: treatment effects (treatment, independent; studies, fixed effect, excluding
Genovese et al.56 and Mease et al.53)
Treatment
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
300mg of SEC 3.492 3.240 1.554 to 6.920 1.178 1.176 0.441 to 1.934
150mg of SEC 3.486 3.218 1.543 to 6.982 1.174 1.169 0.434 to 1.943
UST 2.168 2.131 1.486 to 3.062 0.757 0.757 0.396 to 1.119
CZP 3.076 2.980 1.861 to 4.820 1.094 1.092 0.621 to 1.573
GOL 10.910 10.390 5.869 to 18.920 2.345 2.341 1.770 to 2.940
ADA 4.746 4.602 2.856 to 7.491 1.527 1.526 1.049 to 2.014
INF 10.380 9.983 5.954 to 17.210 2.303 2.301 1.784 to 2.845
ETN 6.269 5.956 3.264 to 11.070 1.787 1.784 1.183 to 2.404
APR 2.278 2.257 1.739 to 2.931 0.814 0.814 0.553 to 1.075
Residual deviancea 23.63
DIC 169.761
a Compared 23 data points.
TABLE 135 Results of model B1: treatment effects (metaregression; treatment, independent; studies, fixed effect,
excluding Genovese et al.56 and Mease et al.53)
Treatments
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
300mg of SEC 9.534 6.872 2.132 to 23.890 1.932 1.928 0.757 to 3.174
150mg of SEC 9.980 6.779 2.091 to 23.470 1.925 1.914 0.738 to 3.156
UST 3.178 3.001 1.748 to 5.410 1.103 1.099 0.558 to 1.688
CZP 6.248 5.400 2.241 to 13.770 1.695 1.686 0.807 to 2.622
GOL 8.068 5.818 2.233 to 14.620 1.757 1.761 0.803 to 2.682
ADA 3.647 3.494 1.940 to 5.920 1.245 1.251 0.663 to 1.778
INF 7.572 7.049 3.629 to 13.280 1.952 1.953 1.289 to 2.587
ETN 6.218 5.936 3.477 to 10.280 1.783 1.781 1.246 to 2.330
APR 2.181 2.165 1.707 to 2.729 0.772 0.772 0.535 to 1.004
Beta 1.149 1.151 2.727 to 0.406
Residual deviancea 22.601
DIC 168.708
a Compared 23 data points.
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TABLE 136 Results of model C1: treatment effects (metaregression; treatment, equal | class; studies, fixed effect,
excluding Genovese et al.56 and Mease et al.53)
Treatment/parameter
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
Biologics as class 3.679 3.649 2.749 to 4.794 1.293 1.294 1.011 to 1.567
Beta 1.680 2.560 4.050 to 2.094
Residual deviancea 52.16
DIC 147.920
a Compared 23 data points.
TABLE 137 Results of model C2: treatment effects (metaregression; treatment, APR = independent, other
biologics = equal | class; studies, fixed effect, excluding Genovese et al.56 and Mease et al.53)
Treatment/parameter
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
Biologics as class (excluding APR) 4.867 4.843 4.192 to 5.682 1.580 1.577 1.433 to 1.737
APR 2.151 2.141 1.730 to 2.622 0.760 0.761 0.548 to 0.964
Beta 1.481 1.455 2.122 to 0.996
Residual deviancea 38.16
DIC 177.825
a Compared 23 data points.
TABLE 138 Results of model C3: treatment effects (metaregression; treatment, APR = independent, equal | class
(ILs, anti-TNFs); studies, fixed effect, excluding Genovese et al.56 and Mease et al.53)
Treatment/parameter
OR Treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI
ILs as class 3.559 3.520 2.289 to 5.069 1.250 1.259 0.828 to 1.623
Anti-TNFs as class 5.392 5.363 4.500 to 6.460 1.681 1.680 1.504 to 1.866
APR 2.195 2.183 1.796 to 2.652 0.781 0.781 0.586 to 0.976
Beta 0.903 0.906 1.725 to 0.087
Residual deviancea 36.30
DIC 175.979
a Compared 23 data points.
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TABLE 139 Results of model D1: treatment effects (metaregression; treatment, APR= independent, exchangeable |
class; studies, fixed effect, excluding Genovese et al.56 and Mease et al.53)
Treatment
OR Predicted mean distribution
Shrunken or independent
treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
300mg of SEC 5.214 5.115 3.706 to 7.350 1.637 1.633 0.713 to 2.563 1.787 1.775 1.296 to 2.335
150mg of SEC 1.778 1.766 1.273 to 2.338
UST 1.180 1.179 0.857 to 1.507
CZP 1.668 1.665 1.283 to 2.067
GOL 1.733 1.729 1.329 to 2.157
ADA 1.341 1.344 0.991 to 1.669
INF 1.869 1.864 1.499 to 2.264
ETN 1.731 1.725 1.355 to 2.141
APR 2.177 2.167 1.791 to 2.621 0.773 0.773 0.583 to 0.964
γa 0.385 0.350 0.148 to 0.824
Beta 1.131 1.128 1.750 to 0.528
Residual
devianceb
22.34
DIC 167.044
a Variance parameter for the random effect across biologics (excluding APR).
b Compared 23 data points.
TABLE 140 Results of model D2: treatment effects [metaregression; treatment, APR= independent, exchangeable |
class (ILs, anti-TNFs); studies, fixed effect, excluding Genovese et al.56 and Mease et al.53]
Treatment
OR Predicted mean distribution
Shrunken or independent
treatment effects (log-odds)
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
300mg of SEC 4.805 4.428 2.225 to 9.507 1.503 1.478 0.383 to 2.754 1.688 1.682 1.012 to 2.390
150mg of SEC 1.679 1.674 0.998 to 2.399
UST 1.127 1.127 0.756 to 1.498
CZP 5.566 5.408 3.436 to 8.554 1.695 1.689 0.670 to 2.750 1.640 1.640 1.218 to 2.064
GOL 1.781 1.778 1.314 to 2.258
ADA 1.376 1.377 0.985 to 1.757
INF 1.904 1.897 1.512 to 2.329
ETN 1.752 1.748 1.359 to 2.165
APR 2.187 2.176 1.796 to 2.642 0.778 0.777 0.586 to 0.972
γa 0.407 0.362 0.123 to 0.968
Beta 1.018 1.019 1.781 to 0.245
Residual
devianceb
22.77
DIC 167.708
a Variance parameter for the random effect across biologics (excluding APR).
b Compared 23 data points.
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Preferred models
The unadjusted model A1 fits the data as well as any of the other models and generates results that reflect
the observed results. The placebo response-adjusted model B1 fits well compared with the unadjusted
model A1 (smaller DIC and residual deviance), but not significantly so as the difference in DIC is < 5 points.
Considering the placebo-adjusted models, it must be borne in mind that without any clear rationale for the
placebo effect, the results must be interpreted with caution. The results (rankings) generated by model B1
are very different from the observed trial results.
Regarding possible class effects, the analyses found that an assumption of equal class effect for the
treatments does not produce a better-fitting model (models C1, C2, C3) than assuming independent
treatment effects (models A1, B1) or similar treatment effects (models D1, D2). There was little difference
in goodness-of-fit statistics (DIC and residual deviance) between models D1 and D2, and we consider the
exchangeable class effect model (D2) which utilised two classes (ILs and anti-TNFs) with APR separate to be
the most clinically plausible. The results (rankings) generated by models D1 and D2 are same, but are very
different from the observed trial results.
Comparing treatment effects in models A1, B1 and D2, the treatment effects are very different from each
other. INF and 300 mg of SEC appeared to be the most effective in models D2 and B1, respectively, but
GOL is the most effective in model A1. UST appeared to be least effective in model A1, whereas APR
appeared to be least effective in models B1 and D2.
In the sensitivity analyses on Genovese et al.56 and Mease et al.,53 excluding those two studies from the
analysis affects the treatment effects, resulting in changes of the treatment effects ranking. Despite the
results of the adjusted model (B1) being sensitive to the exclusion of Mease et al.53 and Genovese et al.56
(with rankings changing), there are two reasons why this analysis has not been adopted as the main one.
First, exclusion of these studies may appear to be selective, and second it is less relevant in the context of
our preferred model that assumes a class effect (compare D2 with and without Mease et al.53 and
Genovese et al.56). Therefore, these two trials were not excluded from our preferred analysis.
Hence, we consider models A1 and D2 including Genovese et al.56 and Mease et al.53 to be our
preferred models.
Comparison of the network meta-analysis of Psoriatic Arthritis Response Criteria
responses in the company submissions (Novartis and UCB Pharma), a previous multiple
technology appraisal (Rodgers et al.) and the current Assessment Group
Each of the two CSs combined evidence using Bayesian evidence synthesis methods to estimate probability
of PsARC responses to inform the economic model. UCB Pharma and the AG included analysis of
subpopulations in the main NMA and analysed both subpopulations (biologic naive and experienced)
separately, whereas Novartis considered overall population as the main NMA, and the analysis included a
more complete set of treatments and trials. The AG refers to the subgroup NMA conducted by Novartis
(i.e. biologic naive) in this comparison. A brief comparison of the methods used and key model
assumptions by the AG, CS and previous MTA is presented in Tables 141 and 142.
A key difference between the NMAs presented concerns the trials included in each analysis. Only the AG
NMA for the biologic-naive subgroup includes all comparators and all trials. The UCB Pharma analysis for
the biologic-naive subgroup includes all treatments but misses only some APR trials. The Novartis NMA
does not include CZP or APR for the biologic-naive subgroup analysis and does not include all trials for the
other treatments. The Rodgers et al.33 analysis was limited to the treatments available at that time.
The evidence synthesis is not clear in UCB Pharmas main submission for the biologic-experienced
subgroup, and results for this subgroup were not reported. Novartis did not conduct a NMA for the
biologic-experienced subgroup. Therefore, it was not plausible to compare the AGs NMA with the CS for
the biologic-experienced subgroup.
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Another key difference relates to the primary time point analysed: most NMAs used 12 weeks, but the
UCB Pharma analysis used 24 weeks as its primary time point, although it did include a 12-week
sensitivity analysis.
All analyses considered a binomial logit model (both companies, previous MTA and AG). Both the AG and
UCB Pharma consider fixed effect on studies, whereas Novartis considers random effects. Both the AG and
UCB Pharma consider baseline risk adjustment to reflect effects of differences in trial-specific placebo
response on treatment effects in the biologic-naive population whereas Novartis did not consider such
adjustment for subgroup analysis.
TABLE 141 Comparison of evidence synthesis of PsARC responses in the CSs (Novartis and UCB Pharma), a previous
MTA33 and the current AG
Domains
compared Rodgers et al., 201133
CS CS
Novartis UCB Pharma AG
Model Binomial logit model Binomial logit model Binomial logit model Binomial logit model
Results
reported
Probability of PsARC
response for each
treatment
RRs of each treatment
compared with SEC;
and probability of
PsARC response for
each treatmenta
ORs reported for the
biologic-naive
subpopulation, but
results were not
reported for the
biologic-experienced
subpopulation
ORs and probability of PsARC
response for each treatment
Time point At 12 weeks (data
from the 12-week or
closest time point after
12 weeks  normally
14 or 16 weeks)
At 12 weeks (data
from the 12-week or
closest time point after
12 weeks  normally
14 or 16 weeks)
Primary analysis at
24 weeks (by
treatments), sensitivity
analysis was conducted
at 12 weeks including
data on 12 weeks or
closest time point after
12 weeksb
At 12 weeks (data from the
12-week or closest time point
after 12 weeks  normally 14
or 16 weeks); UST outcomes
at 24 weeks were included
and assumed equivalent to
outcomes at 12 weeks
Comments  Modelled probabilities
are presented
graphically
 
Data regarding subpopulation of biologic naive
Studies used
in the analysis
ADEPT;55 Genovese
et al.;56 IMPACT;51
IMPACT 2;52 and
Mease et al.53,54
ADEPT;55 Genovese
et al.;56 FUTURE 2;48
GO-REVEAL;50
IMPACT 2;52 and
Mease et al.54
ADEPT;55 Genovese
et al.;56 GO-REVEAL;50
IMPACT;51 IMPACT 2;52
Mease et al.;53,54 and
RAPID-PsA47 (12- to
16-week analysis)
ADEPT;55 FUTURE 2;48 Genovese
et al.;56 GO-REVEAL;50
IMPACT;51 IMPACT 2;52 Mease
et al.;53,54 PALACE 1;60 PALACE
2;61 PALACE 3;65 PSUMMIT 1;58
PSUMMIT 2;59,66 and
RAPID-PsA47
Drugs
evaluated
40mg of ADA;
5 mg/kg of INF; and
25mg of ETN
40mg of ADA; 25 mg
of ETN; 50 and 100mg
of GOL; 5 mg/kg of
INF; and 150 and
300mg of SEC
40mg of ADA; 400mg
of CZP; 25mg of ETN;
50mg of GOL; and
5mg/kg of INF
40 mg of ADA; 30 mg of APR;
400 mg of CZP; 25 mg of ETN;
50 mg of GOL; 5 mg/kg of INF;
150 and 300mg of SEC; and
45mg of UST
Data regarding subpopulation of biologic experienced
Studies used
in the analysis
  Not clear FUTURE 2;48 and PSUMMIT 259,66
Drugs
evaluated
  Not clear 300 mg of SEC; and 45mg of
UST
a The AG considers probabilities to compare with our results.
b The AG considers results at 12 weeks to compare with AG NMA results.
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Another key difference relates to the PsARC responses data included in the analysis. An inconsistency was
identified by the AG in the Novartis submission in PsARC response data for SEC and revised PsARC
response data were provided late in the assessment. Therefore, it is plausible that Novartis NMA used the
incorrect data for the analysis. Additionally, the AGs extracted PsARC response data from some studies do
not match with the Novartis data, particularly for Mease et al.54 trial and two ADA trials (ADEPT,55
Genovese et al.56). The plausible explanation for the difference is that the AG consistently used ITT
denominators rather than the modified ITT approach which was sometimes used by the CS (whereby only
patients who have received at least one dose of their randomised treatment are considered).
The results of the AG NMA are compared with those of the other NMAs in Tables 143 and 144. Table 143
shows the probabilities of PsARC response for the biologic-naive subgroup, estimated by the different
models  Rodgers et al.,33 Novartis and AG (the UCB Pharma results are presented only as ORs)  and
Table 144 compares the ORs from the AG NMA with those from the UCB Pharma analysis. The results of
the AG unadjusted NMA are mostly consistent with the previous MTA as well as the Novartis results,
except for the SEC. The differences are largely because Novartis included a different PsARC response data
set. The estimated probabilities in the AGs analysis are more precise than Novartis results. Given the
differences in model assumptions and included studies, the ranking of the treatment effects is similar
between UCB Pharma and the AGs adjusted NMA (see Table 144).
TABLE 142 Key assumptions in the synthesis models for PsARC responses in the CSs (Novartis and UCB Pharma),
a previous MTA33 and the current AG
Domains
compared
Rodgers et al.,
201133
CS
AGNovartis UCB Pharma
Model Binomial logit model Binomial logit model Binomial logit model Binomial logit model
Fixed or random
effects between
studies
Random effects on
studies
Random effects on
studies
Fixed effects on studies
(for both biologic-naive
and biologic-experienced
subpopulation)
Fixed effects on studies
(for both biologic-naive and
biologic-experienced
subpopulation)
Baselines Common-effect
model was used to
estimate baseline
Common-effect
model was used to
estimate baseline
Common-effect model
was used to estimate
baseline
Common-effect model was
used to estimate baseline
Treatment
effects
Treatments were
assumed to be
independent of
each other
Treatments were
assumed to be
independent of each
other
For the biologic-naive
subpopulation the
treatment effects are
exchangeable within
classes (anti-TNFs = ADA,
IFX, ETN, GOL). For the
biologic-experienced
subpopulation the
treatments were assumed
to be independent of
each other
For the biologic-naive
subpopulation:
1. treatments were assumed
to be independent of
each other
2. treatments as class
considering treatments
are similar within class
(i.e. exchangeable class
effect) and utilise two
classes (ILs and anti-TNFs)
For the biologic-experienced
subpopulation the treatments
were assumed to be
independent of each other
Model adjusted
for placebo
response
Unadjusted Unadjusted Adjusted for biologic-
naive subpopulation,
but unadjusted for
biologic-experienced
subpopulation
Independent treatment
effects models were
unadjusted, but analysis
assuming exchangeable class
effects model was adjusted
for the placebo response
Interaction term
(beta)
  Common interaction term
in adjusted model
Common interaction term in
adjusted model
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TABLE 143 Comparison of probability of PsARC response in Novartis’ submission, a previous MTA33 and the current
AG in the biologic-naive subpopulation
Treatment
Rodgers et al.
(2011),33 mean
(95% CrI) Novartis, mean
AG, median (95% CrI)
Unadjusted, independent
treatment
Adjusted for placebo
response, class
effects assumed
Placebo 0.25 (0.18 to 0.32) Confidential information
has been removed
0.31 (0.26 to 0.36) 0.31 (0.26 to 0.36)
300 mg of SEC NC Confidential information
has been removed
0.59 (0.40 to 0.76) 0.73 (0.57 to 0.86)
150 mg of SEC NC Confidential information
has been removed
0.59 (0.40 to 0.76) 0.73 (0.57 to 0.86)
UST NC NC 0.49 (0.38 to 0.60) 0.59 (0.48 to 0.70)
CZP NC NC 0.57 (0.44 to 0.69) 0.71 (0.60 to 0.81)
50 mg of GOL NC Confidential information
has been removed
0.82 (0.71 to 0.90) 0.71 (0.58 to 0.81)
ADA 0.59 (0.44 to 0.71) Confidential information
has been removed
0.64 (0.53 to 0.75) 0.60 (0.49 to 0.69)
INF 0.80 (0.67 to 0.89) Confidential information
has been removed
0.81 (0.71 to 0.89) 0.74 (0.63 to 0.83)
ETN 0.71 (0.57 to 0.83) Confidential information
has been removed
0.77 (0.65 to 0.86) 0.74 (0.64 to 0.82)
APR NC NC 0.50 (0.41 to 0.59) 0.49 (0.41 to 0.57)
NC, not conducted.
TABLE 144 Comparison of PsARC response (ORs) at 12 weeks between UCB Pharma’s submission and the current
AG in the biologic-naive subpopulation
Treatment
UCB Pharma, mean
(95% CrI)
AG, mean (95% CrI)
Unadjusted, independent
treatment
Adjusted for placebo
response, class
effects assumed
300mg of SEC NC 3.25 (1.56 to 6.89) 6.25 (3.15 to 13.31)
SEC 150 NC 3.24 (1.54 to 6.96) 6.18 (3.10 to 13.30)
UST NC 2.13 (1.49 to 3.07) 3.24 (2.25 to 4.86)
CZP Confidential information
has been removed
2.99 (1.88 to 4.81) 5.56 (3.59 to 9.11)
GOL Confidential information
has been removed
10.37 (5.87 to 18.98) 5.54 (3.23 to 9.06)
ADA Confidential information
has been removed
4.06 (2.70 to 6.21) 3.33 (2.30 to 4.70)
INF Confidential information
has been removed
9.93 (5.91 to 17.06) 6.52 (4.18 to 10.04)
ETN Confidential information
has been removed
7.71 (4.53 to 13.58) 6.50 (4.38 to 9.85)
APR NC 2.26 (1.73 to 2.94) 2.16 (1.76 to 2.64)
NC, not conducted.
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WinBUG codes of preferred model
Model A1: 
model {  
for(i in 1:N) {      
 r[i] ~ dbin(p[i],n[i])      
 logit(p[i]) <- mu[s[i]] + (d[t[i]]-d[b[i]])*(1-equals(t[i],b[i]))    
 rhat[i] <- p[i] * n[i]   
dev[i] <- 2 * (r[i] * (log(r[i])-log(rhat[i]))  + (n[i]-r[i]) * (log(n[i]-r[i]) - log(n[i]-rhat[i])))  
  } 
totresdev <- sum(dev[]) #total resedual deviance  
for (j in 1:ns) { mu[j]~dnorm(0,0.000001) }     
d[1]<-0              
for (k in 2:nt){ d[k] ~ dnorm(0,0.000001)     
OR[k]<- exp(d[k]) } 
} 
 
Model D2: 
model {  
for(i in 1:N) {            
 r[i] ~ dbin(p[i],n[i])           
 logit(p[i]) <- mu[s[i]] + (d[t[i]]-d[b[i]])*(1-equals(t[i],b[i]))  
  + (beta[t[i]]-beta[t[1]])*(mu[s[i]]-(Mean))*(1-equals(t[i],b[i]))   
rhat[i] <- p[i] * n[i]   
dev[i] <- 2 * (r[i] * (log(r[i])-log(rhat[i]))  + (n[i]-r[i]) * (log(n[i]-r[i]) - log(n[i]-rhat[i])))  
  } 
totresdev <- sum(dev[])  
d[1]<-0              
for (i in 2:3) {d[i] ~ dnorm(D.c[1], prec.d)}  
d[4] ~ dnorm(D.c[2], prec.d) 
d[5] ~ dnorm(D.c[1], prec.d)  
for (i in 6:9) {d[i] ~ dnorm(D.c[2], prec.d)} 
d[10]<- D.c[3] 
for (i in 1:3) { D.c[i]~dnorm(0.0,0.000001)} 
prec.d<-1/(sd.d*sd.d) 
sd.d~dunif(0,10) 
for (i in 1:2) {D.pred[i]~dnorm(D.c[i],prec.d)} 
beta[1]<-0 
for (i in 2:nt) { beta[i]<- betaplac } 
betaplac ~ dnorm(0,0.000001)  
for (j in 1:ns) { mu[j]~dnorm(0,0.000001)}  
A ~ dnorm (meanA,precA) 
for (k in 1:nt) { logit(T[k]) <- A + d[k] } 
for (k in 1:nt) { OR[k]<- exp(d[k])} 
} 
 
d[1]=PLA, d[2]=SEC300, d[3]=SEC150, d[4]=CZP, d[5]=UST, d[6]=GOL, d[7]=ADA, d[8]=INF, d[9]=ETA, 
d[10]=APR 
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HAQ-DI score changes conditional on PsARC response/non-response
Detailed methods for the biologic-naive subpopulation
We consider three models to estimate the HAQ-DI score changes conditional on PsARC response. Model
E1 considers that treatments are independent and considers fixed effects across studies. Models E2 and E3
apply a class effects on three groups: anti-TNFs, ILs and APR. This class effect reflects the best-fitting class
effect model for PsARC (see Detailed results for the biologic-naive subpopulation). Model E2 assumes that
the treatments are similar within class (exchangeable) and fixed effect across studies, and model E3
considers that the treatments are equal within class and fixed effect across studies. A detailed description
of the model and underlying assumptions are presented in Table 145.
The model defines TR as treatment responder, TNR as treatment non-responder, PR as placebo responder
and PNR as placebo non-responder; I represents the trial and j the alternative treatments. The observed
quantities (i.e. HAQ-DI score changes in PRs and PNRs, and in TRs and TNRs) have a normal distribution for
the likelihood.
TABLE 145 Description of the models and underlying assumptions for HAQ-DI changes conditional on PsARC response
Model E1 Model E2 Model E3
Likelihood
HAQPNRiednorm(µPNRi,1/varPNRi )
HAQPRiednorm(µPRi ,1/varPRi)
HAQTNRijednorm(µTNRij ,1/varTNRij )
HAQTRijednorm(µTRij ,1/varTRij )
Model
µPNRi = baselinei
µPRi = µPNRi + δ.diff PR
µTNRij = µPNRi + δ.diff TNRj
µTRij = µPNRi + δ.diff TRj
Priors
baselineiednorm(0,0:000001)
δ.diff PRednorm(0,0:000001)
δ.diff TNRjednorm(0,0:000001)
δ.diff TRjednorm(0,0:000001)
Likelihood
HAQPNRiednorm(µPNRi ,1/varPNRi)
HAQPRiednorm(µPRi,1/varPRi )
HAQTNRijednorm(µTNRij ,1/varTNRij )
HAQTRijednorm(µTRij ,1/varTRij )
Model
µPNRi = baselinei
µPRi = µPNRi + δ.diff PR
µTNRij = µPNRi + δ.diff TNRj
µTRij = µPNRi + δ.diff TRj
δ.diff TNRjednorm(δ.diff TNR.C ,1/γ
2
TNR)
δ.diff TRjednorm(δ.diff TR.C ,1/γ
2
TR)
Priors
baselineiednorm(0,0:000001)
δ.diff PRednorm(0,0:000001)
δ.diff TNR.Cednorm(0,0:000001)
δ.diff TR.Cednorm(0,0:000001)
γTNRedunif (0,10)
γTNRedunif (0,10)
Likelihood
HAQPNRiednorm(µPNRi ,1/varPNRi )
HAQPRiednorm(µPRi,1/varPRi)
HAQTNRijednorm(µTNRij ,1/varTNRij )
HAQTRijednorm(µTRij,1/varTRij )
Model
µPNRi = baselinei
µPRi = µPNRi + δ.diff PR
µTNRij = µPNRi + δ.diff TNRj
δ.diff TNRj = δ.diff TNR.C
µTRij = µPNRi + δ.diff TRj
δ.diff TRj = δ.diff TR.C
Priors
baselineiednorm(0,0:000001)
δ.diff PRednorm(0,0:000001)
δ.diff TNR.Cednorm(0,0:000001)
δ.diff TR.Cednorm(0,0:000001)
Assumptions:
l the treatments effects
are independent
l PNR: unconstrained
l difference between PR and PNR:
pooled using FE
l difference between TNR and PNR:
treatments as independent;
pooled within treatments using FE
l difference between TR and PNR:
treatments as independent;
pooled within treatments using FE
Assumptions:
l a random effect is used to describe
differences between treatments
(exchangeability is assumed)
l PNR: unconstrained
l difference between PR and PNR:
pooled using FE
l difference between TNR and PNR:
treatments as independent; pooled
within treatments using FE
l difference between TR and PNR:
treatments as independent; pooled
within treatments using FE
Assumptions:
l the treatments effects are equal
within class
l PNR: unconstrained
l difference between PR and PNR:
pooled using FE
l difference between TNR and PNR:
treatments as independent;
pooled within treatments using FE
l difference between TR and PNR:
treatments as independent;
pooled within treatments using FE
FE, fixed effect; PNR, placebo non-responder; TNR, treatment non-responder.
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Changes in HAQ-DI scores in all groups are assumed relative to changes in HAQ-DI in PNRs  µPNRi. This
parameter was left unconstrained (allowed to differ between trials), and non-informative normal prior
distributions were assigned (baselinei). The relative effects of placebo on those who respond in the placebo
arm (δ.diffPR) were assumed to be additive to µPNRi and were pooled across trials. The relative effects of
treatments on those who do not respond (δ.diffTNRj) and on those who respond (δ.diffTRj) are additive to
µPNRi, and were assumed to be treatment specific. In pooling these parameters, we assumed fixed effects
across studies. Within a fixed-effects model, parameters δ.diffPR, δ.diffTNRj, and δ.diffTRj were assigned
non-informative normal prior distributions.
Detailed results for the biologic-naive subpopulation
Summary results of Health Assessment Questionnaire-Disability Index changes
conditional on Psoriatic Arthritis Response Criteria response
The summary results from three models are presented in Table 146 as absolute changes in HAQ-DI scores
in relation to baseline.
Detailed results of Health Assessment Questionnaire-Disability Index changes conditional
on Psoriatic Arthritis Response Criteria response
The results of HAQ-DI score changes conditional on PsARC response or non-response are presented in
Tables 147149.
TABLE 146 Results of HAQ-DI score changes (median) conditional on PsARC response and non-response in
biologic-naive subpopulation
Treatments Independent treatment Exchangeable | class Equal | class
Studies FE FE FE
E1 E2a E3
PsARC response vs.
non-response
PsARC
response
PsARC non-
response
PsARC
response
PsARC non-
response
PsARC
response
PsARC non-
response E1 rb E2a rb E3 rb
Placebo 0.26 0.26 0.25 0.26 10 0.26 10 0.25 4
150mg of
SEC
0.39 0.08 0.44 0.09 0.31 8 0.35 8
300mg of
SEC
0.55 0.05 0.51 0.08 0.47 0.08 0.49 1 0.43 3 0.39 1
UST 0.49 0.10 0.48 0.09 0.39 4 0.39 4
CZP 0.43 0.07 0.47 0.12 0.36 6 0.35 7
GOL 0.44 0.06 0.49 0.11 0.52 0.13 0.38 5 0.37 5 0.39 1
ADA 0.49 0.13 0.50 0.13 0.36 7 0.37 6
INF 0.66 0.20 0.60 0.14 0.46 2 0.46 1
ETN 0.64 0.20 0.59 0.14 0.44 3 0.45 2
APR 0.36 0.09 0.36 0.09 0.36 0.09 0.27 9 0.27 9 0.27 3
DIC 126.0 133.0 131.4
FE, fixed effect.
a Shrunken estimates.
b Ranking of treatments according to point estimates.
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Preferred models
The model fit statistics (DIC) indicate that neither class effect model (E2 or E3) is a better fit for the data
than the unadjusted, independent treatments model (E1). The fit of both of the class effect models was
similar, but the one that allowed exchangeability within classes (E2) was considered to be the most
clinically plausible. For the purposes of the economic model in Chapter 6, models E1 and E2 were the
preferred models.
Comparison of the network meta-analysis of Health Assessment Questionnaire-
Disability Index score changes conditional on Psoriatic Arthritis Response Criteria
response/non-response in the company submissions (Novartis and UCB Pharma),
a previous multiple technology appraisal (Rodgers et al.) and the current
Assessment Group
The previous MTA by Rodgers et al.33 and the current AG assessment conducted a NMA for HAQ-DI score
changes conditional on PsARC response/non-response outcome using Bayesian methods. Novartis did not
conduct a meta-analysis for this outcome. UCB Pharma conducted meta-analysis for HAQ-DI score change
in PsARC responders and non-responders with data extracted from Rodgers et al.33 The HTA report
assumed an additive effect for the effect of treatment in TRs versus that for PRs (UCB Pharmas
submission, p. 133). Although results of the analysis were presented in the economic section of UCB
Pharmas submission, detailed information about evidence synthesis was not provided. Hence, it is difficult
to compare UCB Pharmas submission with the AG evidence synthesis. The key assumptions for the NMA
are presented in Table 150.
As mentioned before, the NMA of UCB Pharma is difficult to compare with the AGs NMA; therefore, only
the NMA of Rodgers et al.33 was compared with the AGs NMA.
A key difference between the NMAs presented is the trials included in each analysis. The AGs NMA
includes nine active treatments and 13 trials, whereas the Rodgers et al.33 analysis was limited to the
treatments available at that time. Another key difference between Rodgers et al.33 and AGs analyses was
the assumption of the effects on studies. Rodgers et al.33 assumed random effect on studies, whereas the
AG considered fixed effect on studies. Despite differences in model assumption, the results of the current
assessment are fairly similar to those of Rodgers et al.33 (Table 151).
TABLE 147 Results of model E1: treatment effects (treatment, independent; difference between PR/TNR/TR and
PNR pooled using fixed effects)
Treatment
HAQ-DI score changes in PsARC response in
relation to PNR
HAQ-DI score changes in PsARC
non-response in relation to PNR
Mean Median 95% CrI Mean Median 95% CrI
Placebo/baseline effect 0.263 0.263 0.301 to 0.224
150mg of SEC 0.394 0.395 0.553 to 0.236 0.083 0.083 0.389 to 0.220
300mg of SEC 0.547 0.547 0.722 to 0.369 0.053 0.053 0.288 to 0.182
UST 0.488 0.488 0.597 to 0.379 0.098 0.097 0.208 to 0.012
CZP 0.429 0.429 0.530 to 0.326 0.069 0.069 0.194 to 0.057
GOL 0.439 0.439 0.585 to 0.293 0.063 0.064 0.182 to 0.055
ADA 0.489 0.489 0.583 to 0.395 0.135 0.134 0.237 to 0.032
INF 0.660 0.660 0.771 to 0.548 0.196 0.196 0.311 to 0.083
ETN 0.640 0.640 0.767 to 0.515 0.200 0.200 0.348 to 0.054
APR 0.362 0.362 0.432 to 0.291 0.089 0.089 0.157 to 0.022
DIC 125.96
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TABLE 148 Results of model E2: treatment effects [treatment, exchangeable | class (ILs, anti-TNF), APR = independent; difference between PR/TNR/TR and PNR pooled using
fixed effects]
Treatment
HAQ-DI score changes in PsARC response in relation to PNR HAQ-DI score changes in PsARC non-response in relation to PNR
Predicted mean Shrunken/independent estimates Predicted mean Shrunken/independent estimates
Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI Mean Median 95% CrI
Placebo 0.258 0.258 0.296 to 0.220
150mg of SEC 0.432 0.435 0.557 to 0.294 0.085 0.085 0.228 to 0.057
300mg of SEC 0.475 0.474 0.751 to 0.203 0.512 0.509 0.658 to 0.378 0.083 0.083 0.253 to 0.086 0.077 0.078 0.205 to 0.062
UST 0.481 0.480 0.580 to 0.383 0.088 0.087 0.186 to 0.009
CZP 0.468 0.470 0.558 to 0.370 0.116 0.118 0.196 to 0.021
GOL 0.482 0.486 0.594 to 0.354 0.110 0.114 0.188 to 0.013
ADA 0.530 0.529 0.784 to 0.279 0.499 0.500 0.581 to 0.414 0.130 0.130 0.274 to 0.012 0.133 0.132 0.209 to 0.058
INF 0.605 0.603 0.716 to 0.502 0.147 0.144 0.240 to 0.071
ETN 0.593 0.591 0.717 to 0.486 0.147 0.143 0.255 to 0.063
APR 0.361 0.361 0.430 to 0.289 0.088 0.088 0.155 to 0.020
DIC 133.03
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TABLE 149 Results of model E3: treatment effects [treatment, equal | class (ILs, anti-TNF), APR= independent;
difference between PR/TNR/TR and PNR pooled using fixed effects]
Treatment
HAQ-DI score changes in PsARC response in
relation to PNR
HAQ-DI score changes in PsARC
non-response in relation to PNR
Mean Median 95% CrI Mean Median 95% CrI
Placebo/baseline effect 0.254 0.254 0.291 to 0.217
ILs as class 0.473 0.473 0.554 to 0.393 0.083 0.083 0.176 to 0.013
Anti-TNFs as class 0.524 0.524 0.575 to 0.474 0.131 0.131 0.185 to 0.077
APR 0.359 0.359 0.430 to 0.290 0.087 0.087 0.155 to 0.018
DIC 131.37
TABLE 150 Comparison of evidence synthesis of HAQ-DI score changes conditional on PsARC response/non-response
in UCB Pharma’s submission, a previous MTA33 and the current AG
Domains
compared Rodgers et al., 201133 UCB Pharma AGa
Key
assumptions
for model
l Random effect on studies
l For each of the different trials the
true effect may be study specific
and vary across studies but remain
common across biologics
l Changes in HAQ-DI score
considering PNRs as common
baseline
l Effects of treatment response and
non-response on HAQ-DI score
change are treatment specific and
additive to the placebo probability
of non-response
l Difference between treatment
response and placebo
non-response pooled within
treatments using random effect
l Difference between treatment
non-response and placebo
non-response pooled within
treatments using random effect
l Difference between placebo
response and placebo
non-response pooled using
random effect
l Not clear from
the submission
l Fixed effect on studies
l Treatments effects are independent
l Changes in HAQ-DI score
considering PNRs as common
baseline and considered trial specific
l Effects of treatment response and
non-response on HAQ-DI score
change are treatment specific and
additive to placebo non-response
l Difference between treatment
response and placebo non-response
pooled within treatments using
fixed effect
l Difference between treatment
non-response and placebo
non-response pooled within
treatments using fixed effect
l Difference between placebo
response and placebo non-response
pooled using fixed effect
Time points HAQ-DI at 12 weeks conditional on
PsARC response at 12 weeks
At 24 weeks HAQ-DI at 12 weeks conditional on
PsARC response at 12 weeks
Results
reported
Changes in HAQ-DI given PsARC
response/non-response to treatment
Changes in HAQ-DI given
PsARC response/non-
response to treatmentb
Changes in HAQ-DI given PsARC
response/non-response to treatment
Data regarding subpopulation of biologic naive
Studies used
in the analysis
ADEPT;55 Genovese et al.;56 IMPACT;51
IMPACT 2;52 and Mease et al.53,54
ADEPT;55 FUTURE 2;48
GO-REVEAL;50 IMPACT
2;52 SPIRIT-P1;57,67 Mease
et al.;54 and RAPID-PsA47
(24 weeks)
ADEPT;55 FUTURE 2;48 Genovese et al.;56
GO-REVEAL;50 IMPACT;51 IMPACT 2;52
Mease et al.;54 PALACE 1;60 PALACE 2;61
PALACE 3;65 PSUMMIT 1;58 PSUMMIT
2;59,66 and RAPID-PsA47
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TABLE 150 Comparison of evidence synthesis of HAQ-DI score changes conditional on PsARC response/non-response
in UCB Pharma’s submission, a previous MTA33 and the current AG (continued )
Domains
compared Rodgers et al., 201133 UCB Pharma AGa
Drugs
evaluated
40mg of ADA; 5 mg/kg INF; and
25mg of ETN
40mg of ADA; CZP;
25 mg of ETN; 50 mg of
GOL; 5 mg/kg of INF; and
SEC
40mg of ADA; 30 mg of APR; CZP;
25 mg of ETN; 50 mg of GOL; 5 mg/kg
of INF; 150 and 300mg of SEC; and
45mg of UST
Data regarding subpopulation of biologic experienced
Studies used
in the analysis
 FUTURE 2;48 PSUMMIT
2;59,66 and RAPID-PsA47
(24 weeks)
FUTURE 2;48 and PSUMMIT 259,66
Drugs
evaluated
 CZP; SEC; and 45mg of
UST
300mg of SEC; and 45mg of UST
a To compare with CS and previous MTA, AG only presented independent treatment effect model assumptions.
b Results reported in economic section of the submission.
TABLE 151 The HAQ-DI score changes conditional on PsARC response model results in the biologic-naive
subpopulation
Treatment Rodgers et al. (2011),33 mean (95% CrI) AG (independent treatments), median (95% CrI)
HAQ-DI score changes conditional on PsARC response
Placebo 0.244 (0.337 to 0.151) 0.263 (0.301 to 0.224)
150 mg of SEC NC 0.395 (0.553 to 0.236)
300 mg of SEC NC 0.547 (0.722 to 0.369)
CZP NC 0.429 (0.530 to 0.326)
UST NC 0.488 (0.597 to 0.379)
GOL NC 0.439 (0.585 to 0.293)
ADA 0.477 (0.596 to 0.351) 0.489 (0.583 to 0.395)
INF 0.657 (0.793 to 0.523) 0.660 (0.771 to 0.548)
ETN 0.630 (0.805 to 0.455) 0.640 (0.767 to 0.515)
APR NC 0.362 (0.432 to 0.291)
HAQ-DI score changes conditional on PsARC non-response
150mg of SEC NC 0.083 (0.389 to 0.220)
300 mg of SEC NC 0.053 (0.288 to 0.182)
CZP NC 0.069 (0.194 to 0.057)
UST NC 0.097 (0.208 to 0.012)
GOL NC 0.064 (0.182 to 0.055)
ADA 0.130 (0.188 to 0.065) 0.134 (0.237 to 0.032)
INF 0.194 (0.333 to 0.057) 0.196 (0.311 to 0.083)
ETN 0.190 (0.381 to 0.000) 0.200 (0.348 to 0.054)
APR NC 0.089 (0.157 to 0.022)
NC, not conducted.
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WinBUG codes of preferred model
Model E1: 
model { 
for (i in 1:13) { 
prec.HAQ.TR[i] <- 1/(se.HAQ.TR[i] *se.HAQ.TR[i])  
prec.HAQ.PR[i] <- 1/(se.HAQ.PR[i]*se.HAQ.PR[i]) 
prec.HAQ.TNR[i] <-  1/(se.HAQ.TNR[i] * se.HAQ.TNR[i]) 
prec.HAQ.PNR[i] <-  1/(se.HAQ.PNR[i] * se.HAQ.PNR[i]) 
  
HAQ.TR[i] ~ dnorm(TR[i], prec.HAQ.TR[i])  
HAQ.PR[i] ~ dnorm(PR[i], prec.HAQ.PR[i]) 
HAQ.TNR[i] ~ dnorm(TNR[i], prec.HAQ.TNR[i]) 
HAQ.PNR[i] ~ dnorm(PNR[i], prec.HAQ.PNR[i])  
  
  PNR[i]<-baselineHAQ[i] 
PR[i] <- baselineHAQ[i]+ PR.diff 
   
TNR[i] <-baselineHAQ[i]+ TNR.diff[trial.tnf[i]] 
TR[i] <-baselineHAQ[i]+ TR.diff[trial.tnf[i]] 
   } 
baselineHAQ[i ]~ dnorm(0,0.000001)    
for (j in 1:9) {  
TR.diff[j]~ dnorm(0,0.000001)  
   TNR.diff[j]~ dnorm(0,0.000001)  
  } 
PR.diff~ dnorm(0,0.000001) 
for (i in 1:13) { HAQ.PNR[i] ~dnorm(0,0.000001)} 
} 
 
 
Model E2: 
model { 
for (i in 1:13) { 
prec.HAQ.TR[i] <- 1/(se.HAQ.TR[i] *se.HAQ.TR[i])  
prec.HAQ.PR[i] <- 1/(se.HAQ.PR[i]*se.HAQ.PR[i]) 
prec.HAQ.TNR[i] <-  1/(se.HAQ.TNR[i] * se.HAQ.TNR[i]) 
prec.HAQ.PNR[i] <-  1/(se.HAQ.PNR[i] * se.HAQ.PNR[i]) 
  
HAQ.TR[i] ~ dnorm(TR[i], prec.HAQ.TR[i])  
HAQ.PR[i] ~ dnorm(PR[i], prec.HAQ.PR[i]) 
HAQ.TNR[i] ~ dnorm(TNR[i], prec.HAQ.TNR[i]) 
HAQ.PNR[i] ~ dnorm(PNR[i], prec.HAQ.PNR[i])  
   
baselineHAQ[i ]~ dnorm(0,0.000001) 
 
PNR[i]<-baselineHAQ[i] 
PR[i] <- baselineHAQ[i]+ PR.diff 
   
TNR[i] <-baselineHAQ[i]+ TNR.diff[trial.tnf[i]] 
TR[i] <-baselineHAQ[i]+ TR.diff[trial.tnf[i]] 
   } 
 
for (i in 1:2) {TR.diff[i] ~ dnorm(D.TR.c[1], prec.TR)} 
TR.diff[3] ~ dnorm(D.TR.c[2], prec.TR) 
TR.diff[4] ~ dnorm(D.TR.c[1], prec.TR) 
for (i in 5:8) {TR.diff[i] ~ dnorm(D.TR.c[2], prec.TR)} 
TR.diff[9] <- D.TR.c[3] 
 
for (i in 1:2) {TNR.diff[i] ~ dnorm(D.TNR.c[1], prec.TNR)} 
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TNR.diff[3] ~ dnorm(D.TNR.c[2], prec.TNR) 
TNR.diff[4] ~ dnorm(D.TNR.c[1], prec.TNR) 
for (i in 5:8) {TNR.diff[i] ~ dnorm(D.TNR.c[2], prec.TNR)} 
TNR.diff[9] <- D.TNR.c[3] 
 
for (j in 1:3) { 
 D.TR.c[j]~ dnorm(0,0.000001)  
   D.TNR.c[j]~ dnorm(0,0.000001)  
  } 
for (j in 1:2) { 
D.pred.TR[j]~dnorm(D.TR.c[j],prec.TR) 
D.pred.TNR[j]~dnorm(D.TNR.c[j],prec.TNR) 
} 
prec.TR<-1/(sd.TR*sd.TR) 
sd.TR~dunif(0,10) 
prec.TNR<-1/(sd.TNR*sd.TNR) 
sd.TNR~dunif(0,10) 
 
PR.diff~ dnorm(0,0.000001) 
for (i in 1:13) { HAQ.PNR[i] ~dnorm(0,0.000001)} 
} 
d[1]=SEC150, d[2]=SEC300, d[3]=CZP, d[4]=UST, d[5]=GOL, d[6]=ADA, d[7]=INF, d[8]=ETA, d[9]=APR 
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Psoriasis Area and Severity Index response
Detailed methods for the biologic-naive subpopulation
Treatment effect models
The NMA for PASI utilised a framework of analysis that evaluated the probability of PASI responses in
different categories of PASI thresholds (50/75/90) within a single model: the single model included all
categories of PASI and generated a single effect estimate for each treatment and also probabilities of
achieving PASI 50, PASI 75 and PASI 90. Specifically, the model considered a multinomial likelihood and a
probit link for ordered categorical data.117
In brief, trials report rikj, the number of patients in arm k of trial i belonging to different, mutually exclusive
categories j = 1, 2, 3, where these categories represent the different thresholds of PASI score (e.g. 50%,
75%, or 90% improvement). The responses for each arm k of trial i in category j follows a multinomial
distribution as:
r i,k, j = 1, : : :, j∼Multinomial(pi,k, j = 1, : : :, j, ni,k)with∑
j
j = 1pi,k, j = 1, (5)
which has been parameterised as a series of conditional binomial distributions, with parameters of interest
the probabilities, pikj, that a patient in arm k (k = 1, 2, 3) of trial i (i = 1, . . . ; see Table 153) belongs to
category j (j = 1, 2, 3). We use the probit link function, the inverse of the normal cumulative distribution
function Φ, to define the pikj as a function of a set of threshold values, zj. The threshold values (estimated
within the model) are such that the probability that the standard normal (probit score) will take a value
≤ z1 will reflect the probability of obtaining a PASI response of < 50%, that is, 1  PASI 50. The probability
that the standard normal will take a value ≤ z2 will reflect the probability of obtaining a PASI response of
< 75%, that is, 1  PASI 75, and, analogously, evaluating Φ at z3 will approximate 1  PASI 95. Placebo
and treatments are assumed to shift the mean of the distribution. This means that the pooled effect of
taking the experimental treatment instead of the control is to change the probit score (or z-score) of the
control arm, by di,1 SDs. Therefore, the model is written as pik j =Φ(µi + z j + δi,1k Ifk≠1g). The terms zj as the
differences on the standard normal scale between the response to category j and the response to category
j-1 in all the arms of trial i.
We assumed that the baselines, µi,were trial specific (unconstrained) and were given non-informative prior.
A non-informative prior was assigned to the treatment effects parameter (δt). A uniform prior was assigned
to the parameter zj.
Analogously to the analyses on PsARC, alternative assumptions were tested in two analyses. The first
assumed independent treatment effects and did not include any metaregression for placebo effects
(model F1). As the number of trials to inform each treatment effect was small, a fixed-effect model was used.
In a second analysis, we explored the impact on treatment effects of adjusting for placebo responses [i.e.
baseline effects (metaregression model)]. As can be seen from Chapter 4, Data, there are large differences
between trials for PASI responses in placebo arms, ranging between 0% and 27% (0% in IMPACT51 and
27% in the RAPID-PsA47 trial). IMPACT51 had very small sample size and reported 0% response in placebo
arm and 100% response in treatment arm, which leads to very extreme values for placebo adjustment.
Therefore, IMPACT51 could not be included in the metaregression analysis. Unlike the analysis for PsARC,
for PASI we did not assume a class effect as the evidence from individual trials does not support such an
assumption. Table 152 presents the key assumptions for the models implemented for PASI response and
detailed coding of the models is presented in Table 153.
Model F1 considers that treatments are independent of each other and fixed effect on cut-off points/
thresholds. Model G1 considers the same assumption as model F1, but IMPACT was excluded from the
analysis. Model G2 assumes treatments are independent of each other, but treatment effects are adjusted
with the trial-specific baseline effects assuming a common interaction term (beta).
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The preferred model was used to evaluate estimated probability of achieving PASI 50, PASI 75, PASI 90
responses on treatment t, using Tjt = 1 Φ(A + δt + zj), where A is the pooled baseline effect described below.
We adopted the WinBUG code presented in the decision support unit technical support document 2117 for the
analysis although we identified that the model was not specifying the z-score correctly in the linear predictor
specification when the first category of the response data (in this case PASI 50) was missing. A correction was
made to incorporate the correct specification for the z-score in the linear predictor specification.
Baseline effect
The baseline effect, A, was estimated as A = Σµi1
NS
, where µi1 is the baseline effects, where i is the studies
and 1 = placebo; NS is the number of studies (in this case NS = 13).
Detailed results for the biologic-naive subpopulation
Summary results of Psoriasis Area and Severity Index response
Table 154 presents the results of the treatment effects for PASI responses estimated from the three models
with measures of goodness of fit. There were no issues with convergence.
TABLE 152 Summary of models implemented for evidence synthesis of PASI response
Sets of
analyses
Between-studies
assumption Treatment Metaregression
Thresholds
(i.e. cut-off
points)
Baseline effect for
metaregression
F1 FE Independent No baseline adjustment FE 
G1 FE Independent No baseline adjustment FE 
G2 FE Independent Common interaction term with
baseline effect
FE Adjusted with
trial-specific
baseline effects
FE, fixed effect.
TABLE 153 Description of models and underlying assumptions for PASI response and ACR response
Models F1 and G1 Model G2
Likelihood
r ikjeBinomial(pikj , nikj )
Model
qikj = 1− (pikC i, j+1 /pikC i, j )
θikj = µi + δt i, k−δt i, 1 + z j
pikC ij = 1−ADikj
ADikj = ϕ(θik, j−1)
Priors
δtednorm(0,0:000001)
µiednorm(0,0:000001)
z jedunif (0,5)
Likelihood
r ikjeBinomial(pikjnikj )
Model
qikj = 1− (pikC i, j+1 /pikC i, j )
θikj = µi + δt i, k− δt i, 1 + z j + β(µi − µ)
pikC ij = 1− ADikj
ADikj = ϕ(θik, j−1)
Priors
δtednorm(0,0:01)
µiednorm(0,0:01)
β
e
dnorm(0,0:01)
z jedunif (0,5)
Assumptions:
l baselines are unconstrained
l treatments effects are independent
l fixed effects between studies
l fixed effect for each of the j  1 categories over all trials
Assumptions:
l baselines are unconstrained
l treatments effects are independent
l fixed effects between studies
l fixed effect for each of the j  1 categories over all trials
l common interaction term between studies
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Detailed results of Psoriasis Area and Severity Index response
More detailed results of the models F1, G1 and G2 are presented in Tables 155157.
Preferred models
The results of models G1 and F1 are similar except for a small effect on the estimate of effect for INF;
therefore, model F1 is the preferred unadjusted model as it does not exclude a trial. In model G2, DIC and
residual deviance are lower than model G1, indicating that the model fits well with the existing data and
the data support the assumption of adjustment with baseline effects. Therefore, we considered models F1
and G2 to be our preferred models.
Comparison of evidence synthesis of Psoriasis Area and Severity Index responses in the
company submissions (Novartis and UCB Pharma), a previous multiple technology
appraisal (Rodgers et al.) and the current Assessment Group
Both the Novartis and the UCB Pharma submissions combined PASI response evidence using Bayesian
evidence synthesis methods. Each of the two CSs estimated probability of achieving PASI responses in
three categories (50/75/90) to inform the economic model. A brief comparison of the methods used with
key model assumptions, by the AG, CS and previous MTA are presented in Tables 158 and 159.
As mentioned before, UCB Pharma and the AG included subpopulations in the main NMA and analysed
both subpopulations (biologic naive and experienced) separately, whereas Novartis considered overall
population as the main NMA, and the analysis included a more complete set of treatments and trials.
This comparison refers to the Novartis NMA of subgroup (i.e. biologic naive).
TABLE 154 Results of PASI response: treatment effects (median) on a probit scale in the biologic-naive subpopulation
Metaregression No No Yes
Treatments Ind Ind Ind
Cut-off points FE FE FE
F1 ra G1 ra G2 ra
Placebo 1.024  0.983  1.015 
300mg of SEC 1.936 2 1.932 2 1.864 1
150mg of SEC 1.870 3 1.865 3 1.798 2
CZP 0.875 7 0.873 7 1.424 4
UST 1.134 6 1.131 6 1.342 6
GOL 1.645 4 1.635 4 1.141 7
ADA 1.477 5 1.476 5 1.422 5
INF 2.412 1 2.276 1 1.798 2
ETN 0.798 8 0.797 8 0.849 8
APR 0.749 9 0.748 9 0.815 9
Beta   1.310
Residual deviance 76.6b 62.5c 58.4c
DIC 318.9 297.2 293.7
FE, fixed effect; ind, independent.
a Ranking of treatments according to point estimates.
b Compared 65 data points.
c Compared 61 data points.
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TABLE 155 Results of model F1: treatment effects (on a probit scale) and the different cut-off points (PASI 50,
PASI 75 and PASI 90)
Treatment/parameter
Treatment effects
Mean Median 97% CrI
Baseline effect 1.025 1.024 0.903 to 1.149
300mg of SEC 1.941 1.936 2.628 to 1.280
150mg of SEC 1.877 1.870 2.540 to 1.238
CZP 0.877 0.875 1.239 to 0.523
UST 1.135 1.134 1.407 to 0.868
GOL 1.647 1.645 2.100 to 1.212
ADA 1.480 1.477 1.831 to 1.142
INF 2.414 2.412 2.841 to 2.006
ETN 0.801 0.798 1.639 to 0.025
APR 0.750 0.749 0.987 to 0.513
z1, PASI 50   
z2, PASI 75 0.586 0.585 0.523 to 0.651
z3, PASI 90 1.153 1.153 1.059 to 1.251
Residual deviancea 76.6
DIC 318.948
a Compared 65 data points.
TABLE 156 Results of model G1: treatment effects (on a probit scale) and the different cut-off points (PASI 50,
PASI 75 and PASI 90)
Treatment/parameter
Treatment effects
Mean Median 97% CrI
Baseline effect 0.984 0.983 0.867 to 1.103
300mg of SEC 1.935 1.932 2.612 to 1.287
150mg of SEC 1.869 1.865 2.528 to 1.236
CZP 0.874 0.873 1.237 to 0.519
UST 1.131 1.131 1.402 to 0.863
GOL 1.641 1.635 2.097 to 1.212
ADA 1.478 1.476 1.834 to 1.136
INF 2.280 2.276 2.730 to 1.847
ETN 0.800 0.797 1.645 to 0.021
APR 0.748 0.748 0.983 to 0.510
z1, PASI 50   
z2, PASI 75 0.578 0.577 0.516 to 0.642
z3, PASI 90 1.136 1.136 1.043 to 1.235
Residual deviancea 62.54
DIC 297.153
a Compared 61 data points.
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A key difference between the NMAs presented concerns the trials included in each analysis. Only the AGs
NMA for the biologic-naive subgroup includes all comparators and all trials. The Rodgers et al.33 analysis
was limited to the treatments available at that time. The UCB Pharma analysis for the biologic-naive
subgroup includes all treatments, but misses only some APR trials. The Novartis NMA for the biologic-naive
subgroup does not include CZP or APR and does not include all trials for the other treatments. The AG
considered to exclude the RAPID-PsA trial47 in the NMA for the biologic-experienced subgroup, whereas
UCB Pharma included the trial data in the analysis. Novartis did not conduct a NMA for this outcome for
the biologic-experienced subgroup.
Another key difference between the models was the assumption of effects on studies. The AG and
Rodgers et al.33 consider fixed effects on studies, whereas UCB Pharma and Novartis consider random
effect on studies for the biologic-naive subgroup and fixed effect on studies for the biologic-experienced
subgroup analysis. Another difference was the primary time point used. The AG, a previous MTA and
Novartis conducted analyses at the 12-week time point, whereas UCB Pharma conducted primary analysis
at 24 weeks and a sensitivity analysis considering the 12-week time point.
Table 160 shows the NMA results for (probabilities of) PASI response for the biologic-naive subpopulation
estimated by the four NMAs. Across all the analyses, INF has the highest effectiveness following SEC
among the treatment evaluated. The estimated probabilities in the AGs analysis are more precise than
either of the CSs.
Given the differences in model assumptions and the included studies, the results are slightly different for
GOL, ADA and ETN. Between the previous and current assessment, differences in the ADA estimates are
the result of additional data on ADA from the SPIRIT-P1.57,67 In the Novartis submission, the estimated
probabilities are much lower for 50 mg of GOL. The differences are plausible as the AG and Novartis used
TABLE 157 Results of model G2: treatment effects (on a probit scale) and the different cut-off points (PASI 50,
PASI 75 and PASI 90)
Treatment/parameter
Treatment effects
Mean Median 97% CrI
Baseline effect 1.016 1.015 0.888 to 1.153
300mg of SEC 1.860 1.864 2.330 to 1.363
150mg of SEC 1.793 1.798 2.231 to 1.316
CZP 1.433 1.424 1.888 to 1.040
UST 1.346 1.342 1.596 to 1.121
GOL 1.127 1.141 1.499 to 0.667
ADA 1.421 1.422 1.668 to 1.167
INF 1.788 1.798 2.173 to 1.313
ETN 0.846 0.849 1.478 to 0.198
APR 0.816 0.815 0.999 to 0.640
Beta 1.310 1.297 2.164 to 0.495
z1, PASI 50   
z2, PASI 75 0.582 0.582 0.520 to 0.647
z3, PASI 90 1.141 1.141 1.044 to 1.238
Residual deviancea 58.44
DIC 293.702
a Compared 61 data points.
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different sets of data and model assumptions. In the UCB Pharma submission, the estimated probabilities
for ETN are much lower than obtained in previous and current assessments. The difference is largely
because UCB Pharma used different PASI 50 response data in the analysis.
Rodgers et al.33 and Novartis did not include an analysis for the treatment-experienced subgroup. Table 161
presents the PASI results from the AG and UCB Pharma NMAs for the biologic-experienced subpopulation.
However, the results are not comparable between the AG and UCB Pharma analyses as probabilities were
estimated at two different time points (12 weeks and 24 weeks), and it is evident that the PASI response
differs between these two time points.
TABLE 158 Comparison of evidence synthesis of PASI responses in the CSs (Novartis and UCB Pharma), a previous
MTA33 and the current AG
Domains
compared Rodgers et al., 201133
CS
AGNovartis UCB Pharma
Model Conditional multinomial
probit model
Conditional
multinomial probit
model
Conditional multinomial
probit model
Conditional multinomial
probit model
Results
reported
Probability of PASI
response in three
categories: 50, 75
and 90
Probability of PASI
response in three
categories: 50, 75
and 90
Probability of PASI
response in three
categories: 50, 75
and 90
Probability of PASI
response in three
categories: 50, 75
and 90
Time points At 12 weeks (data from
the 12-week or closest
time point after 12
weeks  normally 14 or
16 weeks)
At 12 weeks (data
from the 12-week or
closest time point
after 12 weeks 
normally 14 or
16 weeks)
Primary analysis at
24 weeks (by
treatments), sensitivity
analysis was conducted
at 12 weeks including
data on 12 weeks or
closest time point after
12 weeksa
At 12 weeks (data from
the 12-week or closest
time point after
12 weeks  normally
14 or 16 weeks)
Comments Modelled probabilities
are presented
graphically
Data regarding subpopulation of biologic naive
Studies used
in the analysis
ADEPT;55 IMPACT;51
IMPACT 2;52 and Mease
et al.53
,54
ADEPT;55 FUTURE 2;48
GO-REVEAL;50 and
IMPACT 252
ADEPT;55 GO-REVEAL;50
IMPACT;51 IMPACT 2;52
SPIRIT-P1;57,67 Mease
et al.;53 and RAPID-PsA47
(1216 weeks analysis)
ADEPT;55 FUTURE 2;48
GO-REVEAL;50 IMPACT;51
IMPACT 2;52 Mease
et al.;53 PALACE 1;60
PALACE 2;61 PALACE 3;65
PSUMMIT 1;58 PSUMMIT
2;59,66 RAPID-PsA;47 and
SPIRIT-P157,67
Drugs
evaluated
40mg of ADA; 5 mg/kg
of INF; and 25mg of
ETN
40mg of ADA; 50 mg
of GOL and 100mg;
5 mg/kg of INF; and
150 and 300mg of
SEC
40 mg of ADA; 400 mg
of CZP; 25 mg of ETN;
50 mg of GOL; and
5 mg/kg of INF
40 mg of ADA; 30 mg
of APR; 400 mg of CZP;
25 mg of ETN; 50 mg of
GOL; 5 mg/kg of INF;
150 and 300mg of
SEC; and 45mg of UST
Data regarding subpopulation of biologic experienced
Studies used
in the analysis
  FUTURE 2;48 PSUMMIT
2;59,66 and RAPID-PsA47
(24-week analysis)
FUTURE 2;48 and
PSUMMIT 259,66
Drugs
evaluated
  CZP; 300 mg of SEC;
and 45mg of UST
300mg of SEC; and
45mg of UST
a The AG considers results at 12 weeks to compare with our results.
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TABLE 159 Key assumptions in the synthesis models for PASI responses in the CSs (Novartis and UCB Pharma),
a previous MTA33 and the current AG
Domains
compared
Rodgers et al.,
201133
CS
AGNovartis UCB Pharma
Model Conditional
multinomial probit
model
Conditional
multinomial probit
model
Conditional multinomial
probit model
Conditional multinomial
probit model
Fixed or
random
effects
between
studies
Fixed effects on
studies
Random effects on
studies for biologic-
naive subpopulation
analysis
Random effects on studies
for biologic-naive
subpopulation analysis
and fixed effects for
biologic-experienced
subpopulation analysis
Fixed effects on studies
(for both biologic-naive
and biologic-experienced
subpopulation)
Baselines Common-effect
model was used
to estimate
baseline
Common-effect
model was used to
estimate baseline
Common-effect model was
used to estimate baseline
Common-effect model was
used to estimate baseline
Treatment
effects
Treatments were
assumed to be
independent of
each other
Treatments were
assumed to be
independent of each
other
Treatments were assumed
to be independent of each
other
Treatments were assumed to
be independent of each other
Model
adjusted for
the placebo
response
Unadjusted Unadjusted Unadjusted Considered both unadjusted
and adjusted model for
biologic-naive subpopulation;
considered unadjusted model
for biologic-experienced
subpopulation
Interaction
term (beta)
   Common interaction term for
adjusted model
Probit/logit
score
thresholds
Thresholds were
assumed to be
fixed across trials
Thresholds were
assumed to be fixed
across trials
Thresholds were assumed
to be fixed across trials
Thresholds were assumed to
be fixed across trials
TABLE 160 Comparison of PASI response in the CSs (Novartis and UCB Pharma), a previous MTA33 and the current
AG in the biologic-naive subpopulation
Treatment
Probability of PASI responses in the biologic-naive subpopulation at 12 weeks (12–16 weeks)
Rodgers et al.
(2011),33 mean
(95% CrI)
CS AG, median (95% CI)
Novartis,
mean
UCB Pharma,
mean (95% CI) Unadjusted Adjusted
Placebo
PASI 50 0.131 (0.09 to 0.18) Confidential
information has
been removed
Confidential
information has
been removed
0.15 (0.13 to 0.18) 0.16 (0.12 to 0.19)
PASI 75 0.045 (0.03 to 0.07) Confidential
information has
been removed
Confidential
information has
been removed
0.05 (0.04 to 0.07) 0.06 (0.04 to 0.07)
PASI 90 0.017 (0.01 to 0.03) Confidential
information has
been removed
Confidential
information has
been removed
0.02 (0.01 to 0.02) 0.02 (0.01 to 0.02)
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TABLE 160 Comparison of PASI response in the CSs (Novartis and UCB Pharma), a previous MTA33 and the current
AG in the biologic-naive subpopulation (continued )
Treatment
Probability of PASI responses in the biologic-naive subpopulation at 12 weeks (12–16 weeks)
Rodgers et al.
(2011),33 mean
(95% CrI)
CS AG, median (95% CI)
Novartis,
mean
UCB Pharma,
mean (95% CI) Unadjusted Adjusted
300mg of SEC
PASI 50 NC Confidential
information has
been removed
NC 0.82 (0.61 to 0.94) 0.80 (0.62 to 0.91)
PASI 75 Confidential
information has
been removed
0.63 (0.38 to 0.84) 0.60 (0.40 to 0.78)
PASI 90 Confidential
information has
been removed
0.41 (0.19 to 0.67) 0.38 (0.21 to 0.58)
150 mg of SEC
PASI 50 NC Confidential
information has
been removed
NC 0.80 (0.59 to 0.93) 0.78 (0.60 to 0.90)
PASI 75 Confidential
information has
been removed
0.60 (0.36 to 0.82) 0.58 (0.38 to 0.75)
PASI 90 Confidential
information has
been removed
0.38 (0.18 to 0.63) 0.36 (0.19 to 0.54)
CZP
PASI 50 NC NC Confidential
information has
been removed
0.44 (0.31 to 0.59) 0.66 (0.50 to 0.82)
PASI 75 Confidential
information has
been removed
0.23 (0.14 to 0.36) 0.43 (0.29 to 0.63)
PASI 90 Confidential
information has
been removed
0.10 (0.05 to 0.18) 0.23 (0.13 to 0.41)
UST
PASI 50 NC NC NC 0.54 (0.44 to 0.65) 0.63 (0.52 to 0.74)
PASI 75 0.32 (0.23 to 0.42) 0.40 (0.30 to 0.52)
PASI 90 0.15 (0.09 to 0.22) 0.21 (0.14 to 0.31)
50 mg of GOL
PASI 50 NC Confidential
information has
been removed
Confidential
information has
been removed
0.73 (0.58 to 0.86) 0.55 (0.36 to 0.70)
PASI 75 Confidential
information has
been removed
Confidential
information has
been removed
0.51 (0.35 to 0.68) 0.32 (0.17 to 0.48)
PASI 90 Confidential
information has
been removed
Confidential
information has
been removed
0.30 (0.17 to 0.47) 0.15 (0.07 to 0.27)
continued
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TABLE 160 Comparison of PASI response in the CSs (Novartis and UCB Pharma), a previous MTA33 and the current
AG in the biologic-naive subpopulation (continued )
Treatment
Probability of PASI responses in the biologic-naive subpopulation at 12 weeks (12–16 weeks)
Rodgers et al.
(2011),33 mean
(95% CrI)
CS AG, median (95% CI)
Novartis,
mean
UCB Pharma,
mean (95% CI) Unadjusted Adjusted
ADA
PASI 50 0.738 (0.55 to 0.88) Confidential
information has
been removed
Confidential
information has
been removed
0.68 (0.55 to 0.78) 0.66 (0.54 to 0.76)
PASI 75 0.477 (0.28 to 0.69) Confidential
information has
been removed
Confidential
information has
been removed
0.45 (0.32 to 0.58) 0.43 (0.32 to 0.55)
PASI 90 0.257 (0.12 to 0.45) Confidential
information has
been removed
Confidential
information has
been removed
0.24 (0.15 to 0.36) 0.23 (0.15 to 0.33)
INF
PASI 50 0.913 (0.82 to 0.97) Confidential
information has
been removed
Confidential
information has
been removed
0.92 (0.84 to 0.96) 0.78 (0.61 to 0.88)
PASI 75 0.769 (0.59 to 0.90) Confidential
information has
been removed
Confidential
information has
been removed
0.79 (0.67 to 0.88) 0.58 (0.39 to 0.73)
PASI 90 0.557 (0.35 to 0.77) Confidential
information has
been removed
Confidential
information has
been removed
0.59 (0.44 to 0.73) 0.36 (0.20 to 0.52)
ETN
PASI 50 0.403 (0.24 to 0.59) NC Confidential
information has
been removed
0.41 (0.15 to 0.72) 0.43 (0.20 to 0.69)
PASI 75 0.177 (0.09 to 0.31) Confidential
information has
been removed
0.21 (0.05 to 0.50) 0.23 (0.08 to 0.47)
PASI 90 0.074 (0.03 to 0.15) Confidential
information has
been removed
0.08 (0.01 to 0.29) 0.10 (0.02 to 0.26)
APR
PASI 50 NC NC NC 0.39 (0.31 to 0.49) 0.42 (0.33 to 0.52)
PASI 75 0.20 (0.14 to 0.27) 0.22 (0.16 to 0.30)
PASI 90 0.08 (0.05 to 0.12) 0.09 (0.06 to 0.14)
NC, not conducted.
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TABLE 161 Comparison of PASI response in the UCB Pharma submission and the current AG in the biologic-experienced
subpopulation
Treatment
Probability of PASI responses in the biologic-experienced subpopulation, mean (95% CrI)
UCB Pharma, at 24 weeks AG, at 12 weeks (12–16 weeks)
Placebo
PASI 50 Confidential information has been removed 0.088 (0.01 to 0.28)
PASI 75 Confidential information has been removed 0.012 (0.00 to 0.06)
PASI 90 Confidential information has been removed 0.002 (0.00 to 0.02)
300 mg of SEC
PASI 50 Confidential information has been removed 0.875 (0.46 to 1.00)
PASI 75 Confidential information has been removed 0.598 (0.23 to 0.89)
PASI 90 Confidential information has been removed 0.365 (0.08 to 0.75)
UST
PASI 50 Confidential information has been removed 0.628 (0.29 to 0.89)
PASI 75 Confidential information has been removed 0.279 (0.07 to 0.61)
PASI 90 Confidential information has been removed 0.120 (0.01 to 0.42)
CZP
PASI 50 Confidential information has been removed NC
PASI 75 Confidential information has been removed NC
PASI 90 Confidential information has been removed NC
NC, not conducted.
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WinBUG codes of preferred model
Model F1: 
model{ 
for(i in 1:N){  
p[i,1] <- 1  
for (j in 1:nc[i]-1) {  
r[i,j] ~ dbin(q[i,j],n[i,j])  
q[i,j] <- 1-(p[i,C[i,j+1]]/p[i,C[i,j]]) 
z.index[i,j]<- C[i,j+1]-1 
theta[i,j] <- mu[s[i]] + (d[t[i]] - d[t[1]])*(1-equals(t[i],b[i])) + z[z.index[i,j]] 
rhat[i,j] <- q[i,j] * n[i,j]  
dv[i,j] <- 2 * (r[i,j]*(log(r[i,j])-log(rhat[i,j])) + (n[i,j]-r[i,j])*(log(n[i,j]-r[i,j]) - log(n[i,j]-
rhat[i,j]))) 
} 
  dev[i] <- sum(dv[i,1:nc[i]-1]) 
 for (j in 2:nc[i]) {  
  p[i,C[i,j]] <- 1 - phi.adj[i,j]  
  phi.adj[i,j] <- phi(theta[i,j-1]) 
   } 
 } 
totresdev <- sum(dev[])  
z[1] <- 0  
for (j in 2:Cmax-1) { 
 z.aux[j] ~ dunif(0,5)  
 z[j] <- z[j-1] + z.aux[j]  
  } 
d[1] <- 0  
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }  
for(i in 1:ns){ mu[i] ~ dnorm(0,.000001)} 
for (i in 1:ns) {mu1[i]<-mu[i]*equals(t[1],1)} 
A<-sum(mu1[])/ns 
# calculate prob of achieving PASI50,75,90 on treat k 
for (k in 1:nt) { 
for (j in 1: Cmax-1) { T[j,k] <- 1 - phi(A + d[k] + z[j]) } 
} 
} 
 
Model G2: 
model{ 
for(i in 1:N){ 
            p[i,1] <- 1 
            for (j in 1:nc[i]-1) { 
                        r[i,j] ~ dbin(q[i,j],n[i,j]) 
                        q[i,j] <- 1-(p[i,C[i,j+1]]/p[i,C[i,j]]) 
                        z.index[i,j]<- C[i,j+1]-1 
                        theta[i,j] <- mu[s[i]] + d[t[i]] + z[z.index[i,j]] 
                                    + betaplac * (mu[s[i]] - Mean) * (1-equals(t[i],1))   
                        rhat[i,j] <- q[i,j] * n[i,j] 
         dv[i,j] <- 2 * (r[i,j]*(log(r[i,j])-log(rhat[i,j])) + (n[i,j]-r[i,j])*(log(n[i,j]-r[i,j]) - log(n[i,j]-rhat[i,j]))) 
                                    } 
                        dev[i] <- sum(dv[i,1:nc[i]-1]) 
            for (j in 2:nc[i]) { 
p[i,C[i,j]] <- 1 - phi.adj[i,j] 
phi.adj[i,j] <- phi(theta[i,j-1]) 
              } 
} 
totresdev <- sum(dev[]) 
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
262
z[1] <- 0 
for (j in 2:Cmax-1) { 
z.aux[j] ~ dunif(0,5) 
z[j] <- z[j-1] + z.aux[j] 
                                    } 
d[1] <- 0 
for (k in 2:nt){ d[k] ~ dnorm(0,0.01) } 
for(i in 1:ns){ mu[i] ~ dnorm(0,0.01)} 
betaplac ~ dnorm(0,0.01) 
for (i in 1:ns) {mu1[i]<-mu[i]*equals(t[1],1)} 
A<-sum(mu1[])/ns 
# calculate prob of achieving PASI50,75,90 on treat k 
for (k in 1:nt) { 
for (j in 1: Cmax-1) { T[j,k] <- 1 - phi(A + d[k] + z[j]) } 
} 
} 
d[1]=PLA, d[2]=SEC300, d[3]=SEC150, d[4]=CZP, d[5]=UST, d[6]=GOL, d[7]=ADA, d[8]=INF, d[9]=ETA, 
d[10]=APR 
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American College of Rheumatology response
Detailed methods for the biologic-naive subpopulation
The NMA for ACR utilised a similar framework of analysis to that used to estimate probability of PASI
responses. In brief, the model considered a multinomial likelihood and a probit link for ordered
categorical data.117
Analogously to the analyses on PsARC, sets of alternative assumptions were tested. We explored the effect
of differences in trial-specific placebo responses on treatment effect undertaking a metaregression. In the
context of an adjusted model for placebo response, we explored the possibility of there being class effects.
Three different class groupings were considered: all treatments as a single class; all biologics as a class
with APR separate; and, to reflect the pharmacology, anti-TNFs grouped, ILs grouped and APR separate.
Additionally, we explored two within-class assumptions: assuming treatments within a class to have equal
effectiveness and, alternatively, assuming that those treatments within a class have similar (exchangeable)
effectiveness. Fixed effects across studies were assumed for all models. We have not considered models
assuming exchangeability between classes.
Summary of all treatment effect models explored
All models implemented for evidence synthesis of ACR response are presented in Table 162. Detailed
coding of the models is presented in Table 163.
Model H1 considers that the effectiveness of each treatment is independent of the effectiveness of other
treatments. Model I1 considers the relative effectiveness of the alternative treatments to be independent of
the effectiveness of other treatments, but that the effectiveness of all treatments depends on the response
in the placebo arm. Model J1 considers the treatments to be equal in terms of their effectiveness, but
dependent on the effect of the placebo arm. Models J2 and J3 consider the treatments to be equal in
terms of their effectiveness within class, but dependent on the effect of the placebo arm. Models K1 and
K2 assume the treatments to have a similar, but not equal, effectiveness and to be dependent on the
TABLE 162 Key assumptions of models implemented for evidence synthesis of ACR response
Sets of
analysis
Between studies
assumption Treatment Metaregression Class
H1 FE Independent No baseline adjustment No class effect
I1 FE Independent Common interaction term
with baseline effect
No class effect
J1 FE Equal | class Common interaction term
with baseline effect
Independent class effect:
class= {all treatments}
J2 FE Equal | class, remaining
treatments independenta
Independent class effect:
class= APR independent
{all remaining biologics}
J3 FE Equal | class, remaining
treatments independenta
Independent class effect:
class= {anti-TNFs, ILs};
APR independent
K1 FE Exchangeable | class,
remaining treatments
independenta
Common interaction term
with baseline effect
Independent class effect:
class= APR independent
{all other biologics}
K2 FE Exchangeable | class,
remaining treatments
independenta
Independent class effect:
class= {anti-TNFs, ILs};
APR independent
FE, fixed effect.
a APR independent.
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effect of the placebo arm; this model introduces more flexibility than those that assume treatment effects
to be equal (models J2 and J3), but does not fully assume treatments to differ as in model H1. It does
imply that there are differences between the effectiveness of treatments that we may not be able to
explain but that we should consider. These may be a result of differences between the treatments
themselves or because of differences in the design of the trials used to evaluate each treatment.
TABLE 163 Description of models and underlying assumptions for ACR response
Model H1 Model I1
Likelihood
r ikjeBinomial(pikj , nikj )
Model
qikj = 1−(pikC i, j+1 /pikC i, j )
θikj = µi + δt i, k−δt i, 1 + z j
pikC ij = 1−ADikj
ADikj = ϕ(θik, j−1)
Priors(anti − TNF − naive− analysis)
δtednorm(0,0:000001)
µiednorm(0,0:000001)
z jedunif (0,5)
Priors(anti − TNF − experiensed − analysis)
δtednorm(0,0:01)
µiednorm(0,0:01)
z jedunif (0,5)
Likelihood
r ikjeBinomial(pikjnikj )
Model
qikj = 1−(pikC i, j+1 /pikC i, j )
θikj = µi + δt i, k− δt i, 1 + z j + β(µi − µ)
pikC ij = 1− ADikj
ADikj = ϕ(θik, j−1)
Priors
δtednorm(0,0:01)
µiednorm(0,0:01)
β
e
dnorm(0,0:01)
z jedunif (0,5)
Assumptions:
l baselines are unconstrained
l treatments effects are independent
l fixed effects between studies
l fixed effect for each of the j  1 categories
over all trials
Assumptions:
l baselines are unconstrained
l treatments effects are independent
l fixed effects between studies
l fixed effect for each of the j  1 categories over all trials
l common interaction term between studies
Models J1, J2 and J3 Models K1 and K2
Likelihood
r ikjeBinomial(pikjnikj )
Model
qikj = 1− (pikC i, j+1 /pikC i, j )
θikj = µi + δt i, k−δt i, 1 + z j + β(µi − µ)
pikC ij = 1− ADikj
ADikj = ϕ(θik, j−1)
δteδc
Priors
δcednorm(0,0:01)
µiednorm(0,0:01)
β
e
dnorm(0,0:01)
z jedunif (0,5)
Likelihood
r ikjeBinomial(pikjnikj )
Model
qikj = 1− (pikC i, j+1 /pikC i, j )
θikj = µi + δt i, k− δt i, 1 + z j + β(µi − µ)
pikC ij = 1−ADikj
ADikj = ϕ(θik, j−1)
δtednorm(Classc, 1/γ
2)
Priors
Classcednorm(0,0:01)
µiednorm(0,0:01)
β
e
dnorm(0,0:01)
z jedunif (0,5)
γ
e
dunif (0,10)
J1: class = {all biologics} K1: APR independent; class= {all other biologics}
J2: APR independent; class = {all other biologics} K2: class= {anti-TNFs, ILs}; APR independent
J3: class = {anti-TNFs, ILs}; APR independent
Assumptions:
l baselines are unconstrained
l the treatments effects are equal within class
l fixed effects between studies
l fixed effect for each of the j  1 categories
over all trials
l common interaction term between studies
Assumptions:
l baselines are unconstrained
l a random effect is used to describe differences between treatments
(exchangeability is assumed)
l fixed effects between studies
l fixed effect for each of the j  1 categories over all trials
l common interaction term between studies
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Detailed results for the biologic-naive subpopulation
Summary results of American College of Rheumatology response
Table 164 presents the results of the treatment effects for ACR responses estimated from the seven
models with measures of goodness of fit. There were no issues with convergence.
Detailed results of American College of Rheumatology response
More detailed results of the models H1, I1, J1, J2, J3, K1 and K2 are presented in Tables 165–171.
Preferred models
The unadjusted model H1 fits the data as well as any of the other models and generates results that reflect
the observed results. Considering the placebo-adjusted models, model I1 generated results (rankings)
which do not reflect well the observed trial results; and it must be borne in mind that, without any clear
rationale for the placebo effect, the results must be interpreted with caution. Using an assumption of
equal class effect for the treatments does not produce a better-fitting model (models J1, J2 and J3) than
assuming independent treatment effects (models H1 and I1) or similar (exchangeable) treatment effects
(models K1 and K2). In addition, there was little difference in goodness-of-fit statistics (DIC and residual
deviance) between models K1 and K2, and we consider the exchangeable class effect model, which
utilised two classes (ILs and anti-TNFs) with APR separate, to be the most clinically plausible. Hence, our
preferred models are models H1 and K2.
TABLE 164 Results of ACR response: treatment effects (median) on a probit scale in the biologic-naive
subpopulation
Metaregression No Yes Yes Yes Yes Yes Yes
Treatments Ind Ind = | class {all} = | class
(APR, other)
= | class (ILs,
TNFs, APR)
∼ | classa
(APR, other)
∼ | classa
(ILs, TNFs,
APR)
Cut-off points FE FE FE FE FE FE FE
H1 rb I1 rb J1 rb J2 rb J3 rb K1 rb K2 rb
Placebo 0.952 0.961 0.882 0.966 0.966 0.963 0.961
300mg of SEC 0.914 6 1.397 2 1.274 2 1.236 3
150mg of SEC 0.932 5 1.415 1 1.094 1 1.095 1 1.283 1 1.246 2
UST 0.570 8 0.722 8 0.750 8 0.732 8
CZP 0.811 7 1.265 3 0.830 1 1.193 5 1.176 5
GOL 1.429 2 0.918 7 1.010 7 1.040 7
ADA 1.072 4 1.126 6 0.609 2 1.121 6 1.124 6
INF 1.617 1 1.212 5 1.246 3 1.269 1
ETN 1.362 3 1.214 4 1.215 4 1.228 4
APR 0.509 9 0.592 9 0.610 2 0.014 3 0.581 9 0.576 9
Beta (mean) 1.276 1.327 1.627 1.621 1.099 1.018
Residual
deviancec
120.0 119.1 156.1 148.3 148.3 120.0 120.4
DIC 482.22 480.94 511.66 503.43 503.37 480.90 481.10
= | class, equal class effect; ∼ | class, exchangeable class effect; FE, fixed effect; ind, independent.
a Shrunken estimates.
b Ranking of active treatments according to point estimates.
c Compared with 92 data points.
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TABLE 165 Results of model H1: treatment effects (on a probit scale) and the different cut-off points (ACR 20,
ACR 50 and ACR 70)
Treatment/parameter
Treatment effects
Mean Median 97% CrI
Baseline effect 0.952 0.952 0.874 to 1.031
300mg of SEC 0.915 0.914 1.319 to 0.512
150mg of SEC 0.932 0.932 1.347 to 0.525
UST 0.570 0.570 0.797 to 0.349
CZP 0.811 0.811 1.090 to 0.530
GOL 1.431 1.429 1.810 to 1.068
ADA 1.072 1.072 1.274 to 0.870
INF 1.619 1.617 1.943 to 1.306
ETN 1.364 1.362 1.688 to 1.050
APR 0.509 0.509 0.672 to 0.346
z1, ACR 20   
z2, ACR 50 0.661 0.661 0.615 to 0.709
z3, ACR 70 1.284 1.283 1.213 to 1.356
Residual deviancea 120.00
DIC 482.22
a Compared 92 data points.
TABLE 166 Results of model I1: treatment effects (on a probit scale) and the different cut-off points (ACR 20,
ACR 50 and ACR 70)
Treatment/parameter
Treatment effects
Mean Median 97% CrI
Baseline effect 0.962 0.961 0.880 to 1.046
300mg of SEC 1.402 1.397 1.890 to 0.939
150mg of SEC 1.421 1.415 1.920 to 0.953
UST 0.725 0.722 0.939 to 0.526
CZP 1.268 1.265 1.666 to 0.874
GOL 0.910 0.918 1.362 to 0.433
ADA 1.127 1.126 1.290 to 0.973
INF 1.207 1.212 1.578 to 0.812
ETN 1.209 1.214 1.455 to 0.931
APR 0.594 0.592 0.738 to 0.459
Beta 1.276 1.297 2.164 to 0.274
z1, ACR 20   
z2, ACR 50 0.661 0.661 0.615 to 0.709
z3, ACR 70 1.283 1.282 1.212 to 1.356
Residual deviancea 119.10
DIC 480.94
a Compared 92 data points.
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Comparison of evidence synthesis of American College of Rheumatology responses
in the company submissions, a previous multiple technology appraisal and the
Assessment Group
Both the Novartis and the UCB Pharma submissions combined ACR outcome evidence using Bayesian
evidence synthesis methods. Both submissions estimated probability of achieving ACR responses in three
categories (20/50/70) and conducted binary analysis of the ACR categories separately to inform clinical
effectiveness. However, the AG and a previous MTA estimated probability of achieving ACR responses in
three categories (20/50/70) to inform clinical effectiveness. Therefore, the comparison between the CSs
and AG is limited to the estimation of probability of achieving ACR responses in three categories (20/50/70).
A brief comparison of the methods used with key model assumptions, by the AG, CSs and a previous MTA,
is presented in Tables 172 and 173.
TABLE 167 Results of model J1: treatment effects (on a probit scale) and the different cut-off points (ACR 20,
ACR 50 and ACR 70)
Treatment/parameter
Treatment effects
Mean Median 97% CrI
Baseline effect 0.882 0.882 0.812 to 0.953
All biologics as a class 0.825 0.830 0.992 to 0.624
Beta 1.327 1.236 0.399 to 2.792
z1, ACR 20   
z2, ACR 50 0.656 0.655 0.610 to 0.702
z3, ACR 70 1.272 1.272 1.201 to 1.345
Residual deviancea 156.1
DIC 511.66
a Compared 92 data points.
TABLE 168 Results of model J2: treatment effects (on a probit scale) and the different cut-off points (ACR 20,
ACR 50 and ACR 70)
Treatment/parameter
Treatment effects
Mean Median 97% CrI
Baseline effect 0.967 0.966 0.886 to 1.051
All biologics (except APR) 1.095 1.094 1.190 to 1.005
APR 0.614 0.610 0.773 to 0.474
Beta 1.627 1.627 2.365 to 0.926
z1, ACR 20   
z2, ACR 50 0.657 0.656 0.611 to 0.704
z3, ACR 70 1.272 1.271 1.201 to 1.345
Residual deviancea 148.30
DIC 503.43
a Compared 92 data points.
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TABLE 169 Results of model J3: treatment effects (on a probit scale) and the different cut-off points (ACR 20,
ACR 50 and ACR 70)
Treatment/parameter
Treatment effects
Mean Median 97% CrI
Baseline effect 0.967 0.966 0.886 to 1.049
ILs as class 1.095 1.095 1.189 to 1.005
Anti-TNFs as class 0.612 0.609 0.767 to 0.474
APR 0.021 0.014 19.450 to 19.720
Beta 1.621 1.619 2.349 to 0.918
z1, ACR 20
z2, ACR 50 0.657 0.656 0.611 to 0.704
z3, ACR 70 1.272 1.271 1.201 to 1.344
Residual deviancea 148.30
DIC
a Compared 92 data points.
TABLE 170 Results of model K1: treatment effects (on a probit scale) and the different cut-off points (ACR 20,
ACR 50 and ACR 70)
Treatment/parameter
Predicted mean distribution Shrunken or independent estimates
Mean Median 97% CrI Mean Median 97% CrI
Baseline effect    0.963 0.963 0.880 to 1.049
300mg of SEC 1.137 1.135 1.750 to 0.534 1.278 1.274 1.582 to 0.994
150mg of SEC 1.287 1.283 1.597 to 0.998
UST 0.750 0.750 0.919 to 0.582
CZP 1.195 1.193 1.437 to 0.961
GOL 1.007 1.010 1.264 to 0.733
ADA 1.122 1.121 1.257 to 0.990
INF 1.244 1.246 1.479 to 1.005
ETN 1.214 1.215 1.410 to 1.013
APR    0.581 0.581 0.700 to 0.465
Beta    1.099 1.103 1.646 to 0.534
γa    0.264 0.240 0.123 to 0.547
z1, ACR 20      
z2, ACR 50    0.660 0.660 0.614 to 0.709
z3, ACR 70    1.280 1.280 1.209 to 1.354
Residual devianceb 120.00
DIC 480.90
a Variance parameter for the random effect across biologics (excluding APR).
b Compared 92 data points.
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Like other outcomes, a key difference between the ACR NMAs presented concerned the trials included in
each analysis. The AGs NMA for the biologic-naive subgroup includes all comparators and all trials.
Rodgers et al.s33 analysis was limited to the treatments available at that time. The UCB Pharma analysis for
the biologic-naive subgroup includes all treatments, but misses one APR trial. The Novartis NMA for the
biologic-naive subgroup included a more complete set of treatments and trials for this outcome. Both
submissions included the RAPID-PsA trial47 in the biologic-experienced subgroup analysis, whereas the
AG excluded the RAPID-PsA trial47 from the analysis. It should be noted that this comparison refers to
Novartis NMAs of subgroups. As mentioned before, the Novartis submission presented a NMA for all
patients (treatment naive and experienced combined).
A key difference between models was the assumption of effects on studies. The AG and Rodgers et al.33
consider fixed effects on studies, whereas UCB Pharma and Novartis consider random effect on studies for
the biologic-naive subgroup and fixed effect on studies for the biologic-experienced subgroup analysis.
Like other outcomes, another key difference relates to the primary time point used. The AG, the previous
MTA and Novartis conducted analyses at the 12-week time point, whereas UCB Pharma conducted
primary analysis at 24 weeks and sensitivity analysis considering a 12-week time point.
Table 174 shows the three NMA results for (probabilities of) ACR response for the biologic-naive
subpopulation. In comparison with the Novartis analysis and the AG unadjusted analysis, the estimated
probabilities in the three categories are lower for INF, but higher for ADA. The differences are largely
because Novartis included a different data set. UCB Pharma chose binary analysis of ACR 20 and ACR 50
TABLE 171 Results of model K2: treatment effects (on a probit scale) and the different cut-off points (ACR 20,
ACR 50 and ACR 70)
Treatment/parameter
Predicted mean distribution Shrunken or independent estimates
Mean Median 97% CrI Mean Median 97% CrI
Baseline effect    0.961 0.961 0.878 to 1.046
300mg of SEC 1.069 1.054 1.869 to 0.345 1.234 1.236 1.609 to 0.845
150mg of SEC 1.243 1.246 1.628 to 0.854
UST 0.733 0.732 0.913 to 0.552
CZP 1.167 1.170 1.862 to 0.464 1.178 1.176 1.443 to 0.924
GOL 1.038 1.040 1.350 to 0.718
ADA 1.123 1.124 1.259 to 0.988
INF 1.268 1.269 1.530 to 1.003
ETN 1.228 1.228 1.432 to 1.021
APR    0.576 0.576 0.700 to 0.453
Beta 1.018 1.028 1.671 to 0.334
γa 0.280 0.248 0.107 to 0.643
z1, ACR 20      
z2, ACR 50 0.661 0.660 0.615 to 0.708
z3, ACR 70 1.281 1.281 1.210 to 1.354
Residual devianceb 120.40
DIC
a Variance parameter for the random effect across biologics (excluding APR).
b Compared 92 data points.
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TABLE 172 Comparison of evidence synthesis of ACR responses in CSs (Novartis and UCB Pharma), the previous
MTA and the current AG
Domains
compared
Rodgers et al.,
201133
CS
AGNovartis UCB Pharma
Model Conditional
multinomial probit
model
Conditional multinomial
probit model
Conditional multinomial
probit model
Conditional multinomial
probit model
Results
reported
Probability of ACR
response in three
categories 20/50/70
Probability of ACR
response in three
categories 20/50/70
Probability of ACR
response in three
categories 20/50/70 for
biologic-experienced
subpopulation, but did
not present probabilities
for the biologic-naive
subpopulation
Probability of ACR
response in three
categories 20/50/70
Time points At 12 weeks (data
from the 12-week
or closest time point
after 12 weeks 
normally 14 or
16 weeks)
At 12 weeks (data from
the 12-week or closest
time point after
12 weeks  normally
14 or 16 weeks)
Primary analysis at
24 weeks (by
treatments), sensitivity
analysis was conducted
at 12 weeks including
data on 12 weeks or
closest time point after
12 weeksa
At 12 weeks (data from
the 12-week or closest
time point after
12 weeks  normally
14 or 16 weeks)
Comments Modelled probabilities
are presented
graphically
Data regarding biologic-naive subpopulation
Studies
used in the
analysis
ADEPT;55 Genovese
et al.;56 IMPACT;51
IMPACT 2;52 and
Mease et al.53,54
ADEPT;55 FUTURE 2;48
Genovese et al.;56
GO-REVEAL;50
IMPACT 2;52 Mease
et al.;54 PALACE 1;60
PSUMMIT 1;58
PSUMMIT 2;59,66 and
RAPID-PsA47
ADEPT;55 Genovese
et al.;56 GO-REVEAL;50
IMPACT;51 IMPACT 2;52
SPIRIT-P1;57,67 PALACE 1;60
PALACE 3;65 PSUMMIT 1;58
Mease et al.;53,54 and
RAPID-PsA47 (1216 weeks
analysis)
ADEPT;55 FUTURE 2;48
Genovese et al.;56
GO-REVEAL;50 IMPACT 2;52
Mease et al.;54 PALACE 1;60
PALACE 2;61 PALACE 3;65
PSUMMIT 1;58 PSUMMIT
2;59,66 RAPID-PsA;47 and
SPIRIT-P157,67
Drugs
evaluated
40mg of ADA;
5 mg/kg of INF; and
25mg of ETN
40mg of ADA; 20 and
30mg of APR; 200 and
400mg of CZP; 25 mg
of ETN; 50 and 100mg
of GOL; 5 mg/kg of INF;
150 and 300mg of SEC;
45 and 90mg of UST
40mg of ADA; 20 mg of
APR and 30mg; 400 mg
of CZP; 25 mg of ETN;
50 mg of GOL; and
5mg/kg of INF
40 mg of ADA; 30 mg
of APR; 400 mg of CZP;
25 mg of ETN; 50 mg of
GOL; 5 mg/kg of INF; 150
and 300mg of SEC; and
45mg of UST
Data regarding biologic-experienced subpopulation
Studies
used in the
analysis
NC FUTURE 2;48 PALACE 1;60
PSUMMIT 2;59,66 and
RAPID-PsA47
bFUTURE 1;46 FUTURE 2;48
PSUMMIT 2;59,66 and
RAPID-PsA47 (24 weeks
analysis)
FUTURE 2;48 and
PSUMMIT 259,
Drugs
evaluated
NC 20 and 30mg of APR;
200 and 400mg of CZP;
150 and 300mg of SEC;
and, 45 and 90mg of
UST
CZP; 300 mg of SEC; and
45mg of UST
300mg of SEC; and
45mg of UST
NC, not conducted.
a The AG considers results at 12 weeks to compare with our results.
b Included patients from the Latin America sites.
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over probability of achieving ACR responses in three categories (20/50/70) to be the preferred analysis, and
did not present the results of probability of ACR responses for the biologic-naive subgroup. Therefore, it
was not plausible to compare the AGs results for the biologic-naive population with UCB Pharma results.
While comparing results of the biologic-experienced subgroup, the results are not comparable between
the AG and UCB Pharma, as probabilities were estimated at two different time points (12 weeks and
24 weeks). There are differences in the Novartis and AG estimates, largely because Novartis included a
different data set (Table 175).
TABLE 173 Key assumptions in the synthesis models for ACR responses in CSs (Novartis and UCB Pharma),
the previous MTA and the current AG
Domains
compared
Rodgers et al.,
201133
CS
AGNovartis UCB Pharma
Model Conditional
multinomial
probit model
Conditional multinomial
probit model
Conditional multinomial
probit model
Conditional multinomial probit
model
Fixed or
random
effects
between
studies
Fixed effects on
studies
Random effect on
studies for biologic-naive
subgroup analysis; and
fixed effects on studies
for biologic-experienced
subgroup analysis
Random effect on
studies for biologic-naive
subpopulation analysis
and fixed effect for
biologic-experienced
subpopulation analysis
Fixed effects on studies (for
both subpopulation analyses)
Baselines Common-effect
model was used
to estimate
baseline
Common-effect model
was used to estimate
baseline
Common-effect model
was used to estimate
baseline
Common-effect model was
used to estimate baseline
Treatment
effects
Treatments were
assumed to be
independent of
each other
Treatments were
assumed to be
independent of each
other
Treatments were
assumed to be
independent of each
other
For the biologic-naive
subpopulation:
1. Treatments were assumed
to be independent of
each other
2. Treatments as class-
considering treatments are
similar within class (i.e.
exchangeable class effect)
and utilise two classes
(ILs and anti-TNFs)
For the biologic-experienced
subpopulation, treatments
were assumed to be
independent of each other
Model
adjusted
for the
placebo
response
Unadjusted Unadjusted Unadjusted Independent treatment
effects model was unadjusted,
but analysis assuming
exchangeable class effects
model was adjusted for the
placebo response
Interaction
term (beta)
   Common interaction term for
adjusted model
Probit/logit
score
thresholds
Thresholds were
assumed to be
fixed across trials
Thresholds were
assumed to be fixed
across trials
Thresholds were
assumed to be fixed
across trials
Thresholds were assumed to
be fixed across trials
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TABLE 174 Comparison of ACR response in the CSs (Novartis and UCB Pharma), the previous MTA and the current
AG in the biologic-naive subpopulation
Treatment
Probability of ACR responses in the biologic-naive subpopulation at 12 weeks (12–16 weeks)
Rodgers et al.
(2011),33 mean
(95% CrI) Novartis, mean
AG, median (95% CrI)
Unadjusted Adjusted
Placebo
ACR 20 0.14 (0.11 to 0.17) Confidential information
has been removed
0.17 (0.15 to 0.19) 0.17 (0.15 to 0.19)
ACR 50 0.05 (0.04 to 0.07) Confidential information
has been removed
0.05 (0.04 to 0.06) 0.05 (0.04 to 0.06)
ACR 70 0.01 (0.01 to 0.03) Confidential information
has been removed
0.01 (0.01 to 0.02) 0.01 (0.01 to 0.02)
300 mg of SEC
ACR 20 NC Confidential information
has been removed
0.49 (0.33 to 0.64) 0.61 (0.46 to 0.75)
ACR 50 Confidential information
has been removed
0.24 (0.14 to 0.38) 0.35 (0.22 to 0.50)
ACR 70 Confidential information
has been removed
0.09 (0.04 to 0.18) 0.16 (0.08 to 0.27)
150 mg of SEC
ACR 20 NC Confidential information
has been removed
0.49 (0.34 to 0.65) 0.61 (0.46 to 0.75)
ACR 50 Confidential information
has been removed
0.25 (0.14 to 0.39) 0.35 (0.22 to 0.51)
ACR 70 Confidential information
has been removed
0.10 (0.04 to 0.19) 0.16 (0.08 to 0.27)
45 mg of UST
ACR 20 NC Confidential information
has been removed
0.35 (0.27 to 0.44) 0.41 (0.34 to 0.49)
ACR 50 Confidential information
has been removed
0.15 (0.10 to 0.21) 0.19 (0.14 to 0.25)
ACR 70 Confidential information
has been removed
0.05 (0.03 to 0.08) 0.07 (0.04 to 0.10)
CZP
ACR 20 NC Confidential information
has been removed
0.44 (0.34 to 0.55) 0.58 (0.49 to 0.69)
ACR 50 Confidential information
has been removed
0.21 (0.14 to 0.30) 0.33 (0.24 to 0.43)
ACR 70 Confidential information
has been removed
0.08 (0.04 to 0.13) 0.14 (0.09 to 0.22)
50 mg of GOL
ACR 20 NC Confidential information
has been removed
0.68 (0.55 to 0.80) 0.53 (0.40 to 0.66)
ACR 50 Confidential information
has been removed
0.43 (0.30 to 0.57) 0.28 (0.18 to 0.40)
ACR 70 Confidential information
has been removed
0.21 (0.12 to 0.33) 0.11 (0.06 to 0.19)
continued
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TABLE 174 Comparison of ACR response in the CSs (Novartis and UCB Pharma), the previous MTA and the current
AG in the biologic-naive subpopulation (continued )
Treatment
Probability of ACR responses in the biologic-naive subpopulation at 12 weeks (12–16 weeks)
Rodgers et al.
(2011),33 mean
(95% CrI) Novartis, mean
AG, median (95% CrI)
Unadjusted Adjusted
ADA
ACR 20 0.56 (0.43 to 0.69) Confidential information
has been removed
0.55 (0.47 to 0.62) 0.56 (0.50 to 0.63)
ACR 50 0.31 (0.21 to 0.44) Confidential information
has been removed
0.29 (0.23 to 0.36) 0.31 (0.26 to 0.37)
ACR 70 0.13 (0.08 to 0.21) Confidential information
has been removed
0.12 (0.09 to 0.17) 0.13 (0.10 to 0.17)
INF
ACR 20 0.68 (0.53 to 0.81) Confidential information
has been removed
0.75 (0.65 to 0.83) 0.62 (0.51 to 0.72)
ACR 50 0.43 (0.29 to 0.59) Confidential information
has been removed
0.50 (0.39 to 0.62) 0.36 (0.26 to 0.47)
ACR 70 0.20 (0.11 to 0.33) Confidential information
has been removed
0.27 (0.18 to 0.38) 0.17 (0.10 to 0.24)
ETN
ACR 20 0.61 (0.46 to 0.75) Confidential information
has been removed
0.66 (0.55 to 0.76) 0.61 (0.51 to 0.69)
ACR 50 0.36 (0.23 to 0.52) Confidential information
has been removed
0.40 (0.29 to 0.52) 0.35 (0.27 to 0.43)
ACR 70 0.16 (0.09 to 0.26) Confidential information
has been removed
0.19 (0.12 to 0.29) 0.16 (0.11 to 0.21)
30 mg of APR
ACR 20 NC Confidential information
has been removed
0.33 (0.27 to 0.39) 0.35 (0.30 to 0.41)
ACR 50 Confidential information
has been removed
0.13 (0.10 to 0.17) 0.15 (0.12 to 0.19)
ACR 70 Confidential information
has been removed
0.04 (0.03 to 0.06) 0.05 (0.03 to 0.07)
NC, not conducted.
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TABLE 175 Comparison of ACR response in UCB Pharma submission and the current AG in the biologic-experienced
subpopulation
Treatment
Probability of ACR responses in the biologic-experienced subpopulation
CS
AG at 12 weeks
(12–16 weeks),
median (95% CrI)Novartis, mean
UCB Pharma, at 24 weeks,
mean (95% CrI)
Placebo
ACR 20 Confidential information has
been removed
Confidential information has
been removed
0.14 (0.08 to 0.22)
ACR 50 Confidential information has
been removed
Confidential information has
been removed
0.03 (0.01 to 0.06)
ACR 70 Confidential information has
been removed
Confidential information has
been removed
0.01 (0.00 to 0.02)
300 mg of SEC
ACR 20 Confidential information has
been removed
Confidential information has
been removed
0.36 (0.19 to 0.57)
ACR 50 Confidential information has
been removed
Confidential information has
been removed
0.11 (0.04 to 0.25)
ACR 70 Confidential information has
been removed
Confidential information has
been removed
0.03 (0.01 to 0.11)
45 mg of UST
ACR 20 Confidential information has
been removed
Confidential information has
been removed
0.42 (0.26 to 0.59)
ACR 50 Confidential information has
been removed
Confidential information has
been removed
0.14 (0.06 to 0.27)
ACR 70 Confidential information has
been removed
Confidential information has
been removed
0.05 (0.01 to 0.12)
CZP
ACR 20 Confidential information has
been removed
Confidential information has
been removed
NC
ACR 50 Confidential information has
been removed
Confidential information has
been removed
NC
ACR 70 Confidential information has
been removed
Confidential information has
been removed
NC
NC, not conducted.
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WinBUG codes of preferred model
Model H1: 
model{ 
for(i in 1:N){  
p[i,1] <- 1  
for (j in 1:nc[i]-1) {  
r[i,j] ~ dbin(q[i,j],n[i,j])  
q[i,j] <- 1-(p[i,C[i,j+1]]/p[i,C[i,j]]) 
z.index[i,j]<- C[i,j+1]-1 
theta[i,j] <- mu[s[i]] + (d[t[i]] - d[t[1]])*(1-equals(t[i],b[i])) + z[z.index[i,j]] 
rhat[i,j] <- q[i,j] * n[i,j]        
dv[i,j] <- 2 * (r[i,j]*(log(r[i,j])-log(rhat[i,j])) + (n[i,j]-r[i,j])*(log(n[i,j]-r[i,j]) - log(n[i,j]-
rhat[i,j]))) 
} 
  dev[i] <- sum(dv[i,1:nc[i]-1]) 
 for (j in 2:nc[i]) {  
  p[i,C[i,j]] <- 1 - phi.adj[i,j] 
          phi.adj[i,j] <- phi(theta[i,j-1])    
   } 
 } 
totresdev <- sum(dev[])  
z[1] <- 0  
for (j in 2:Cmax-1) { 
 z.aux[j] ~ dunif(0,5)  
 z[j] <- z[j-1] + z.aux[j]  
  } 
d[1] <- 0  
for (k in 2:nt){ d[k] ~ dnorm(0,0.000001) }  
for(i in 1:ns){ mu[i] ~ dnorm(0,0.000001)} 
 
for (i in 1:ns) { 
mu1[i]<-mu[i]*equals(t[1],1)} 
A<-sum(mu1[])/ns 
 
# calculate prob of achieving ACR20/50/70 on treat k 
for (k in 1:nt) { 
for (j in 1: Cmax-1) { T[j,k] <- 1 - phi(A + d[k] + z[j]) } 
} 
} 
 
Model K2: 
model{ 
for(i in 1:N){ 
            p[i,1] <- 1 
            for (j in 1:nc[i]-1) { 
                        r[i,j] ~ dbin(q[i,j],n[i,j]) 
                        q[i,j] <- 1-(p[i,C[i,j+1]]/p[i,C[i,j]]) 
                        z.index[i,j]<- C[i,j+1]-1 
                        theta[i,j] <- mu[s[i]] + d[t[i]] + z[z.index[i,j]] 
                                    + betaplac * (mu[s[i]] - Mean) * (1-equals(t[i],1))   
                        rhat[i,j] <- q[i,j] * n[i,j] 
         dv[i,j] <- 2 * (r[i,j]*(log(r[i,j])-log(rhat[i,j])) + (n[i,j]-r[i,j])*(log(n[i,j]-r[i,j]) - log(n[i,j]-rhat[i,j]))) 
                                    } 
                        dev[i] <- sum(dv[i,1:nc[i]-1]) 
            for (j in 2:nc[i]) { 
             p[i,C[i,j]] <- 1 - phi.adj[i,j] 
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
276
            phi.adj[i,j] <- phi(theta[i,j-1]) 
            } 
} 
totresdev <- sum(dev[]) 
z[1] <- 0 
  
for (j in 2:Cmax-1) { 
            z.aux[j] ~ dunif(0,5) 
            z[j] <- z[j-1] + z.aux[j] 
                                    } 
d[1] <- 0 
for (k in 2:4){ d[k] ~dnorm( D.c[1], prec.d) } 
for (k in 5:9){ d[k] ~dnorm( D.c[2], prec.d) } 
d[10] <-D.c[3] 
for (i in 1:3) {D.c[i] ~ dnorm(0,0.01) } 
prec.d<- 1/(sd.d*sd.d) 
sd.d~dunif(0,10) 
for (i in 1:2) {D.pred[i]~dnorm(D.c[i],prec.d)} 
for(i in 1:ns){ mu[i] ~ dnorm(0,0.01)} 
betaplac ~ dnorm(0,0.01) 
 
for (i in 1:ns) { 
mu1[i]<-mu[i]*equals(t[1],1)} 
A<-sum(mu1[])/ns 
  
# calculate prob of achieving ACR20/50/70 on treat k 
for (k in 1:nt) { 
for (j in 1: Cmax-1) { T[j,k] <- 1 - phi(A + d[k] + z[j]) } 
} 
} 
d[1]=PLA, d[2]=SEC300, d[3]=SEC150, d[4]=UST, d[5]=CZP, d[6]=GOL, d[7]=ADA, d[8]=INF, d[9]=ETA, 
d[10]=APR 
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
© Queens Printer and Controller of HMSO 2017. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
277
Appendix 4 Search strategy for cost-effectiveness
studies
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations
The search strategy was developed in MEDLINE (via Ovid) by an information specialist, with input from the
project team. The strategy included terms for PsA combined, using the Boolean operator AND, with terms
for the eight drugs. No language or geographical limits were applied. A search strategy to limit retrieval to
economic evaluations was used, where available. The search strategy was adapted for use in the other
resources searched.
The following databases were searched: MEDLINE; MEDLINE In-Process & Other Non-Indexed Citations;
CENTRAL; Conference Proceedings Citation Index  Science; EconLit; EMBASE; NHS EED; PubMed; and the SCI.
The results from the searches were imported into an EndNote library (x7, Thomson Reuters, CA, USA) and
de-duplicated. After de-duplication in EndNote, a total of 722 records were available for screening.
Via Ovid: http://ovidsp.ovid.com/
Date range searched: 1946 to present.
Date searched: 15 February 2016.
Records retrieved: 73.
Search strategy
1. Arthritis, Psoriatic/ (4255)
2. (psoria$ adj2 (arthrit$ or arthropath$)).ti,ab. (6719)
3. 1 or 2 (7560)
4. Certolizumab Pegol/ (329)
5. (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7).af. (873)
6. 4 or 5 (873)
7. 3 and 6 (69)
8. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (144)
9. 3 and 8 (33)
10. (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5).af. (530)
11. (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).ed. (5,936,425)
12. 3 and 10 and 11 (93)
13. (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9).af. (142)
14. (2014$ or 2015$ or 2016$).ed. (2,019,613)
15. 3 and 13 and 14 (29)
16. Ustekinumab/ (386)
17. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (684)
18. 16 or 17 (684)
19. (2012$ or 2013$ or 2014$ or 2015$ or 2016$).ed. (3,931,892)
20. 3 and 18 and 19 (97)
21. (inflectra or remsima or CT-P13).af. (45)
22. 3 and 21 (2)
23. Etanercept/ (4522)
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
© Queens Printer and Controller of HMSO 2017. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
279
24. (etanercept or enbrel or 185243-69-0).af. (6317)
25. Infliximab/ (7584)
26. (infliximab or remicade or 170277-31-3).af. (10,459)
27. Adalimumab/ (3151)
28. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (4791)
29. or/23-28 (15,794)
30. (2009$ or 2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).ed. (6,691,099)
31. 3 and 29 and 30 (686)
32. 7 or 9 or 12 or 15 or 20 or 22 or 31 (846)
33. economics/ (26,633)
34. exp costs and cost analysis/ (193,882)
35. economics, dental/ (1876)
36. exp economics, hospital/ (21,057)
37. economics, medical/ (8845)
38. economics, nursing/ (3933)
39. economics, pharmaceutical/ (2601)
40. (economic$ or cost$ or price or prices or pricing or pharmacoeconomic$).ti,ab. (563,319)
41. (expenditure$ not energy).ti,ab. (20,845)
42. value for money.ti,ab. (1132)
43. budget$.ti,ab. (21,354)
44. or/33-43 (695,859)
45. ((energy or oxygen) adj cost).ti,ab. (3171)
46. (metabolic adj cost).ti,ab. (962)
47. ((energy or oxygen) adj expenditure).ti,ab. (18,791)
48. or/45-47 (22,130)
49. 44 not 48 (690,811)
50. letter.pt. (901,537)
51. editorial.pt. (393,586)
52. historical article.pt. (326,263)
53. or/50-52 (1,605,365)
54. 49 not 53 (659,853)
55. exp animals/ not humans/ (4,184,674)
56. 54 not 55 (613,314)
57. 32 and 56 (73)
Key
/ = indexing term (MeSH heading).
exp = exploded indexing term (MeSH heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
af = terms in any field.
ed = entry date  date added to database.
pt = publication type.
adj = terms next to each other (order specified).
adj2 = terms within two words of each other (any order).
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Cochrane Central Register of Controlled Trials
Via Wiley Online Library: http://onlinelibrary.wiley.com/
Issue 1 of 12, January 2016.
Date searched: 16 February 2016.
Records retrieved: 240.
Search strategy
#1 MeSH descriptor: [Arthritis, Psoriatic] this term only (224)
#2 (psoria* near/2 (arthrit* or arthropath*)):ti,ab,kw (582)
#3 #1 or #2 (582)
#4 MeSH descriptor: [Certolizumab Pegol] this term only (57)
#5 (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7):ti,ab,kw (211)
#6 #4 or #5 (211)
#7 #3 and #6 (29)
#8 (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6):ti,ab,kw (140)
#9 #3 and #8 (30)
#10 (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5):ti,ab,kw Publication Year from
2010 to 2016 (227)
#11 #3 and #10 Publication Year from 2010 to 2016 (43)
#12 (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9):ti,ab,kw Publication Year
from 2014 to 2016 (48)
#13 #3 and #12 Publication Year from 2014 to 2016 (24)
#14 MeSH descriptor: [Ustekinumab] this term only (48)
#15 (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0):ti,ab,kw Publication Year
from 2012 to 2016 (111)
#16 #14 or #15 Publication Year from 2012 to 2016 (111)
#17 #3 and #16 Publication Year from 2012 to 2016 (41)
#18 (inflectra or remsima or CT-P13):ti,ab,kw (16)
#19 #3 and #18 (4)
#20 MeSH descriptor: [Etanercept] this term only (381)
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#21 (etanercept or enbrel or 185243-69-0):ti,ab,kw Publication Year from 2009 to 2016 (638)
#22 MeSH descriptor: [Infliximab] this term only (431)
#23 (infliximab or remicade or 170277-31-3):ti,ab,kw Publication Year from 2009 to 2016 (718)
#24 MeSH descriptor: [Adalimumab] this term only (236)
#25 (adalimumab or humira or D2E7 or (D2 next E7) or 331731-18-1):ti,ab,kw Publication Year from
2009 to 2016 (775)
#26 #20 or #21 or #22 or #23 or #24 or #25 Publication Year from 2009 to 2016 (1685)
#27 #3 and #26 Publication Year from 2009 to 2016 (123)
#28 #7 or #9 or #11 or #13 or #17 or #19 or #27 (265)
#29 #7 or #9 or #11 or #13 or #17 or #19 or #27 in Trials (240)
Key
MeSH descriptor = indexing term (MeSH heading).
* = truncation.
ti,ab,kw = terms in either title or abstract or keyword fields.
near/2 = terms within two words of each other (any order).
next = terms are next to each other.
Conference Proceedings Citation Index – Science
Via Web of Science, Thomson Reuters: http://thomsonreuters.com/thomson-reuters-web-of-science/
Date range searched: 1990 to 12 February 2016.
Date searched: 15 February 2016.
Records retrieved: four.
Search strategy
# 22 4 #21 OR #19
Indexes=CPCI-S Timespan=All years
# 21 3 #20 not #16
Indexes=CPCI-S Timespan=2009-2016
# 20 3 #15 AND #14 AND #3
Indexes=CPCI-S Timespan=2009-2016
# 19 1 #18 not #16
Indexes=CPCI-S Timespan=All years
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# 18 1 #17 AND #15 AND #3
Indexes=CPCI-S Timespan=All years
# 17 868 #9 OR #8 OR #7 OR #6 OR #5 OR #4
Indexes=CPCI-S Timespan=All years
# 16 305,948 TS=(rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or
cat or cats or bovine or sheep or guinea*)
Indexes=CPCI-S Timespan=All years
# 15 389,653 TS=(economic* or cost* or price or prices or pricing or pharmacoeconomic*)
Indexes=CPCI-S Timespan=All years
# 14 1811 #13
Indexes=CPCI-S Timespan=2009-2016
# 13 4801 #12 OR #11 OR #10
Indexes=CPCI-S Timespan=All years
# 12 1317 TS=(adalimumab or humira or D2E7 or D2-E7 or 331731-18-1)
Indexes=CPCI-S Timespan=All years
# 11 2706 TS=(infliximab or remicade or 170277-31-3)
Indexes=CPCI-S Timespan=All years
# 10 1338 TS=(etanercept or enbrel or 185243-69-0)
Indexes=CPCI-S Timespan=All years
# 9 7 TS=(inflectra or remsima or CT-P13)
Indexes=CPCI-S Timespan=All years
# 8 177 TS=(ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0)
Indexes=CPCI-S Timespan=All years
# 7 69 TS=(apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9)
Indexes=CPCI-S Timespan=All years
# 6 176 TS=(golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5)
Indexes=CPCI-S Timespan=All years
# 5 76 TS=(secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6)
Indexes=CPCI-S Timespan=All years
# 4 367 TS=(Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7)
Indexes=CPCI-S Timespan=All years
# 3 1638 #2 OR #1
Indexes=CPCI-S Timespan=All years
# 2 30 TS=(psoria* same arthropath*)
Indexes=CPCI-S Timespan=All years
# 1 1625 TS=(psoria* same arthrit*)
Indexes=CPCI-S Timespan=All years
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
© Queens Printer and Controller of HMSO 2017. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
283
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
* = truncation.
  = phrase search.
EconLit
Via Ovid: http://ovidsp.ovid.com/
Date range searched: 1886 to January 2016.
Date searched: 15 February 2016.
Records retrieved: one.
Search strategy
1. (psoria$ adj2 (arthrit$ or arthropath$)).ti,ab. (4)
2. (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7).af. (0)
3. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (0)
4. (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5).af. (1)
5. (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9).af. (0)
6. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (0)
7. (inflectra or remsima or CT-P13).af. (1)
8. (etanercept or enbrel or 185243-69-0).af. (9)
9. (infliximab or remicade or 170277-31-3).af. (11)
10. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (4)
11. 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (16)
12. 1 and 11 (1)
Key
$ = truncation.
ti,ab = terms in either title or abstract fields.
af = all fields.
adj2 = terms within two words of each other (any order).
EMBASE
Via Ovid: http://ovidsp.ovid.com/
Date range searched: 1974 to 2016 February 12.
Date searched: 15 February 2016.
Records retrieved: 429.
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Search strategy
1. psoriatic arthritis/ (13,665)
2. (psoria$ adj2 (arthrit$ or arthropath$)).ti,ab. (11,842)
3. 1 or 2 (16,004)
4. certolizumab pegol/ (3636)
5. (Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7).af. (4412)
6. 4 or 5 (4412)
7. 3 and 6 (593)
8. secukinumab/ (674)
9. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (752)
10. 8 or 9 (752)
11. 3 and 10 (236)
12. golimumab/ (3205)
13. (golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5).af. (3296)
14. 12 or 13 (3296)
15. (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).em. (7,964,340)
16. 3 and 14 and 15 (734)
17. apremilast/ (493)
18. (apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9).af. (529)
19. 17 or 18 (529)
20. (2014$ or 2015$ or 2016$).em. (3,487,544)
21. 3 and 19 and 20 (180)
22. ustekinumab/ (2546)
23. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (2662)
24. 22 or 23 (2662)
25. (2012$ or 2013$ or 2014$ or 2015$ or 2016$).em. (6,135,553)
26. 3 and 24 and 25 (579)
27. (inflectra or remsima or CT-P13).af. (137)
28. 3 and 27 (20)
29. etanercept/ (22,267)
30. (etanercept or enbrel or 185243-69-0).af. (23,098)
31. infliximab/ (34,699)
32. (infliximab or remicade or 170277-31-3).af. (35,399)
33. adalimumab/ (19,622)
34. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (20,032)
35. or/29-34 (48,727)
36. (2009$ or 2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).em. (9,322,795)
37. 3 and 35 and 36 (3158)
38. 7 or 11 or 16 or 21 or 26 or 28 or 37 (3754)
39. Health Economics/ (35,095)
40. exp Economic Evaluation/ (238,057)
41. exp Health Care Cost/ (228,961)
42. pharmacoeconomics/ (6245)
43. 39 or 40 or 41 or 42 (427,297)
44. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
(717,152)
45. (expenditure$ not energy).ti,ab. (27,886)
46. (value adj2 money).ti,ab. (1653)
47. budget$.ti,ab. (27,874)
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48. 44 or 45 or 46 or 47 (744,311)
49. 43 or 48 (940,487)
50. letter.pt. (924,109)
51. editorial.pt. (499,866)
52. note.pt. (628,173)
53. 50 or 51 or 52 (2,052,148)
54. 49 not 53 (858,063)
55. (metabolic adj cost).ti,ab. (1050)
56. ((energy or oxygen) adj cost).ti,ab. (3462)
57. ((energy or oxygen) adj expenditure).ti,ab. (23,424)
58. 55 or 56 or 57 (27,048)
59. 54 not 58 (852,398)
60. animal/ (1,703,995)
61. exp animal experiment/ (1,909,383)
62. nonhuman/ (4,685,261)
63. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or
cats or bovine or sheep).ti,ab,sh. (5,233,856)
64. 60 or 61 or 62 or 63 (7,617,710)
65. exp human/ (16,737,281)
66. human experiment/ (347,954)
67. 65 or 66 (16,738,727)
68. 64 not (64 and 67) (5,838,485)
69. 59 not 68 (781,570)
70. 38 and 69 (429)
Key
/ = indexing term (Emtree heading).
exp = exploded indexing term (Emtree heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
af = all fields.
pt = publication type.
sh = subject heading field.
adj2 = terms within two words of each other (any order).
em = entry week  date added to the database.
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NHS Economic Evaluations Database
URL: www.crd.york.ac.uk/CRDWeb/
Date range searched: inception to 31 March 2015.
Date searched: 16 February 2016.
Records retrieved: 14.
Search strategy
1 (MeSH DESCRIPTOR Arthritis, Psoriatic) in NHS EED 11
2 (((psoria* NEAR2 (arthrit* or arthropath*)))) in NHS EED 17
3 (((arthrit* or arthropath*) NEAR2 psoria*)) in NHS EED 12
4 MeSH DESCRIPTOR Certolizumab Pegol in NHS EED 2
5 ((Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7)) in NHS EED 3
6 ((secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6)) in NHS EED 0
7 ((golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5)) in NHS EED where lpd from
1 January 2010 to 31 March 2015
2
8 ((apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9) ) in NHS EED where lpd from
1 January 2014 to 31 March 2015
0
9 MeSH DESCRIPTOR Ustekinumab in NHS EED 7
10 ((ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0) ) in NHS EED where lpd from
1 January 2012 to 31 March 2015
9
11 ((inflectra or remsima or CT-P13)) in NHS EED 0
12 MeSH DESCRIPTOR Etanercept in NHS EED 52
13 MeSH DESCRIPTOR Infliximab in NHS EED 75
14 MeSH DESCRIPTOR Adalimumab in NHS EED 47
15 ((etanercept or enbrel or 185243-69-0)) in NHS EED where lpd from 1 January 2009 to 31 March 2015 61
16 ((infliximab or remicade or 170277-31-3)) in NHS EED where lpd from 1 January 2009 to 31 March 2015 85
17 ((adalimumab or humira or D2E7 or D2-E7 or 331731-18-1) ) in NHS EED where lpd from 1 January 2009 to
31 March 2015
64
18 #1 OR #2 OR #3 17
19 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 135
20 #18 AND #19 14
Key
MeSH DESCRIPTOR = indexing term (MeSH heading).
* = truncation.
NEAR2 = terms within two words of each other (order specified).
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PubMed
URL: www.ncbi.nlm.nih.gov/pubmed/
Date searched: 16 February 2016.
Records retrieved: 58.
Search strategy
((economic evaluation*[TIAB] OR economic analy*[TIAB] OR cost analy*[TIAB] OR cost effectiveness[TIAB]
OR cost benefit*[TIAB] OR cost utilit*[TIAB]) OR (Costs and Cost Analysis[Mesh])) AND ((((Arthritis,
Psoriatic[Mesh:noexp]) OR (psoria*[Title/Abstract] AND arthrit*[Title/Abstract]) OR (psoria*[Title/Abstract]
AND arthropath*[Title/Abstract]))) AND ((Certolizumab Pegol[Mesh:noexp]) OR (Certolizumab OR Cimzia
OR CZP OR CDP870 OR CDP-870 OR 428863-50-7) OR (secukinumab OR Cosentyx OR AIN457 OR
AIN-457 OR 1229022-83-6) OR ((golimumab OR simponi OR CNTO148 OR CNTO-148 OR 476181-74-5)
AND 2010/01/01[Date - Entrez] : 3000[Date - Entrez]) OR ((apremilast OR otezla OR otezia OR
CC10004 OR CC-10004 OR 608141-41-9) AND (2014/01/01[Date - Entrez] : 3000[Date - Entrez])) OR
(Ustekinumab[Mesh:noexp]) OR ((ustekinumab OR stelara OR CNTO1275 OR CNTO-1275 OR 815610-63-
0) AND (2012/01/01[Date - Entrez] : 3000[Date - Entrez])) OR (inflectra OR remsima OR CT-P13) OR
(Etanercept[Mesh:noexp]) OR ((etanercept OR enbrel OR 185243-69-0) AND (2009/01/01[Date - Entrez] :
3000[Date - Entrez])) OR (Infliximab[Mesh:noexp]) OR ((infliximab OR remicade OR 170277-31-3) AND
(2009/01/01[Date - Entrez] : 3000[Date - Entrez])) OR (Adalimumab[Mesh:noexp]) OR ((adalimumab OR
humira OR D2E7 OR D2-E7 OR 331731-18-1) AND (2009/01/01[Date - Entrez] : 3000[Date - Entrez]))))
Key
[Mesh] = exploded indexing term (MeSH heading).
[Mesh:noexp] = indexing term (MeSH heading) not exploded.
* = truncation.
[Title/Abstract]) = terms in either title or abstract fields.
[Date - Entrez] = date added to the database.
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Science Citation Index
Via Web of Science, Thomson Reuters: http://thomsonreuters.com/thomson-reuters-web-of-science/
Date range searched: 1900 to 12 February 2016.
Date searched: 15 February 2016.
Records retrieved: 111.
Search strategy
# 23 111 #22 OR #19
Indexes=SCI-EXPANDED Timespan=All years
# 22 95 #21
Indexes=SCI-EXPANDED Timespan=2009-2016
# 21 143 #20 not #16
Indexes=SCI-EXPANDED Timespan=All years
# 20 149 #15 AND #14 AND #3
Indexes=SCI-EXPANDED Timespan=All years
# 19 38 #18 not #16
Indexes=SCI-EXPANDED Timespan=All years
# 18 39 #17 AND #15 AND #3
Indexes=SCI-EXPANDED Timespan=All years
# 17 3,371 #9 OR #8 OR #7 OR #6 OR #5 OR #4
Indexes=SCI-EXPANDED Timespan=All years
# 16 3,889,643 TS=(rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or
cat or cats or bovine or sheep or guinea*)
Indexes=SCI-EXPANDED Timespan=All years
# 15 1,036,604 TS=(economic* or cost* or price or prices or pricing or pharmacoeconomic*)
Indexes=SCI-EXPANDED Timespan=All years
# 14 23,253 #13
Indexes=SCI-EXPANDED Timespan=All years
# 13 23,253 #12 OR #11 OR #10
Indexes=SCI-EXPANDED Timespan=All years
# 12 6,187 TS=(adalimumab or humira or D2E7 or D2-E7 or 331731-18-1)
Indexes=SCI-EXPANDED Timespan=All years
# 11 15,582 TS=(infliximab or remicade or 170277-31-3)
Indexes=SCI-EXPANDED Timespan=All years
# 10 8,277 TS=(etanercept or enbrel or 185243-69-0)
Indexes=SCI-EXPANDED Timespan=All years
# 9 56 TS=(inflectra or remsima or CT-P13)
Indexes=SCI-EXPANDED Timespan=All years
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# 8 962 TS=(ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0)
Indexes=SCI-EXPANDED Timespan=All years
# 7 240 TS=(apremilast or otezla or otezia or CC10004 or CC-10004 or 608141-41-9)
Indexes=SCI-EXPANDED Timespan=All years
# 6 709 TS=(golimumab or simponi or CNTO148 or CNTO-148 or 476181-74-5)
Indexes=SCI-EXPANDED Timespan=All years
# 5 275 TS=(secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6)
Indexes=SCI-EXPANDED Timespan=All years
# 4 1,407 TS=(Certolizumab or Cimzia or CZP or CDP870 or CDP-870 or 428863-50-7)
Indexes=SCI-EXPANDED Timespan=All years
# 3 11,992 #2 OR #1
Indexes=SCI-EXPANDED Timespan=All years
# 2 659 TS=(psoria* same arthropath*)
Indexes=SCI-EXPANDED Timespan=All years
# 1 11,744 TS=(psoria* same arthrit*)
Indexes=SCI-EXPANDED Timespan=All years
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
* = truncation.
SAME = terms within the same sentence.
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Appendix 5 Quality assessment checklists for
company-submitted models
Checklist for the Novartis model
Study question Grade Comments
1. Costs and effects examined ✓
2. Alternatives compared ✗ In the one prior DMARD population
and the anti-TNF experienced
population
3. The viewpoint(s)/perspective of the analysis is clearly stated
(e.g. NHS, society)
✓
Selection of alternatives
4. All relevant alternatives are compared (including do-nothing
if applicable)
✗ In the one prior DMARD population,
other anti-TNFs can be applicable
5. The alternatives being compared are clearly described (who did what,
to whom, where and how often)
✓
6. The rationale for choosing the alternative programmes or interventions
compared is stated
✓
Form of evaluation
7. The choice of form of economic evaluation is justified in relation to the
questions addressed
✓
8. If a cost-minimisation design is chosen, have equivalent outcomes been
adequately demonstrated?
N/A
Effectiveness data
9. The source(s) of effectiveness estimates used are stated (e.g. single
study, selection of studies, systematic review, expert opinion)
✓
10. Effectiveness data from RCT or review of RCTs ✓
11. Potential biases identified (especially if data not from RCTs) ✓
12. Details of the method of synthesis or meta-analysis of estimates are
given (if based on an overview of a number of effectiveness studies)
✓ WinBUGS code presented
Costs
13. All the important and relevant resource use included ✗ Severe psoriasis costs are not
accounted
14. All the important and relevant resource use measured accurately
(with methodology)
✓
15. Appropriate unit costs estimated (with methodology) ✓
16. Unit costs reported separately from resource use data ✓
17. Productivity costs treated separately from other costs ✓
18. The year and country to which unit costs apply is stated with
appropriate adjustments for inflation and/or currency conversion
✓
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Study question Grade Comments
Benefit measurement and valuation
19. The primary outcome measure(s) for the economic evaluation are
clearly stated
✓
20. Methods to value health states and other benefits are stated ✓
21. Details of the individuals from whom valuations were obtained
are given
✓
Decision modelling
22. Details of any decision model used are given (e.g. decision tree,
Markov model)
✓
23. The choice of model used and the key input parameters on which it is
based are adequately detailed and justified
✓
24. All model outputs described adequately ✓
Discounting
25. Discount rate used for both costs and benefits ✓
26. Do discount rates accord with NHS guidance? ✓
Allowance for uncertainty
Stochastic analysis of patient-level data
27. Details of statistical tests and CIs are given for stochastic data N/A
28. Uncertainty around cost-effectiveness expressed (e.g. CI around ICER,
cost-effectiveness acceptability curves)
N/A
29. Sensitivity analysis used to assess uncertainty in non-stochastic
variables (e.g. unit costs, discount rates) and analytic decisions
(e.g. methods to handle missing data)
N/A
Stochastic analysis of decision models
30. Are all appropriate input parameters included with uncertainty? ✓
31. Is second-order uncertainty (uncertainty in means) included rather
than first order (uncertainty between patients)?
✓
32. Are the probability distributions adequately detailed and appropriate? ✓
33. Sensitivity analysis used to assess uncertainty in non-stochastic
variables (e.g. unit costs, discount rates) and analytic decisions
(e.g. methods to handle missing data)
✓
Deterministic analysis
34. The approach to sensitivity analysis is given (e.g. univariate, threshold
analysis, etc.)
✓
35. The choice of variables for sensitivity analysis is justified ✓
36. The ranges over which the variables are varied are stated ✓
Presentation of results
37. Incremental analysis is reported using appropriate decision rules ✓
38. Major outcomes are presented in a disaggregated as well as
aggregated form
✓
39. Applicable to the NHS setting ✓
N/A, not applicable.
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Checklist for the UCB Pharma model
Study question Grade Comments
1. Costs and effects examined ✓
2. Alternatives compared ✗ In the one prior DMARD
population
3. The viewpoint(s)/perspective of the analysis is clearly stated
(e.g. NHS, society)
✓
Selection of alternatives
4. All relevant alternatives are compared (including do-nothing if applicable) ✓
5. The alternatives being compared are clearly described (who did what,
to whom, where and how often)
✗ It was not clear how the SEC was
modelled as the cost refers to a
mix of the two strengths of SEC,
150 mg and 300mg
6. The rationale for choosing the alternative programmes or interventions
compared is stated
✓
Form of evaluation
7. The choice of form of economic evaluation is justified in relation to the
questions addressed
✓
8. If a cost-minimisation design is chosen, have equivalent outcomes been
adequately demonstrated?
N/A
Effectiveness data
9. The source(s) of effectiveness estimates used are stated (e.g. single
study, selection of studies, systematic review, expert opinion)
✓
10. Effectiveness data from RCT or review of RCTs ✓
11. Potential biases identified (especially if data not from RCTs) ✓
12. Details of the method of synthesis or meta-analysis of estimates are
given (if based on an overview of a number of effectiveness studies)
✓ WinBUGS code presented
Costs
13. All the important and relevant resource use included ✗ Severe psoriasis costs are not
accounted
14. All the important and relevant resource use measured accurately
(with methodology)
✓
15. Appropriate unit costs estimated (with methodology) ✓
16. Unit costs reported separately from resource use data ✓
17. Productivity costs treated separately from other costs ✓
18. The year and country to which unit costs apply is stated with appropriate
adjustments for inflation and/or currency conversion
✓
Benefit measurement and valuation
19. The primary outcome measure(s) for the economic evaluation are
clearly stated
✓
20. Methods to value health states and other benefits are stated ✓
21. Details of the individuals from whom valuations were obtained are given ✓
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Study question Grade Comments
Decision modelling
22. Details of any decision model used are given (e.g. decision tree,
Markov model)
✓
23. The choice of model used and the key input parameters on which it is
based are adequately detailed and justified
✓
24. All model outputs described adequately ✓
Discounting
25. Discount rate used for both costs and benefits ✓
26. Do discount rates accord with NHS guidance? ✓
Allowance for uncertainty
Stochastic analysis of patient-level data
27. Details of statistical tests and CIs are given for stochastic data N/A
28. Uncertainty around cost-effectiveness expressed (e.g. CI around ICER,
cost-effectiveness acceptability curves)
N/A
29. Sensitivity analysis used to assess uncertainty in non-stochastic variables
(e.g. unit costs, discount rates) and analytic decisions (e.g. methods to
handle missing data)
N/A
Stochastic analysis of decision models
30. Are all appropriate input parameters included with uncertainty? ✓
31. Is second-order uncertainty (uncertainty in means) included rather than
first order (uncertainty between patients)?
✓
32. Are the probability distributions adequately detailed and appropriate? ✓
33. Sensitivity analysis used to assess uncertainty in non-stochastic variables
(e.g. unit costs, discount rates) and analytic decisions (e.g. methods to
handle missing data)
✓
Deterministic analysis
34. The approach to sensitivity analysis is given (e.g. univariate, threshold
analysis, etc.)
✓
35. The choice of variables for sensitivity analysis is justified ✓
36. The ranges over which the variables are varied are stated ✓
Presentation of results
37. Incremental analysis is reported using appropriate decision rules ✗ Reporting the incremental results
was not performed properly
38. Major outcomes are presented in a disaggregated as well as
aggregated form
✓
39. Applicable to the NHS setting ✓
N/A, not applicable.
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Appendix 6 Clinical effectiveness inputs applied
in the company models
Subpopulation 1: biologic naive, one prior DMARD
TABLE 177 Response parameters applied in model for subpopulation 1: Novartis
Treatment PsARC PASI 50 PASI 75 PASI 90 Source
150mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
FUTURE 248 trial subgroup
(one prior DMARD)
SoC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
FUTURE 248 trial subgroup
(one prior DMARD)
TABLE 176 Response parameters applied in model for subpopulation 1: UCB Pharma
Treatment PsARC PASI 50 PASI 75 PASI 90 Source
CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
RAPID-PsA47 trial subgroup
(one prior DMARD)
cDMARD Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
RAPID-PsA47 trial subgroup
(one prior DMARD)
TABLE 178 Health Assessment Questionnaire-Disability Index score change according to the PsARC response for
subpopulation 1: UCB Pharma
Treatment PsARC responders PsARC non-responders Source
CZP Confidential information has been
removed
Confidential information has been
removed
RAPID-PsA47 trial subgroup
(one prior DMARD)
cDMARD Confidential information has been
removed
Confidential information has been
removed
RAPID-PsA47 trial subgroup
(one prior DMARD)
TABLE 179 Health Assessment Questionnaire-Disability Index score change according to the PsARC response for
subpopulation 1: Novartis
Treatment PsARC responders PsARC non-responders Source
150mg of
SEC
Confidential information has been
removed
Confidential information has been
removed
FUTURE 248 subgroup
(one prior DMARD)
SoC Confidential information has been
removed
Confidential information has been
removed
FUTURE 248 subgroup
(one prior DMARD)
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Subpopulation 2: biologic naive (one or more prior DMARDs, UCB
Pharma; two or more prior DMARDs, Novartis)
TABLE 180 Response parameters applied in model for subpopulation 1: UCB Pharma
Treatment PsARC PASI 50 PASI 75 PASI 90 Source
CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, naive
population
150 mg of SEC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information
has been
removed
ETN Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, naive
population
INF Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, naive
population
ADA Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, naive
population
GOL Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, naive
population
TABLE 181 Response parameters applied in model for subpopulation 2: Novartis
Treatment PsARC PASI 50 PASI 75 PASI 90 Source
150mg of SEC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, overall
population
CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, overall
population
ETN Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, overall
population
INF Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, overall
population
ADA Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, overall
population
GOL Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, overall
population
SoC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
NMA, overall
population
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Subpopulation 3: biologic experienced
TABLE 183 Health Assessment Questionnaire-Disability Index score change according to the PsARC response for
subpopulation 2: Novartis
Treatment PsARC responders PsARC non-responders Source
150mg of SEC Confidential information has
been removed
Confidential information has
been removed
FUTURE 2 trial48
CZP 0.558 0.15 Assumption: average TNF
effect
ETN 0.64 0.2 Cawson et al., 201436
INF 0.66 0.2 Cawson et al., 201436
ADA 0.49 0.14 Cawson et al., 201436
GOL 0.44 0.06 Cawson et al., 201436
SoC Confidential information has
been removed
Confidential information has
been removed
FUTURE 2 trial48
TABLE 182 Health Assessment Questionnaire-Disability Index score change according to the PsARC response for
subpopulation 2: UCB Pharma
Treatment PsARC responders PsARC non-responders Source
CZP Confidential information has
been removed
Confidential information has
been removed
NMA, naive population
150 mg of SEC Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
ETN Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
INF Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
ADA Confidential information has
been removed
Confidential information has
been removed
NMA, naive population
GOL Confidential information has
been removed
Confidential information has
been removed
Confidential information has
been removed
TABLE 184 Response parameters applied in model for subpopulation 3: UCB Pharma
Treatment PsARC PASI 50 PASI 75 PASI 90 Source
CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
RAPID-PsA trial,47
experienced subgroup
300mg of SEC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Assumption
UST Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Assumption
Mix/SoC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
RAPID-PsA trial,47
experienced subgroup
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TABLE 185 Response parameters applied in model for subpopulation 3: Novartis
Treatment PsARC PASI 50 PASI 75 PASI 90 Source
300mg of
SEC
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Common efficacy reduction
from the FUTURE 2 trial48
CZP Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Common efficacy reduction
from the FUTURE 2 trial48
UST Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Common efficacy reduction
from the FUTURE 2 trial48
SoC Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Common efficacy reduction
from the FUTURE 2 trial48
TABLE 186 Health Assessment Questionnaire-Disability Index score change according to the PsARC response for
subpopulation 3: UCB Pharma
Treatment PsARC responders PsARC non-responders Source
CZP Confidential information has
been removed
Confidential information has
been removed
RAPID-PsA trial47
300mg of SEC Confidential information has
been removed
Confidential information has
been removed
Assumption
UST Confidential information has
been removed
Confidential information has
been removed
Assumption
Mix/SoC Confidential information has
been removed
Confidential information has
been removed
RAPID-PsA trial47
TABLE 187 Health Assessment Questionnaire-Disability Index score change according to the PsARC response for
subpopulation 3: Novartis
Treatment PsARC responders PsARC non-responders Source
300mg of SEC Confidential information has
been removed
Confidential information has
been removed
Assumption
CZP Confidential information has
been removed
Confidential information has
been removed
Assumption
UST Confidential information has
been removed
Confidential information has
been removed
Assumption
SoC Confidential information has
been removed
Confidential information has
been removed
Assumption
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Appendix 7 R code for the updated York model
Confidential information has been removed.
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Appendix 8 Cost-effectiveness results using
infliximab and etanercept biosimilar prices,
subpopulation 2
In a separate scenario analysis, biosimilar prices,
134 as opposed to list prices for ETN and INF, were used in
subpopulation 2 (see Chapter 6, Choice of intervention and comparators). This reduces the acquisition
cost for ETN from £2332 to £2139 in the first cycle and subsequent cycles. For INF, the acquisition cost
falls from £7147 to £6432 in the first cycle and from £3395 to £3056 in subsequent cycles. The results for
the three subgroups according to concomitant psoriasis are shown below (see Tables 188190).
Table 188 shows the results for the mildmoderate psoriasis subgroup. In this subgroup, CZP is the least
effective biologic treatment, generating 7.226 QALYs, whereas INF generates the highest numbers of
QALYs (7.890). Fully incremental analysis shows that 300 mg of SEC is dominated by ADA, GOL and ETN,
GOL is dominated by ETN, and CZP and ADA are extendedly dominated. Of the remaining non-dominated
alternatives, the ICER of ETN versus BSC is £18,906 per QALY and the ICER of INF versus ETN is £114,044
per QALY.
The individual pairwise ICERs for CZP and 300 mg of SEC compared with BSC are £21,560 and £29,564
per QALY, respectively.
Table 189 shows the results for the mildmoderate psoriasis subgroup. In this subgroup, CZP is the least
effective biologic treatment, generating 7.537 QALYs, whereas INF generates the highest number of QALYs
(8.161). Performing fully incremental analysis shows that CZP is dominated by 150mg of SEC, GOL is
dominated by ETN, and 150mg of SEC and ADA are extendedly dominated. Of the remaining non-dominated
alternatives, the ICER of ETN versus BSC is £20,951 per QALY and the ICER of INF versus ETN is £170,815
per QALY.
The individual pairwise ICERs for CZP and 150 mg of SEC compared with BSC are £24,107 and £22,032
per QALY, respectively.
For the no concomitant psoriasis subgroup (PASI score = 0) (Table 190), INF maintains its position as the
most effective treatment (8.543 QALYs), whereas 150 mg of SEC is now the least effective treatment
(7.972 QALYs). As expected in this subgroup, the ICERs versus BSC increase compared with the
TABLE 188 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, biosimilar prices
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 95,965 5.312    
CZP 137,240 7.226 Extendedly dominated   21,560
300mg of SEC 157,086 7.379 Dominated   29,564
ADA 138,109 7.411 Extendedly dominated   20,074
GOL 142,850 7.637 Dominated   20,161
ETN_Sim 141,477 7.719 45,512 2.407 18,906 18,906
INF_Sim 160,993 7.890 19,517 0.171 114,044 25,220
ETN_Sim, etanercept biosimilar; INF_Sim, infliximab biosimilar.
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mildmoderate and severe psoriasis subgroups as a result of benefits being driven entirely by HAQ-DI
benefits as opposed to HAQ-DI and PASI. The incremental cost-effectiveness analysis shows that GOL is
dominated by ETN. CZP, 150 mg of SEC and ADA are extendedly dominated. Of the non-dominated
alternatives, the ICER of ETN versus BSC is £22,512 per QALY and the ICER of INF versus ETN is £289,542
per QALY.
The individual pairwise ICERs for CZP and 150 mg of SEC compared with BSC are £26,117 and £24,782
per QALY, respectively.
TABLE 189 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, biosimilar prices
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 67,000 5.676    
CZP 111,856 7.537 Dominated   24,107
150mg of SEC 108,508 7.560 Extendedly dominated   22,032
ADA 114,039 7.708 Extendedly dominated   23,153
GOL 119,624 7.923 Dominated   23,418
ETN_Sim 116,218 8.025 49,217 2.349 20,951 20,951
INF_Sim 139,436 8.161 23,218 0.136 170,815 29,148
ETN_Sim, etanercept biosimilar; INF_Sim, infliximab biosimilar.
TABLE 190 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, biosimilar prices
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 51,436 6.188    
150mg of SEC 95,632 7.972 Extendedly dominated   24,782
CZP 98,060 7.974 Extendedly dominated   26,117
ADA 100,893 8.125 Extendedly dominated   25,542
GOL 106,895 8.325 Dominated   25,951
ETN_Sim 102,484 8.456 51,047 2.268 22,512 22,512
INF_Sim 127,531 8.543 25,047 0.087 289,542 32,325
ETN_Sim, etanercept biosimilar; INF_Sim, infliximab biosimilar.
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Appendix 9 Estimating health-related quality of
life for the updated York model
In order to generate an estimate of the lifetime QALYs for each of the treatments, the disease-specificmeasures, HAQ-DI and PASI, at each cycle of the model, must be mapped onto the utilities scores
associated with particular HAQ-DI and PASI combinations. This assumes that HAQ-DI and PASI capture all
of the relevant information regarding a PsA patients quality of life. In the previous York model,33 this
relationship was estimated from analyses provided by the company (Wyeth), it carried out ordinary least
squares regressions of EQ-5D utility versus HAQ-DI, PASI and an interaction term HAQ-DI × PASI, in
participants in key RCTs. The utility function is given below with standard errors in parentheses:
Expected utility = 0:897(0:006)−0:298(0:006) × HAQ-DI−0:004(0:0003) × PASI (6)
The interaction between HAQ-DI and PASI did not reach statistical significance at the 5% level and was
therefore excluded from the regression model. Table 191 presents the results of Wyeth linear regressions
of utility versus HAQ-DI, PASI and HAQ-DI × PASI.
The Psoriasis Randomized Etanercept study in Subjects with psoriaTic Arthritis (PRESTA) trial42 was used to
determine this algorithm. The PRESTA trial is a 24-week clinical study comparing two forms of ETN and
includes 752 patients with PsA. The study was originally designed to detect any differences in treatment
efficacy for skin manifestations of psoriasis, but these patients also had diagnosed (by a rheumatologist) PsA.
Comparison of the Wyeth algorithm with that from other companies, in the previous York model, showed
that the results were similar in all data sets. This indicates that the relationship between HAQ-DI, PASI and
utility is stable across independent clinical trials, and gives some assurance about the generalisability to the
wider PsA population.
We performed a systematic search to identify any subsequent papers which include mapping functions
from HAQ-DI and PASI to utilities (post December 2009). This was not restricted to utilities measured using
the EQ-5D. The search strategy can be seen in Appendix 10. This identified 2573 potentially relevant
records after deduplication. After initial screening, 40 of these records were actually related to PsA and
contained information on (preference-rated) quality of life. Of these, only 11 suggested the use of a
mapping function to link a preference-based measure of quality of life, such as the EQ-5D or the SF-36, to
disease-specific measures, including the HAQ-DI and PASI. Five of these were available only as conference
abstracts. The remaining six papers were screened for inclusion (see Table 192 for a summary of these
studies). In conclusion, none of the papers offers a mapping function that will allow the disease-specific
measures, HAQ-DI and PASI to be mapped onto a utility score. The existing York utility algorithm is
therefore used in the current version of the economic model.
TABLE 191 Full results of Wyeth’s linear regressions of utility vs. HAQ-DI, PASI and HAQ-DI × PASI
Wyeth
Coefficients Variance–covariance matrices
Mean SE z p> z Intercept HAQ-DI PASI HAQ-DI × PASI
Intercept 0.895 0.007 128.652 0.000 0.000048430
HAQ-DI 0.295 0.008 37.157 0.000 0.000030080 0.000062880
PASI 0.004 0.000 9.039 0.000 0.000001640 0.000000947 0.000000207
HAQ-DI × PASI 0.000 0.000 0.669 0.504 0.000001311 0.000002207 0.000000136 0.000000183
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TABLE 192 Utilities papers screened for inclusion
Publication
(first author
and year of
publication) Population Measures included
Mapping function
made explicit in
paper?
Relevant for economic
model?
Adams et al.,
2010152
Patients with RA and
PsA (n = 504)
HAQ-DI, SF-6D, EQ-5D,
EULAR and DAS
Yes, presented
separately for EQ-5D
and SF-6D
Does not include the PASI
Adams et al.,
2011153
Patients with RA and
PsA (n = 504)
HAQ-DI, SF-36, EQ-5D
(revised) and EQ-5D
(original)
Yes, presented
separately for EQ-5D
and SF-6D
Does not include the PASI
Brodszky et al.,
2010154
Patients with PsA
(n= 183)
Hungarian versions
of HAQ-DI, EQ-5D,
PsAQoL, DAS28, VAS,
PASI and BASDI
No, looked at
correlations between
measures individually
but no mapping
No
Gratacós et al.,
2014155
Patients with PsA
(n= 287)
PASI, HAQ-DI, number
of swollen and tender
joints, SF-36 and EQ-5D
Yes, multivariate
analysis conducted
Does not include the
HAQ-DI in the EQ-5D
model; instead includes
the number of swollen
and tender joints and the
PASI. EQ-5D not included
in the HAQ-DI model
Leung et al.,
2013156
Patients with PsA
(n= 86)
EQ-5D and SF-6D Not undertaken.
Does not include the
HAQ-DI or PASI
No
Picchianti-
Diamanti
et al., 2010157
Patients with RA and
PsA (n = 80)
HAQ-DI, SF-36 and DAS Not undertaken.
Reports scores
separately
No
BASDI, Bath Ankylosing Spondylitis Disease Activity Index; DAS, Disease Activity Score; DAS28, Disease Activity Score 28;
PsAQoL, Psoriatic Arthritis Quality of Life; SF-6D, Short-Form Six-Dimension.
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Appendix 10 Search strategy for utility studies
Database
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations.
Ovid MEDLINE(R).
Date range searched: 1946 to present.
Search strategy
1. (sf36 or sf 36).ti,ab. (15,462)
2. (eq5d or eq 5d or euroqol or euro qol).ti,ab. (5427)
3. (short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six
or short form thirtysix or short form thirty six).ti,ab. (7310)
4. (hrql or hrqol or h qol or hql or hqol).ti,ab. (12,181)
5. (hye or hyes or health$ year$ equivalent$ or health utilit$).ti,ab. (1375)
6. health related quality of life.ti,ab. (26,941)
7. rosser.ti,ab. (74)
8. (standard gamble$ or time trade off or time tradeoff or tto or willingness to pay).ti,ab. (4653)
9. (utilities or utility or daly or dalys or disability adjusted life).ti,ab. (140,271)
10. Quality of Life/ (132,981)
11. (quality of life or life quality).ti,ab. (178,851)
12. health status indicators/ (20,944)
13. quality adjusted life year/ (8035)
14. (qaly$ or quality adjusted).ti,ab. (9209)
15. (qwb$ or hui or hui1 or hui2 or hui3 or qwi).ti,ab. (1249)
16. (quality of wellbeing or quality of well being).ti,ab. (360)
17. preference based.ti,ab. (841)
18. (dermatology life quality index or health status).ti,ab. (42,673)
19. (state$ adj2 (value or values or valuing or valued)).ti,ab. (2630)
20. (dlqi or hspv).ti,ab. (688)
21. general health questionnaire.ti,ab. (3748)
22. nottingham health profile.ti,ab. (1019)
23. patient generated index.ti,ab. (44)
24. sickness impact profile.ti,ab. (1019)
25. (ghq or nhp or pgi or sip or uksip or wtp).ti,ab. (10,048)
26. or/1-25 (425,323)
27. (PSAQoL or psoriatic arthritis quality of life or PsA quality of life).ti,ab. (14)
28. (PASI or psoriasis area severity index).ti,ab. (1737)
29. (PsARC or Psoriatic Arthritis Response Criteria).ti,ab. (44)
30. (HAQ-DI or Health Assessment Questionnaire).ti,ab. (3581)
31. or/27-30 (5285)
32. Arthritis, Psoriatic/ (4270)
33. (psoria$ adj2 (arthrit$ or arthropath$)).ti,ab. (6737)
34. 32 or 33 (7581)
35. 26 and 34 (655)
36. 31 and 34 (424)
37. 35 or 36 (918)
38. (letter or editorial or comment).pt. (1,456,654)
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39. 37 not 38 (902)
40. exp animals/ not humans/ (4,189,142)
41. 39 not 40 (899)
42. limit 41 to yr=2009 -Current (595)
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Appendix 11 Identifying additional psoriatic
arthritis health state costs
Methods
This is a very broad literature and an exhaustive review was beyond the time constraints of this appraisal.
Instead, a rapid review was undertaken of the following sources, since the previous MTA (December 2009):
l evidence presented to previous NICE appraisals of PsA treatments
l the CSs to the current appraisal
l citation searches using Rodgers et al.33
Relevant cost data for the economic model must satisfy the following criteria:
l The data should be specific to patients with PsA.
l The data must show a causal relationship from the HAQ-DI and PASI to subsequent health service
utilisation and costs.
l The data should report mean costs conditional on the HAQ-DI and PASI and measures of
sampling uncertainty.
l The data should measure costs not charges or prices.
l Preferably data would be taken from the UK; where this is not possible, it is important to assess
whether or not studies from other countries are likely to be generalisable to the UK, particularly
countries with mixed public/private financing such as the USA.
l The data should measure all direct health-care costs in the hospital, outpatient and community;
productivity losses should be reported separately (the base-case model excludes productivity losses in
accordance with the NICE reference case).
l The data should estimate the costs of medications separately from those of other health services;
the economic model includes these costs separately from the effect of HAQ-DI/PASI on costs.
l The data should state the price year, the currency and other data to allow adjustment to the UK
in 2016.
Results
An additional relevant reference was found from the recent STA for APR in PsA. In this, the company
identified a paper by Poole et al.138 The citation searches for Rodgers et al.33 did not identify any further
published studies. One conference abstract was identified;158 however, the costs relating to PsA patients
have not been published and contact with the author did not receive a response. The GOL and UST STAs
both used the Rodgers et al.s33 algorithms for costs. The advantages and disadvantages of the previous
York HAQ-DI costs and Poole et al.s138 costs are discussed in Chapter 6, Health state costs.
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Appendix 12 Metaregression results
Results utilising the metaregression estimates for effectiveness parameters are presented in Tables 193–198for each of the subpopulations and subgroups.
Subpopulation 1
TABLE 193 Treatment effects from metaregression for moderate–severe psoriasis, subpopulation 1: fully
incremental cost-effectiveness analysis
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 95,965 5.312    
CZP 161,347 8.596 65,382 3.284 19,908 19,908
300mg of SEC 186,956 8.677 25,609 0.082 313,571 27,033
TABLE 194 Treatment effects from metaregression for mild–moderate psoriasis, subpopulation 1: fully incremental
cost-effectiveness analysis
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 67,000 5.676    
150mg of SEC 134,957 8.869 67,956 3.192 21,287 21,287
CZP 138,698 8.870 3741 0.002 2,010,048 22,446
TABLE 195 Treatment effects from metaregression for no concomitant psoriasis, subpopulation 1: fully incremental
cost-effectiveness analysis
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 51,436 6.188    
150mg of SEC 122,938 9.243 71,502 3.055 23,408 23,408
CZP 126,253 9.256 3315 0.013 252,218 24,388
DOI: 10.3310/hta21560 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 56
© Queens Printer and Controller of HMSO 2017. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
309
Subpopulation 2
TABLE 196 Treatment effects from metaregression for moderate–severe psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 95,965 5.312    
ADA 136,766 7.342   Extendedly
dominated
20,092
GOL 141,113 7.486   Dominated Confidential information
has been removed
CZP 139,489 7.496 43,524 2.185 19,923 19,923
300mg of SEC 165,222 7.586   Dominated Confidential information
has been removed
ETN 143,538 7.626 4049 0.130 31,090 20,552
INF 165,132 7.685 21,594 0.059 366,216 29,138
TABLE 197 Treatment effects from metaregression analysis for mild–moderate psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 67,000 5.676    
ADA 112,468 7.642   Dominated 23,130
GOL 116,438 7.788   Dominated Confidential information
has been removed
CZP 115,516 7.791   Dominated Confidential information
has been removed
150mg of SEC 111,894 7.796 44,894 2.120 21,177 21,177
ETN 118,339 7.933 6445 0.137 47,137 22,750
INF 142,056 7.971 23,717 0.038 616,950 32,703
TABLE 198 Treatment effects from metaregression for no concomitant psoriasis, subpopulation 2: fully incremental
cost-effectiveness analysis
Treatment Cost (£) QALYs
Incremental
cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 51,436 6.188    
ADA 99,209 8.063   Extendedly
dominated
25,485
150mg of SEC 99,225 8.199 47,789 2.011 23,768 23,768
CZP 102,418 8.205   Extendedly
dominated
Confidential information
has been removed
GOL 102,993 8.212   Extendedly
dominated
Confidential information
has been removed
ETN 104,635 8.363 5410 0.164 32,926 24,460
INF 129,401 8.373 24,766 0.010 2,571,503 35,689
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Appendix 13 Results from alternative scenarios
Baseline Health Assessment Questionnaire-Disability Index according
to subpopulation
TABLE 199 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 1: fully
incremental cost-effectiveness analysis, subpopulation-specific baseline HAQ-DI score
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 95,460 5.540    
CZP 159,431 8.629 63,971 3.089 20,709 20,709
300mg of SEC 179,172 8.775 19,741 0.146 134,880 25,873
TABLE 200 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 1: fully
incremental cost-effectiveness analysis, subpopulation-specific baseline HAQ-DI score
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 66,495 5.904    
CZP 135,426 8.917 Dominated   22,874
150mg of SEC 131,980 8.935 65,485 3.031 21,604 21,604
TABLE 201 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 1: fully
incremental cost-effectiveness analysis, subpopulation-specific baseline HAQ-DI score
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 50,931 6.414    
150mg of SEC 119,783 9.315 68,852 2.901 23,732 23,732
CZP 122,312 9.322 2529 0.007 351,603 24,543
TABLE 202 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, subpopulation-specific baseline HAQ-DI score
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 96,544 5.049    
CZP 137,839 6.942 Extendedly dominated   21,809
300mg of SEC 157,685 7.095 Dominated   29,877
ADA 138,709 7.127 42,165 2.078 20,295 20,295
GOL 143,451 7.350 Extendedly dominated   20,384
ETN 145,186 7.432 6477 0.306 21,183 20,409
INF 167,727 7.603 22,541 0.171 131,805 27,866
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TABLE 203 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, subpopulation-specific baseline HAQ-DI score
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 67,580 5.416    
CZP 112,455 7.255 Dominated   24,395
150mg of SEC 109,107 7.278 41,527 1.863 22,294 22,294
ADA 114,639 7.425 Extendedly dominated   23,418
GOL 120,225 7.638 Extendedly dominated   23,687
ETN 119,927 7.741 10,820 0.462 23,400 22,514
INF 146,170 7.876 26,243 0.136 193,511 31,938
TABLE 204 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, subpopulation-specific baseline HAQ-DI score
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 52,016 5.930    
150mg of SEC 96,231 7.692 Extendedly dominated   25,096
CZP 98,659 7.694 Extendedly dominated   26,444
ADA 101,493 7.844 Extendedly dominated   25,851
GOL 107,496 8.042 Dominated   26,267
ETN 106,193 8.173 54,178 2.243 24,150 24,150
INF 134,265 8.259 28,072 0.086 326,736 35,311
TABLE 205 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, subpopulation-specific baseline HAQ-DI score
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 97,192 4.756    
UST 119,384 5.750 22,192 0.995 22,309 22,309
300mg of SEC 144,796 6.045 25,412 0.294 86,320 36,926
TABLE 206 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, subpopulation-specific baseline HAQ-DI score
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 68,228 5.124    
UST 92,503 6.086 24,276 0.962 25,239 25,239
300mg of SEC 119,826 6.361 27,323 0.275 99,385 41,721
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Alternative Health Assessment Questionnaire-Disability Index costs from
Poole et al.
TABLE 207 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, subpopulation-specific baseline HAQ-DI score
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 52,664 5.641    
UST 77,968 6.556 25,305 0.916 27,638 27,638
300mg of SEC 106,235 6.804 28,267 0.248 114,170 46,057
TABLE 208 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, HAQ-DI costs from Poole et al.138
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 137,167 5.312    
CZP 143,130 7.226 Extendedly dominated   3115
300mg of SEC 165,077 7.379 Dominated   13,500
ADA 143,610 7.411 Extendedly dominated   3069
GOL 144,712 7.637 Dominated   3244
ETN 144,009 7.719 6843 2.407 2842 2842
INF 170,780 7.890 26,771 0.171 156,435 13,036
TABLE 209 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, HAQ-DI costs from Poole et al.138
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 137,167 5.676    
CZP 143,130 7.537 Dominated   3205
150mg of SEC 140,366 7.560 3199 1.884 1698 1698
ADA 143,610 7.708 Extendedly dominated   3171
GOL 144,712 7.923 Dominated   3358
ETN 144,009 8.025 3643 0.465 7832 2913
INF 170,780 8.161 26,771 0.136 196,949 13,526
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TABLE 210 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, HAQ-DI costs from Poole et al.138
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 137,167 6.188    
150mg of SEC 140,366 7.972 3199 1.783 1794 1794
CZP 143,130 7.974 Extendedly dominated   3341
ADA 143,610 8.125 Extendedly dominated   3328
GOL 144,712 8.325 Dominated   3531
ETN 144,009 8.456 6843 2.268 3018 3018
INF 170,780 8.543 26,771 0.087 309,469 14,279
TABLE 211 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, HAQ-DI costs from Poole et al.138
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 137,167 5.312    
UST 140,006 6.334 2840 1.022 2778 2778
300mg of SEC 163,788 6.632 23,781 0.299 79,576 20,154
TABLE 212 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, HAQ-DI costs from Poole et al.138
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 137,167 5.676    
UST 140,006 6.666 2840 0.989 2870 2870
300mg of SEC 163,788 6.945 23,781 0.280 85,064 20,981
TABLE 213 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, HAQ-DI costs from Poole et al.138
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 137,167 6.188    
UST 140,006 7.132 2840 0.943 3010 3010
300mg of SEC 163,788 7.384 23,781 0.252 94,184 22,264
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Withdrawal scenario 1
TABLE 214 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, withdrawal scenario 1
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 95,965 5.312    
CZP 137,240 7.226 Extendedly dominated   21,560
ADA 138,109 7.411 42,144 2.100 20,074 20,074
GOL 142,850 7.637 4741 0.226 20,976 20,161
ETN 144,585 7.719 1735 0.082 21,215 20,197
300mg of SEC 172,821 7.835 Dominated   30,461
INF 167,126 7.890 22,541 0.171 131,716 27,599
TABLE 215 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, withdrawal scenario 1
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 67,000 5.676    
CZP 111,856 7.537 Extendedly dominated   24,107
ADA 114,039 7.708 Extendedly dominated   23,153
GOL 119,624 7.923 Dominated   23,418
150mg of SEC 115,157 7.938 48,157 2.262 21,291 21,291
ETN 119,326 8.025 4169 0.087 47,734 22,274
INF 145,569 8.161 26,243 0.136 193,063 31,616
TABLE 216 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, withdrawal scenario 1
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 51,436 6.188    
CZP 98,060 7.974 Extendedly dominated   26,117
ADA 100,893 8.125 Extendedly dominated   25,542
150mg of SEC 103,136 8.323 Extendedly dominated   24,219
GOL 106,895 8.325 Dominated   25,951
ETN 105,592 8.456 54,156 2.268 23,883 23,883
INF 133,664 8.543 28,071 0.087 324,502 34,930
TABLE 217 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, withdrawal scenario 1
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 95,965 5.312    
UST 118,127 6.334 22,162 1.022 21,685 21,685
300mg of SEC 164,019 7.208 45,892 0.875 52,454 35,876
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Withdrawal scenario 2
TABLE 218 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, withdrawal scenario 1
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 67,000 5.676    
UST 91,246 6.666 24,246 0.989 24,510 24,510
300mg of SEC 141,128 7.495 49,881 0.830 60,105 40,749
TABLE 219 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, withdrawal scenario 1
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 51,436 6.188    
UST 76,712 7.132 25,275 0.943 26,797 26,797
300mg of SEC 128,564 7.898 51,852 0.767 67,626 45,105
TABLE 220 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, withdrawal scenario 2
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 95,965 5.312    
CZP 145,291 7.575 Extendedly dominated   21,791
300mg of SEC 168,369 7.761 Dominated   29,562
ADA 146,695 7.798 Extendedly dominated   20,406
GOL 152,626 8.069 56,661 2.758 20,545 20,545
ETN 154,686 8.168 2060 0.099 20,827 20,555
INF 180,980 8.375 26,294 0.207 127,152 27,750
TABLE 221 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, withdrawal scenario 2
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 67,000 5.676    
CZP 120,762 7.874 Dominated   24,459
150mg of SEC 116,558 7.902 49,558 2.226 22,267 22,267
ADA 123,771 8.080 Extendedly dominated   23,623
GOL 130,746 8.338 Dominated   23,946
ETN 130,329 8.462 13,771 0.560 24,593 22,734
INF 161,129 8.626 30,800 0.164 187,663 31,911
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TABLE 222 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 2: fully
incremental cost-effectiveness analysis, withdrawal scenario 2
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 51,436 6.188    
150mg of SEC 104,305 8.292 Extendedly dominated   25,138
CZP 107,389 8.294 Extendedly dominated   26,570
ADA 111,192 8.475 Extendedly dominated   26,129
GOL 118,682 8.716 Dominated   26,604
ETN 117,041 8.874 65,605 2.686 24,427 24,427
INF 150,067 8.978 33,026 0.104 316,876 35,352
TABLE 223 Treatment effects from independent analysis for moderate–severe psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, withdrawal scenario 2
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 95,965 5.312    
UST 122,062 6.507 26,098 1.196 21,829 21,829
300mg of SEC 152,067 6.858 30,004 0.351 85,485 36,276
TABLE 224 Treatment effects from independent analysis for mild–moderate psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, withdrawal scenario 2
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 67,000 5.676    
UST 95,632 6.833 28,631 1.156 24,763 24,763
300mg of SEC 127,960 7.160 32,328 0.328 98,657 41,081
TABLE 225 Treatment effects from independent analysis for no concomitant psoriasis, subpopulation 3: fully
incremental cost-effectiveness analysis, withdrawal scenario 2
Treatment Cost (£) QALYs Incremental cost (£)
Incremental
QALYs
ICER vs. next
best option (£) ICER vs. BSC (£)
BSC 51,436 6.188    
UST 81,319 7.289 29,883 1.101 27,142 27,142
300mg of SEC 114,795 7.584 33,476 0.295 113,494 45,389
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Appendix 14 Quality assessment checklists for
published cost-effectiveness models
Checklist for the Rodgers et al.33 model
Study question Grade Comments
1. Costs and effects examined ✓
2. Alternatives compared ✓
3. The viewpoint(s)/perspective of the analysis is clearly stated (e.g. NHS, society) ✓
Selection of alternatives
4. All relevant alternatives are compared (including do-nothing if applicable) ✗ UST, GOL, SEC and CZP
not included
5. The alternatives being compared are clearly described (who did what, to whom,
where and how often)
✓
6. The rationale for choosing the alternative programmes or interventions compared
is stated
✓
Form of evaluation
7. The choice of form of economic evaluation is justified in relation to the
questions addressed
✓
8. If a cost-minimisation design is chosen, have equivalent outcomes been
adequately demonstrated?
N/A
Effectiveness data
9. The source(s) of effectiveness estimates used are stated (e.g. single study,
selection of studies, systematic review, expert opinion)
✓
10. Effectiveness data from RCT or review of RCTs ✓
11. Potential biases identified (especially if data not from RCTs) ✓
12. Details of the method of synthesis or meta-analysis of estimates are given
(if based on an overview of a number of effectiveness studies)
✓ WinBUGS code
presented
Costs
13. All the important and relevant resource use included ✓
14. All the important and relevant resource use measured accurately
(with methodology)
✓
15. Appropriate unit costs estimated (with methodology) ✓
16. Unit costs reported separately from resource use data ✓
17. Productivity costs treated separately from other costs ✓
18. The year and country to which unit costs apply is stated with appropriate
adjustments for inflation and/or currency conversion
✓
Benefit measurement and valuation
19. The primary outcome measure(s) for the economic evaluation are clearly stated ✓
20. Methods to value health states and other benefits are stated ✓
21. Details of the individuals from whom valuations were obtained are given ✓
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Study question Grade Comments
Decision modelling
22. Details of any decision model used are given (e.g. decision tree, Markov model) ✓
23. The choice of model used and the key input parameters on which it is based are
adequately detailed and justified
✓
24. All model outputs described adequately ✓
Discounting
25. Discount rate used for both costs and benefits ✓
26. Do discount rates accord with NHS guidance? ✓
Allowance for uncertainty
Stochastic analysis of patient-level data
27. Details of statistical tests and CIs are given for stochastic data N/A
28. Uncertainty around cost-effectiveness expressed (e.g. CI around ICER,
cost-effectiveness acceptability curves)
N/A
29. Sensitivity analysis used to assess uncertainty in non-stochastic variables
(e.g. unit costs, discount rates) and analytic decisions (e.g. methods to handle
missing data)
N/A
Stochastic analysis of decision models
30. Are all appropriate input parameters included with uncertainty? ✓
31. Is second-order uncertainty (uncertainty in means) included rather than first
order (uncertainty between patients)?
✓
32. Are the probability distributions adequately detailed and appropriate? ✓
33. Sensitivity analysis used to assess uncertainty in non-stochastic variables
(e.g. unit costs, discount rates) and analytic decisions (e.g. methods to handle
missing data)
✓
Deterministic analysis
34. The approach to sensitivity analysis is given (e.g. univariate, threshold
analysis, etc.)
✓
35. The choice of variables for sensitivity analysis is justified ✓
36. The ranges over which the variables are varied are stated ✓
Presentation of results
37. Incremental analysis is reported using appropriate decision rules ✓
38. Major outcomes are presented in a disaggregated as well as aggregated form ✓
39. Applicable to the NHS setting ✓
N/A, not applicable.
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Checklist for the golimumab model70
Study question Grade Comments
1. Costs and effects examined ✓
2. Alternatives compared ✓
3. The viewpoint(s)/perspective of the analysis is clearly stated
(e.g. NHS, society)
✓
Selection of alternatives
4. All relevant alternatives are compared (including do-nothing
if applicable)
✗ Biologics compared with palliative
care, which is defined as DMARDs
Comparators UST, SEC and CZP not
included
5. The alternatives being compared are clearly described (who did what,
to whom, where and how often)
✗ Does not describe what the series of
DMARDs are
6. The rationale for choosing the alternative programmes or interventions
compared is stated
✓
Form of evaluation
7. The choice of form of economic evaluation is justified in relation to
the questions addressed
✓
8. If a cost-minimisation design is chosen, have equivalent outcomes
been adequately demonstrated?
N/A
Effectiveness data
9. The source(s) of effectiveness estimates used are stated (e.g. single
study, selection of studies, systematic review, expert opinion)
✓
10. Effectiveness data from RCT or review of RCTs ✓
11. Potential biases identified (especially if data not from RCTs) ✓
12. Details of the method of synthesis or meta-analysis of estimates are
given (if based on an overview of a number of effectiveness studies)
✓ WinBUGS code presented
Costs
13. All the important and relevant resource use included ✓
14. All the important and relevant resource use measured accurately
(with methodology)
✓
15. Appropriate unit costs estimated (with methodology) ✓
16. Unit costs reported separately from resource use data ✓
17. Productivity costs treated separately from other costs N/A
18. The year and country to which unit costs apply is stated with
appropriate adjustments for inflation and/or currency conversion
✓
Benefit measurement and valuation
19. The primary outcome measure(s) for the economic evaluation are
clearly stated
✓
20. Methods to value health states and other benefits are stated ✓
21. Details of the individuals from whom valuations were obtained
are given
✓
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Study question Grade Comments
Decision modelling
22. Details of any decision model used are given (e.g. decision tree,
Markov model)
✓
23. The choice of model used and the key input parameters on which it
is based are adequately detailed and justified
✓
24. All model outputs described adequately ✓
Discounting
25. Discount rate used for both costs and benefits ✓
26. Do discount rates accord with NHS guidance? ✓
Allowance for uncertainty
Stochastic analysis of patient-level data
27. Details of statistical tests and CIs are given for stochastic data N/A
28. Uncertainty around cost-effectiveness expressed (e.g. CI around ICER,
cost-effectiveness acceptability curves)
N/A
29. Sensitivity analysis used to assess uncertainty in non-stochastic
variables (e.g. unit costs, discount rates) and analytic decisions
(e.g. methods to handle missing data)
N/A
Stochastic analysis of decision models
30. Are all appropriate input parameters included with uncertainty? ✓
31. Is second-order uncertainty (uncertainty in means) included rather
than first order (uncertainty between patients)?
✓
32. Are the probability distributions adequately detailed
and appropriate?
✓
33. Sensitivity analysis used to assess uncertainty in non-stochastic
variables (e.g. unit costs, discount rates) and analytic decisions
(e.g. methods to handle missing data)
✓
Deterministic analysis
34. The approach to sensitivity analysis is given (e.g. univariate, threshold
analysis, etc.)
✓
35. The choice of variables for sensitivity analysis is justified ✓
36. The ranges over which the variables are varied are stated ✓
Presentation of results
37. Incremental analysis is reported using appropriate decision rules ✗ Calculated incorrectly
38. Major outcomes are presented in a disaggregated as well as
aggregated form
✗
39. Applicable to the NHS setting ✓
N/A, not applicable.
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Checklist for the ustekinumab model66
Study question Grade Comments
1. Costs and effects examined ✓
2. Alternatives compared ✓
3. The viewpoint(s)/perspective of the analysis is clearly stated
(e.g. NHS, society)
✓
Selection of alternatives
4. All relevant alternatives are compared (including do-nothing
if applicable)
✗ Conventional management was not
specifically defined, but reflects
treatment with non-biologics. SEC and
CZP not included
5. The alternatives being compared are clearly described
(who did what, to whom, where and how often)
✗ Does not describe what the series of
DMARDs are
6. The rationale for choosing the alternative programmes or
interventions compared is stated
✓
Form of evaluation
7. The choice of form of economic evaluation is justified in relation to
the questions addressed
✓
8. If a cost-minimisation design is chosen, have equivalent outcomes
been adequately demonstrated?
N/A
Effectiveness data
9. The source(s) of effectiveness estimates used are stated
(e.g. single study, selection of studies, systematic review,
expert opinion)
✓
10. Effectiveness data from RCT or review of RCTs ✓
11. Potential biases identified (especially if data not from RCTs) ✓
12. Details of the method of synthesis or meta-analysis of estimates
are given (if based on an overview of a number of effectiveness
studies)
✓ WinBUGS code presented
Costs
13. All the important and relevant resource use included ✓
14. All the important and relevant resource use measured accurately
(with methodology)
✓
15. Appropriate unit costs estimated (with methodology) ✓
16. Unit costs reported separately from resource use data ✓
17. Productivity costs treated separately from other costs N/A
18. The year and country to which unit costs apply is stated with
appropriate adjustments for inflation and/or currency conversion
✓
Benefit measurement and valuation
19. The primary outcome measure(s) for the economic evaluation are
clearly stated
✓
20. Methods to value health states and other benefits are stated ✓
21. Details of the individuals from whom valuations were obtained
are given
✓
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Study question Grade Comments
Decision modelling
22. Details of any decision model used are given (e.g. decision tree,
Markov model)
✓
23. The choice of model used and the key input parameters on which
it is based are adequately detailed and justified
✓
24. All model outputs described adequately ✓
Discounting
25. Discount rate used for both costs and benefits ✓
26. Do discount rates accord with NHS guidance? ✓
Allowance for uncertainty
Stochastic analysis of patient-level data
27. Details of statistical tests and CIs are given for stochastic data N/A
28. Uncertainty around cost-effectiveness expressed (e.g. CI around
ICER, cost-effectiveness acceptability curves)
N/A
29. Sensitivity analysis used to assess uncertainty in non-stochastic
variables (e.g. unit costs, discount rates) and analytic decisions
(e.g. methods to handle missing data)
N/A
Stochastic analysis of decision models
30. Are all appropriate input parameters included with uncertainty? ✓
31. Is second-order uncertainty (uncertainty in means) included rather
than first order (uncertainty between patients)?
✓
32. Are the probability distributions adequately detailed
and appropriate?
✓
33. Sensitivity analysis used to assess uncertainty in non-stochastic
variables (e.g. unit costs, discount rates) and analytic decisions
(e.g. methods to handle missing data)
✓
Deterministic analysis
34. The approach to sensitivity analysis is given (e.g. univariate,
threshold analysis, etc.)
✓
35. The choice of variables for sensitivity analysis is justified ✓
36. The ranges over which the variables are varied are stated ✓
Presentation of results
37. Incremental analysis is reported using appropriate decision rules ✓
38. Major outcomes are presented in a disaggregated as well as
aggregated form
✓
39. Applicable to the NHS setting ✓
N/A, not applicable.
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Checklist for the Cawson et al.36 model
Study question Grade Comments
1. Costs and effects examined ✓
2. Alternatives compared ✓
3. The viewpoint(s)/perspective of the analysis is clearly stated
(e.g. NHS, society)
✓
Selection of alternatives
4. All relevant alternatives are compared (including
do-nothing if applicable)
✗ Conventional management was not
specifically defined, but reflects
treatment with non-biologics. SEC and
CZP not included
5. The alternatives being compared are clearly described
(who did what, to whom, where and how often)
✗ Does not describe what the series of
DMARDs are
6. The rationale for choosing the alternative programmes or
interventions compared is stated
✓
Form of evaluation
7. The choice of form of economic evaluation is justified in
relation to the questions addressed
✓
8. If a cost-minimisation design is chosen, have equivalent
outcomes been adequately demonstrated?
N/A
Effectiveness data
9. The source(s) of effectiveness estimates used are stated
(e.g. single study, selection of studies, systematic review,
expert opinion)
✓
10. Effectiveness data from RCT or review of RCTs ✓
11. Potential biases identified (especially if data not
from RCTs)
✓
12. Details of the method of synthesis or meta-analysis of
estimates are given (if based on an overview of a number
of effectiveness studies)
✓ WinBUGS code presented
Costs
13. All the important and relevant resource use included ✓
14. All the important and relevant resource use measured
accurately (with methodology)
✓
15. Appropriate unit costs estimated (with methodology) ✓
16. Unit costs reported separately from resource use data ✓
17. Productivity costs treated separately from other costs N/A
18. The year and country to which unit costs apply is stated
with appropriate adjustments for inflation and/or
currency conversion
✓
Benefit measurement and valuation
19. The primary outcome measure(s) for the economic
evaluation are clearly stated
✓
20. Methods to value health states and other benefits
are stated
✓
21. Details of the individuals from whom valuations were
obtained are given
✓
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Study question Grade Comments
Decision modelling
22. Details of any decision model used are given (e.g. decision
tree, Markov model)
✓
23. The choice of model used and the key input parameters
on which it is based are adequately detailed and justified
✓
24. All model outputs described adequately ✓
Discounting
25. Discount rate used for both costs and benefits ✓
26. Do discount rates accord with NHS guidance? ✓
Allowance for uncertainty
Stochastic analysis of patient-level data
27. Details of statistical tests and CIs are given for
stochastic data
N/A
28. Uncertainty around cost-effectiveness expressed (e.g. CI
around ICER, cost-effectiveness acceptability curves)
N/A
29. Sensitivity analysis used to assess uncertainty in
non-stochastic variables (e.g. unit costs, discount rates)
and analytic decisions (e.g. methods to handle
missing data)
N/A
Stochastic analysis of decision models
30. Are all appropriate input parameters included
with uncertainty?
✓
31. Is second-order uncertainty (uncertainty in means)
included rather than first order (uncertainty
between patients)?
✓
32. Are the probability distributions adequately detailed
and appropriate?
✓
33. Sensitivity analysis used to assess uncertainty in
non-stochastic variables (e.g. unit costs, discount rates)
and analytic decisions (e.g. methods to handle
missing data)
✓
Deterministic analysis
34. The approach to sensitivity analysis is given (e.g.
univariate, threshold analysis, etc.)
✓
35. The choice of variables for sensitivity analysis is justified ✓
36. The ranges over which the variables are varied are stated ✓
Presentation of results
37. Incremental analysis is reported using appropriate
decision rules
✓
38. Major outcomes are presented in a disaggregated as well
as aggregated form
✓
39. Applicable to the NHS setting ✓
N/A, not applicable.
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